data_1bfy_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1bfy _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 21.4 mttm . . . . . 0 N--CA 1.452 -0.35 0 CA-C-O 122.026 0.917 . . . . 0.0 112.77 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.4 mtpt -74.0 170.39 15.52 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.734 -178.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 38.2 m-85 -146.89 147.18 30.53 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 122.863 0.465 . . . . 0.0 110.648 -177.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 51.4 p -64.95 165.61 10.57 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 120.644 0.259 . . . . 0.0 111.075 167.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 4.4 t -68.77 -97.56 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 105.97 -1.863 . . . . 0.0 105.97 159.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.5 t -172.95 -41.65 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.578 1.951 . . . . 0.0 107.133 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 9.8 p -147.79 -38.62 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 114.495 1.294 . . . . 0.0 114.495 176.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 13.6 p -64.97 -41.47 95.41 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 120.345 1.43 . . . . 0.0 111.282 -170.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 109.39 47.67 0.85 Allowed Glycine 0 CA--C 1.527 0.793 0 C-N-CA 124.805 1.193 . . . . 0.0 111.779 175.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -114.87 89.4 3.09 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.129 0.972 . . . . 0.0 109.041 176.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 16.0 mt -63.82 125.52 20.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.509 -0.744 . . . . 0.0 109.601 176.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 39.9 t80 -81.56 138.89 35.35 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 173.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.1 t-20 -122.88 114.33 29.73 Favored Pre-proline 0 N--CA 1.456 -0.157 0 C-N-CA 123.862 0.865 . . . . 0.0 110.292 174.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -67.46 -38.89 13.61 Favored 'Trans proline' 0 N--CA 1.448 -1.196 0 C-N-CA 121.337 1.358 . . . . 0.0 111.777 -174.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -59.87 -30.86 69.27 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 118.141 0.428 . . . . 0.0 111.05 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -87.39 -31.73 19.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.477 0.711 . . . . 0.0 109.886 176.261 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.21 -159.4 37.05 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -166.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -139.91 61.16 17.31 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 125.485 1.514 . . . . 0.0 107.535 170.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -63.41 -30.65 72.59 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.527 2.151 . . . . 0.0 111.212 -170.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -59.9 -28.24 67.41 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 124.283 1.033 . . . . 0.0 109.858 179.155 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 21.6 m-80 -102.36 -26.22 13.36 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 125.73 1.612 . . . . 0.0 110.874 -175.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 135.83 10.96 1.31 Allowed Glycine 0 CA--C 1.531 1.077 0 C-N-CA 124.177 0.894 . . . . 0.0 113.86 169.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 70.7 t -112.95 110.22 31.41 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.294 0 CA-C-N 118.644 1.222 . . . . 0.0 108.709 -174.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -63.63 155.06 77.91 Favored Pre-proline 0 CA--C 1.535 0.366 0 O-C-N 121.631 -0.668 . . . . 0.0 111.073 -176.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.27 149.02 83.48 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 121.19 1.26 . . . . 0.0 110.665 170.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.26 15.76 80.98 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-O 118.368 -1.24 . . . . 0.0 112.616 -175.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 88.0 m -89.08 116.16 27.15 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 119.805 1.803 . . . . 0.0 107.073 177.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -57.84 136.06 56.93 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 170.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -44.18 -37.68 3.3 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 123.851 0.86 . . . . 0.0 111.79 171.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 56.9 pttt -67.22 -42.39 84.13 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 117.561 -1.656 . . . . 0.0 109.986 -178.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -71.36 -18.33 62.38 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 125.806 1.642 . . . . 0.0 111.138 -176.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 22.7 mt -53.38 133.4 52.87 Favored Pre-proline 0 N--CA 1.448 -0.569 0 CA-C-N 119.194 0.906 . . . . 0.0 108.941 174.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -64.9 142.17 74.35 Favored 'Trans proline' 0 N--CA 1.445 -1.331 0 C-N-CA 122.106 1.871 . . . . 0.0 109.946 179.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -68.47 -12.34 61.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 O-C-N 121.946 -0.471 . . . . 0.0 111.962 178.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -74.77 -17.18 60.68 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 118.275 0.489 . . . . 0.0 112.193 169.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 87.6 t90 -75.27 147.61 40.11 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 121.55 0.691 . . . . 0.0 109.529 179.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 59.3 t -131.51 161.22 41.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 125.097 1.359 . . . . 0.0 107.633 -177.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -43.79 144.49 1.42 Allowed Pre-proline 0 CA--C 1.537 0.475 0 C-N-CA 124.775 1.23 . . . . 0.0 110.031 170.406 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -64.34 -42.43 17.4 Favored 'Trans proline' 0 N--CA 1.452 -0.945 0 C-N-CA 122.271 1.981 . . . . 0.0 111.569 -176.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 88.9 mt -135.41 44.9 2.51 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 123.904 0.881 . . . . 0.0 109.983 -176.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -158.36 152.01 23.44 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 106.007 -1.849 . . . . 0.0 106.007 179.296 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -120.78 86.65 0.4 Allowed Glycine 0 C--N 1.335 0.506 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -169.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.8 p -145.46 -51.85 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 123.115 0.566 . . . . 0.0 110.699 -178.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 109.36 154.68 15.79 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -176.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -64.46 107.79 1.47 Allowed 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 118.153 0.976 . . . . 0.0 109.572 177.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -160.46 157.89 28.43 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 172.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 44.6 54.24 6.62 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.321 1.848 . . . . 0.0 111.549 173.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.6 p90 -100.28 117.86 35.37 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 126.507 1.923 . . . . 0.0 108.705 -179.261 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -85.17 148.11 26.27 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 123.526 0.73 . . . . 0.0 109.06 176.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -79.46 138.7 37.67 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.0 t -102.46 105.0 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 C-N-CA 125.419 1.488 . . . . 0.0 108.266 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -72.87 68.64 0.9 Allowed 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 126.348 1.859 . . . . 0.0 113.178 -179.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 43.3 mm-40 . . . . . 0 C--O 1.255 1.364 0 CA-C-O 116.78 -1.581 . . . . 0.0 108.332 154.843 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 12.1 mttm . . . . . 0 N--CA 1.446 -0.641 0 CA-C-O 121.72 0.772 . . . . 0.0 112.448 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt -76.76 174.29 10.66 Favored 'General case' 0 N--CA 1.442 -0.853 0 C-N-CA 125.617 1.567 . . . . 0.0 109.252 177.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -147.49 145.63 29.21 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 122.773 0.429 . . . . 0.0 110.167 -177.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 42.0 m -74.96 141.59 44.02 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 172.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 41.2 t -74.84 -112.08 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.494 0 N-CA-C 105.735 -1.95 . . . . 0.0 105.735 164.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 9.6 t -160.18 -158.2 0.61 Allowed 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 170.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 17.4 m -75.26 56.81 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 C-N-CA 124.079 0.952 . . . . 0.0 111.737 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 15.6 p -153.19 -55.85 0.12 Allowed 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.989 1.316 . . . . 0.0 109.452 177.24 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.71 -150.36 23.42 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 123.716 0.674 . . . . 0.0 113.248 -169.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 44.8 t80 -130.14 160.5 33.59 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 125.948 1.699 . . . . 0.0 107.666 179.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.6 mt -47.72 125.36 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 C-N-CA 124.6 1.16 . . . . 0.0 111.341 176.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 27.0 t80 -70.19 136.6 50.19 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 170.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.7 t-20 -120.02 113.02 34.46 Favored Pre-proline 0 N--CA 1.454 -0.232 0 C-N-CA 123.861 0.864 . . . . 0.0 109.707 175.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.74 -38.15 32.35 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 121.696 1.597 . . . . 0.0 111.342 -175.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -63.09 -28.81 70.33 Favored 'General case' 0 N--CA 1.444 -0.754 0 O-C-N 123.188 0.305 . . . . 0.0 111.333 -176.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -86.44 -32.97 20.57 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.807 0.843 . . . . 0.0 109.716 172.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.39 -158.86 42.23 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -166.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.3 61.59 17.41 Favored Pre-proline 0 C--O 1.237 0.435 0 C-N-CA 125.235 1.414 . . . . 0.0 107.891 171.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -64.24 -28.16 64.21 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 122.536 2.157 . . . . 0.0 111.222 -170.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -64.18 -30.25 71.32 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 123.24 0.616 . . . . 0.0 109.683 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 33.9 m-80 -93.0 -30.94 15.07 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 125.085 1.354 . . . . 0.0 110.747 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.15 5.88 1.52 Allowed Glycine 0 CA--C 1.531 1.06 0 C-N-CA 124.26 0.933 . . . . 0.0 113.915 170.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 50.2 t -103.44 112.1 35.64 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.266 0 CA-C-N 118.45 1.125 . . . . 0.0 108.559 -175.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -64.59 154.87 83.5 Favored Pre-proline 0 CA--C 1.533 0.32 0 O-C-N 121.784 -0.573 . . . . 0.0 110.416 -177.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.79 150.05 73.67 Favored 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 121.495 1.463 . . . . 0.0 110.851 170.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 79.33 14.44 81.55 Favored Glycine 0 CA--C 1.526 0.724 0 C-N-CA 125.708 1.623 . . . . 0.0 113.348 -176.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 93.9 m -94.35 114.77 26.88 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 120.149 1.974 . . . . 0.0 108.501 -178.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -56.42 135.24 54.15 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 169.423 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -42.69 -35.36 1.1 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 113.172 0.804 . . . . 0.0 113.172 171.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 53.8 pttt -68.3 -38.5 81.7 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 118.646 -1.221 . . . . 0.0 110.051 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -78.0 -16.9 57.73 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 125.005 1.322 . . . . 0.0 109.99 -173.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 19.7 mt -54.97 132.02 67.61 Favored Pre-proline 0 N--CA 1.442 -0.836 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 174.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -57.64 134.69 64.72 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 123.162 2.575 . . . . 0.0 109.359 177.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -74.57 -7.4 53.0 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.298 -0.876 . . . . 0.0 111.966 -176.499 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -77.4 -10.23 59.34 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.491 1.116 . . . . 0.0 112.598 165.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 77.2 t90 -66.93 156.35 36.07 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 118.88 0.764 . . . . 0.0 110.516 177.661 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.4 p -123.91 154.57 30.6 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 125.886 1.675 . . . . 0.0 108.579 -177.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.0 m -34.57 148.55 0.1 Allowed Pre-proline 0 CA--C 1.541 0.609 0 C-N-CA 126.693 1.997 . . . . 0.0 113.715 172.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -76.49 -37.82 1.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 122.964 2.443 . . . . 0.0 113.057 -174.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 96.1 mt -132.3 30.7 4.16 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.908 0.883 . . . . 0.0 109.434 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -152.16 -173.9 4.7 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 -177.087 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -134.43 58.19 0.69 Allowed Glycine 0 C--N 1.339 0.714 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -176.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -133.86 158.74 42.55 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 C-N-CA 125.296 1.438 . . . . 0.0 107.947 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.5 -174.49 35.65 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 111.413 -0.675 . . . . 0.0 111.413 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 52.8 mtpt -71.03 -60.62 2.13 Favored 'General case' 0 CA--C 1.529 0.154 0 O-C-N 121.978 -0.719 . . . . 0.0 109.999 175.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 54.67 -68.53 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 129.357 3.063 . . . . 0.0 114.202 176.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -138.46 140.48 39.25 Favored 'General case' 0 CA--C 1.527 0.092 0 C-N-CA 125.26 1.424 . . . . 0.0 108.203 178.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 7.6 p90 -156.29 110.13 2.74 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -168.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -86.27 133.44 33.82 Favored 'General case' 0 C--O 1.225 -0.204 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -71.52 135.67 47.19 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 178.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.8 t -97.72 109.99 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 C-N-CA 126.39 1.876 . . . . 0.0 106.393 177.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -72.72 60.2 0.49 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.878 1.671 . . . . 0.0 114.308 -174.073 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 . . . . . 0 C--O 1.26 1.627 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 152.236 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 8.9 mttm . . . . . 0 CA--C 1.52 -0.21 0 CA-C-O 120.89 0.376 . . . . 0.0 111.109 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -71.37 171.35 11.37 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 123.557 0.743 . . . . 0.0 110.2 174.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -145.52 148.55 33.34 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.481 0.713 . . . . 0.0 111.253 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.5 m -80.07 122.16 26.43 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 123.294 0.638 . . . . 0.0 110.021 176.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 7.2 t -58.91 94.72 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.326 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 168.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 59.3 m -66.37 141.34 57.99 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -171.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . 0.305 12.7 p 54.37 20.5 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 125.845 1.658 . . . . 0.0 113.293 -171.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 66.9 m -139.03 -162.43 1.32 Allowed 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.591 1.557 . . . . 0.0 107.967 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.36 62.56 0.37 Allowed Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 178.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 6.1 t80 -150.82 66.13 0.92 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 124.069 0.947 . . . . 0.0 109.718 -173.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.1 mt -37.79 125.19 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 124.724 1.21 . . . . 0.0 112.791 -175.205 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.401 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 25.9 t80 -78.05 135.62 37.77 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 175.539 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 57.2 t-20 -120.11 111.52 35.38 Favored Pre-proline 0 N--CA 1.452 -0.338 0 C-N-CA 123.913 0.885 . . . . 0.0 109.807 176.103 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -64.98 -37.96 31.04 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.406 1.404 . . . . 0.0 111.479 -175.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -61.21 -29.91 70.11 Favored 'General case' 0 N--CA 1.446 -0.67 0 O-C-N 123.393 0.433 . . . . 0.0 111.074 -176.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -87.24 -33.17 19.4 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 123.962 0.905 . . . . 0.0 109.705 173.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.44 -158.14 39.83 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -167.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -142.54 62.36 12.81 Favored Pre-proline 0 CA--C 1.537 0.476 0 C-N-CA 125.503 1.521 . . . . 0.0 107.746 172.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.06 -33.98 81.25 Favored 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 122.558 2.172 . . . . 0.0 111.179 -170.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -57.41 -29.89 64.51 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.833 1.253 . . . . 0.0 110.35 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 21.3 m-80 -99.26 -23.4 15.21 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 125.554 1.541 . . . . 0.0 110.98 -176.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 131.52 7.42 3.1 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 124.571 1.081 . . . . 0.0 113.321 169.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.0 t -107.53 110.23 31.1 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.261 0 CA-C-N 118.313 1.057 . . . . 0.0 108.612 -174.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -64.08 155.16 79.86 Favored Pre-proline 0 CA--C 1.534 0.329 0 O-C-N 121.783 -0.573 . . . . 0.0 110.537 -177.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -59.58 149.9 79.42 Favored 'Trans proline' 0 N--CA 1.449 -1.127 0 C-N-CA 121.308 1.339 . . . . 0.0 110.679 170.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.65 23.45 76.79 Favored Glycine 0 CA--C 1.524 0.656 0 C-N-CA 125.469 1.509 . . . . 0.0 112.891 -175.16 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 94.2 m -97.81 117.66 32.63 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 119.514 1.657 . . . . 0.0 107.703 176.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -61.08 137.37 58.24 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 173.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -44.12 -35.11 2.03 Favored 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 113.588 0.959 . . . . 0.0 113.588 172.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 5.8 pttt -69.73 -37.89 76.66 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 120.813 -1.179 . . . . 0.0 110.144 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -73.64 -20.42 60.58 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 125.226 1.41 . . . . 0.0 109.799 -175.018 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.401 HD13 ' CZ ' ' A' ' 13' ' ' TYR . 19.4 mt -54.36 131.07 62.03 Favored Pre-proline 0 N--CA 1.441 -0.882 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 176.317 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -60.66 135.84 62.99 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.094 1.863 . . . . 0.0 108.551 178.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -72.73 -5.41 37.56 Favored 'General case' 0 CA--C 1.54 0.567 0 O-C-N 121.89 -0.507 . . . . 0.0 111.744 -178.585 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.4 -26.41 66.42 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.98 1.312 . . . . 0.0 112.08 164.488 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 83.8 t90 -69.86 149.14 48.18 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.644 0.735 . . . . 0.0 110.639 -174.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 5.2 m -123.12 157.55 28.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 C-N-CA 125.913 1.685 . . . . 0.0 109.645 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.5 m -39.65 144.02 0.52 Allowed Pre-proline 0 CA--C 1.532 0.287 0 C-N-CA 126.351 1.861 . . . . 0.0 113.187 177.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -70.19 -31.94 17.71 Favored 'Trans proline' 0 N--CA 1.451 -1.003 0 C-N-CA 123.227 2.618 . . . . 0.0 112.832 -173.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 16.1 tp -149.32 35.87 0.73 Allowed 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.68 -0.637 . . . . 0.0 110.732 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.5 m -131.19 -47.41 1.0 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.625 0.77 . . . . 0.0 110.607 -178.306 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.43 62.32 1.65 Allowed Glycine 0 CA--C 1.531 1.057 0 C-N-CA 123.608 0.623 . . . . 0.0 112.254 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.1 p -151.69 159.18 4.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 172.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -68.04 167.56 42.39 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 54.9 mtpt -50.33 -58.13 6.35 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.757 0.823 . . . . 0.0 111.215 177.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.8 t0 21.11 85.83 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 128.275 2.63 . . . . 0.0 115.016 -172.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER 75.2 150.66 0.11 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.825 1.65 . . . . 0.0 110.228 178.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.3 p90 -171.02 109.44 0.31 Allowed 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -163.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 52.5 mt-10 -87.27 135.81 33.17 Favored 'General case' 0 CA--C 1.519 -0.228 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -176.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -76.88 137.55 39.21 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -178.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.1 t -98.47 109.91 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.042 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 176.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -74.69 59.62 0.87 Allowed 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 126.197 1.799 . . . . 0.0 113.914 -171.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 . . . . . 0 C--O 1.259 1.596 0 CA-C-N 114.845 -1.07 . . . . 0.0 108.372 156.286 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 38.1 mttm . . . . . 0 N--CA 1.449 -0.483 0 CA-C-O 122.012 0.91 . . . . 0.0 112.911 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 72.7 mttt -80.37 165.61 22.1 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 115.219 -0.9 . . . . 0.0 108.653 -176.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -144.92 136.25 25.17 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.04 -179.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.8 t -92.11 135.79 33.69 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 111.689 0.255 . . . . 0.0 111.689 172.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 48.0 t -77.56 47.45 0.6 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 127.223 2.209 . . . . 0.0 109.389 177.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 10.9 m 43.39 -124.27 0.81 Allowed 'General case' 0 CA--C 1.548 0.902 0 O-C-N 120.266 -1.521 . . . . 0.0 111.93 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 45.1 t -82.75 70.63 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 O-C-N 120.541 -1.35 . . . . 0.0 108.919 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 42.5 t -133.0 -70.04 0.55 Allowed 'General case' 0 CA--C 1.529 0.153 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 175.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.15 60.58 0.96 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -131.91 -57.63 0.98 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.904 0.882 . . . . 0.0 110.393 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 74.0 mt 75.17 119.15 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 C-N-CA 127.135 2.174 . . . . 0.0 111.683 -175.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.407 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 44.1 t80 -82.03 132.41 35.25 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 170.076 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 56.8 t-20 -118.87 112.64 36.46 Favored Pre-proline 0 C--O 1.227 -0.12 0 C-N-CA 124.348 1.059 . . . . 0.0 109.403 174.04 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -65.53 -38.23 26.27 Favored 'Trans proline' 0 N--CA 1.447 -1.265 0 C-N-CA 121.111 1.208 . . . . 0.0 111.573 -174.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -57.47 -32.22 66.74 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-N 117.97 0.35 . . . . 0.0 111.03 -179.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 60.1 m-20 -90.06 -29.83 18.11 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.705 0.802 . . . . 0.0 110.232 177.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.08 -158.67 41.35 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -168.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -141.87 60.82 11.71 Favored Pre-proline 0 CA--C 1.539 0.555 0 C-N-CA 125.373 1.469 . . . . 0.0 107.763 172.17 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -62.17 -33.64 81.16 Favored 'Trans proline' 0 N--CA 1.455 -0.767 0 C-N-CA 122.403 2.068 . . . . 0.0 111.173 -170.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -55.85 -31.35 62.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 125.011 1.324 . . . . 0.0 110.641 177.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.6 m-80 -97.83 -27.76 14.15 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 125.521 1.528 . . . . 0.0 110.663 -177.059 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.23 9.34 1.44 Allowed Glycine 0 CA--C 1.532 1.154 0 C-N-CA 124.345 0.974 . . . . 0.0 113.829 169.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 54.7 t -110.06 111.63 37.0 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.248 0 CA-C-N 118.579 1.189 . . . . 0.0 109.065 -174.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -63.62 154.8 78.79 Favored Pre-proline 0 C--N 1.328 -0.335 0 O-C-N 121.9 -0.5 . . . . 0.0 111.056 -177.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -59.94 150.15 79.84 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 121.423 1.416 . . . . 0.0 110.744 171.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 72.22 16.67 77.08 Favored Glycine 0 CA--C 1.525 0.704 0 CA-C-O 118.289 -1.284 . . . . 0.0 112.798 -174.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 92.4 m -87.75 117.6 26.69 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-N 119.951 1.875 . . . . 0.0 107.386 176.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -56.56 133.28 53.42 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.167 170.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -42.67 -38.31 2.0 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 123.326 0.65 . . . . 0.0 112.053 170.231 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.415 ' HZ1' ' CG ' ' A' ' 32' ' ' ASP . 19.1 pttp -66.34 -39.08 88.97 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 118.181 -1.408 . . . . 0.0 109.945 -177.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.415 ' CG ' ' HZ1' ' A' ' 31' ' ' LYS . 84.6 m-20 -81.66 -11.37 59.11 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 126.108 1.763 . . . . 0.0 110.626 -172.304 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.407 HD13 ' CZ ' ' A' ' 13' ' ' TYR . 22.8 mt -56.42 134.28 76.57 Favored Pre-proline 0 N--CA 1.443 -0.801 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 171.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo -58.08 138.35 85.5 Favored 'Trans proline' 0 N--CA 1.454 -0.796 0 C-N-CA 123.556 2.838 . . . . 0.0 110.932 176.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -69.92 -15.02 63.0 Favored 'General case' 0 N--CA 1.448 -0.55 0 O-C-N 121.071 -1.018 . . . . 0.0 111.822 177.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -78.96 -9.75 59.62 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.59 1.156 . . . . 0.0 112.065 169.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 76.9 t90 -72.22 156.12 39.49 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.086 0.857 . . . . 0.0 110.369 175.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 13.1 t -130.76 143.58 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 125.174 1.389 . . . . 0.0 108.227 -170.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 20.2 t -68.18 137.33 91.7 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 123.438 0.695 . . . . 0.0 109.629 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -68.15 127.85 16.59 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 122.749 2.299 . . . . 0.0 111.42 177.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 29.1 mt 61.26 44.73 9.5 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.759 1.223 . . . . 0.0 111.97 174.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 14.4 t -149.05 178.63 8.54 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -176.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -105.28 171.43 18.62 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 171.439 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.324 3.9 p 48.07 -149.39 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 CA-C-O 117.447 -1.263 . . . . 0.0 111.219 -173.421 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -146.13 -143.3 3.89 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-N 121.475 1.943 . . . . 0.0 111.131 -173.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.4 ptmt -78.11 115.53 17.9 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 172.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -158.43 -63.59 0.08 Allowed 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.029 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -105.0 97.53 7.37 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.638 1.175 . . . . 0.0 109.392 179.509 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.7 p90 -141.12 135.16 30.63 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.201 1.001 . . . . 0.0 109.189 -178.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 22.6 mt-10 -108.44 155.06 21.01 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 124.734 1.213 . . . . 0.0 109.519 178.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -78.96 143.22 35.98 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 123.635 0.774 . . . . 0.0 109.646 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.3 t -112.07 108.38 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 C-N-CA 126.679 1.991 . . . . 0.0 106.564 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -81.18 55.21 2.46 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 125.005 1.322 . . . . 0.0 113.098 -175.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 . . . . . 0 C--O 1.25 1.119 0 C-N-CA 124.911 1.285 . . . . 0.0 109.681 176.454 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 43.2 mttm . . . . . 0 N--CA 1.452 -0.366 0 CA-C-O 122.286 1.041 . . . . 0.0 112.618 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 3.7 mtpt -78.91 166.97 21.8 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.205 -177.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -147.68 149.31 32.23 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.068 0.547 . . . . 0.0 111.067 -179.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 57.4 p -74.38 170.82 14.87 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 123.281 0.633 . . . . 0.0 112.214 172.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 42.1 t -83.16 -53.06 6.07 Favored 'General case' 0 C--O 1.224 -0.254 0 C-N-CA 125.203 1.401 . . . . 0.0 109.074 162.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 85.9 m 61.25 22.74 13.04 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.017 0.927 . . . . 0.0 111.569 -173.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 66.1 t -123.34 -65.15 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 C-N-CA 124.421 1.088 . . . . 0.0 108.453 166.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 26.5 p -94.56 -60.53 1.69 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 118.633 0.651 . . . . 0.0 110.706 175.527 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 138.6 45.98 0.07 OUTLIER Glycine 0 CA--C 1.531 1.075 0 C-N-CA 124.873 1.225 . . . . 0.0 112.166 -176.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -111.13 103.27 11.69 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 125.122 1.369 . . . . 0.0 109.705 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.6 mt -72.52 123.73 27.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 O-C-N 120.919 -1.113 . . . . 0.0 110.085 178.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.403 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 48.4 t80 -79.38 138.59 37.71 Favored 'General case' 0 C--O 1.236 0.392 0 C-N-CA 124.396 1.078 . . . . 0.0 108.451 170.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -124.02 114.33 27.99 Favored Pre-proline 0 C--O 1.226 -0.141 0 C-N-CA 124.005 0.922 . . . . 0.0 109.995 174.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -65.95 -39.46 19.3 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 120.954 1.102 . . . . 0.0 111.969 -175.309 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -58.66 -31.4 68.14 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 118.318 0.508 . . . . 0.0 111.149 -178.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -88.91 -30.86 18.53 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.505 0.722 . . . . 0.0 109.954 177.569 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.52 -159.99 41.13 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 124.095 0.855 . . . . 0.0 110.997 -168.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.04 61.25 17.2 Favored Pre-proline 0 CA--C 1.539 0.532 0 C-N-CA 125.445 1.498 . . . . 0.0 107.712 170.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_endo -63.45 -28.3 70.93 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.237 1.958 . . . . 0.0 111.229 -171.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -61.56 -28.49 69.37 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 123.534 0.734 . . . . 0.0 110.076 178.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.4 m-80 -99.84 -26.93 13.86 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 125.236 1.414 . . . . 0.0 110.958 -177.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 133.2 17.12 1.15 Allowed Glycine 0 CA--C 1.531 1.052 0 C-N-CA 124.216 0.913 . . . . 0.0 113.635 170.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 78.5 t -115.43 109.59 28.87 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.272 0 CA-C-N 118.466 1.133 . . . . 0.0 108.381 -175.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -63.39 155.67 73.71 Favored Pre-proline 0 C--N 1.328 -0.327 0 O-C-N 121.671 -0.643 . . . . 0.0 111.23 -176.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.0 149.02 86.68 Favored 'Trans proline' 0 N--CA 1.448 -1.147 0 C-N-CA 121.279 1.32 . . . . 0.0 110.619 171.046 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.39 16.61 78.81 Favored Glycine 0 N--CA 1.445 -0.709 0 CA-C-O 118.307 -1.274 . . . . 0.0 112.693 -174.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 81.7 m -87.95 117.72 27.0 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 119.873 1.836 . . . . 0.0 106.942 176.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -58.58 136.51 57.61 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 171.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -45.76 -37.3 5.83 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 122.975 0.51 . . . . 0.0 111.337 171.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 48.0 pttt -66.41 -38.49 87.58 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 117.783 -1.567 . . . . 0.0 110.468 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -76.1 -18.88 58.98 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 125.012 1.325 . . . . 0.0 110.506 -174.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.403 HD13 ' CZ ' ' A' ' 13' ' ' TYR . 21.7 mt -53.81 133.92 56.67 Favored Pre-proline 0 N--CA 1.446 -0.627 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 175.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -65.18 139.66 61.53 Favored 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 122.133 1.889 . . . . 0.0 109.7 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -66.3 -11.33 50.07 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 123.708 0.803 . . . . 0.0 111.54 177.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.4 -22.11 61.91 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.64 1.176 . . . . 0.0 112.11 170.285 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 84.9 t90 -73.39 155.7 39.08 Favored 'General case' 0 N--CA 1.455 -0.209 0 O-C-N 121.527 -0.733 . . . . 0.0 110.386 -177.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.72 159.68 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 C-N-CA 125.541 1.536 . . . . 0.0 109.232 -177.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 44.4 t -68.17 134.91 91.43 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 124.228 1.011 . . . . 0.0 109.668 -177.083 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -62.1 126.33 18.45 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.475 2.117 . . . . 0.0 110.883 178.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 41.0 mt 64.92 34.84 8.75 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.467 1.107 . . . . 0.0 111.615 174.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 41.5 t -151.61 160.95 43.44 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 106.399 -1.704 . . . . 0.0 106.399 -175.041 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -115.94 110.13 2.14 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 -174.125 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 36.0 t 78.84 123.35 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 C-N-CA 126.547 1.939 . . . . 0.0 108.785 -171.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -156.59 173.12 34.36 Favored Glycine 0 C--N 1.334 0.459 0 N-CA-C 107.696 -2.162 . . . . 0.0 107.696 178.04 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 53.87 74.05 0.35 Allowed 'General case' 0 CA--C 1.534 0.346 0 CA-C-O 122.941 1.353 . . . . 0.0 110.295 -170.773 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -152.59 -69.67 0.16 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 113.707 -1.588 . . . . 0.0 108.151 170.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -113.67 101.3 9.19 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 124.93 1.292 . . . . 0.0 108.453 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -140.27 131.93 27.25 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.092 1.357 . . . . 0.0 107.783 -175.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -96.63 149.35 21.89 Favored 'General case' 0 C--O 1.223 -0.297 0 C-N-CA 124.903 1.281 . . . . 0.0 109.28 -176.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -75.76 140.86 42.61 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-N 119.042 0.837 . . . . 0.0 109.218 178.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.2 t -106.63 107.57 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 C-N-CA 125.611 1.564 . . . . 0.0 106.8 176.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -76.85 57.03 1.25 Allowed 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 125.619 1.568 . . . . 0.0 113.075 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 . . . . . 0 C--O 1.251 1.144 0 CA-C-O 117.278 -1.344 . . . . 0.0 108.462 159.113 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.5 mmmt . . . . . 0 CA--C 1.52 -0.185 0 CA-C-O 121.391 0.615 . . . . 0.0 110.08 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 44.1 mtpt -74.12 169.75 16.89 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.568 -177.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -143.02 142.59 31.62 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 119.582 -0.247 . . . . 0.0 110.724 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.8 t -85.15 141.7 30.01 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 119.61 -0.836 . . . . 0.0 109.977 170.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 52.2 t -71.19 170.46 12.94 Favored 'General case' 0 CA--C 1.539 0.54 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 154.332 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.3 p -69.28 81.02 0.36 Allowed 'General case' 0 CA--C 1.533 0.32 0 O-C-N 120.97 -1.081 . . . . 0.0 110.725 -173.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 99.1 t 66.98 -74.88 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.456 -0.158 0 C-N-CA 126.014 1.725 . . . . 0.0 108.154 -170.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 48.1 t 43.05 -122.68 0.72 Allowed 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.77 1.228 . . . . 0.0 109.803 174.382 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -177.42 41.11 0.1 OUTLIER Glycine 0 CA--C 1.527 0.806 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 166.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -148.45 74.6 1.29 Allowed 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.748 0.785 . . . . 0.0 109.397 -169.443 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 12.6 mt -59.82 131.67 24.57 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 O-C-N 121.699 -0.626 . . . . 0.0 109.657 175.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.408 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 33.9 t80 -82.82 138.17 34.05 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 174.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -124.17 112.47 28.26 Favored Pre-proline 0 N--CA 1.454 -0.241 0 C-N-CA 124.229 1.011 . . . . 0.0 109.705 175.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -66.19 -35.19 33.78 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.076 1.184 . . . . 0.0 111.395 -174.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -65.13 -27.71 68.93 Favored 'General case' 0 N--CA 1.443 -0.792 0 O-C-N 123.313 0.383 . . . . 0.0 110.934 -176.112 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -87.37 -31.57 20.05 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.328 1.051 . . . . 0.0 109.788 171.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.27 -151.82 50.28 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -167.027 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 25.6 t0 -151.87 63.94 5.55 Favored Pre-proline 0 N--CA 1.443 -0.799 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 171.643 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -64.91 -28.28 58.49 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.701 2.267 . . . . 0.0 111.634 -166.214 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -62.37 -24.93 67.64 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 123.701 0.801 . . . . 0.0 109.727 -178.205 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.9 m-80 -111.37 17.12 20.47 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.062 1.345 . . . . 0.0 109.993 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 95.73 3.95 60.67 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.325 0.964 . . . . 0.0 114.63 170.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.9 t -104.16 107.84 23.28 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.23 0 CA-C-N 119.127 1.464 . . . . 0.0 109.345 -172.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -65.36 153.89 88.87 Favored Pre-proline 0 CA--C 1.536 0.44 0 O-C-N 121.614 -0.679 . . . . 0.0 110.697 -176.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_endo -58.38 149.11 76.24 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 121.575 1.517 . . . . 0.0 111.135 170.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.66 19.33 79.21 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 125.004 1.288 . . . . 0.0 112.47 -175.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 99.8 m -94.27 114.45 26.54 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 119.61 1.705 . . . . 0.0 106.811 176.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -59.72 138.24 57.82 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 170.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.434 ' CD1' ' CD2' ' A' ' 49' ' ' PHE . 2.1 t80 -42.14 -38.63 1.76 Allowed 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 113.194 0.813 . . . . 0.0 113.194 171.189 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 55.8 pttt -64.99 -40.13 94.51 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 118.345 -1.342 . . . . 0.0 110.224 -178.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -78.73 -12.45 60.02 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 125.057 1.343 . . . . 0.0 111.169 -175.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.408 HD13 ' CZ ' ' A' ' 13' ' ' TYR . 21.8 mt -57.23 132.76 80.94 Favored Pre-proline 0 N--CA 1.442 -0.873 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 172.508 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -63.5 137.3 59.08 Favored 'Trans proline' 0 N--CA 1.442 -1.519 0 C-N-CA 121.641 1.56 . . . . 0.0 108.605 176.357 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -70.56 -3.47 18.25 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 123.543 0.737 . . . . 0.0 111.977 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -73.96 -24.71 59.67 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.968 1.707 . . . . 0.0 111.983 166.38 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 78.9 t90 -65.75 158.5 27.42 Favored 'General case' 0 CA--C 1.528 0.112 0 O-C-N 121.746 -0.596 . . . . 0.0 109.805 178.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.408 ' CG2' ' HA2' ' A' ' 43' ' ' GLY . 8.0 p -141.34 145.73 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 C-N-CA 123.895 0.878 . . . . 0.0 109.935 -173.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 53.2 t -66.92 125.12 90.33 Favored Pre-proline 0 C--O 1.24 0.597 0 C-N-CA 123.392 0.677 . . . . 0.0 110.029 178.472 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -66.04 133.7 34.27 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 123.26 2.64 . . . . 0.0 111.035 -175.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 48.4 mt 60.23 30.06 19.54 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 124.536 1.134 . . . . 0.0 112.042 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 8.4 t -142.67 -68.19 0.36 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.097 0.959 . . . . 0.0 108.841 -176.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . 0.408 ' HA2' ' CG2' ' A' ' 38' ' ' VAL . . . 85.71 17.98 60.8 Favored Glycine 0 CA--C 1.532 1.127 0 CA-C-O 118.613 -1.104 . . . . 0.0 114.737 177.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.8 p -72.17 -54.98 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 CA-C-N 119.761 1.781 . . . . 0.0 112.94 -176.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.95 -152.82 24.32 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 108.514 -1.834 . . . . 0.0 108.514 -170.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.55 33.89 0.78 Allowed 'General case' 0 CA--C 1.53 0.189 0 CA-C-N 118.217 1.009 . . . . 0.0 112.063 169.281 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -98.27 -49.66 4.62 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 125.086 1.354 . . . . 0.0 110.114 -161.406 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -94.23 67.23 3.53 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.057 1.343 . . . . 0.0 108.597 178.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.434 ' CD2' ' CD1' ' A' ' 30' ' ' PHE . 20.5 p90 -101.81 115.06 29.7 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 124.232 1.013 . . . . 0.0 109.214 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -99.27 142.92 30.13 Favored 'General case' 0 CA--C 1.519 -0.22 0 N-CA-C 108.164 -1.051 . . . . 0.0 108.164 174.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -73.04 134.78 44.75 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 15.3 t -93.29 108.86 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 174.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -78.64 51.28 1.06 Allowed 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 124.536 1.135 . . . . 0.0 113.489 -173.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 . . . . . 0 C--O 1.259 1.589 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 149.719 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 14.9 mttt . . . . . 0 N--CA 1.453 -0.31 0 CA-C-O 121.968 0.889 . . . . 0.0 112.672 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 58.9 mttt -75.02 167.07 22.63 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.241 -0.891 . . . . 0.0 109.492 -174.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -145.48 144.08 30.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.937 178.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 13.5 m -76.89 150.95 35.98 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-O 119.303 -0.379 . . . . 0.0 110.988 169.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 46.3 t -65.07 171.13 3.83 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-O 121.345 0.593 . . . . 0.0 110.136 170.003 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 1.9 t -71.52 -42.87 67.44 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 124.944 1.298 . . . . 0.0 111.402 -176.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 29.5 m -140.5 24.22 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -178.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 18.4 p -147.56 -166.37 2.5 Favored 'General case' 0 N--CA 1.455 -0.198 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 168.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.93 -82.0 0.99 Allowed Glycine 0 CA--C 1.525 0.705 0 N-CA-C 109.211 -1.556 . . . . 0.0 109.211 175.009 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 63.5 m-85 21.0 65.27 0.03 OUTLIER 'General case' 0 C--N 1.346 0.418 0 C-N-CA 128.452 2.701 . . . . 0.0 111.941 -175.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 23.4 mt -58.55 121.59 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.015 -173.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -73.29 138.12 45.27 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 173.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 62.1 t-20 -125.65 111.99 25.27 Favored Pre-proline 0 N--CA 1.454 -0.243 0 C-N-CA 123.975 0.91 . . . . 0.0 109.541 176.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -63.65 -39.69 33.73 Favored 'Trans proline' 0 N--CA 1.448 -1.204 0 C-N-CA 121.267 1.311 . . . . 0.0 111.355 -173.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -56.12 -32.82 64.57 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 117.977 0.353 . . . . 0.0 111.254 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -91.76 -29.84 16.57 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.453 0.701 . . . . 0.0 110.334 179.271 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 66.17 -159.0 47.63 Favored Glycine 0 CA--C 1.53 1.03 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -170.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.19 61.1 16.26 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 125.615 1.566 . . . . 0.0 107.393 171.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -61.59 -35.53 80.77 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.757 2.305 . . . . 0.0 111.451 -168.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -57.67 -31.38 66.28 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 124.875 1.27 . . . . 0.0 110.516 179.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 -92.21 -28.12 17.23 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 125.218 1.407 . . . . 0.0 110.469 -179.468 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.62 0.48 2.91 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.4 1.0 . . . . 0.0 113.205 171.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 75.2 t -100.97 111.08 29.52 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.206 0 CA-C-N 118.225 1.012 . . . . 0.0 109.002 -172.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -64.53 154.95 82.95 Favored Pre-proline 0 CA--C 1.533 0.308 0 O-C-N 121.765 -0.584 . . . . 0.0 110.929 -176.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -58.77 149.33 78.17 Favored 'Trans proline' 0 N--CA 1.449 -1.117 0 C-N-CA 121.425 1.416 . . . . 0.0 110.84 170.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.41 14.98 79.1 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 125.813 1.673 . . . . 0.0 113.082 -174.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.7 m -87.07 120.1 27.99 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 120.05 1.925 . . . . 0.0 107.871 178.343 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -59.81 134.45 57.04 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 172.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -43.04 -37.87 2.1 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 123.44 0.696 . . . . 0.0 112.176 169.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -68.13 -38.89 82.71 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 117.756 -1.578 . . . . 0.0 110.261 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -76.63 -17.57 59.09 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 124.989 1.316 . . . . 0.0 110.704 -175.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 23.0 mt -52.49 132.76 44.64 Favored Pre-proline 0 N--CA 1.445 -0.705 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -63.43 140.13 74.56 Favored 'Trans proline' 0 N--CA 1.445 -1.355 0 C-N-CA 122.234 1.956 . . . . 0.0 109.697 178.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 74.5 m-20 -69.98 -10.16 57.64 Favored 'General case' 0 N--CA 1.444 -0.772 0 C-N-CA 123.529 0.731 . . . . 0.0 111.914 -179.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -77.21 -12.02 59.89 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 124.232 1.013 . . . . 0.0 112.57 168.355 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -73.36 153.35 40.52 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 118.853 0.751 . . . . 0.0 110.303 177.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 97.4 t -137.02 150.01 26.44 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 125.573 1.549 . . . . 0.0 107.973 -171.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 13.2 t -79.48 130.63 67.61 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 124.854 1.262 . . . . 0.0 109.117 -176.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -64.98 147.91 89.37 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.461 2.108 . . . . 0.0 110.769 -178.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.2 mm? 68.8 -62.31 0.39 Allowed 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 126.323 1.849 . . . . 0.0 111.734 -179.495 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -59.03 -54.56 45.71 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 125.977 1.711 . . . . 0.0 110.787 178.354 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 106.84 -115.53 4.71 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -176.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.9 t -63.71 105.92 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 O-C-N 121.263 -1.139 . . . . 0.0 110.684 -167.437 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -130.74 -165.59 11.56 Favored Glycine 0 CA--C 1.527 0.809 0 C-N-CA 125.848 1.69 . . . . 0.0 109.323 178.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 55.22 61.74 2.78 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 123.112 1.434 . . . . 0.0 110.376 -173.723 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -156.19 157.49 35.98 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 156.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 45.09 37.83 2.79 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.117 1.767 . . . . 0.0 113.047 173.136 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 7.5 p90 -78.07 131.62 37.38 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 124.14 0.976 . . . . 0.0 110.335 -172.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -97.93 135.34 39.79 Favored 'General case' 0 C--O 1.227 -0.085 0 C-N-CA 123.929 0.892 . . . . 0.0 108.813 -179.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -72.66 138.18 46.52 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 176.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 32.2 t -105.53 105.81 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.054 0 C-N-CA 127.216 2.207 . . . . 0.0 105.418 176.579 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -81.91 54.17 2.39 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.427 1.091 . . . . 0.0 112.927 -173.574 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 . . . . . 0 C--O 1.251 1.143 0 C-N-CA 124.983 1.313 . . . . 0.0 109.617 176.508 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 21.9 mttm . . . . . 0 N--CA 1.454 -0.275 0 CA-C-O 122.438 1.113 . . . . 0.0 112.358 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 28.5 mtpt -72.57 170.27 14.76 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.824 -176.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 35.7 m-85 -149.12 145.69 27.33 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 -177.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 44.9 p -71.42 170.62 12.86 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.213 0.53 . . . . 0.0 112.152 170.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 2.2 t -108.26 166.63 10.61 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 126.998 2.119 . . . . 0.0 105.948 166.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 1.2 p -48.0 -50.3 28.01 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 124.683 1.193 . . . . 0.0 111.665 169.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 4.7 m -148.57 16.2 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 N-CA-C 114.111 1.152 . . . . 0.0 114.111 -173.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 79.7 m -109.18 119.6 40.02 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 119.945 1.248 . . . . 0.0 111.742 178.387 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -75.88 54.35 3.0 Favored Glycine 0 CA--C 1.532 1.137 0 O-C-N 121.55 -0.719 . . . . 0.0 111.411 172.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -111.54 -47.03 3.2 Favored 'General case' 0 N--CA 1.46 0.071 0 C-N-CA 124.556 1.142 . . . . 0.0 110.353 176.175 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 11.5 mt 71.32 128.06 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 C-N-CA 125.561 1.544 . . . . 0.0 111.491 -177.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -76.06 141.61 42.0 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 172.103 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 -125.77 115.58 24.6 Favored Pre-proline 0 N--CA 1.456 -0.174 0 C-N-CA 123.679 0.792 . . . . 0.0 110.421 175.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -67.48 -39.63 12.09 Favored 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 121.053 1.169 . . . . 0.0 111.695 -176.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -59.04 -31.08 68.53 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 118.585 0.63 . . . . 0.0 111.152 -178.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -88.47 -31.71 18.62 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 123.589 0.755 . . . . 0.0 110.023 176.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.9 -162.02 35.69 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -166.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -138.28 61.3 25.47 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 125.187 1.395 . . . . 0.0 107.735 171.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -62.8 -31.38 78.21 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 122.332 2.021 . . . . 0.0 111.154 -170.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -59.69 -30.65 68.93 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 123.864 0.866 . . . . 0.0 110.731 178.189 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -96.08 -28.07 14.78 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 124.87 1.268 . . . . 0.0 110.51 -178.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.71 16.96 0.97 Allowed Glycine 0 CA--C 1.531 1.081 0 C-N-CA 124.395 0.998 . . . . 0.0 113.992 169.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.1 t -116.72 112.29 38.72 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.304 0 CA-C-N 118.578 1.189 . . . . 0.0 109.006 -175.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.44 156.73 75.71 Favored Pre-proline 0 CA--C 1.533 0.316 0 O-C-N 121.898 -0.501 . . . . 0.0 111.136 -177.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -59.68 150.14 78.49 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 121.376 1.384 . . . . 0.0 110.802 170.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.57 16.32 79.06 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 125.816 1.674 . . . . 0.0 113.212 -175.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.9 m -89.48 118.56 29.22 Favored 'General case' 0 N--CA 1.445 -0.689 0 CA-C-N 119.923 1.862 . . . . 0.0 108.276 179.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -59.65 134.09 56.7 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 170.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -43.17 -37.04 1.92 Allowed 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 123.596 0.758 . . . . 0.0 112.731 170.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -68.76 -37.84 79.64 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 118.043 -1.463 . . . . 0.0 110.291 -178.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -77.29 -17.49 58.31 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 125.506 1.522 . . . . 0.0 110.462 -176.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 19.2 mt -55.81 133.56 72.77 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 173.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -62.97 137.1 60.44 Favored 'Trans proline' 0 N--CA 1.445 -1.359 0 C-N-CA 121.823 1.682 . . . . 0.0 108.98 175.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -71.43 -4.6 27.34 Favored 'General case' 0 N--CA 1.445 -0.683 0 O-C-N 121.95 -0.469 . . . . 0.0 111.728 -179.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.58 -22.65 63.51 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 125.034 1.333 . . . . 0.0 112.182 165.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 81.3 t90 -71.29 152.3 43.39 Favored 'General case' 0 N--CA 1.456 -0.174 0 O-C-N 121.484 -0.76 . . . . 0.0 111.237 -176.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.5 t -127.59 146.49 33.23 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 C-N-CA 125.72 1.608 . . . . 0.0 108.356 179.173 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -76.31 160.95 76.64 Favored Pre-proline 0 CA--C 1.538 0.519 0 C-N-CA 122.605 0.362 . . . . 0.0 110.158 -176.152 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -67.11 117.42 4.78 Favored 'Trans proline' 0 N--CA 1.45 -1.058 0 C-N-CA 121.9 1.733 . . . . 0.0 110.687 -170.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 50.5 mt 65.32 51.73 1.54 Allowed 'General case' 0 CA--C 1.534 0.33 0 C-N-CA 125.255 1.422 . . . . 0.0 111.623 177.667 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.0 t -142.9 -179.48 6.38 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 124.275 1.03 . . . . 0.0 108.539 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -107.19 -67.21 0.64 Allowed Glycine 0 CA--C 1.526 0.743 0 C-N-CA 124.504 1.05 . . . . 0.0 111.223 -175.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 25.2 m -72.66 164.03 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 CA-C-N 116.803 0.302 . . . . 0.0 110.201 -179.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -121.4 114.03 2.47 Favored Glycine 0 C--N 1.334 0.441 0 N-CA-C 110.396 -1.082 . . . . 0.0 110.396 -170.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mtpt 62.38 -88.02 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 125.412 1.485 . . . . 0.0 110.388 178.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 46.83 -72.48 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 128.799 2.84 . . . . 0.0 114.303 -172.219 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -127.92 116.78 20.63 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 126.014 1.725 . . . . 0.0 108.925 -176.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 4.9 p90 -149.99 112.68 4.77 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.194 1.397 . . . . 0.0 107.28 -171.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -82.91 145.53 29.35 Favored 'General case' 0 C--O 1.225 -0.225 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 44.9 tt0 -71.91 136.8 47.02 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 175.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.1 t -102.41 104.34 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 C-N-CA 126.248 1.819 . . . . 0.0 106.336 177.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -78.2 88.35 4.27 Favored 'General case' 0 N--CA 1.438 -1.03 0 CA-C-O 123.215 1.484 . . . . 0.0 109.125 172.182 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 . . . . . 0 C--O 1.257 1.483 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 158.701 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 51.2 mttm . . . . . 0 N--CA 1.453 -0.306 0 CA-C-O 121.877 0.846 . . . . 0.0 112.704 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -80.71 165.02 22.35 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -176.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -141.3 140.95 33.94 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 123.069 0.548 . . . . 0.0 111.069 178.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.3 t -99.4 140.88 32.92 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 113.084 0.772 . . . . 0.0 113.084 175.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.4 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 42.2 t -78.68 50.48 0.98 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.846 2.058 . . . . 0.0 109.399 177.458 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 5.7 m 53.84 -94.41 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.828 0 O-C-N 120.624 -1.297 . . . . 0.0 112.475 174.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.92 -28.93 5.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 125.246 1.418 . . . . 0.0 110.849 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . 0.4 ' HB3' ' SG ' ' A' ' 6' ' ' CYS . 53.4 t -78.25 124.69 28.37 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 124.419 1.088 . . . . 0.0 109.44 -169.286 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -86.45 78.94 1.88 Allowed Glycine 0 CA--C 1.523 0.588 0 CA-C-O 119.211 -0.772 . . . . 0.0 111.283 -170.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -134.88 -57.76 0.82 Allowed 'General case' 0 CA--C 1.532 0.267 0 CA-C-N 117.796 0.798 . . . . 0.0 112.889 176.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 55.9 mt 75.22 121.25 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 126.637 1.975 . . . . 0.0 111.894 -173.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 77.2 t80 -83.22 138.23 33.7 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 169.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 55.1 t-20 -128.32 115.29 19.93 Favored Pre-proline 0 N--CA 1.454 -0.23 0 C-N-CA 124.582 1.153 . . . . 0.0 109.461 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.27 -39.48 17.55 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 121.779 1.653 . . . . 0.0 112.267 -172.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -55.13 -32.78 62.34 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 118.002 0.365 . . . . 0.0 110.749 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -95.06 -26.03 16.22 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 123.504 0.722 . . . . 0.0 109.9 -177.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.3 -157.46 36.58 Favored Glycine 0 CA--C 1.527 0.788 0 C-N-CA 124.684 1.135 . . . . 0.0 110.979 -170.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.76 62.31 12.23 Favored Pre-proline 0 CA--C 1.538 0.495 0 C-N-CA 125.062 1.345 . . . . 0.0 107.941 170.137 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -62.43 -33.34 79.65 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.697 2.264 . . . . 0.0 111.185 -170.264 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -56.76 -29.56 62.72 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 124.661 1.184 . . . . 0.0 110.728 178.376 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 -99.07 -30.8 12.11 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.267 1.427 . . . . 0.0 110.615 -177.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 140.15 7.49 0.95 Allowed Glycine 0 CA--C 1.531 1.077 0 C-N-CA 123.874 0.75 . . . . 0.0 114.061 169.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.6 t -106.58 112.52 40.02 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.217 0 CA-C-N 118.885 1.342 . . . . 0.0 109.04 -176.664 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -63.91 154.18 82.2 Favored Pre-proline 0 C--N 1.328 -0.351 0 O-C-N 121.982 -0.448 . . . . 0.0 110.585 -178.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -59.19 148.08 87.59 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 121.352 1.368 . . . . 0.0 110.771 170.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 77.77 15.59 81.09 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 124.819 1.2 . . . . 0.0 112.546 -176.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 97.2 m -89.18 118.87 29.19 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 119.698 1.749 . . . . 0.0 107.492 177.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -58.61 135.26 57.32 Favored 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 171.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -46.01 -34.66 4.18 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 123.173 0.589 . . . . 0.0 112.426 171.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.418 ' HZ1' ' CG ' ' A' ' 32' ' ' ASP . 19.5 pttp -66.54 -40.02 88.86 Favored 'General case' 0 N--CA 1.453 -0.287 0 C-N-CA 118.076 -1.45 . . . . 0.0 110.083 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.418 ' CG ' ' HZ1' ' A' ' 31' ' ' LYS . 83.9 m-20 -80.62 -12.49 59.49 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.831 1.652 . . . . 0.0 110.588 -171.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 17.7 mt -57.2 132.67 80.82 Favored Pre-proline 0 N--CA 1.441 -0.877 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 172.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -61.91 138.95 76.95 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 123.044 2.496 . . . . 0.0 109.904 178.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -64.66 -17.7 64.3 Favored 'General case' 0 N--CA 1.451 -0.397 0 O-C-N 121.819 -0.551 . . . . 0.0 112.024 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -75.54 -14.75 60.42 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 123.751 0.821 . . . . 0.0 112.696 173.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 78.8 t90 -70.05 150.66 46.37 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.319 0.581 . . . . 0.0 111.2 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 74.5 t -124.47 150.76 29.35 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 C-N-CA 125.656 1.582 . . . . 0.0 109.927 -173.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 49.8 t -57.86 136.66 83.41 Favored Pre-proline 0 CA--C 1.537 0.449 0 C-N-CA 125.844 1.658 . . . . 0.0 111.574 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -59.07 123.52 13.66 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 121.842 1.695 . . . . 0.0 110.14 173.592 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.2 mm? 66.71 21.79 10.5 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.701 1.201 . . . . 0.0 112.692 178.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -146.59 177.82 8.77 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 176.64 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -146.61 78.61 0.24 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -166.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.2 p -143.58 -73.23 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 123.542 0.737 . . . . 0.0 109.928 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 145.71 162.97 9.98 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 107.828 -2.109 . . . . 0.0 107.828 -173.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.5 ptmt -66.54 -18.7 65.51 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.836 1.318 . . . . 0.0 113.351 176.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 30.09 -93.74 0.01 OUTLIER 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 129.564 3.145 . . . . 0.0 111.964 -176.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.34 64.84 0.95 Allowed 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 166.034 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.3 m-30 -45.72 156.12 0.14 Allowed 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 125.093 1.357 . . . . 0.0 111.632 174.071 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -88.49 147.89 24.43 Favored 'General case' 0 C--O 1.225 -0.196 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 -175.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -74.55 141.49 44.79 Favored 'General case' 0 N--CA 1.442 -0.851 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.7 t -106.21 113.72 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.915 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 175.224 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -73.79 56.55 0.56 Allowed 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.546 1.539 . . . . 0.0 113.423 -178.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 . . . . . 0 C--O 1.254 1.338 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 158.363 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.4 mttm . . . . . 0 N--CA 1.452 -0.339 0 CA-C-O 122.039 0.923 . . . . 0.0 112.38 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 76.6 mttt -70.73 169.73 13.88 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.239 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 48.9 m-85 -147.65 142.74 27.09 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 118.636 -0.697 . . . . 0.0 110.815 -177.205 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.2 m -79.95 146.43 32.09 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 119.014 0.825 . . . . 0.0 109.811 172.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 46.6 t -67.45 176.01 2.53 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 166.642 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 90.0 m -76.4 -74.18 0.24 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.619 1.567 . . . . 0.0 112.297 -167.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 41.2 t -115.73 2.35 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 124.555 1.142 . . . . 0.0 110.557 177.547 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 10.4 t -80.58 -164.98 0.79 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.766 1.626 . . . . 0.0 108.725 -179.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -135.98 49.21 0.89 Allowed Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 44.3 m-85 -133.41 158.86 41.97 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.14 0.976 . . . . 0.0 110.168 179.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 13.8 mt -119.9 127.66 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 125.548 1.539 . . . . 0.0 108.224 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.0 t80 -78.39 140.21 38.73 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 124.807 1.243 . . . . 0.0 108.353 169.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 50.7 t-20 -124.81 111.87 27.29 Favored Pre-proline 0 N--CA 1.458 -0.072 0 C-N-CA 123.99 0.916 . . . . 0.0 109.963 176.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -63.73 -39.75 32.75 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 121.11 1.206 . . . . 0.0 111.59 -173.221 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -57.99 -31.92 67.39 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 118.052 0.387 . . . . 0.0 111.401 -179.065 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -86.88 -34.5 19.41 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 123.195 0.598 . . . . 0.0 109.787 177.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 58.43 -161.96 11.11 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -164.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -139.34 67.52 38.76 Favored Pre-proline 0 CA--C 1.535 0.396 0 C-N-CA 124.509 1.123 . . . . 0.0 108.299 169.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -58.63 -30.02 90.9 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.805 1.67 . . . . 0.0 110.855 -176.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 85.1 m-20 -60.2 -31.97 70.65 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 124.075 0.95 . . . . 0.0 110.753 178.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.2 m-80 -98.8 -24.19 15.1 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 124.136 0.974 . . . . 0.0 110.292 -177.016 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 133.11 10.65 1.92 Allowed Glycine 0 CA--C 1.531 1.046 0 C-N-CA 124.484 1.04 . . . . 0.0 113.251 171.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.3 t -110.0 109.87 30.04 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.273 0 CA-C-N 118.593 1.197 . . . . 0.0 109.298 -175.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -64.04 154.06 83.14 Favored Pre-proline 0 C--N 1.328 -0.356 0 O-C-N 121.803 -0.561 . . . . 0.0 110.754 -178.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_endo -59.13 146.88 92.97 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.317 1.345 . . . . 0.0 110.659 171.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.53 20.18 77.08 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 125.329 1.442 . . . . 0.0 112.699 -177.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 96.9 m -91.87 121.36 33.41 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 119.443 1.622 . . . . 0.0 107.869 176.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.5 t0 -62.96 136.81 58.04 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 171.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -44.66 -35.7 2.75 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 123.332 0.653 . . . . 0.0 112.455 171.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.6 pttp -67.89 -36.68 80.64 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 118.482 -1.287 . . . . 0.0 110.369 -179.109 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -80.68 -16.74 53.2 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.485 1.514 . . . . 0.0 110.277 -174.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.9 mt -55.39 134.22 70.09 Favored Pre-proline 0 N--CA 1.445 -0.719 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 173.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_endo -64.33 138.27 59.91 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 122.425 2.083 . . . . 0.0 109.616 176.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -66.09 -12.63 56.85 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 123.054 0.541 . . . . 0.0 111.943 178.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.15 -19.6 64.02 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.782 1.233 . . . . 0.0 112.337 171.012 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 74.8 t90 -66.31 156.64 33.82 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 121.748 0.785 . . . . 0.0 111.985 -176.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -129.88 149.81 33.99 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 C-N-CA 126.904 2.082 . . . . 0.0 109.815 -178.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 14.6 t -73.64 138.38 77.27 Favored Pre-proline 0 C--O 1.236 0.351 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 -175.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -56.82 111.5 0.82 Allowed 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.1 1.866 . . . . 0.0 110.084 178.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 15.3 mt 79.15 16.63 0.94 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.352 1.861 . . . . 0.0 112.231 179.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.9 t -147.92 99.7 3.11 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-O 123.19 1.471 . . . . 0.0 108.786 -174.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -78.33 52.9 3.83 Favored Glycine 0 CA--C 1.528 0.859 0 O-C-N 120.878 -1.139 . . . . 0.0 111.754 -177.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 51.7 t -99.5 -71.2 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 175.068 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 127.73 -163.42 21.43 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 33.5 mtpt -86.61 168.72 13.38 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 169.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -163.54 -82.93 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 124.738 1.215 . . . . 0.0 108.288 168.265 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.1 mm-40 -99.55 -49.75 4.3 Favored 'General case' 0 C--O 1.226 -0.156 0 C-N-CA 125.22 1.408 . . . . 0.0 110.184 -171.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 29.8 p90 49.32 92.43 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.194 1.798 . . . . 0.0 112.7 177.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 50.2 mt-10 -74.6 137.26 42.2 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 62.8 tt0 -75.93 134.75 40.15 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.197 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 24.5 t -101.47 115.99 44.25 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.127 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 175.337 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -70.82 55.46 0.17 Allowed 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 125.893 1.677 . . . . 0.0 114.174 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 . . . . . 0 C--O 1.253 1.264 0 C-N-CA 126.698 1.999 . . . . 0.0 107.593 161.925 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 18.7 mttt . . . . . 0 N--CA 1.453 -0.295 0 CA-C-O 122.004 0.907 . . . . 0.0 112.979 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -76.27 167.98 20.87 Favored 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 115.085 -0.961 . . . . 0.0 109.649 -176.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -148.24 135.98 20.81 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 122.748 0.419 . . . . 0.0 112.11 -178.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 19.9 m -75.4 134.95 40.8 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 119.311 -0.376 . . . . 0.0 111.118 169.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 36.6 t -68.85 140.37 55.21 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.284 0.634 . . . . 0.0 110.187 170.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 75.1 p -25.84 -82.36 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 129.661 3.185 . . . . 0.0 114.899 -175.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.1 m -127.41 54.97 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 C-N-CA 125.347 1.459 . . . . 0.0 108.535 -172.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 37.3 t -141.09 -78.09 0.28 Allowed 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.3 -161.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 131.23 -33.11 2.85 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.334 -0.707 . . . . 0.0 111.334 -176.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 28.0 m-85 -57.09 139.79 51.3 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-N 118.352 1.076 . . . . 0.0 110.051 177.161 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.7 mt -106.1 120.01 56.38 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.242 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.518 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 44.9 t80 -72.49 138.38 46.97 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 169.714 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 53.8 t-20 -124.25 112.18 28.21 Favored Pre-proline 0 N--CA 1.455 -0.215 0 C-N-CA 124.08 0.952 . . . . 0.0 109.59 175.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -63.18 -39.2 40.13 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 C-N-CA 121.137 1.225 . . . . 0.0 112.082 -172.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -58.91 -31.56 68.75 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 117.751 0.251 . . . . 0.0 111.205 -179.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -87.76 -32.06 19.32 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.472 0.709 . . . . 0.0 109.877 177.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.32 -159.03 41.74 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -167.296 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.49 61.38 16.13 Favored Pre-proline 0 CA--C 1.539 0.544 0 C-N-CA 125.556 1.542 . . . . 0.0 107.763 171.31 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -62.7 -30.04 78.05 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 122.404 2.069 . . . . 0.0 111.329 -170.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -61.18 -29.6 69.9 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 123.922 0.889 . . . . 0.0 110.383 179.111 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -96.63 -28.32 14.4 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 125.232 1.413 . . . . 0.0 110.687 -178.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.52 12.78 1.35 Allowed Glycine 0 CA--C 1.531 1.092 0 C-N-CA 124.296 0.951 . . . . 0.0 113.673 169.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.3 t -110.02 111.01 34.25 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.208 0 CA-C-N 118.447 1.124 . . . . 0.0 108.464 -175.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -64.3 155.34 80.32 Favored Pre-proline 0 CA--C 1.535 0.382 0 O-C-N 121.787 -0.571 . . . . 0.0 110.981 -177.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.57 149.55 81.55 Favored 'Trans proline' 0 N--CA 1.449 -1.093 0 C-N-CA 121.399 1.399 . . . . 0.0 110.944 171.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 74.08 15.69 79.82 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 125.125 1.345 . . . . 0.0 112.848 -175.185 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 76.3 m -87.98 119.27 28.18 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 119.813 1.806 . . . . 0.0 107.183 177.56 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -61.07 137.65 58.23 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 172.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -46.33 -35.76 5.69 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 123.346 0.658 . . . . 0.0 111.71 172.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 54.2 pttt -68.2 -39.2 82.49 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 118.232 -1.387 . . . . 0.0 110.205 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -73.26 -21.16 60.68 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 125.126 1.37 . . . . 0.0 110.164 -175.193 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 21.3 mt -53.23 133.97 51.25 Favored Pre-proline 0 N--CA 1.446 -0.665 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 176.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -66.13 139.58 56.18 Favored 'Trans proline' 0 N--CA 1.444 -1.434 0 C-N-CA 122.093 1.862 . . . . 0.0 109.658 178.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -67.91 -9.17 42.85 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 123.806 0.843 . . . . 0.0 111.546 177.602 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -73.15 -22.69 60.47 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.779 1.232 . . . . 0.0 112.061 169.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 81.1 t90 -69.69 152.83 44.22 Favored 'General case' 0 N--CA 1.455 -0.221 0 O-C-N 121.628 -0.67 . . . . 0.0 110.464 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 99.2 t -131.87 152.69 37.34 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 C-N-CA 124.887 1.275 . . . . 0.0 108.862 -178.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 20.1 t -69.21 140.44 90.62 Favored Pre-proline 0 CA--C 1.54 0.568 0 C-N-CA 124.526 1.131 . . . . 0.0 110.425 -177.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -63.09 118.59 5.5 Favored 'Trans proline' 0 N--CA 1.452 -0.922 0 C-N-CA 122.575 2.183 . . . . 0.0 111.305 175.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 13.2 mt 70.19 43.54 0.85 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.85 1.26 . . . . 0.0 111.176 170.053 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 53.7 t -153.61 176.05 12.52 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 106.117 -1.808 . . . . 0.0 106.117 -171.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -80.42 -156.74 13.69 Favored Glycine 0 CA--C 1.528 0.867 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 173.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.9 m -51.98 126.93 8.2 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 O-C-N 122.099 -0.647 . . . . 0.0 109.632 171.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -126.2 -175.66 14.24 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 58.57 78.32 0.26 Allowed 'General case' 0 CA--C 1.537 0.446 0 CA-C-O 122.471 1.129 . . . . 0.0 110.444 -172.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -153.81 -99.68 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 114.174 -1.376 . . . . 0.0 107.653 168.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -76.39 60.74 1.6 Allowed 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 119.4 1.0 . . . . 0.0 111.493 178.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -75.93 146.1 39.93 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 121.441 -0.787 . . . . 0.0 109.911 173.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -114.38 141.53 47.52 Favored 'General case' 0 N--CA 1.464 0.232 0 C-N-CA 124.235 1.014 . . . . 0.0 108.592 175.409 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -77.54 138.58 39.26 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 29.9 t -103.65 104.5 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 C-N-CA 126.021 1.728 . . . . 0.0 107.039 178.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -77.12 57.72 1.44 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.639 1.576 . . . . 0.0 112.618 179.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 . . . . . 0 C--O 1.255 1.367 0 CA-C-O 117.349 -1.31 . . . . 0.0 108.446 156.776 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 40.4 mttm . . . . . 0 N--CA 1.455 -0.208 0 CA-C-O 122.056 0.931 . . . . 0.0 112.402 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.418 ' HZ3' ' C ' ' A' ' 54' ' ' GLU . 55.7 mttt -82.12 167.71 18.47 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.499 -171.425 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -146.92 136.17 22.64 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 113.411 0.893 . . . . 0.0 113.411 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.7 m -80.98 147.89 30.01 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 123.89 0.876 . . . . 0.0 111.695 169.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 36.1 t -79.31 14.65 1.46 Allowed 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 125.19 1.396 . . . . 0.0 112.631 175.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.8 m 65.64 -72.37 0.07 Allowed 'General case' 0 CA--C 1.538 0.511 0 O-C-N 119.413 -2.054 . . . . 0.0 112.588 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 69.4 t -70.54 -61.88 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 C-N-CA 123.968 0.907 . . . . 0.0 109.123 -174.341 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 8.1 p -95.41 173.58 7.45 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 172.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -72.74 -73.3 0.87 Allowed Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.141 -1.584 . . . . 0.0 109.141 177.174 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 22.19 63.88 0.03 OUTLIER 'General case' 0 C--N 1.345 0.408 0 C-N-CA 127.785 2.434 . . . . 0.0 111.93 -172.346 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.1 mt -62.38 115.05 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 CA-C-N 115.38 -0.827 . . . . 0.0 109.617 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 41.2 t80 -68.59 129.03 38.72 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 172.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 49.8 t-20 -117.36 111.25 40.2 Favored Pre-proline 0 N--CA 1.455 -0.176 0 C-N-CA 123.76 0.824 . . . . 0.0 109.212 175.044 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.11 -38.32 46.35 Favored 'Trans proline' 0 N--CA 1.448 -1.189 0 C-N-CA 121.015 1.143 . . . . 0.0 111.386 -174.355 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 -57.92 -32.63 67.95 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 117.959 0.345 . . . . 0.0 111.098 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -88.15 -32.14 18.8 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.591 0.756 . . . . 0.0 109.98 177.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.5 -159.4 41.87 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.821 -0.911 . . . . 0.0 110.821 -167.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.58 61.05 14.96 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 125.441 1.496 . . . . 0.0 107.732 171.37 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -62.75 -32.4 78.18 Favored 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.438 2.092 . . . . 0.0 111.393 -169.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -59.68 -30.73 68.97 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 123.986 0.914 . . . . 0.0 110.642 178.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -94.34 -28.55 15.49 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 125.115 1.366 . . . . 0.0 110.515 -178.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.72 13.67 1.22 Allowed Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.413 1.006 . . . . 0.0 113.739 169.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 54.7 t -112.45 111.61 36.9 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.285 0 CA-C-N 118.45 1.125 . . . . 0.0 108.602 -174.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -64.12 155.15 80.1 Favored Pre-proline 0 CA--C 1.533 0.304 0 O-C-N 121.708 -0.62 . . . . 0.0 111.132 -176.156 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.2 149.5 80.08 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.127 1.218 . . . . 0.0 110.589 169.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 68.87 20.29 74.29 Favored Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.402 1.477 . . . . 0.0 112.885 -173.001 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 65.1 m -88.03 120.78 29.71 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 120.058 1.929 . . . . 0.0 107.558 174.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -59.75 134.08 56.7 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 172.312 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -42.2 -38.35 1.72 Allowed 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.126 0.57 . . . . 0.0 112.092 168.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 57.9 pttt -67.32 -41.72 84.81 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 117.579 -1.649 . . . . 0.0 110.185 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -71.83 -19.28 62.0 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 125.586 1.554 . . . . 0.0 110.577 -174.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 22.0 mt -52.52 133.11 44.86 Favored Pre-proline 0 N--CA 1.443 -0.802 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 173.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -65.17 141.48 69.59 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 122.275 1.984 . . . . 0.0 110.113 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.2 -15.95 60.98 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 124.198 0.999 . . . . 0.0 111.912 177.279 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -66.83 -22.83 65.99 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.268 1.027 . . . . 0.0 112.181 170.683 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 89.2 t90 -78.35 149.16 33.48 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-O 121.628 0.727 . . . . 0.0 111.102 -174.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 2.2 m -126.99 156.29 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 C-N-CA 125.847 1.659 . . . . 0.0 109.892 -174.03 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 7.7 t -63.36 137.09 96.98 Favored Pre-proline 0 CA--C 1.543 0.689 0 C-N-CA 122.958 0.503 . . . . 0.0 110.347 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -69.6 95.81 0.55 Allowed 'Trans proline' 0 N--CA 1.451 -1.022 0 C-N-CA 123.128 2.552 . . . . 0.0 110.66 -178.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 56.3 mt 85.42 59.11 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 126.813 2.045 . . . . 0.0 111.058 173.293 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 13.1 t -147.22 -94.67 0.09 Allowed 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -176.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 157.38 -41.85 0.53 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.4 t -70.5 148.0 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.97 177.7 49.8 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 176.321 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.9 ptmt -65.38 106.44 1.38 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 165.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -138.85 -65.84 0.49 Allowed 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 173.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -101.13 106.51 17.77 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 -178.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -142.29 128.7 20.07 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 51.7 mt-10 -104.2 141.88 35.49 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 124.443 1.097 . . . . 0.0 108.606 -175.221 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -75.49 142.69 42.85 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 119.913 1.233 . . . . 0.0 109.73 -179.354 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.2 t -112.38 106.56 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 C-N-CA 127.629 2.372 . . . . 0.0 106.737 177.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -82.93 53.74 2.52 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 124.968 1.307 . . . . 0.0 113.372 -173.261 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . 0.418 ' C ' ' HZ3' ' A' ' 3' ' ' LYS . 7.5 pt-20 . . . . . 0 C--O 1.25 1.095 0 C-N-CA 124.451 1.1 . . . . 0.0 110.256 179.762 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.0 mttm . . . . . 0 N--CA 1.451 -0.378 0 CA-C-O 122.121 0.962 . . . . 0.0 113.012 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -78.0 163.13 26.22 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.595 -178.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -138.31 140.51 39.58 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 118.971 -0.538 . . . . 0.0 109.852 175.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.3 t -90.69 160.31 15.92 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 118.014 0.37 . . . . 0.0 111.151 173.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 51.5 t -81.37 -121.01 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 125.558 1.543 . . . . 0.0 107.452 175.435 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 12.6 t -160.49 -46.08 0.05 OUTLIER 'General case' 0 CA--C 1.535 0.368 0 O-C-N 121.427 -0.796 . . . . 0.0 110.415 -175.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.5 p -104.65 -66.75 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 C-N-CA 123.42 0.688 . . . . 0.0 111.271 179.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.5 p -67.59 -38.77 84.5 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 123.713 0.805 . . . . 0.0 110.626 -176.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.73 31.03 30.77 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 179.197 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 18.6 m-85 -65.76 87.21 0.09 Allowed 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 117.742 0.771 . . . . 0.0 109.439 168.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.4 mt -57.44 111.04 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 C-N-CA 123.293 0.637 . . . . 0.0 109.293 172.4 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 20.1 t80 -73.69 133.37 43.37 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 173.203 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 50.7 t-20 -121.45 112.78 32.52 Favored Pre-proline 0 N--CA 1.455 -0.191 0 C-N-CA 124.255 1.022 . . . . 0.0 109.753 177.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -62.85 -38.83 45.51 Favored 'Trans proline' 0 N--CA 1.45 -1.03 0 C-N-CA 121.474 1.449 . . . . 0.0 112.083 -171.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -58.75 -32.31 69.15 Favored 'General case' 0 N--CA 1.446 -0.625 0 O-C-N 123.151 0.282 . . . . 0.0 111.059 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -87.46 -31.38 20.05 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.494 0.717 . . . . 0.0 109.92 177.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.11 -157.36 43.32 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -166.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.31 61.57 12.08 Favored Pre-proline 0 CA--C 1.54 0.588 0 C-N-CA 125.457 1.503 . . . . 0.0 107.455 171.035 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -61.87 -33.86 83.43 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.62 2.213 . . . . 0.0 111.2 -169.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -56.1 -30.48 62.13 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 125.438 1.495 . . . . 0.0 110.66 178.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.0 m-80 -97.02 -32.84 11.79 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 125.531 1.533 . . . . 0.0 110.432 -177.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 139.39 11.24 0.77 Allowed Glycine 0 CA--C 1.53 1.013 0 C-N-CA 123.898 0.761 . . . . 0.0 114.015 171.106 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 68.6 t -109.31 112.18 39.36 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.215 0 CA-C-N 118.898 1.349 . . . . 0.0 108.791 -176.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.19 154.35 82.97 Favored Pre-proline 0 CA--C 1.533 0.306 0 O-C-N 121.91 -0.494 . . . . 0.0 110.904 -177.564 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -58.38 147.02 87.55 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 121.408 1.405 . . . . 0.0 110.947 170.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 77.04 15.39 81.69 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 125.051 1.31 . . . . 0.0 112.838 -176.326 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 98.7 m -87.78 117.48 26.65 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 119.956 1.878 . . . . 0.0 107.421 177.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -57.86 135.48 56.86 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 171.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -43.88 -36.95 2.59 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 123.389 0.676 . . . . 0.0 112.154 170.421 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.408 ' HZ1' ' CG ' ' A' ' 32' ' ' ASP . 19.7 pttp -66.51 -39.98 88.96 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 118.017 -1.473 . . . . 0.0 110.066 -178.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.408 ' CG ' ' HZ1' ' A' ' 31' ' ' LYS . 82.6 m-20 -80.04 -12.86 59.66 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 125.718 1.607 . . . . 0.0 110.741 -172.617 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 22.5 mt -56.36 132.8 76.24 Favored Pre-proline 0 N--CA 1.444 -0.752 0 CA-C-O 118.356 -0.831 . . . . 0.0 108.949 174.221 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -54.89 136.26 71.53 Favored 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 124.152 3.235 . . . . 0.0 110.551 176.555 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.73 -18.44 63.52 Favored 'General case' 0 CA--C 1.533 0.296 0 O-C-N 121.352 -0.843 . . . . 0.0 111.319 -179.482 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -76.55 -11.48 59.88 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 125.876 1.67 . . . . 0.0 112.104 171.092 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -71.65 149.77 45.24 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 119.07 0.85 . . . . 0.0 110.526 176.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 2.1 m -128.39 153.45 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 C-N-CA 126.082 1.753 . . . . 0.0 109.881 -175.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 8.2 t -73.71 138.48 77.05 Favored Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 123.658 0.783 . . . . 0.0 111.042 -175.079 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -58.64 127.53 24.88 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 123.416 2.744 . . . . 0.0 111.77 -177.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 24.5 mt 54.65 34.89 22.5 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.688 1.195 . . . . 0.0 111.857 -179.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.1 t -131.93 -176.22 3.99 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -139.01 47.57 0.91 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.036 -0.825 . . . . 0.0 111.036 -175.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -155.65 156.98 4.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 177.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.78 -179.6 50.03 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 178.405 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.8 ptmt -62.69 -19.56 64.0 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 170.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 29.26 -94.42 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 129.408 3.083 . . . . 0.0 111.529 -176.258 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.1 mm-40 -145.91 69.93 1.23 Allowed 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 164.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.4 m-30 -47.73 156.26 0.33 Allowed 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 125.656 1.582 . . . . 0.0 110.375 169.18 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -94.82 147.46 23.32 Favored 'General case' 0 C--O 1.225 -0.236 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -172.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -75.05 143.9 43.26 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 118.726 0.693 . . . . 0.0 109.198 -179.308 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 11.0 t -107.95 110.88 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 C-N-CA 126.121 1.768 . . . . 0.0 106.494 177.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -76.03 55.29 0.91 Allowed 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 125.454 1.502 . . . . 0.0 113.272 -177.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 117.231 -1.366 . . . . 0.0 108.085 158.569 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 56.4 mttm . . . . . 0 N--CA 1.451 -0.399 0 N-CA-C 113.351 0.871 . . . . 0.0 113.351 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -77.71 163.65 25.97 Favored 'General case' 0 N--CA 1.447 -0.591 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.201 -179.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 23.6 m-85 -144.55 146.69 32.49 Favored 'General case' 0 CA--C 1.528 0.124 0 CA-C-O 119.046 -0.502 . . . . 0.0 110.732 176.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.5 t -99.0 143.48 29.24 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 174.251 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 48.9 t -82.65 120.23 25.3 Favored 'General case' 0 C--N 1.344 0.346 0 C-N-CA 126.678 1.991 . . . . 0.0 109.963 177.745 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 20.2 m -41.6 -76.18 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 127.617 2.367 . . . . 0.0 114.063 -175.256 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.2 p -99.7 48.5 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 O-C-N 121.233 -0.917 . . . . 0.0 109.653 -168.024 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 46.6 t -160.95 -60.95 0.06 Allowed 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -160.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.7 -13.48 63.9 Favored Glycine 0 CA--C 1.53 1.007 0 CA-C-O 119.025 -0.875 . . . . 0.0 113.137 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -59.19 143.32 49.33 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 119.42 1.61 . . . . 0.0 109.902 173.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 18.2 mt -112.04 121.22 64.07 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 123.89 0.876 . . . . 0.0 109.148 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 68.3 t80 -80.93 140.76 35.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 172.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 64.9 t-20 -124.68 120.1 25.79 Favored Pre-proline 0 C--O 1.224 -0.278 0 C-N-CA 124.252 1.021 . . . . 0.0 109.732 177.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -68.65 -40.49 7.35 Favored 'Trans proline' 0 N--CA 1.442 -1.507 0 C-N-CA 120.697 0.932 . . . . 0.0 112.122 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -60.4 -31.05 70.0 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 119.155 0.889 . . . . 0.0 110.95 -177.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.2 m-20 -90.11 -29.52 18.27 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.336 0.655 . . . . 0.0 109.967 177.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.48 -160.05 40.86 Favored Glycine 0 CA--C 1.529 0.951 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -165.615 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -139.64 62.43 23.17 Favored Pre-proline 0 CA--C 1.538 0.498 0 C-N-CA 125.181 1.393 . . . . 0.0 107.679 169.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -61.64 -32.12 86.99 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.345 2.03 . . . . 0.0 111.137 -171.244 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -57.05 -31.69 65.44 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.898 1.279 . . . . 0.0 110.587 178.39 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -95.43 -32.7 12.78 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.15 1.38 . . . . 0.0 110.483 -178.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.83 14.67 0.66 Allowed Glycine 0 CA--C 1.531 1.08 0 C-N-CA 124.053 0.835 . . . . 0.0 114.108 170.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.6 t -112.9 112.7 41.54 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.264 0 CA-C-N 118.808 1.304 . . . . 0.0 109.053 -176.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -64.58 155.94 79.62 Favored Pre-proline 0 C--N 1.328 -0.338 0 O-C-N 121.967 -0.458 . . . . 0.0 111.116 -177.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.64 148.29 88.27 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 121.569 1.513 . . . . 0.0 110.981 171.489 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.94 17.25 79.34 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 125.296 1.427 . . . . 0.0 112.662 -175.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 93.3 m -87.76 117.65 26.73 Favored 'General case' 0 N--CA 1.442 -0.875 0 CA-C-N 119.838 1.819 . . . . 0.0 107.59 176.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -58.1 134.35 56.37 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.401 171.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -40.47 -40.08 1.14 Allowed 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 123.901 0.88 . . . . 0.0 112.415 169.069 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.2 pttp -68.48 -38.29 80.9 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 118.295 -1.362 . . . . 0.0 109.973 -176.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -78.34 -15.62 58.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.805 1.642 . . . . 0.0 110.3 -174.358 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 19.4 mt -54.97 133.9 67.42 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-O 118.389 -0.815 . . . . 0.0 109.308 174.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_exo -57.69 137.3 80.53 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 123.597 2.865 . . . . 0.0 110.883 176.18 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -66.03 -18.43 65.33 Favored 'General case' 0 N--CA 1.45 -0.459 0 O-C-N 121.299 -0.875 . . . . 0.0 111.426 176.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -82.93 -6.21 59.37 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.563 1.545 . . . . 0.0 111.944 173.699 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 71.0 t90 -69.94 160.43 31.89 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 119.053 0.842 . . . . 0.0 110.093 172.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -139.5 150.17 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 C-N-CA 125.585 1.554 . . . . 0.0 108.465 176.656 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.4 p -83.68 165.27 40.75 Favored Pre-proline 0 CA--C 1.539 0.557 0 N-CA-C 108.785 -0.821 . . . . 0.0 108.785 -179.182 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.51 124.13 9.61 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 121.301 1.334 . . . . 0.0 110.842 -168.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 12.6 mt 66.29 44.17 2.56 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 125.258 1.423 . . . . 0.0 112.201 172.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.3 t -138.45 179.63 6.35 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.913 0.885 . . . . 0.0 108.818 -177.345 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -100.98 -87.81 1.99 Allowed Glycine 0 CA--C 1.526 0.72 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 178.047 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.6 p -82.99 102.2 8.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 178.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -108.54 145.82 16.44 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 108.751 -1.74 . . . . 0.0 108.751 176.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER 59.5 101.78 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.42 1.488 . . . . 0.0 111.749 -170.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -138.8 -75.73 0.37 Allowed 'General case' 0 CA--C 1.521 -0.139 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 160.341 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 10.3 tm0? -144.69 55.34 1.25 Allowed 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 124.739 1.216 . . . . 0.0 107.846 -174.575 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 4.1 m-30 -55.51 150.99 11.09 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 125.059 1.343 . . . . 0.0 108.894 175.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -87.39 150.86 23.53 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.491 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -78.83 145.84 34.04 Favored 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 123.676 0.791 . . . . 0.0 109.088 179.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 14.5 t -110.84 111.44 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 C-N-CA 126.622 1.969 . . . . 0.0 107.081 174.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -71.86 67.09 0.59 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.305 1.842 . . . . 0.0 113.116 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 . . . . . 0 C--O 1.255 1.372 0 CA-C-O 117.86 -1.067 . . . . 0.0 111.098 164.514 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 7.9 mttm . . . . . 0 N--CA 1.449 -0.519 0 CA-C-O 121.61 0.719 . . . . 0.0 111.586 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 78.7 mttt -73.9 174.6 8.29 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 124.907 1.283 . . . . 0.0 109.46 174.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -144.32 131.03 20.13 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-O 118.831 -0.604 . . . . 0.0 111.628 176.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.6 m -79.87 143.72 34.07 Favored 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 123.872 0.869 . . . . 0.0 110.811 174.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 9.0 t -70.43 -175.68 1.07 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.209 1.404 . . . . 0.0 109.569 168.014 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 63.5 m -82.29 -99.26 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 123.688 0.795 . . . . 0.0 110.06 -176.612 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.8 p -87.33 -30.69 5.76 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 O-C-N 120.967 -1.083 . . . . 0.0 110.85 -178.071 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 50.8 t -39.62 -55.48 1.86 Allowed 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 128.931 2.892 . . . . 0.0 112.365 175.247 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 100.91 -15.06 58.48 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-O 119.043 -0.865 . . . . 0.0 113.279 177.404 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -62.38 159.32 15.57 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.307 1.553 . . . . 0.0 111.574 176.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 28.7 mt -123.4 124.94 70.87 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 C-N-CA 125.227 1.411 . . . . 0.0 107.282 175.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 72.5 t80 -78.28 135.38 37.53 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 167.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -118.01 116.75 35.83 Favored Pre-proline 0 C--O 1.225 -0.204 0 C-N-CA 124.24 1.016 . . . . 0.0 109.948 175.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -64.82 -42.57 14.66 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 121.927 1.751 . . . . 0.0 111.793 -178.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -61.98 -28.61 69.68 Favored 'General case' 0 N--CA 1.446 -0.658 0 O-C-N 123.27 0.356 . . . . 0.0 110.862 -174.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -90.63 -31.62 16.58 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.997 0.919 . . . . 0.0 110.399 174.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.98 -162.07 31.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.289 0.947 . . . . 0.0 110.984 -165.177 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -137.94 62.27 32.58 Favored Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 125.894 1.678 . . . . 0.0 107.485 171.878 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.1 -33.32 82.66 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 122.75 2.3 . . . . 0.0 111.28 -170.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -56.79 -28.99 62.25 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.674 1.189 . . . . 0.0 110.738 178.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.6 m-80 -102.11 -26.47 13.35 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 125.607 1.563 . . . . 0.0 110.684 -175.516 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.81 6.86 1.68 Allowed Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.167 0.889 . . . . 0.0 113.786 168.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 75.7 t -107.58 109.87 29.77 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.156 0 CA-C-N 118.595 1.198 . . . . 0.0 108.509 -174.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.87 155.97 81.25 Favored Pre-proline 0 C--N 1.329 -0.321 0 O-C-N 121.734 -0.604 . . . . 0.0 111.086 -176.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.32 147.68 89.91 Favored 'Trans proline' 0 N--CA 1.449 -1.102 0 C-N-CA 121.496 1.464 . . . . 0.0 111.032 171.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.28 14.98 81.8 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.682 -176.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 99.2 m -86.67 113.72 22.77 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 119.798 1.799 . . . . 0.0 107.546 178.042 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -53.4 133.26 40.44 Favored 'General case' 0 N--CA 1.446 -0.654 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 167.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 5.1 t80 -45.2 -31.84 1.64 Allowed 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 173.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 7.3 pttt -68.57 -45.65 71.49 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 118.398 -1.321 . . . . 0.0 110.065 179.538 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -67.58 -19.51 65.27 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 125.58 1.552 . . . . 0.0 111.222 -175.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 15.2 mt -53.29 131.37 52.27 Favored Pre-proline 0 N--CA 1.443 -0.812 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 176.089 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_endo -61.96 140.34 84.21 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 122.393 2.062 . . . . 0.0 109.455 -178.432 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -67.35 -14.38 62.87 Favored 'General case' 0 CA--C 1.535 0.373 0 O-C-N 121.968 -0.457 . . . . 0.0 111.87 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -75.34 -15.07 60.51 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.491 0.716 . . . . 0.0 112.204 171.545 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 85.5 t90 -73.7 151.8 40.62 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 176.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 12.1 p -141.29 164.61 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 C-N-CA 124.927 1.291 . . . . 0.0 107.777 -177.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.3 t -48.79 138.86 12.17 Favored Pre-proline 0 CA--C 1.54 0.561 0 C-N-CA 124.391 1.076 . . . . 0.0 110.111 176.606 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -59.89 -36.88 89.11 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.323 2.015 . . . . 0.0 112.881 -173.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 41.0 mt -136.95 42.11 2.45 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.301 0.641 . . . . 0.0 110.096 -175.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -164.71 173.68 11.59 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 -174.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -133.35 67.84 0.55 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 -174.14 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.7 p -128.92 141.42 46.66 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 172.289 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.38 147.84 49.18 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 6.2 ptmt -60.19 -38.52 83.52 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 117.226 0.513 . . . . 0.0 111.549 -179.472 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -72.35 71.63 0.91 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 124.295 1.038 . . . . 0.0 109.682 178.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 4.0 tp-100 -171.92 -38.66 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 125.728 1.611 . . . . 0.0 109.666 -175.524 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -57.84 137.21 56.86 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.048 0.939 . . . . 0.0 109.636 -176.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -96.01 149.49 21.52 Favored 'General case' 0 C--O 1.22 -0.496 0 C-N-CA 124.627 1.171 . . . . 0.0 109.364 -175.104 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -71.93 138.49 48.14 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 119.883 1.219 . . . . 0.0 110.039 -178.381 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.3 t -101.2 107.86 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 C-N-CA 125.467 1.507 . . . . 0.0 107.08 177.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -72.06 65.95 0.59 Allowed 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 126.348 1.859 . . . . 0.0 113.397 -177.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 . . . . . 0 C--O 1.257 1.467 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 150.768 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 9.6 mttm . . . . . 0 N--CA 1.448 -0.531 0 CA-C-O 121.449 0.643 . . . . 0.0 111.494 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 58.2 mttt -71.02 171.33 11.05 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 124.678 1.191 . . . . 0.0 109.862 172.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -141.69 134.35 28.48 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 172.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.5 t -85.8 154.53 21.52 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 118.312 0.506 . . . . 0.0 111.282 174.281 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 19.9 t -75.01 170.2 16.48 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 125.15 1.38 . . . . 0.0 107.852 172.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 6.9 t -125.72 16.7 8.09 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.063 0.945 . . . . 0.0 110.497 177.248 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 74.1 t -132.5 -60.54 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.34 0.179 0 C-N-CA 123.932 0.893 . . . . 0.0 109.52 -179.1 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.6 p -95.92 -89.31 0.26 Allowed 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 176.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 164.12 28.95 0.02 OUTLIER Glycine 0 CA--C 1.529 0.94 0 C-N-CA 125.487 1.518 . . . . 0.0 110.638 176.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -80.73 73.66 7.69 Favored 'General case' 0 N--CA 1.453 -0.322 0 O-C-N 121.819 -0.812 . . . . 0.0 108.83 -170.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.0 mt -45.35 112.52 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 C-N-CA 123.33 0.652 . . . . 0.0 110.978 -178.484 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 35.7 t80 -73.53 134.44 43.82 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 173.041 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 46.3 t-20 -123.07 114.63 29.35 Favored Pre-proline 0 N--CA 1.446 -0.652 0 C-N-CA 123.437 0.695 . . . . 0.0 109.387 176.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -65.36 -43.77 10.21 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 122.317 2.012 . . . . 0.0 111.327 -177.256 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -56.84 -29.39 62.79 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 123.636 0.774 . . . . 0.0 111.226 -176.679 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -100.45 -23.41 14.74 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.879 0.872 . . . . 0.0 110.455 179.033 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.11 -160.59 30.73 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 124.829 1.204 . . . . 0.0 110.983 -172.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -140.34 61.4 16.69 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 125.281 1.432 . . . . 0.0 107.497 171.719 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_endo -62.38 -30.86 81.14 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 122.199 1.933 . . . . 0.0 111.076 -172.009 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -59.02 -29.65 67.43 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 124.463 1.105 . . . . 0.0 110.337 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -98.81 -29.29 13.06 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 125.544 1.537 . . . . 0.0 110.964 -177.154 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.36 18.24 0.93 Allowed Glycine 0 CA--C 1.532 1.15 0 C-N-CA 124.249 0.928 . . . . 0.0 113.798 170.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.2 t -117.26 110.02 29.71 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.216 0 CA-C-N 118.334 1.067 . . . . 0.0 108.443 -175.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -63.36 155.76 73.14 Favored Pre-proline 0 CA--C 1.534 0.337 0 O-C-N 121.835 -0.541 . . . . 0.0 110.976 -177.253 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -60.54 149.37 87.16 Favored 'Trans proline' 0 N--CA 1.449 -1.129 0 C-N-CA 121.464 1.443 . . . . 0.0 110.717 171.509 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.04 14.93 81.76 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 125.129 1.347 . . . . 0.0 113.047 -175.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 97.8 m -89.34 114.89 26.36 Favored 'General case' 0 N--CA 1.443 -0.815 0 CA-C-N 119.919 1.86 . . . . 0.0 107.836 178.541 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -56.17 134.72 53.15 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 169.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -42.38 -35.6 1.06 Allowed 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 123.709 0.803 . . . . 0.0 112.881 171.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 51.0 pttt -69.69 -42.48 74.05 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.625 -178.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -68.08 -21.44 64.97 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 125.658 1.583 . . . . 0.0 110.438 -176.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 21.8 mt -53.63 130.6 55.08 Favored Pre-proline 0 N--CA 1.445 -0.688 0 CA-C-N 118.758 0.708 . . . . 0.0 109.216 175.331 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -63.94 140.52 73.3 Favored 'Trans proline' 0 N--CA 1.445 -1.335 0 C-N-CA 122.479 2.12 . . . . 0.0 109.758 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -57.84 -23.22 51.78 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.537 0.735 . . . . 0.0 111.522 175.225 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.57 -18.75 63.66 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 124.745 1.218 . . . . 0.0 112.057 177.633 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 80.1 t90 -75.55 154.54 36.76 Favored 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 121.629 -0.669 . . . . 0.0 110.095 -179.563 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.1 t -139.73 149.57 22.43 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 C-N-CA 124.905 1.282 . . . . 0.0 108.569 -169.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.1 t -73.41 127.39 88.98 Favored Pre-proline 0 CA--C 1.545 0.757 0 C-N-CA 122.974 0.509 . . . . 0.0 110.879 179.153 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.43 139.76 50.41 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 123.196 2.597 . . . . 0.0 111.646 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 57.6 mt 58.56 31.94 21.6 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.54 1.136 . . . . 0.0 111.706 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 43.5 t -147.76 -57.61 0.24 Allowed 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -173.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.94 26.8 63.75 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 111.946 -0.461 . . . . 0.0 111.946 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 95.6 t -111.35 155.99 12.6 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 C-N-CA 124.341 1.056 . . . . 0.0 109.182 177.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -67.91 155.69 52.94 Favored Glycine 0 CA--C 1.528 0.867 0 C-N-CA 124.469 1.033 . . . . 0.0 111.743 -176.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.1 ptmt -67.86 -42.89 80.62 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -175.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -76.87 77.65 3.46 Favored 'General case' 0 N--CA 1.456 -0.166 0 CA-C-O 122.426 1.108 . . . . 0.0 108.879 -170.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -179.37 -30.06 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 128.582 2.753 . . . . 0.0 108.97 -168.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -57.06 141.42 45.9 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.628 0.771 . . . . 0.0 110.888 169.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -111.66 145.16 39.74 Favored 'General case' 0 C--O 1.22 -0.458 0 C-N-CA 125.08 1.352 . . . . 0.0 109.551 -177.805 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -65.62 136.34 56.2 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-N 118.778 0.717 . . . . 0.0 110.415 -176.02 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.8 t -94.74 109.53 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 175.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -69.0 82.13 0.31 Allowed 'General case' 0 N--CA 1.443 -0.796 0 C-N-CA 125.503 1.521 . . . . 0.0 110.706 175.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 . . . . . 0 C--O 1.251 1.154 0 CA-C-O 117.229 -1.367 . . . . 0.0 110.471 169.387 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 22.6 mttm . . . . . 0 N--CA 1.45 -0.431 0 CA-C-O 122.674 1.226 . . . . 0.0 112.319 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 66.2 mttt -73.61 170.65 14.76 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.439 -0.801 . . . . 0.0 109.836 -178.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.402 ' CE1' ' HB2' ' A' ' 30' ' ' PHE . 55.3 m-85 -142.07 141.64 32.77 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 122.501 0.32 . . . . 0.0 111.323 176.419 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 91.1 m -78.25 142.44 37.85 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 123.47 0.708 . . . . 0.0 109.605 172.108 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 24.8 t -79.58 135.48 36.61 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 125.071 1.348 . . . . 0.0 108.428 175.048 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.0 m -45.32 -56.79 4.55 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.496 1.519 . . . . 0.0 114.197 -168.135 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 14.5 p -153.35 35.91 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 120.939 0.399 . . . . 0.0 110.59 -173.321 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 2.8 m -121.79 -65.25 1.14 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.485 0.714 . . . . 0.0 109.188 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 116.78 56.33 0.31 Allowed Glycine 0 CA--C 1.53 0.995 0 C-N-CA 124.717 1.151 . . . . 0.0 111.948 176.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -139.18 87.66 2.22 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.457 1.103 . . . . 0.0 109.052 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.4 mt -57.23 127.13 15.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 O-C-N 121.439 -0.788 . . . . 0.0 111.035 -176.541 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.407 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 27.7 t80 -81.4 137.29 35.7 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 172.448 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 51.7 t-20 -122.55 112.44 31.02 Favored Pre-proline 0 C--N 1.339 0.136 0 C-N-CA 124.168 0.987 . . . . 0.0 109.841 175.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_endo -65.15 -37.44 32.23 Favored 'Trans proline' 0 N--CA 1.45 -1.086 0 C-N-CA 121.28 1.32 . . . . 0.0 111.51 -173.567 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -58.34 -32.09 68.2 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 117.726 0.239 . . . . 0.0 111.322 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -87.49 -32.8 19.26 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.489 0.716 . . . . 0.0 109.868 177.029 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.26 -156.41 45.16 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 -168.093 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -143.37 61.29 9.83 Favored Pre-proline 0 CA--C 1.542 0.669 0 C-N-CA 125.705 1.602 . . . . 0.0 107.442 172.26 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.01 -33.41 83.27 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.671 2.247 . . . . 0.0 111.618 -169.056 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -58.15 -30.99 66.79 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 124.688 1.195 . . . . 0.0 110.394 178.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -92.4 -29.42 16.31 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 125.245 1.418 . . . . 0.0 110.351 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.14 -4.01 3.13 Favored Glycine 0 CA--C 1.529 0.938 0 C-N-CA 124.477 1.037 . . . . 0.0 113.148 172.101 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 74.3 t -94.3 109.78 22.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -172.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -62.98 154.84 75.35 Favored Pre-proline 0 CA--C 1.534 0.354 0 O-C-N 121.767 -0.583 . . . . 0.0 110.488 -177.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -59.08 149.27 80.98 Favored 'Trans proline' 0 N--CA 1.449 -1.138 0 C-N-CA 121.123 1.215 . . . . 0.0 110.417 169.499 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.03 17.93 80.22 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 125.32 1.438 . . . . 0.0 113.3 -175.355 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 98.0 m -92.1 119.41 31.75 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-N 119.983 1.892 . . . . 0.0 107.312 177.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -65.2 142.99 58.13 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 173.168 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . 0.402 ' HB2' ' CE1' ' A' ' 4' ' ' TYR . 2.2 t80 -49.22 -33.11 11.84 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 123.639 0.775 . . . . 0.0 112.366 175.106 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 10.4 pttm -67.27 -37.17 83.01 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 119.254 -0.978 . . . . 0.0 110.926 178.291 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 -77.43 -21.0 53.7 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 124.742 1.217 . . . . 0.0 110.09 -174.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.407 HD13 ' CZ ' ' A' ' 13' ' ' TYR . 22.4 mt -55.64 133.68 71.71 Favored Pre-proline 0 N--CA 1.445 -0.693 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.214 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -59.45 134.8 60.68 Favored 'Trans proline' 0 N--CA 1.449 -1.123 0 C-N-CA 122.746 2.297 . . . . 0.0 109.374 175.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.59 -3.84 33.48 Favored 'General case' 0 N--CA 1.447 -0.577 0 O-C-N 121.632 -0.667 . . . . 0.0 112.346 -176.489 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -76.23 -12.42 60.09 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.131 0.972 . . . . 0.0 112.596 164.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 80.6 t90 -67.15 148.92 51.21 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 118.981 0.81 . . . . 0.0 111.297 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 62.7 t -125.97 144.47 35.98 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 126.732 2.013 . . . . 0.0 108.718 -175.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.8 p -82.82 132.57 51.0 Favored Pre-proline 0 CA--C 1.543 0.695 0 CA-C-N 120.038 1.29 . . . . 0.0 110.06 177.064 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -79.12 139.84 15.32 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.617 2.211 . . . . 0.0 111.066 -175.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 18.1 tp 60.37 31.87 20.5 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 124.497 1.119 . . . . 0.0 111.262 -178.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 33.3 m -125.65 -97.83 0.42 Allowed 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.977 1.311 . . . . 0.0 109.357 -179.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 143.88 114.18 0.95 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 108.325 -1.91 . . . . 0.0 108.325 -164.628 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.265 0.4 OUTLIER 76.94 -173.2 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 125.151 1.38 . . . . 0.0 110.402 -171.721 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -129.53 -123.69 2.56 Favored Glycine 0 N--CA 1.449 -0.442 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 23.4 mtpt -82.23 167.86 18.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.429 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -159.45 -75.49 0.07 Allowed 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 124.656 1.183 . . . . 0.0 108.827 172.642 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -124.06 -38.65 2.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 127.268 2.227 . . . . 0.0 109.739 -177.626 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 25.2 p90 53.15 173.47 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.235 2.214 . . . . 0.0 112.882 -176.324 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -138.72 136.55 35.91 Favored 'General case' 0 CA--C 1.521 -0.155 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 172.491 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -74.22 137.27 42.95 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 176.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.6 t -97.59 113.97 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.823 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 175.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -74.09 51.56 0.42 Allowed 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.3 1.44 . . . . 0.0 114.113 -178.499 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 28.9 mt-10 . . . . . 0 C--O 1.253 1.288 0 C-N-CA 125.921 1.688 . . . . 0.0 107.587 157.143 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 33.2 mttt . . . . . 0 N--CA 1.451 -0.403 0 N-CA-C 113.408 0.892 . . . . 0.0 113.408 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -70.67 162.61 28.69 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.54 178.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -144.99 137.18 25.92 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 124.248 1.019 . . . . 0.0 111.423 -178.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.8 m -75.92 155.59 35.01 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.232 1.013 . . . . 0.0 110.975 173.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 15.3 t -97.49 -37.49 9.95 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.236 1.814 . . . . 0.0 109.3 174.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 86.1 m 76.14 -62.46 0.43 Allowed 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 125.455 1.502 . . . . 0.0 112.016 166.407 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 31.2 m -78.79 43.72 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-N 119.284 0.947 . . . . 0.0 110.656 178.001 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 10.4 t 177.05 -102.49 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -156.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 121.21 64.77 0.24 Allowed Glycine 0 CA--C 1.53 0.974 0 C-N-CA 125.302 1.43 . . . . 0.0 111.035 -176.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -114.51 -57.55 2.26 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.301 1.04 . . . . 0.0 111.055 176.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . 0.251 57.8 mt 79.84 110.73 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 C-N-CA 127.548 2.339 . . . . 0.0 110.997 -170.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 51.6 t80 -74.23 141.6 45.4 Favored 'General case' 0 C--O 1.236 0.357 0 C-N-CA 124.203 1.001 . . . . 0.0 108.859 171.055 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 63.9 t-20 -126.57 116.57 22.88 Favored Pre-proline 0 C--O 1.224 -0.289 0 C-N-CA 123.488 0.715 . . . . 0.0 110.9 173.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -68.25 -41.46 6.97 Favored 'Trans proline' 0 N--CA 1.445 -1.369 0 C-N-CA 121.13 1.22 . . . . 0.0 112.042 -177.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -60.05 -30.9 69.5 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 118.706 0.684 . . . . 0.0 110.855 -178.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 -86.62 -32.71 20.45 Favored 'General case' 0 CA--C 1.53 0.192 0 C-N-CA 123.406 0.682 . . . . 0.0 109.512 176.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.89 -159.86 42.71 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -164.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -137.56 61.79 32.67 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 168.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -61.74 -38.22 62.12 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.11 2.54 . . . . 0.0 111.257 -167.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -51.02 -30.35 15.13 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.769 1.628 . . . . 0.0 110.825 177.145 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -101.48 -18.12 16.12 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 125.818 1.647 . . . . 0.0 110.976 -175.159 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 130.56 -5.18 5.87 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.583 1.087 . . . . 0.0 113.324 172.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 78.6 t -100.22 108.7 23.42 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.202 0 CA-C-N 118.2 1.0 . . . . 0.0 109.103 -171.658 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -64.73 155.16 83.31 Favored Pre-proline 0 CA--C 1.533 0.305 0 O-C-N 121.767 -0.583 . . . . 0.0 111.072 -175.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -57.95 147.64 80.81 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 121.322 1.348 . . . . 0.0 110.723 170.564 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 71.51 21.68 78.69 Favored Glycine 0 CA--C 1.525 0.714 0 C-N-CA 125.653 1.596 . . . . 0.0 112.945 -174.272 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.9 m -91.75 121.92 33.83 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 119.994 1.897 . . . . 0.0 107.818 174.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -63.87 137.87 58.23 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 174.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -42.95 -38.37 2.2 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.167 0.987 . . . . 0.0 111.733 170.277 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . 0.445 ' HZ1' ' CG ' ' A' ' 32' ' ' ASP . 20.6 pttp -67.26 -39.73 86.14 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 118.572 -1.251 . . . . 0.0 110.493 -179.448 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.445 ' CG ' ' HZ1' ' A' ' 31' ' ' LYS . 81.9 m-20 -82.54 -11.45 58.43 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 125.906 1.683 . . . . 0.0 110.716 -172.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 19.6 mt -54.53 133.16 63.54 Favored Pre-proline 0 N--CA 1.441 -0.878 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 171.653 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -53.83 134.53 59.42 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 123.785 2.99 . . . . 0.0 109.432 176.059 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.39 -11.2 60.0 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.146 -0.972 . . . . 0.0 111.705 -175.299 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -78.01 -10.1 59.44 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 126.493 1.917 . . . . 0.0 112.181 167.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 78.3 t90 -66.97 158.14 31.61 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 119.089 0.859 . . . . 0.0 109.971 173.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.8 p -136.52 155.09 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 124.712 1.205 . . . . 0.0 108.71 -176.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.6 t -56.4 136.02 76.26 Favored Pre-proline 0 CA--C 1.534 0.339 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -58.59 -28.98 87.73 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 123.045 2.496 . . . . 0.0 113.214 -174.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.6 tp -150.8 51.5 0.86 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 118.72 0.691 . . . . 0.0 111.075 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . 0.258 1.7 p -142.84 -64.68 0.4 Allowed 'General case' 0 N--CA 1.464 0.266 0 O-C-N 122.053 -0.405 . . . . 0.0 110.552 159.715 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 142.87 -136.33 7.04 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 -179.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.4 t 61.77 -83.65 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 C-N-CA 126.097 1.759 . . . . 0.0 112.352 173.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.58 -139.28 6.76 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -170.02 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 48.4 mtpt -113.77 93.75 4.52 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 124.925 1.29 . . . . 0.0 108.608 174.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 55.6 p-10 -144.72 169.73 17.45 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 170.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER 36.93 47.02 0.54 Allowed 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 127.218 2.207 . . . . 0.0 113.324 -177.377 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 21.3 p90 -95.29 113.79 25.51 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.372 0.669 . . . . 0.0 110.053 179.628 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -98.33 149.4 22.67 Favored 'General case' 0 C--O 1.223 -0.31 0 C-N-CA 125.77 1.628 . . . . 0.0 108.726 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -79.72 142.02 35.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 120.273 1.397 . . . . 0.0 110.031 -178.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.2 t -105.98 109.64 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 126.35 1.86 . . . . 0.0 107.376 176.248 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -72.63 66.55 0.73 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.994 1.718 . . . . 0.0 113.131 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 . . . . . 0 C--O 1.256 1.435 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.241 158.845 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.6 mttm . . . . . 0 N--CA 1.451 -0.42 0 CA-C-O 122.072 0.939 . . . . 0.0 112.432 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -78.39 166.76 22.26 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.236 -174.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -151.62 150.39 30.23 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 123.367 0.667 . . . . 0.0 112.409 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.5 m -78.28 156.24 29.77 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 123.876 0.87 . . . . 0.0 112.355 171.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 34.0 t -70.93 166.71 20.62 Favored 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 125.026 1.33 . . . . 0.0 108.768 166.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 5.4 m -45.16 -41.88 8.51 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 126.463 1.905 . . . . 0.0 112.302 170.208 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.3 p -160.98 -32.74 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 113.53 0.937 . . . . 0.0 113.53 -172.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.9 p -77.58 172.46 13.33 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 120.213 1.369 . . . . 0.0 110.58 -177.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -89.5 51.69 3.65 Favored Glycine 0 CA--C 1.527 0.83 0 O-C-N 121.318 -0.864 . . . . 0.0 111.732 -176.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -125.84 86.73 2.57 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 118.25 1.025 . . . . 0.0 110.445 -177.557 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 15.9 mt -67.63 127.26 28.97 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 O-C-N 121.73 -0.607 . . . . 0.0 109.605 174.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 40.0 t80 -78.48 136.94 37.71 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 170.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.6 t-20 -122.19 113.11 31.24 Favored Pre-proline 0 C--O 1.227 -0.123 0 C-N-CA 124.312 1.045 . . . . 0.0 110.34 177.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -65.33 -38.98 24.24 Favored 'Trans proline' 0 N--CA 1.445 -1.359 0 C-N-CA 120.97 1.114 . . . . 0.0 112.246 -177.133 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -59.74 -32.13 70.28 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 118.562 0.619 . . . . 0.0 111.102 -178.054 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -88.06 -32.02 18.97 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 123.471 0.709 . . . . 0.0 109.75 178.083 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.1 -158.62 37.85 Favored Glycine 0 CA--C 1.529 0.952 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 -165.35 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.76 61.69 11.32 Favored Pre-proline 0 CA--C 1.54 0.595 0 C-N-CA 125.955 1.702 . . . . 0.0 107.113 171.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -61.11 -33.86 90.51 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.572 2.181 . . . . 0.0 111.045 -170.227 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -54.58 -30.61 54.83 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 125.294 1.437 . . . . 0.0 110.736 178.175 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -102.97 -23.03 13.73 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 125.432 1.493 . . . . 0.0 110.778 -174.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 132.42 11.05 2.02 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 124.287 0.946 . . . . 0.0 113.401 169.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 70.6 t -110.3 108.76 26.23 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 CA-C-N 118.544 1.172 . . . . 0.0 108.762 -175.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -63.1 155.04 75.25 Favored Pre-proline 0 CA--C 1.535 0.379 0 O-C-N 121.662 -0.649 . . . . 0.0 110.876 -178.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.79 148.78 86.8 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 121.118 1.212 . . . . 0.0 110.719 170.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.46 17.0 78.81 Favored Glycine 0 CA--C 1.526 0.73 0 C-N-CA 125.256 1.408 . . . . 0.0 112.963 -174.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 54.1 m -88.6 122.01 31.59 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 119.797 1.798 . . . . 0.0 107.977 178.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -63.88 135.56 56.66 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 171.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -40.39 -41.63 1.42 Allowed 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.4 0.68 . . . . 0.0 111.634 167.348 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.3 pttt -66.91 -34.74 78.44 Favored 'General case' 0 CA--C 1.536 0.429 0 O-C-N 120.241 -1.537 . . . . 0.0 110.823 -178.381 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -76.49 -22.1 54.94 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 125.13 1.372 . . . . 0.0 109.801 -177.64 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 15.8 mt -55.85 134.31 72.95 Favored Pre-proline 0 N--CA 1.445 -0.693 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_endo -62.05 137.3 66.0 Favored 'Trans proline' 0 N--CA 1.443 -1.443 0 C-N-CA 121.755 1.637 . . . . 0.0 108.889 176.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -72.46 -3.35 23.81 Favored 'General case' 0 N--CA 1.444 -0.741 0 O-C-N 121.914 -0.491 . . . . 0.0 111.908 -179.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.06 -23.16 64.01 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 125.509 1.524 . . . . 0.0 112.315 164.179 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 84.6 t90 -70.56 152.43 43.96 Favored 'General case' 0 CA--C 1.53 0.176 0 O-C-N 121.628 -0.67 . . . . 0.0 110.855 -176.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.6 t -139.24 151.8 23.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 C-N-CA 125.901 1.68 . . . . 0.0 107.441 -173.288 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 9.8 t -54.12 133.14 59.75 Favored Pre-proline 0 CA--C 1.541 0.632 0 C-N-CA 125.557 1.543 . . . . 0.0 110.119 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -59.19 -52.49 4.86 Favored 'Trans proline' 0 N--CA 1.459 -0.546 0 C-N-CA 123.674 2.916 . . . . 0.0 113.699 -166.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 96.1 mt -128.68 59.92 1.53 Allowed 'General case' 0 N--CA 1.462 0.135 0 C-N-CA 123.68 0.792 . . . . 0.0 109.541 -173.2 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -162.9 -66.79 0.05 OUTLIER 'General case' 0 CA--C 1.529 0.158 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 -171.637 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 101.1 51.76 1.13 Allowed Glycine 0 CA--C 1.528 0.879 0 C-N-CA 123.641 0.638 . . . . 0.0 112.493 175.21 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 34.7 m -125.56 152.92 32.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 C-N-CA 123.953 0.901 . . . . 0.0 108.91 168.002 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.12 -175.59 44.97 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 110.81 -0.916 . . . . 0.0 110.81 175.334 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 41.2 mtpt -78.41 84.43 4.57 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 122.931 0.492 . . . . 0.0 109.824 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -139.28 150.73 45.79 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.502 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.4 tp-100 48.32 55.82 8.3 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.993 2.117 . . . . 0.0 112.17 175.003 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -103.24 115.88 31.41 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.746 0.818 . . . . 0.0 110.077 -179.254 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -86.24 146.36 26.57 Favored 'General case' 0 C--O 1.226 -0.175 0 C-N-CA 125.431 1.492 . . . . 0.0 109.206 178.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -81.42 141.82 33.56 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 119.089 0.859 . . . . 0.0 109.36 -179.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.4 t -109.03 102.49 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.837 0 C-N-CA 127.109 2.164 . . . . 0.0 107.757 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -76.59 76.36 3.28 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 126.207 1.803 . . . . 0.0 112.682 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 51.2 mm-40 . . . . . 0 C--O 1.255 1.392 0 CA-C-O 116.671 -1.633 . . . . 0.0 108.414 153.42 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.3 mttm . . . . . 0 N--CA 1.455 -0.203 0 CA-C-O 121.568 0.699 . . . . 0.0 111.394 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -75.33 168.27 20.32 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 124.213 1.005 . . . . 0.0 108.567 174.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 29.4 m-85 -144.62 139.12 27.86 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-O 118.899 -0.572 . . . . 0.0 112.306 -179.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.8 m -87.1 137.78 32.06 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 119.175 0.898 . . . . 0.0 111.298 178.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 40.8 t -62.73 149.7 43.14 Favored 'General case' 0 C--N 1.34 0.171 0 CA-C-N 118.699 0.682 . . . . 0.0 109.708 174.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 58.1 m -43.05 -36.67 1.68 Allowed 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 125.477 1.511 . . . . 0.0 112.113 172.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 m -129.71 -40.76 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 123.368 0.667 . . . . 0.0 112.46 178.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 m -76.79 160.65 29.11 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.346 0.976 . . . . 0.0 112.413 -171.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -99.38 12.59 61.67 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 119.222 -0.766 . . . . 0.0 112.406 174.106 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 38.8 m-85 -60.58 -43.91 96.81 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 118.873 1.336 . . . . 0.0 111.308 -175.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.7 mt 69.64 113.01 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 C-N-CA 126.137 1.775 . . . . 0.0 111.368 -177.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' TYR . . . . . 0.405 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 80.4 t80 -69.62 132.49 46.28 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 171.109 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -120.35 113.23 33.88 Favored Pre-proline 0 N--CA 1.456 -0.168 0 C-N-CA 124.205 1.002 . . . . 0.0 109.685 177.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -59.67 -42.19 49.0 Favored 'Trans proline' 0 N--CA 1.45 -1.045 0 C-N-CA 122.017 1.811 . . . . 0.0 112.443 -176.561 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -59.64 -31.41 69.5 Favored 'General case' 0 N--CA 1.447 -0.606 0 O-C-N 123.108 0.255 . . . . 0.0 111.653 -178.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 -90.09 -29.59 18.24 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 123.304 0.641 . . . . 0.0 110.422 177.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.79 -154.99 42.38 Favored Glycine 0 CA--C 1.53 1.029 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -167.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -146.34 61.33 6.95 Favored Pre-proline 0 CA--C 1.543 0.702 0 C-N-CA 125.595 1.558 . . . . 0.0 107.842 173.558 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -61.33 -34.53 87.17 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 122.944 2.429 . . . . 0.0 111.599 -168.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -54.64 -29.88 53.55 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 125.253 1.421 . . . . 0.0 111.38 177.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -98.03 -33.98 10.97 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 125.493 1.517 . . . . 0.0 109.774 -177.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 141.27 11.51 0.56 Allowed Glycine 0 CA--C 1.532 1.132 0 C-N-CA 123.933 0.778 . . . . 0.0 114.06 169.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 52.2 t -107.61 112.73 41.35 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.245 0 CA-C-N 119.174 1.487 . . . . 0.0 108.947 -177.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -65.05 153.79 88.19 Favored Pre-proline 0 C--N 1.329 -0.283 0 O-C-N 122.016 -0.428 . . . . 0.0 110.406 -179.367 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -59.22 146.77 93.5 Favored 'Trans proline' 0 N--CA 1.449 -1.113 0 C-N-CA 121.631 1.554 . . . . 0.0 110.955 172.185 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 78.03 18.01 77.43 Favored Glycine 0 CA--C 1.524 0.642 0 CA-C-O 118.553 -1.137 . . . . 0.0 112.764 -177.159 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 83.0 m -89.96 120.84 31.52 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 119.577 1.689 . . . . 0.0 107.678 177.133 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -57.55 133.55 55.35 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 169.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -48.43 -32.27 7.45 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.753 174.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -68.73 -40.89 79.67 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 119.375 -0.93 . . . . 0.0 109.345 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -75.36 -15.32 60.48 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 125.546 1.539 . . . . 0.0 110.494 -172.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.405 HD13 ' CZ ' ' A' ' 13' ' ' TYR . 12.9 mt -55.94 132.17 73.59 Favored Pre-proline 0 N--CA 1.441 -0.891 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 172.427 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -63.41 140.2 75.09 Favored 'Trans proline' 0 N--CA 1.443 -1.486 0 C-N-CA 122.633 2.222 . . . . 0.0 109.042 178.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.37 -18.12 57.23 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 122.555 0.342 . . . . 0.0 111.224 177.243 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.25 -18.53 62.44 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.784 1.234 . . . . 0.0 112.076 176.357 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 73.3 t90 -68.76 159.47 32.24 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 121.668 0.747 . . . . 0.0 110.943 -178.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 15.9 m -136.51 151.4 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.796 0 C-N-CA 125.66 1.584 . . . . 0.0 109.279 -171.294 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.3 t -72.31 135.75 81.83 Favored Pre-proline 0 CA--C 1.537 0.472 0 C-N-CA 124.428 1.091 . . . . 0.0 108.886 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.58 131.7 30.55 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 122.173 1.916 . . . . 0.0 110.058 179.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 57.1 mt 56.97 49.46 13.89 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.544 0.738 . . . . 0.0 110.991 176.363 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 53.8 t -163.58 -176.62 4.77 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 127.877 2.471 . . . . 0.0 105.092 -174.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.71 -100.35 0.56 Allowed Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.161 0.886 . . . . 0.0 111.08 178.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.3 m -142.35 160.13 19.64 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.117 0 C-N-CA 123.93 0.892 . . . . 0.0 108.687 -177.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 142.84 149.05 5.06 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 177.165 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.8 ptmt -161.75 -177.58 5.96 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 125.291 1.436 . . . . 0.0 107.447 169.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 t0 69.59 -63.24 0.39 Allowed 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 126.992 2.117 . . . . 0.0 111.817 169.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 38.5 tt0 -56.73 -22.68 37.08 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.707 2.003 . . . . 0.0 113.188 174.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 6.0 m-30 -45.18 143.95 1.48 Allowed 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.865 1.666 . . . . 0.0 109.494 170.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -75.16 155.39 37.01 Favored 'General case' 0 C--O 1.224 -0.263 0 CA-C-N 119.429 1.013 . . . . 0.0 108.555 -177.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -83.03 133.87 35.06 Favored 'General case' 0 N--CA 1.442 -0.837 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 173.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 13.4 t -93.51 116.59 35.04 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.983 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 172.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -70.96 56.88 0.2 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.683 1.993 . . . . 0.0 114.491 -177.454 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 . . . . . 0 C--O 1.255 1.352 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 159.832 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.379 20.6 ptm . . . . . 0 N--CA 1.475 0.813 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 21.4 mttm 58.72 167.41 0.05 Allowed 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 125.885 1.674 . . . . 0.0 112.77 -165.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.4 mtpt -74.0 170.39 15.52 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.734 -178.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 38.2 m-85 -146.89 147.18 30.53 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 122.863 0.465 . . . . 0.0 110.648 -177.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 51.4 p -64.95 165.61 10.57 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 120.644 0.259 . . . . 0.0 111.075 167.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 4.4 t -68.77 -97.56 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 105.97 -1.863 . . . . 0.0 105.97 159.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.5 t -172.95 -41.65 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.578 1.951 . . . . 0.0 107.133 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 9.8 p -147.79 -38.62 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 114.495 1.294 . . . . 0.0 114.495 176.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 13.6 p -64.97 -41.47 95.41 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 120.345 1.43 . . . . 0.0 111.282 -170.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 109.39 47.67 0.85 Allowed Glycine 0 CA--C 1.527 0.793 0 C-N-CA 124.805 1.193 . . . . 0.0 111.779 175.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -114.87 89.4 3.09 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.129 0.972 . . . . 0.0 109.041 176.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 16.0 mt -63.82 125.52 20.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.509 -0.744 . . . . 0.0 109.601 176.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 39.9 t80 -81.56 138.89 35.35 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 173.077 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.1 t-20 -122.88 114.33 29.73 Favored Pre-proline 0 N--CA 1.456 -0.157 0 C-N-CA 123.862 0.865 . . . . 0.0 110.292 174.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -67.46 -38.89 13.61 Favored 'Trans proline' 0 N--CA 1.448 -1.196 0 C-N-CA 121.337 1.358 . . . . 0.0 111.777 -174.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -59.87 -30.86 69.27 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 118.141 0.428 . . . . 0.0 111.05 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -87.39 -31.73 19.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.477 0.711 . . . . 0.0 109.886 176.261 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.21 -159.4 37.05 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -166.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -139.91 61.16 17.31 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 125.485 1.514 . . . . 0.0 107.535 170.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -63.41 -30.65 72.59 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.527 2.151 . . . . 0.0 111.212 -170.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -59.9 -28.24 67.41 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 124.283 1.033 . . . . 0.0 109.858 179.155 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 21.6 m-80 -102.36 -26.22 13.36 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 125.73 1.612 . . . . 0.0 110.874 -175.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 135.83 10.96 1.31 Allowed Glycine 0 CA--C 1.531 1.077 0 C-N-CA 124.177 0.894 . . . . 0.0 113.86 169.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 70.7 t -112.95 110.22 31.41 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.294 0 CA-C-N 118.644 1.222 . . . . 0.0 108.709 -174.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -63.63 155.06 77.91 Favored Pre-proline 0 CA--C 1.535 0.366 0 O-C-N 121.631 -0.668 . . . . 0.0 111.073 -176.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.27 149.02 83.48 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 121.19 1.26 . . . . 0.0 110.665 170.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.26 15.76 80.98 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-O 118.368 -1.24 . . . . 0.0 112.616 -175.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 88.0 m -89.08 116.16 27.15 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 119.805 1.803 . . . . 0.0 107.073 177.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -57.84 136.06 56.93 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 170.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -44.18 -37.68 3.3 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 123.851 0.86 . . . . 0.0 111.79 171.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 56.9 pttt -67.22 -42.39 84.13 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 117.561 -1.656 . . . . 0.0 109.986 -178.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -71.36 -18.33 62.38 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 125.806 1.642 . . . . 0.0 111.138 -176.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 22.7 mt -53.38 133.4 52.87 Favored Pre-proline 0 N--CA 1.448 -0.569 0 CA-C-N 119.194 0.906 . . . . 0.0 108.941 174.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -64.9 142.17 74.35 Favored 'Trans proline' 0 N--CA 1.445 -1.331 0 C-N-CA 122.106 1.871 . . . . 0.0 109.946 179.472 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -68.47 -12.34 61.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 O-C-N 121.946 -0.471 . . . . 0.0 111.962 178.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -74.77 -17.18 60.68 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 118.275 0.489 . . . . 0.0 112.193 169.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 87.6 t90 -75.27 147.61 40.11 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 121.55 0.691 . . . . 0.0 109.529 179.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 59.3 t -131.51 161.22 41.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 125.097 1.359 . . . . 0.0 107.633 -177.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -43.79 144.49 1.42 Allowed Pre-proline 0 CA--C 1.537 0.475 0 C-N-CA 124.775 1.23 . . . . 0.0 110.031 170.406 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -64.34 -42.43 17.4 Favored 'Trans proline' 0 N--CA 1.452 -0.945 0 C-N-CA 122.271 1.981 . . . . 0.0 111.569 -176.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 88.9 mt -135.41 44.9 2.51 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 123.904 0.881 . . . . 0.0 109.983 -176.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -158.36 152.01 23.44 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 106.007 -1.849 . . . . 0.0 106.007 179.296 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -120.78 86.65 0.4 Allowed Glycine 0 C--N 1.335 0.506 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -169.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.8 p -145.46 -51.85 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 123.115 0.566 . . . . 0.0 110.699 -178.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 109.36 154.68 15.79 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -176.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -64.46 107.79 1.47 Allowed 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 118.153 0.976 . . . . 0.0 109.572 177.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -160.46 157.89 28.43 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 172.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 44.6 54.24 6.62 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.321 1.848 . . . . 0.0 111.549 173.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.6 p90 -100.28 117.86 35.37 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 126.507 1.923 . . . . 0.0 108.705 -179.261 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -85.17 148.11 26.27 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 123.526 0.73 . . . . 0.0 109.06 176.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -79.46 138.7 37.67 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.0 t -102.46 105.0 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 C-N-CA 125.419 1.488 . . . . 0.0 108.266 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -72.87 68.64 0.9 Allowed 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 126.348 1.859 . . . . 0.0 113.178 -179.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 43.3 mm-40 . . . . . 0 C--O 1.255 1.364 0 CA-C-O 116.78 -1.581 . . . . 0.0 108.332 154.843 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.476 0.86 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 12.1 mttm -59.83 144.91 47.33 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-O 121.72 0.772 . . . . 0.0 112.448 172.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt -76.76 174.29 10.66 Favored 'General case' 0 N--CA 1.442 -0.853 0 C-N-CA 125.617 1.567 . . . . 0.0 109.252 177.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -147.49 145.63 29.21 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 122.773 0.429 . . . . 0.0 110.167 -177.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 42.0 m -74.96 141.59 44.02 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 172.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 41.2 t -74.84 -112.08 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.494 0 N-CA-C 105.735 -1.95 . . . . 0.0 105.735 164.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 9.6 t -160.18 -158.2 0.61 Allowed 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 170.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 17.4 m -75.26 56.81 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 C-N-CA 124.079 0.952 . . . . 0.0 111.737 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 15.6 p -153.19 -55.85 0.12 Allowed 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.989 1.316 . . . . 0.0 109.452 177.24 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.71 -150.36 23.42 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 123.716 0.674 . . . . 0.0 113.248 -169.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 44.8 t80 -130.14 160.5 33.59 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 125.948 1.699 . . . . 0.0 107.666 179.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.6 mt -47.72 125.36 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 C-N-CA 124.6 1.16 . . . . 0.0 111.341 176.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 27.0 t80 -70.19 136.6 50.19 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 170.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.7 t-20 -120.02 113.02 34.46 Favored Pre-proline 0 N--CA 1.454 -0.232 0 C-N-CA 123.861 0.864 . . . . 0.0 109.707 175.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.74 -38.15 32.35 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 121.696 1.597 . . . . 0.0 111.342 -175.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -63.09 -28.81 70.33 Favored 'General case' 0 N--CA 1.444 -0.754 0 O-C-N 123.188 0.305 . . . . 0.0 111.333 -176.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -86.44 -32.97 20.57 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.807 0.843 . . . . 0.0 109.716 172.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.39 -158.86 42.23 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -166.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.3 61.59 17.41 Favored Pre-proline 0 C--O 1.237 0.435 0 C-N-CA 125.235 1.414 . . . . 0.0 107.891 171.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -64.24 -28.16 64.21 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 122.536 2.157 . . . . 0.0 111.222 -170.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -64.18 -30.25 71.32 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 123.24 0.616 . . . . 0.0 109.683 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 33.9 m-80 -93.0 -30.94 15.07 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 125.085 1.354 . . . . 0.0 110.747 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.15 5.88 1.52 Allowed Glycine 0 CA--C 1.531 1.06 0 C-N-CA 124.26 0.933 . . . . 0.0 113.915 170.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 50.2 t -103.44 112.1 35.64 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.266 0 CA-C-N 118.45 1.125 . . . . 0.0 108.559 -175.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -64.59 154.87 83.5 Favored Pre-proline 0 CA--C 1.533 0.32 0 O-C-N 121.784 -0.573 . . . . 0.0 110.416 -177.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.79 150.05 73.67 Favored 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 121.495 1.463 . . . . 0.0 110.851 170.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 79.33 14.44 81.55 Favored Glycine 0 CA--C 1.526 0.724 0 C-N-CA 125.708 1.623 . . . . 0.0 113.348 -176.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 93.9 m -94.35 114.77 26.88 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 120.149 1.974 . . . . 0.0 108.501 -178.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -56.42 135.24 54.15 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 169.423 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -42.69 -35.36 1.1 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 113.172 0.804 . . . . 0.0 113.172 171.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 53.8 pttt -68.3 -38.5 81.7 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 118.646 -1.221 . . . . 0.0 110.051 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -78.0 -16.9 57.73 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 125.005 1.322 . . . . 0.0 109.99 -173.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 19.7 mt -54.97 132.02 67.61 Favored Pre-proline 0 N--CA 1.442 -0.836 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 174.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -57.64 134.69 64.72 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 123.162 2.575 . . . . 0.0 109.359 177.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -74.57 -7.4 53.0 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.298 -0.876 . . . . 0.0 111.966 -176.499 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -77.4 -10.23 59.34 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.491 1.116 . . . . 0.0 112.598 165.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 77.2 t90 -66.93 156.35 36.07 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 118.88 0.764 . . . . 0.0 110.516 177.661 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.4 p -123.91 154.57 30.6 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 125.886 1.675 . . . . 0.0 108.579 -177.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.0 m -34.57 148.55 0.1 Allowed Pre-proline 0 CA--C 1.541 0.609 0 C-N-CA 126.693 1.997 . . . . 0.0 113.715 172.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -76.49 -37.82 1.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 122.964 2.443 . . . . 0.0 113.057 -174.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 96.1 mt -132.3 30.7 4.16 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.908 0.883 . . . . 0.0 109.434 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -152.16 -173.9 4.7 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 -177.087 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -134.43 58.19 0.69 Allowed Glycine 0 C--N 1.339 0.714 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -176.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -133.86 158.74 42.55 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 C-N-CA 125.296 1.438 . . . . 0.0 107.947 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.5 -174.49 35.65 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 111.413 -0.675 . . . . 0.0 111.413 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 52.8 mtpt -71.03 -60.62 2.13 Favored 'General case' 0 CA--C 1.529 0.154 0 O-C-N 121.978 -0.719 . . . . 0.0 109.999 175.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 54.67 -68.53 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 129.357 3.063 . . . . 0.0 114.202 176.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -138.46 140.48 39.25 Favored 'General case' 0 CA--C 1.527 0.092 0 C-N-CA 125.26 1.424 . . . . 0.0 108.203 178.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 7.6 p90 -156.29 110.13 2.74 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -168.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -86.27 133.44 33.82 Favored 'General case' 0 C--O 1.225 -0.204 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -71.52 135.67 47.19 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 178.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.8 t -97.72 109.99 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 C-N-CA 126.39 1.876 . . . . 0.0 106.393 177.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -72.72 60.2 0.49 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.878 1.671 . . . . 0.0 114.308 -174.073 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 . . . . . 0 C--O 1.26 1.627 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 152.236 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 49.7 mtt . . . . . 0 N--CA 1.476 0.844 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 8.9 mttm -87.25 142.91 27.54 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-O 120.89 0.376 . . . . 0.0 111.109 -178.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -71.37 171.35 11.37 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 123.557 0.743 . . . . 0.0 110.2 174.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -145.52 148.55 33.34 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.481 0.713 . . . . 0.0 111.253 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.5 m -80.07 122.16 26.43 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 123.294 0.638 . . . . 0.0 110.021 176.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 7.2 t -58.91 94.72 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.326 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 168.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 59.3 m -66.37 141.34 57.99 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -171.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . 0.305 12.7 p 54.37 20.5 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 125.845 1.658 . . . . 0.0 113.293 -171.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 66.9 m -139.03 -162.43 1.32 Allowed 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.591 1.557 . . . . 0.0 107.967 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.36 62.56 0.37 Allowed Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 178.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 6.1 t80 -150.82 66.13 0.92 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 124.069 0.947 . . . . 0.0 109.718 -173.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.1 mt -37.79 125.19 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 124.724 1.21 . . . . 0.0 112.791 -175.205 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.401 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 25.9 t80 -78.05 135.62 37.77 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 175.539 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 57.2 t-20 -120.11 111.52 35.38 Favored Pre-proline 0 N--CA 1.452 -0.338 0 C-N-CA 123.913 0.885 . . . . 0.0 109.807 176.103 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -64.98 -37.96 31.04 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.406 1.404 . . . . 0.0 111.479 -175.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -61.21 -29.91 70.11 Favored 'General case' 0 N--CA 1.446 -0.67 0 O-C-N 123.393 0.433 . . . . 0.0 111.074 -176.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -87.24 -33.17 19.4 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 123.962 0.905 . . . . 0.0 109.705 173.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.44 -158.14 39.83 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -167.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -142.54 62.36 12.81 Favored Pre-proline 0 CA--C 1.537 0.476 0 C-N-CA 125.503 1.521 . . . . 0.0 107.746 172.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.06 -33.98 81.25 Favored 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 122.558 2.172 . . . . 0.0 111.179 -170.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -57.41 -29.89 64.51 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.833 1.253 . . . . 0.0 110.35 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 21.3 m-80 -99.26 -23.4 15.21 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 125.554 1.541 . . . . 0.0 110.98 -176.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 131.52 7.42 3.1 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 124.571 1.081 . . . . 0.0 113.321 169.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.0 t -107.53 110.23 31.1 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.261 0 CA-C-N 118.313 1.057 . . . . 0.0 108.612 -174.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -64.08 155.16 79.86 Favored Pre-proline 0 CA--C 1.534 0.329 0 O-C-N 121.783 -0.573 . . . . 0.0 110.537 -177.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -59.58 149.9 79.42 Favored 'Trans proline' 0 N--CA 1.449 -1.127 0 C-N-CA 121.308 1.339 . . . . 0.0 110.679 170.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.65 23.45 76.79 Favored Glycine 0 CA--C 1.524 0.656 0 C-N-CA 125.469 1.509 . . . . 0.0 112.891 -175.16 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 94.2 m -97.81 117.66 32.63 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 119.514 1.657 . . . . 0.0 107.703 176.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -61.08 137.37 58.24 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 173.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -44.12 -35.11 2.03 Favored 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 113.588 0.959 . . . . 0.0 113.588 172.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 5.8 pttt -69.73 -37.89 76.66 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 120.813 -1.179 . . . . 0.0 110.144 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -73.64 -20.42 60.58 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 125.226 1.41 . . . . 0.0 109.799 -175.018 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.401 HD13 ' CZ ' ' A' ' 13' ' ' TYR . 19.4 mt -54.36 131.07 62.03 Favored Pre-proline 0 N--CA 1.441 -0.882 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 176.317 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -60.66 135.84 62.99 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.094 1.863 . . . . 0.0 108.551 178.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -72.73 -5.41 37.56 Favored 'General case' 0 CA--C 1.54 0.567 0 O-C-N 121.89 -0.507 . . . . 0.0 111.744 -178.585 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.4 -26.41 66.42 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.98 1.312 . . . . 0.0 112.08 164.488 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 83.8 t90 -69.86 149.14 48.18 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.644 0.735 . . . . 0.0 110.639 -174.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 5.2 m -123.12 157.55 28.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 C-N-CA 125.913 1.685 . . . . 0.0 109.645 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.5 m -39.65 144.02 0.52 Allowed Pre-proline 0 CA--C 1.532 0.287 0 C-N-CA 126.351 1.861 . . . . 0.0 113.187 177.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -70.19 -31.94 17.71 Favored 'Trans proline' 0 N--CA 1.451 -1.003 0 C-N-CA 123.227 2.618 . . . . 0.0 112.832 -173.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 16.1 tp -149.32 35.87 0.73 Allowed 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.68 -0.637 . . . . 0.0 110.732 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.5 m -131.19 -47.41 1.0 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.625 0.77 . . . . 0.0 110.607 -178.306 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.43 62.32 1.65 Allowed Glycine 0 CA--C 1.531 1.057 0 C-N-CA 123.608 0.623 . . . . 0.0 112.254 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.1 p -151.69 159.18 4.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 172.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -68.04 167.56 42.39 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 54.9 mtpt -50.33 -58.13 6.35 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.757 0.823 . . . . 0.0 111.215 177.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.8 t0 21.11 85.83 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 128.275 2.63 . . . . 0.0 115.016 -172.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER 75.2 150.66 0.11 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.825 1.65 . . . . 0.0 110.228 178.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.3 p90 -171.02 109.44 0.31 Allowed 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -163.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 52.5 mt-10 -87.27 135.81 33.17 Favored 'General case' 0 CA--C 1.519 -0.228 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -176.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -76.88 137.55 39.21 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -178.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.1 t -98.47 109.91 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.042 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 176.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -74.69 59.62 0.87 Allowed 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 126.197 1.799 . . . . 0.0 113.914 -171.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 . . . . . 0 C--O 1.259 1.596 0 CA-C-N 114.845 -1.07 . . . . 0.0 108.372 156.286 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.408 4.9 ptt? . . . . . 0 N--CA 1.469 0.503 0 N-CA-C 104.824 -2.287 . . . . 0.0 104.824 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 38.1 mttm 62.54 162.0 0.09 Allowed 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 126.278 1.831 . . . . 0.0 112.911 -171.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 72.7 mttt -80.37 165.61 22.1 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 115.219 -0.9 . . . . 0.0 108.653 -176.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -144.92 136.25 25.17 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.04 -179.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.8 t -92.11 135.79 33.69 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 111.689 0.255 . . . . 0.0 111.689 172.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 48.0 t -77.56 47.45 0.6 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 127.223 2.209 . . . . 0.0 109.389 177.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 10.9 m 43.39 -124.27 0.81 Allowed 'General case' 0 CA--C 1.548 0.902 0 O-C-N 120.266 -1.521 . . . . 0.0 111.93 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 45.1 t -82.75 70.63 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 O-C-N 120.541 -1.35 . . . . 0.0 108.919 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 42.5 t -133.0 -70.04 0.55 Allowed 'General case' 0 CA--C 1.529 0.153 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 175.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.15 60.58 0.96 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -131.91 -57.63 0.98 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.904 0.882 . . . . 0.0 110.393 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 74.0 mt 75.17 119.15 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 C-N-CA 127.135 2.174 . . . . 0.0 111.683 -175.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.407 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 44.1 t80 -82.03 132.41 35.25 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 170.076 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 56.8 t-20 -118.87 112.64 36.46 Favored Pre-proline 0 C--O 1.227 -0.12 0 C-N-CA 124.348 1.059 . . . . 0.0 109.403 174.04 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -65.53 -38.23 26.27 Favored 'Trans proline' 0 N--CA 1.447 -1.265 0 C-N-CA 121.111 1.208 . . . . 0.0 111.573 -174.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -57.47 -32.22 66.74 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-N 117.97 0.35 . . . . 0.0 111.03 -179.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 60.1 m-20 -90.06 -29.83 18.11 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.705 0.802 . . . . 0.0 110.232 177.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.08 -158.67 41.35 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -168.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -141.87 60.82 11.71 Favored Pre-proline 0 CA--C 1.539 0.555 0 C-N-CA 125.373 1.469 . . . . 0.0 107.763 172.17 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -62.17 -33.64 81.16 Favored 'Trans proline' 0 N--CA 1.455 -0.767 0 C-N-CA 122.403 2.068 . . . . 0.0 111.173 -170.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -55.85 -31.35 62.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 125.011 1.324 . . . . 0.0 110.641 177.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.6 m-80 -97.83 -27.76 14.15 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 125.521 1.528 . . . . 0.0 110.663 -177.059 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.23 9.34 1.44 Allowed Glycine 0 CA--C 1.532 1.154 0 C-N-CA 124.345 0.974 . . . . 0.0 113.829 169.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 54.7 t -110.06 111.63 37.0 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.248 0 CA-C-N 118.579 1.189 . . . . 0.0 109.065 -174.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -63.62 154.8 78.79 Favored Pre-proline 0 C--N 1.328 -0.335 0 O-C-N 121.9 -0.5 . . . . 0.0 111.056 -177.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -59.94 150.15 79.84 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 121.423 1.416 . . . . 0.0 110.744 171.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 72.22 16.67 77.08 Favored Glycine 0 CA--C 1.525 0.704 0 CA-C-O 118.289 -1.284 . . . . 0.0 112.798 -174.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 92.4 m -87.75 117.6 26.69 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-N 119.951 1.875 . . . . 0.0 107.386 176.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -56.56 133.28 53.42 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.167 170.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -42.67 -38.31 2.0 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 123.326 0.65 . . . . 0.0 112.053 170.231 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.415 ' HZ1' ' CG ' ' A' ' 32' ' ' ASP . 19.1 pttp -66.34 -39.08 88.97 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 118.181 -1.408 . . . . 0.0 109.945 -177.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.415 ' CG ' ' HZ1' ' A' ' 31' ' ' LYS . 84.6 m-20 -81.66 -11.37 59.11 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 126.108 1.763 . . . . 0.0 110.626 -172.304 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.407 HD13 ' CZ ' ' A' ' 13' ' ' TYR . 22.8 mt -56.42 134.28 76.57 Favored Pre-proline 0 N--CA 1.443 -0.801 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 171.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo -58.08 138.35 85.5 Favored 'Trans proline' 0 N--CA 1.454 -0.796 0 C-N-CA 123.556 2.838 . . . . 0.0 110.932 176.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -69.92 -15.02 63.0 Favored 'General case' 0 N--CA 1.448 -0.55 0 O-C-N 121.071 -1.018 . . . . 0.0 111.822 177.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -78.96 -9.75 59.62 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.59 1.156 . . . . 0.0 112.065 169.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 76.9 t90 -72.22 156.12 39.49 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.086 0.857 . . . . 0.0 110.369 175.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 13.1 t -130.76 143.58 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 125.174 1.389 . . . . 0.0 108.227 -170.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 20.2 t -68.18 137.33 91.7 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 123.438 0.695 . . . . 0.0 109.629 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -68.15 127.85 16.59 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 122.749 2.299 . . . . 0.0 111.42 177.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 29.1 mt 61.26 44.73 9.5 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.759 1.223 . . . . 0.0 111.97 174.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 14.4 t -149.05 178.63 8.54 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -176.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -105.28 171.43 18.62 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 171.439 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.324 3.9 p 48.07 -149.39 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 CA-C-O 117.447 -1.263 . . . . 0.0 111.219 -173.421 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -146.13 -143.3 3.89 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-N 121.475 1.943 . . . . 0.0 111.131 -173.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.4 ptmt -78.11 115.53 17.9 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 172.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -158.43 -63.59 0.08 Allowed 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.029 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -105.0 97.53 7.37 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.638 1.175 . . . . 0.0 109.392 179.509 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.7 p90 -141.12 135.16 30.63 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.201 1.001 . . . . 0.0 109.189 -178.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 22.6 mt-10 -108.44 155.06 21.01 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 124.734 1.213 . . . . 0.0 109.519 178.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -78.96 143.22 35.98 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 123.635 0.774 . . . . 0.0 109.646 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.3 t -112.07 108.38 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 C-N-CA 126.679 1.991 . . . . 0.0 106.564 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -81.18 55.21 2.46 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 125.005 1.322 . . . . 0.0 113.098 -175.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 . . . . . 0 C--O 1.25 1.119 0 C-N-CA 124.911 1.285 . . . . 0.0 109.681 176.454 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.378 23.2 ptm . . . . . 0 N--CA 1.473 0.7 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 43.2 mttm 60.15 168.36 0.08 Allowed 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 126.013 1.725 . . . . 0.0 112.618 -170.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 3.7 mtpt -78.91 166.97 21.8 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.205 -177.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -147.68 149.31 32.23 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.068 0.547 . . . . 0.0 111.067 -179.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 57.4 p -74.38 170.82 14.87 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 123.281 0.633 . . . . 0.0 112.214 172.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 42.1 t -83.16 -53.06 6.07 Favored 'General case' 0 C--O 1.224 -0.254 0 C-N-CA 125.203 1.401 . . . . 0.0 109.074 162.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 85.9 m 61.25 22.74 13.04 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.017 0.927 . . . . 0.0 111.569 -173.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 66.1 t -123.34 -65.15 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 C-N-CA 124.421 1.088 . . . . 0.0 108.453 166.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 26.5 p -94.56 -60.53 1.69 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 118.633 0.651 . . . . 0.0 110.706 175.527 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 138.6 45.98 0.07 OUTLIER Glycine 0 CA--C 1.531 1.075 0 C-N-CA 124.873 1.225 . . . . 0.0 112.166 -176.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -111.13 103.27 11.69 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 125.122 1.369 . . . . 0.0 109.705 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.6 mt -72.52 123.73 27.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 O-C-N 120.919 -1.113 . . . . 0.0 110.085 178.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.403 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 48.4 t80 -79.38 138.59 37.71 Favored 'General case' 0 C--O 1.236 0.392 0 C-N-CA 124.396 1.078 . . . . 0.0 108.451 170.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -124.02 114.33 27.99 Favored Pre-proline 0 C--O 1.226 -0.141 0 C-N-CA 124.005 0.922 . . . . 0.0 109.995 174.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -65.95 -39.46 19.3 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 120.954 1.102 . . . . 0.0 111.969 -175.309 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -58.66 -31.4 68.14 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 118.318 0.508 . . . . 0.0 111.149 -178.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -88.91 -30.86 18.53 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.505 0.722 . . . . 0.0 109.954 177.569 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.52 -159.99 41.13 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 124.095 0.855 . . . . 0.0 110.997 -168.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.04 61.25 17.2 Favored Pre-proline 0 CA--C 1.539 0.532 0 C-N-CA 125.445 1.498 . . . . 0.0 107.712 170.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_endo -63.45 -28.3 70.93 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.237 1.958 . . . . 0.0 111.229 -171.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -61.56 -28.49 69.37 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 123.534 0.734 . . . . 0.0 110.076 178.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.4 m-80 -99.84 -26.93 13.86 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 125.236 1.414 . . . . 0.0 110.958 -177.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 133.2 17.12 1.15 Allowed Glycine 0 CA--C 1.531 1.052 0 C-N-CA 124.216 0.913 . . . . 0.0 113.635 170.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 78.5 t -115.43 109.59 28.87 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.272 0 CA-C-N 118.466 1.133 . . . . 0.0 108.381 -175.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -63.39 155.67 73.71 Favored Pre-proline 0 C--N 1.328 -0.327 0 O-C-N 121.671 -0.643 . . . . 0.0 111.23 -176.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.0 149.02 86.68 Favored 'Trans proline' 0 N--CA 1.448 -1.147 0 C-N-CA 121.279 1.32 . . . . 0.0 110.619 171.046 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.39 16.61 78.81 Favored Glycine 0 N--CA 1.445 -0.709 0 CA-C-O 118.307 -1.274 . . . . 0.0 112.693 -174.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 81.7 m -87.95 117.72 27.0 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 119.873 1.836 . . . . 0.0 106.942 176.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -58.58 136.51 57.61 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 171.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -45.76 -37.3 5.83 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 122.975 0.51 . . . . 0.0 111.337 171.526 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 48.0 pttt -66.41 -38.49 87.58 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 117.783 -1.567 . . . . 0.0 110.468 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -76.1 -18.88 58.98 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 125.012 1.325 . . . . 0.0 110.506 -174.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.403 HD13 ' CZ ' ' A' ' 13' ' ' TYR . 21.7 mt -53.81 133.92 56.67 Favored Pre-proline 0 N--CA 1.446 -0.627 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 175.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -65.18 139.66 61.53 Favored 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 122.133 1.889 . . . . 0.0 109.7 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -66.3 -11.33 50.07 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 123.708 0.803 . . . . 0.0 111.54 177.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.4 -22.11 61.91 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.64 1.176 . . . . 0.0 112.11 170.285 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 84.9 t90 -73.39 155.7 39.08 Favored 'General case' 0 N--CA 1.455 -0.209 0 O-C-N 121.527 -0.733 . . . . 0.0 110.386 -177.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.72 159.68 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 C-N-CA 125.541 1.536 . . . . 0.0 109.232 -177.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 44.4 t -68.17 134.91 91.43 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 124.228 1.011 . . . . 0.0 109.668 -177.083 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -62.1 126.33 18.45 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.475 2.117 . . . . 0.0 110.883 178.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 41.0 mt 64.92 34.84 8.75 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.467 1.107 . . . . 0.0 111.615 174.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 41.5 t -151.61 160.95 43.44 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 106.399 -1.704 . . . . 0.0 106.399 -175.041 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -115.94 110.13 2.14 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 -174.125 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 36.0 t 78.84 123.35 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 C-N-CA 126.547 1.939 . . . . 0.0 108.785 -171.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -156.59 173.12 34.36 Favored Glycine 0 C--N 1.334 0.459 0 N-CA-C 107.696 -2.162 . . . . 0.0 107.696 178.04 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 53.87 74.05 0.35 Allowed 'General case' 0 CA--C 1.534 0.346 0 CA-C-O 122.941 1.353 . . . . 0.0 110.295 -170.773 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -152.59 -69.67 0.16 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 113.707 -1.588 . . . . 0.0 108.151 170.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -113.67 101.3 9.19 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 124.93 1.292 . . . . 0.0 108.453 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -140.27 131.93 27.25 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.092 1.357 . . . . 0.0 107.783 -175.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -96.63 149.35 21.89 Favored 'General case' 0 C--O 1.223 -0.297 0 C-N-CA 124.903 1.281 . . . . 0.0 109.28 -176.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -75.76 140.86 42.61 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-N 119.042 0.837 . . . . 0.0 109.218 178.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.2 t -106.63 107.57 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 C-N-CA 125.611 1.564 . . . . 0.0 106.8 176.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -76.85 57.03 1.25 Allowed 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 125.619 1.568 . . . . 0.0 113.075 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 . . . . . 0 C--O 1.251 1.144 0 CA-C-O 117.278 -1.344 . . . . 0.0 108.462 159.113 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.404 ' N ' ' OE2' ' A' ' 16' ' ' GLU . 8.1 mtt . . . . . 0 N--CA 1.478 0.932 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.5 mmmt -91.67 149.56 21.57 Favored 'General case' 0 CA--C 1.52 -0.185 0 CA-C-O 121.391 0.615 . . . . 0.0 110.08 -175.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 44.1 mtpt -74.12 169.75 16.89 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.568 -177.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -143.02 142.59 31.62 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 119.582 -0.247 . . . . 0.0 110.724 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.8 t -85.15 141.7 30.01 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 119.61 -0.836 . . . . 0.0 109.977 170.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 52.2 t -71.19 170.46 12.94 Favored 'General case' 0 CA--C 1.539 0.54 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 154.332 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.3 p -69.28 81.02 0.36 Allowed 'General case' 0 CA--C 1.533 0.32 0 O-C-N 120.97 -1.081 . . . . 0.0 110.725 -173.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 99.1 t 66.98 -74.88 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.456 -0.158 0 C-N-CA 126.014 1.725 . . . . 0.0 108.154 -170.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 48.1 t 43.05 -122.68 0.72 Allowed 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.77 1.228 . . . . 0.0 109.803 174.382 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -177.42 41.11 0.1 OUTLIER Glycine 0 CA--C 1.527 0.806 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 166.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -148.45 74.6 1.29 Allowed 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.748 0.785 . . . . 0.0 109.397 -169.443 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 12.6 mt -59.82 131.67 24.57 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 O-C-N 121.699 -0.626 . . . . 0.0 109.657 175.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.408 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 33.9 t80 -82.82 138.17 34.05 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 174.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -124.17 112.47 28.26 Favored Pre-proline 0 N--CA 1.454 -0.241 0 C-N-CA 124.229 1.011 . . . . 0.0 109.705 175.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -66.19 -35.19 33.78 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.076 1.184 . . . . 0.0 111.395 -174.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . 0.404 ' OE2' ' N ' ' A' ' 1' ' ' MET . 20.1 mt-10 -65.13 -27.71 68.93 Favored 'General case' 0 N--CA 1.443 -0.792 0 O-C-N 123.313 0.383 . . . . 0.0 110.934 -176.112 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -87.37 -31.57 20.05 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.328 1.051 . . . . 0.0 109.788 171.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.27 -151.82 50.28 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -167.027 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 25.6 t0 -151.87 63.94 5.55 Favored Pre-proline 0 N--CA 1.443 -0.799 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 171.643 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -64.91 -28.28 58.49 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.701 2.267 . . . . 0.0 111.634 -166.214 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -62.37 -24.93 67.64 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 123.701 0.801 . . . . 0.0 109.727 -178.205 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.9 m-80 -111.37 17.12 20.47 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.062 1.345 . . . . 0.0 109.993 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 95.73 3.95 60.67 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.325 0.964 . . . . 0.0 114.63 170.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.9 t -104.16 107.84 23.28 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.23 0 CA-C-N 119.127 1.464 . . . . 0.0 109.345 -172.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -65.36 153.89 88.87 Favored Pre-proline 0 CA--C 1.536 0.44 0 O-C-N 121.614 -0.679 . . . . 0.0 110.697 -176.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_endo -58.38 149.11 76.24 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 121.575 1.517 . . . . 0.0 111.135 170.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.66 19.33 79.21 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 125.004 1.288 . . . . 0.0 112.47 -175.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 99.8 m -94.27 114.45 26.54 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 119.61 1.705 . . . . 0.0 106.811 176.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -59.72 138.24 57.82 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 170.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.434 ' CD1' ' CD2' ' A' ' 49' ' ' PHE . 2.1 t80 -42.14 -38.63 1.76 Allowed 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 113.194 0.813 . . . . 0.0 113.194 171.189 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 55.8 pttt -64.99 -40.13 94.51 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 118.345 -1.342 . . . . 0.0 110.224 -178.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -78.73 -12.45 60.02 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 125.057 1.343 . . . . 0.0 111.169 -175.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.408 HD13 ' CZ ' ' A' ' 13' ' ' TYR . 21.8 mt -57.23 132.76 80.94 Favored Pre-proline 0 N--CA 1.442 -0.873 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 172.508 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -63.5 137.3 59.08 Favored 'Trans proline' 0 N--CA 1.442 -1.519 0 C-N-CA 121.641 1.56 . . . . 0.0 108.605 176.357 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -70.56 -3.47 18.25 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 123.543 0.737 . . . . 0.0 111.977 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -73.96 -24.71 59.67 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.968 1.707 . . . . 0.0 111.983 166.38 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 78.9 t90 -65.75 158.5 27.42 Favored 'General case' 0 CA--C 1.528 0.112 0 O-C-N 121.746 -0.596 . . . . 0.0 109.805 178.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.408 ' CG2' ' HA2' ' A' ' 43' ' ' GLY . 8.0 p -141.34 145.73 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 C-N-CA 123.895 0.878 . . . . 0.0 109.935 -173.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 53.2 t -66.92 125.12 90.33 Favored Pre-proline 0 C--O 1.24 0.597 0 C-N-CA 123.392 0.677 . . . . 0.0 110.029 178.472 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -66.04 133.7 34.27 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 123.26 2.64 . . . . 0.0 111.035 -175.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 48.4 mt 60.23 30.06 19.54 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 124.536 1.134 . . . . 0.0 112.042 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 8.4 t -142.67 -68.19 0.36 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.097 0.959 . . . . 0.0 108.841 -176.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . 0.408 ' HA2' ' CG2' ' A' ' 38' ' ' VAL . . . 85.71 17.98 60.8 Favored Glycine 0 CA--C 1.532 1.127 0 CA-C-O 118.613 -1.104 . . . . 0.0 114.737 177.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.8 p -72.17 -54.98 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 CA-C-N 119.761 1.781 . . . . 0.0 112.94 -176.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.95 -152.82 24.32 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 108.514 -1.834 . . . . 0.0 108.514 -170.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.55 33.89 0.78 Allowed 'General case' 0 CA--C 1.53 0.189 0 CA-C-N 118.217 1.009 . . . . 0.0 112.063 169.281 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -98.27 -49.66 4.62 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 125.086 1.354 . . . . 0.0 110.114 -161.406 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -94.23 67.23 3.53 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.057 1.343 . . . . 0.0 108.597 178.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.434 ' CD2' ' CD1' ' A' ' 30' ' ' PHE . 20.5 p90 -101.81 115.06 29.7 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 124.232 1.013 . . . . 0.0 109.214 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -99.27 142.92 30.13 Favored 'General case' 0 CA--C 1.519 -0.22 0 N-CA-C 108.164 -1.051 . . . . 0.0 108.164 174.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -73.04 134.78 44.75 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 15.3 t -93.29 108.86 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 174.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -78.64 51.28 1.06 Allowed 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 124.536 1.135 . . . . 0.0 113.489 -173.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 . . . . . 0 C--O 1.259 1.589 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 149.719 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.357 20.7 ptm . . . . . 0 N--CA 1.476 0.837 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 14.9 mttt 62.18 171.6 0.13 Allowed 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 125.867 1.667 . . . . 0.0 112.672 -171.155 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 58.9 mttt -75.02 167.07 22.63 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.241 -0.891 . . . . 0.0 109.492 -174.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -145.48 144.08 30.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.937 178.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 13.5 m -76.89 150.95 35.98 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-O 119.303 -0.379 . . . . 0.0 110.988 169.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 46.3 t -65.07 171.13 3.83 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-O 121.345 0.593 . . . . 0.0 110.136 170.003 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 1.9 t -71.52 -42.87 67.44 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 124.944 1.298 . . . . 0.0 111.402 -176.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 29.5 m -140.5 24.22 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -178.413 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 18.4 p -147.56 -166.37 2.5 Favored 'General case' 0 N--CA 1.455 -0.198 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 168.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.93 -82.0 0.99 Allowed Glycine 0 CA--C 1.525 0.705 0 N-CA-C 109.211 -1.556 . . . . 0.0 109.211 175.009 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 63.5 m-85 21.0 65.27 0.03 OUTLIER 'General case' 0 C--N 1.346 0.418 0 C-N-CA 128.452 2.701 . . . . 0.0 111.941 -175.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 23.4 mt -58.55 121.59 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.015 -173.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 35.2 t80 -73.29 138.12 45.27 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 173.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 62.1 t-20 -125.65 111.99 25.27 Favored Pre-proline 0 N--CA 1.454 -0.243 0 C-N-CA 123.975 0.91 . . . . 0.0 109.541 176.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -63.65 -39.69 33.73 Favored 'Trans proline' 0 N--CA 1.448 -1.204 0 C-N-CA 121.267 1.311 . . . . 0.0 111.355 -173.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -56.12 -32.82 64.57 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 117.977 0.353 . . . . 0.0 111.254 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -91.76 -29.84 16.57 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.453 0.701 . . . . 0.0 110.334 179.271 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 66.17 -159.0 47.63 Favored Glycine 0 CA--C 1.53 1.03 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -170.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.19 61.1 16.26 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 125.615 1.566 . . . . 0.0 107.393 171.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -61.59 -35.53 80.77 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.757 2.305 . . . . 0.0 111.451 -168.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -57.67 -31.38 66.28 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 124.875 1.27 . . . . 0.0 110.516 179.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 -92.21 -28.12 17.23 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 125.218 1.407 . . . . 0.0 110.469 -179.468 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.62 0.48 2.91 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.4 1.0 . . . . 0.0 113.205 171.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 75.2 t -100.97 111.08 29.52 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.206 0 CA-C-N 118.225 1.012 . . . . 0.0 109.002 -172.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -64.53 154.95 82.95 Favored Pre-proline 0 CA--C 1.533 0.308 0 O-C-N 121.765 -0.584 . . . . 0.0 110.929 -176.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -58.77 149.33 78.17 Favored 'Trans proline' 0 N--CA 1.449 -1.117 0 C-N-CA 121.425 1.416 . . . . 0.0 110.84 170.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.41 14.98 79.1 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 125.813 1.673 . . . . 0.0 113.082 -174.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.7 m -87.07 120.1 27.99 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 120.05 1.925 . . . . 0.0 107.871 178.343 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -59.81 134.45 57.04 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 172.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -43.04 -37.87 2.1 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 123.44 0.696 . . . . 0.0 112.176 169.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -68.13 -38.89 82.71 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 117.756 -1.578 . . . . 0.0 110.261 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -76.63 -17.57 59.09 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 124.989 1.316 . . . . 0.0 110.704 -175.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 23.0 mt -52.49 132.76 44.64 Favored Pre-proline 0 N--CA 1.445 -0.705 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -63.43 140.13 74.56 Favored 'Trans proline' 0 N--CA 1.445 -1.355 0 C-N-CA 122.234 1.956 . . . . 0.0 109.697 178.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 74.5 m-20 -69.98 -10.16 57.64 Favored 'General case' 0 N--CA 1.444 -0.772 0 C-N-CA 123.529 0.731 . . . . 0.0 111.914 -179.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -77.21 -12.02 59.89 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 124.232 1.013 . . . . 0.0 112.57 168.355 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -73.36 153.35 40.52 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 118.853 0.751 . . . . 0.0 110.303 177.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 97.4 t -137.02 150.01 26.44 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 125.573 1.549 . . . . 0.0 107.973 -171.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 13.2 t -79.48 130.63 67.61 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 124.854 1.262 . . . . 0.0 109.117 -176.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -64.98 147.91 89.37 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.461 2.108 . . . . 0.0 110.769 -178.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.2 mm? 68.8 -62.31 0.39 Allowed 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 126.323 1.849 . . . . 0.0 111.734 -179.495 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -59.03 -54.56 45.71 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 125.977 1.711 . . . . 0.0 110.787 178.354 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 106.84 -115.53 4.71 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -176.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.9 t -63.71 105.92 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 O-C-N 121.263 -1.139 . . . . 0.0 110.684 -167.437 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -130.74 -165.59 11.56 Favored Glycine 0 CA--C 1.527 0.809 0 C-N-CA 125.848 1.69 . . . . 0.0 109.323 178.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 55.22 61.74 2.78 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 123.112 1.434 . . . . 0.0 110.376 -173.723 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -156.19 157.49 35.98 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 156.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 45.09 37.83 2.79 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.117 1.767 . . . . 0.0 113.047 173.136 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 7.5 p90 -78.07 131.62 37.38 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 124.14 0.976 . . . . 0.0 110.335 -172.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -97.93 135.34 39.79 Favored 'General case' 0 C--O 1.227 -0.085 0 C-N-CA 123.929 0.892 . . . . 0.0 108.813 -179.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -72.66 138.18 46.52 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 176.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 32.2 t -105.53 105.81 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.054 0 C-N-CA 127.216 2.207 . . . . 0.0 105.418 176.579 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -81.91 54.17 2.39 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.427 1.091 . . . . 0.0 112.927 -173.574 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 . . . . . 0 C--O 1.251 1.143 0 C-N-CA 124.983 1.313 . . . . 0.0 109.617 176.508 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.352 5.9 ptt? . . . . . 0 N--CA 1.474 0.741 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 21.9 mttm 54.64 173.38 0.02 OUTLIER 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 125.102 1.361 . . . . 0.0 112.358 -168.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 28.5 mtpt -72.57 170.27 14.76 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.824 -176.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 35.7 m-85 -149.12 145.69 27.33 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 -177.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 44.9 p -71.42 170.62 12.86 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.213 0.53 . . . . 0.0 112.152 170.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 2.2 t -108.26 166.63 10.61 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 126.998 2.119 . . . . 0.0 105.948 166.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 1.2 p -48.0 -50.3 28.01 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 124.683 1.193 . . . . 0.0 111.665 169.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 4.7 m -148.57 16.2 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 N-CA-C 114.111 1.152 . . . . 0.0 114.111 -173.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 79.7 m -109.18 119.6 40.02 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 119.945 1.248 . . . . 0.0 111.742 178.387 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -75.88 54.35 3.0 Favored Glycine 0 CA--C 1.532 1.137 0 O-C-N 121.55 -0.719 . . . . 0.0 111.411 172.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -111.54 -47.03 3.2 Favored 'General case' 0 N--CA 1.46 0.071 0 C-N-CA 124.556 1.142 . . . . 0.0 110.353 176.175 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 11.5 mt 71.32 128.06 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 C-N-CA 125.561 1.544 . . . . 0.0 111.491 -177.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -76.06 141.61 42.0 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 172.103 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 -125.77 115.58 24.6 Favored Pre-proline 0 N--CA 1.456 -0.174 0 C-N-CA 123.679 0.792 . . . . 0.0 110.421 175.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -67.48 -39.63 12.09 Favored 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 121.053 1.169 . . . . 0.0 111.695 -176.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -59.04 -31.08 68.53 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 118.585 0.63 . . . . 0.0 111.152 -178.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -88.47 -31.71 18.62 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 123.589 0.755 . . . . 0.0 110.023 176.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.9 -162.02 35.69 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -166.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -138.28 61.3 25.47 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 125.187 1.395 . . . . 0.0 107.735 171.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -62.8 -31.38 78.21 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 122.332 2.021 . . . . 0.0 111.154 -170.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -59.69 -30.65 68.93 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 123.864 0.866 . . . . 0.0 110.731 178.189 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -96.08 -28.07 14.78 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 124.87 1.268 . . . . 0.0 110.51 -178.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.71 16.96 0.97 Allowed Glycine 0 CA--C 1.531 1.081 0 C-N-CA 124.395 0.998 . . . . 0.0 113.992 169.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.1 t -116.72 112.29 38.72 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.304 0 CA-C-N 118.578 1.189 . . . . 0.0 109.006 -175.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.44 156.73 75.71 Favored Pre-proline 0 CA--C 1.533 0.316 0 O-C-N 121.898 -0.501 . . . . 0.0 111.136 -177.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -59.68 150.14 78.49 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 121.376 1.384 . . . . 0.0 110.802 170.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.57 16.32 79.06 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 125.816 1.674 . . . . 0.0 113.212 -175.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.9 m -89.48 118.56 29.22 Favored 'General case' 0 N--CA 1.445 -0.689 0 CA-C-N 119.923 1.862 . . . . 0.0 108.276 179.138 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -59.65 134.09 56.7 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 170.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -43.17 -37.04 1.92 Allowed 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 123.596 0.758 . . . . 0.0 112.731 170.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -68.76 -37.84 79.64 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 118.043 -1.463 . . . . 0.0 110.291 -178.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -77.29 -17.49 58.31 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 125.506 1.522 . . . . 0.0 110.462 -176.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 19.2 mt -55.81 133.56 72.77 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 173.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -62.97 137.1 60.44 Favored 'Trans proline' 0 N--CA 1.445 -1.359 0 C-N-CA 121.823 1.682 . . . . 0.0 108.98 175.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -71.43 -4.6 27.34 Favored 'General case' 0 N--CA 1.445 -0.683 0 O-C-N 121.95 -0.469 . . . . 0.0 111.728 -179.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.58 -22.65 63.51 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 125.034 1.333 . . . . 0.0 112.182 165.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 81.3 t90 -71.29 152.3 43.39 Favored 'General case' 0 N--CA 1.456 -0.174 0 O-C-N 121.484 -0.76 . . . . 0.0 111.237 -176.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.5 t -127.59 146.49 33.23 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 C-N-CA 125.72 1.608 . . . . 0.0 108.356 179.173 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -76.31 160.95 76.64 Favored Pre-proline 0 CA--C 1.538 0.519 0 C-N-CA 122.605 0.362 . . . . 0.0 110.158 -176.152 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -67.11 117.42 4.78 Favored 'Trans proline' 0 N--CA 1.45 -1.058 0 C-N-CA 121.9 1.733 . . . . 0.0 110.687 -170.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 50.5 mt 65.32 51.73 1.54 Allowed 'General case' 0 CA--C 1.534 0.33 0 C-N-CA 125.255 1.422 . . . . 0.0 111.623 177.667 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.0 t -142.9 -179.48 6.38 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 124.275 1.03 . . . . 0.0 108.539 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -107.19 -67.21 0.64 Allowed Glycine 0 CA--C 1.526 0.743 0 C-N-CA 124.504 1.05 . . . . 0.0 111.223 -175.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 25.2 m -72.66 164.03 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 CA-C-N 116.803 0.302 . . . . 0.0 110.201 -179.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -121.4 114.03 2.47 Favored Glycine 0 C--N 1.334 0.441 0 N-CA-C 110.396 -1.082 . . . . 0.0 110.396 -170.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mtpt 62.38 -88.02 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 125.412 1.485 . . . . 0.0 110.388 178.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 46.83 -72.48 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 128.799 2.84 . . . . 0.0 114.303 -172.219 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -127.92 116.78 20.63 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 126.014 1.725 . . . . 0.0 108.925 -176.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 4.9 p90 -149.99 112.68 4.77 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.194 1.397 . . . . 0.0 107.28 -171.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -82.91 145.53 29.35 Favored 'General case' 0 C--O 1.225 -0.225 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 44.9 tt0 -71.91 136.8 47.02 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 175.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.1 t -102.41 104.34 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 C-N-CA 126.248 1.819 . . . . 0.0 106.336 177.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -78.2 88.35 4.27 Favored 'General case' 0 N--CA 1.438 -1.03 0 CA-C-O 123.215 1.484 . . . . 0.0 109.125 172.182 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 . . . . . 0 C--O 1.257 1.483 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 158.701 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.387 24.9 ptm . . . . . 0 N--CA 1.474 0.75 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 51.2 mttm 64.04 167.82 0.16 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 126.65 1.98 . . . . 0.0 112.704 -172.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -80.71 165.02 22.35 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -176.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -141.3 140.95 33.94 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 123.069 0.548 . . . . 0.0 111.069 178.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.3 t -99.4 140.88 32.92 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 113.084 0.772 . . . . 0.0 113.084 175.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 42.2 t -78.68 50.48 0.98 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.846 2.058 . . . . 0.0 109.399 177.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 5.7 m 53.84 -94.41 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.828 0 O-C-N 120.624 -1.297 . . . . 0.0 112.475 174.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.92 -28.93 5.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 125.246 1.418 . . . . 0.0 110.849 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 53.4 t -78.25 124.69 28.37 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 124.419 1.088 . . . . 0.0 109.44 -169.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -86.45 78.94 1.88 Allowed Glycine 0 CA--C 1.523 0.588 0 CA-C-O 119.211 -0.772 . . . . 0.0 111.283 -170.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -134.88 -57.76 0.82 Allowed 'General case' 0 CA--C 1.532 0.267 0 CA-C-N 117.796 0.798 . . . . 0.0 112.889 176.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 55.9 mt 75.22 121.25 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 126.637 1.975 . . . . 0.0 111.894 -173.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 77.2 t80 -83.22 138.23 33.7 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 169.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 55.1 t-20 -128.32 115.29 19.93 Favored Pre-proline 0 N--CA 1.454 -0.23 0 C-N-CA 124.582 1.153 . . . . 0.0 109.461 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.27 -39.48 17.55 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 121.779 1.653 . . . . 0.0 112.267 -172.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -55.13 -32.78 62.34 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 118.002 0.365 . . . . 0.0 110.749 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -95.06 -26.03 16.22 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 123.504 0.722 . . . . 0.0 109.9 -177.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.3 -157.46 36.58 Favored Glycine 0 CA--C 1.527 0.788 0 C-N-CA 124.684 1.135 . . . . 0.0 110.979 -170.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.76 62.31 12.23 Favored Pre-proline 0 CA--C 1.538 0.495 0 C-N-CA 125.062 1.345 . . . . 0.0 107.941 170.137 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -62.43 -33.34 79.65 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.697 2.264 . . . . 0.0 111.185 -170.264 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -56.76 -29.56 62.72 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 124.661 1.184 . . . . 0.0 110.728 178.376 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 -99.07 -30.8 12.11 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.267 1.427 . . . . 0.0 110.615 -177.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 140.15 7.49 0.95 Allowed Glycine 0 CA--C 1.531 1.077 0 C-N-CA 123.874 0.75 . . . . 0.0 114.061 169.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.6 t -106.58 112.52 40.02 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.217 0 CA-C-N 118.885 1.342 . . . . 0.0 109.04 -176.664 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -63.91 154.18 82.2 Favored Pre-proline 0 C--N 1.328 -0.351 0 O-C-N 121.982 -0.448 . . . . 0.0 110.585 -178.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -59.19 148.08 87.59 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 121.352 1.368 . . . . 0.0 110.771 170.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 77.77 15.59 81.09 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 124.819 1.2 . . . . 0.0 112.546 -176.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 97.2 m -89.18 118.87 29.19 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 119.698 1.749 . . . . 0.0 107.492 177.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -58.61 135.26 57.32 Favored 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 171.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -46.01 -34.66 4.18 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 123.173 0.589 . . . . 0.0 112.426 171.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.418 ' HZ1' ' CG ' ' A' ' 32' ' ' ASP . 19.5 pttp -66.54 -40.02 88.86 Favored 'General case' 0 N--CA 1.453 -0.287 0 C-N-CA 118.076 -1.45 . . . . 0.0 110.083 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.418 ' CG ' ' HZ1' ' A' ' 31' ' ' LYS . 83.9 m-20 -80.62 -12.49 59.49 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.831 1.652 . . . . 0.0 110.588 -171.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 17.7 mt -57.2 132.67 80.82 Favored Pre-proline 0 N--CA 1.441 -0.877 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 172.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -61.91 138.95 76.95 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 123.044 2.496 . . . . 0.0 109.904 178.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -64.66 -17.7 64.3 Favored 'General case' 0 N--CA 1.451 -0.397 0 O-C-N 121.819 -0.551 . . . . 0.0 112.024 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -75.54 -14.75 60.42 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 123.751 0.821 . . . . 0.0 112.696 173.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 78.8 t90 -70.05 150.66 46.37 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.319 0.581 . . . . 0.0 111.2 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 74.5 t -124.47 150.76 29.35 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 C-N-CA 125.656 1.582 . . . . 0.0 109.927 -173.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 49.8 t -57.86 136.66 83.41 Favored Pre-proline 0 CA--C 1.537 0.449 0 C-N-CA 125.844 1.658 . . . . 0.0 111.574 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -59.07 123.52 13.66 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 121.842 1.695 . . . . 0.0 110.14 173.592 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.2 mm? 66.71 21.79 10.5 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.701 1.201 . . . . 0.0 112.692 178.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -146.59 177.82 8.77 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 176.64 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -146.61 78.61 0.24 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -166.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.2 p -143.58 -73.23 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 123.542 0.737 . . . . 0.0 109.928 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 145.71 162.97 9.98 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 107.828 -2.109 . . . . 0.0 107.828 -173.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.5 ptmt -66.54 -18.7 65.51 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.836 1.318 . . . . 0.0 113.351 176.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 30.09 -93.74 0.01 OUTLIER 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 129.564 3.145 . . . . 0.0 111.964 -176.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.34 64.84 0.95 Allowed 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 166.034 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.3 m-30 -45.72 156.12 0.14 Allowed 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 125.093 1.357 . . . . 0.0 111.632 174.071 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -88.49 147.89 24.43 Favored 'General case' 0 C--O 1.225 -0.196 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 -175.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -74.55 141.49 44.79 Favored 'General case' 0 N--CA 1.442 -0.851 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.7 t -106.21 113.72 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.915 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 175.224 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -73.79 56.55 0.56 Allowed 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.546 1.539 . . . . 0.0 113.423 -178.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 . . . . . 0 C--O 1.254 1.338 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 158.363 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.411 13.5 ptt? . . . . . 0 N--CA 1.476 0.865 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.4 mttm 57.79 174.94 0.05 Allowed 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 126.343 1.857 . . . . 0.0 112.38 -166.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 76.6 mttt -70.73 169.73 13.88 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.239 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 48.9 m-85 -147.65 142.74 27.09 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 118.636 -0.697 . . . . 0.0 110.815 -177.205 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.2 m -79.95 146.43 32.09 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 119.014 0.825 . . . . 0.0 109.811 172.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 46.6 t -67.45 176.01 2.53 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 166.642 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 90.0 m -76.4 -74.18 0.24 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.619 1.567 . . . . 0.0 112.297 -167.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 41.2 t -115.73 2.35 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 124.555 1.142 . . . . 0.0 110.557 177.547 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 10.4 t -80.58 -164.98 0.79 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.766 1.626 . . . . 0.0 108.725 -179.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -135.98 49.21 0.89 Allowed Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 44.3 m-85 -133.41 158.86 41.97 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.14 0.976 . . . . 0.0 110.168 179.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 13.8 mt -119.9 127.66 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 125.548 1.539 . . . . 0.0 108.224 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 25.0 t80 -78.39 140.21 38.73 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 124.807 1.243 . . . . 0.0 108.353 169.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 50.7 t-20 -124.81 111.87 27.29 Favored Pre-proline 0 N--CA 1.458 -0.072 0 C-N-CA 123.99 0.916 . . . . 0.0 109.963 176.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -63.73 -39.75 32.75 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 121.11 1.206 . . . . 0.0 111.59 -173.221 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -57.99 -31.92 67.39 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 118.052 0.387 . . . . 0.0 111.401 -179.065 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -86.88 -34.5 19.41 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 123.195 0.598 . . . . 0.0 109.787 177.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 58.43 -161.96 11.11 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -164.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -139.34 67.52 38.76 Favored Pre-proline 0 CA--C 1.535 0.396 0 C-N-CA 124.509 1.123 . . . . 0.0 108.299 169.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -58.63 -30.02 90.9 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.805 1.67 . . . . 0.0 110.855 -176.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 85.1 m-20 -60.2 -31.97 70.65 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 124.075 0.95 . . . . 0.0 110.753 178.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.2 m-80 -98.8 -24.19 15.1 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 124.136 0.974 . . . . 0.0 110.292 -177.016 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 133.11 10.65 1.92 Allowed Glycine 0 CA--C 1.531 1.046 0 C-N-CA 124.484 1.04 . . . . 0.0 113.251 171.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.3 t -110.0 109.87 30.04 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.273 0 CA-C-N 118.593 1.197 . . . . 0.0 109.298 -175.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -64.04 154.06 83.14 Favored Pre-proline 0 C--N 1.328 -0.356 0 O-C-N 121.803 -0.561 . . . . 0.0 110.754 -178.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_endo -59.13 146.88 92.97 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.317 1.345 . . . . 0.0 110.659 171.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.53 20.18 77.08 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 125.329 1.442 . . . . 0.0 112.699 -177.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 96.9 m -91.87 121.36 33.41 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 119.443 1.622 . . . . 0.0 107.869 176.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.5 t0 -62.96 136.81 58.04 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 171.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -44.66 -35.7 2.75 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 123.332 0.653 . . . . 0.0 112.455 171.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.6 pttp -67.89 -36.68 80.64 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 118.482 -1.287 . . . . 0.0 110.369 -179.109 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -80.68 -16.74 53.2 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.485 1.514 . . . . 0.0 110.277 -174.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 20.9 mt -55.39 134.22 70.09 Favored Pre-proline 0 N--CA 1.445 -0.719 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 173.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_endo -64.33 138.27 59.91 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 122.425 2.083 . . . . 0.0 109.616 176.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -66.09 -12.63 56.85 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 123.054 0.541 . . . . 0.0 111.943 178.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.15 -19.6 64.02 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.782 1.233 . . . . 0.0 112.337 171.012 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 74.8 t90 -66.31 156.64 33.82 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 121.748 0.785 . . . . 0.0 111.985 -176.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -129.88 149.81 33.99 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 C-N-CA 126.904 2.082 . . . . 0.0 109.815 -178.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 14.6 t -73.64 138.38 77.27 Favored Pre-proline 0 C--O 1.236 0.351 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 -175.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -56.82 111.5 0.82 Allowed 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.1 1.866 . . . . 0.0 110.084 178.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 15.3 mt 79.15 16.63 0.94 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.352 1.861 . . . . 0.0 112.231 179.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.9 t -147.92 99.7 3.11 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-O 123.19 1.471 . . . . 0.0 108.786 -174.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -78.33 52.9 3.83 Favored Glycine 0 CA--C 1.528 0.859 0 O-C-N 120.878 -1.139 . . . . 0.0 111.754 -177.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 51.7 t -99.5 -71.2 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 175.068 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 127.73 -163.42 21.43 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 33.5 mtpt -86.61 168.72 13.38 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 169.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -163.54 -82.93 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 124.738 1.215 . . . . 0.0 108.288 168.265 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.1 mm-40 -99.55 -49.75 4.3 Favored 'General case' 0 C--O 1.226 -0.156 0 C-N-CA 125.22 1.408 . . . . 0.0 110.184 -171.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 29.8 p90 49.32 92.43 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.194 1.798 . . . . 0.0 112.7 177.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 50.2 mt-10 -74.6 137.26 42.2 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 62.8 tt0 -75.93 134.75 40.15 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.197 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 24.5 t -101.47 115.99 44.25 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.127 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 175.337 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -70.82 55.46 0.17 Allowed 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 125.893 1.677 . . . . 0.0 114.174 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 . . . . . 0 C--O 1.253 1.264 0 C-N-CA 126.698 1.999 . . . . 0.0 107.593 161.925 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.366 19.2 ptm . . . . . 0 N--CA 1.473 0.713 0 N-CA-C 106.819 -1.549 . . . . 0.0 106.819 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 18.7 mttt 62.6 167.47 0.12 Allowed 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 126.228 1.811 . . . . 0.0 112.979 -171.051 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -76.27 167.98 20.87 Favored 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 115.085 -0.961 . . . . 0.0 109.649 -176.541 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -148.24 135.98 20.81 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 122.748 0.419 . . . . 0.0 112.11 -178.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 19.9 m -75.4 134.95 40.8 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 119.311 -0.376 . . . . 0.0 111.118 169.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 36.6 t -68.85 140.37 55.21 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.284 0.634 . . . . 0.0 110.187 170.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 75.1 p -25.84 -82.36 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 129.661 3.185 . . . . 0.0 114.899 -175.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.1 m -127.41 54.97 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 C-N-CA 125.347 1.459 . . . . 0.0 108.535 -172.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 37.3 t -141.09 -78.09 0.28 Allowed 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.3 -161.224 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 131.23 -33.11 2.85 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.334 -0.707 . . . . 0.0 111.334 -176.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 28.0 m-85 -57.09 139.79 51.3 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-N 118.352 1.076 . . . . 0.0 110.051 177.161 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.7 mt -106.1 120.01 56.38 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.242 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.518 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 44.9 t80 -72.49 138.38 46.97 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 169.714 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 53.8 t-20 -124.25 112.18 28.21 Favored Pre-proline 0 N--CA 1.455 -0.215 0 C-N-CA 124.08 0.952 . . . . 0.0 109.59 175.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -63.18 -39.2 40.13 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 C-N-CA 121.137 1.225 . . . . 0.0 112.082 -172.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -58.91 -31.56 68.75 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 117.751 0.251 . . . . 0.0 111.205 -179.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -87.76 -32.06 19.32 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.472 0.709 . . . . 0.0 109.877 177.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.32 -159.03 41.74 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -167.296 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.49 61.38 16.13 Favored Pre-proline 0 CA--C 1.539 0.544 0 C-N-CA 125.556 1.542 . . . . 0.0 107.763 171.31 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -62.7 -30.04 78.05 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 122.404 2.069 . . . . 0.0 111.329 -170.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -61.18 -29.6 69.9 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 123.922 0.889 . . . . 0.0 110.383 179.111 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -96.63 -28.32 14.4 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 125.232 1.413 . . . . 0.0 110.687 -178.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.52 12.78 1.35 Allowed Glycine 0 CA--C 1.531 1.092 0 C-N-CA 124.296 0.951 . . . . 0.0 113.673 169.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.3 t -110.02 111.01 34.25 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.208 0 CA-C-N 118.447 1.124 . . . . 0.0 108.464 -175.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -64.3 155.34 80.32 Favored Pre-proline 0 CA--C 1.535 0.382 0 O-C-N 121.787 -0.571 . . . . 0.0 110.981 -177.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.57 149.55 81.55 Favored 'Trans proline' 0 N--CA 1.449 -1.093 0 C-N-CA 121.399 1.399 . . . . 0.0 110.944 171.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 74.08 15.69 79.82 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 125.125 1.345 . . . . 0.0 112.848 -175.185 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 76.3 m -87.98 119.27 28.18 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 119.813 1.806 . . . . 0.0 107.183 177.56 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -61.07 137.65 58.23 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 172.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -46.33 -35.76 5.69 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 123.346 0.658 . . . . 0.0 111.71 172.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 54.2 pttt -68.2 -39.2 82.49 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 118.232 -1.387 . . . . 0.0 110.205 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -73.26 -21.16 60.68 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 125.126 1.37 . . . . 0.0 110.164 -175.193 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 21.3 mt -53.23 133.97 51.25 Favored Pre-proline 0 N--CA 1.446 -0.665 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 176.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -66.13 139.58 56.18 Favored 'Trans proline' 0 N--CA 1.444 -1.434 0 C-N-CA 122.093 1.862 . . . . 0.0 109.658 178.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -67.91 -9.17 42.85 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 123.806 0.843 . . . . 0.0 111.546 177.602 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -73.15 -22.69 60.47 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.779 1.232 . . . . 0.0 112.061 169.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 81.1 t90 -69.69 152.83 44.22 Favored 'General case' 0 N--CA 1.455 -0.221 0 O-C-N 121.628 -0.67 . . . . 0.0 110.464 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 99.2 t -131.87 152.69 37.34 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 C-N-CA 124.887 1.275 . . . . 0.0 108.862 -178.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 20.1 t -69.21 140.44 90.62 Favored Pre-proline 0 CA--C 1.54 0.568 0 C-N-CA 124.526 1.131 . . . . 0.0 110.425 -177.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -63.09 118.59 5.5 Favored 'Trans proline' 0 N--CA 1.452 -0.922 0 C-N-CA 122.575 2.183 . . . . 0.0 111.305 175.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 13.2 mt 70.19 43.54 0.85 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.85 1.26 . . . . 0.0 111.176 170.053 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 53.7 t -153.61 176.05 12.52 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 106.117 -1.808 . . . . 0.0 106.117 -171.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -80.42 -156.74 13.69 Favored Glycine 0 CA--C 1.528 0.867 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 173.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.9 m -51.98 126.93 8.2 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 O-C-N 122.099 -0.647 . . . . 0.0 109.632 171.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -126.2 -175.66 14.24 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 58.57 78.32 0.26 Allowed 'General case' 0 CA--C 1.537 0.446 0 CA-C-O 122.471 1.129 . . . . 0.0 110.444 -172.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -153.81 -99.68 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 114.174 -1.376 . . . . 0.0 107.653 168.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -76.39 60.74 1.6 Allowed 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 119.4 1.0 . . . . 0.0 111.493 178.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -75.93 146.1 39.93 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 121.441 -0.787 . . . . 0.0 109.911 173.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -114.38 141.53 47.52 Favored 'General case' 0 N--CA 1.464 0.232 0 C-N-CA 124.235 1.014 . . . . 0.0 108.592 175.409 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -77.54 138.58 39.26 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 29.9 t -103.65 104.5 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 C-N-CA 126.021 1.728 . . . . 0.0 107.039 178.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -77.12 57.72 1.44 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.639 1.576 . . . . 0.0 112.618 179.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 . . . . . 0 C--O 1.255 1.367 0 CA-C-O 117.349 -1.31 . . . . 0.0 108.446 156.776 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.373 20.4 ptt? . . . . . 0 N--CA 1.472 0.668 0 N-CA-C 105.561 -2.014 . . . . 0.0 105.561 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 40.4 mttm 59.73 170.29 0.08 Allowed 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 125.47 1.508 . . . . 0.0 112.402 -172.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.418 ' HZ3' ' C ' ' A' ' 54' ' ' GLU . 55.7 mttt -82.12 167.71 18.47 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.499 -171.425 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -146.92 136.17 22.64 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 113.411 0.893 . . . . 0.0 113.411 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.7 m -80.98 147.89 30.01 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 123.89 0.876 . . . . 0.0 111.695 169.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 36.1 t -79.31 14.65 1.46 Allowed 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 125.19 1.396 . . . . 0.0 112.631 175.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.8 m 65.64 -72.37 0.07 Allowed 'General case' 0 CA--C 1.538 0.511 0 O-C-N 119.413 -2.054 . . . . 0.0 112.588 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 69.4 t -70.54 -61.88 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 C-N-CA 123.968 0.907 . . . . 0.0 109.123 -174.341 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 8.1 p -95.41 173.58 7.45 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 172.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -72.74 -73.3 0.87 Allowed Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.141 -1.584 . . . . 0.0 109.141 177.174 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 22.19 63.88 0.03 OUTLIER 'General case' 0 C--N 1.345 0.408 0 C-N-CA 127.785 2.434 . . . . 0.0 111.93 -172.346 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.1 mt -62.38 115.05 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 CA-C-N 115.38 -0.827 . . . . 0.0 109.617 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 41.2 t80 -68.59 129.03 38.72 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 172.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 49.8 t-20 -117.36 111.25 40.2 Favored Pre-proline 0 N--CA 1.455 -0.176 0 C-N-CA 123.76 0.824 . . . . 0.0 109.212 175.044 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.11 -38.32 46.35 Favored 'Trans proline' 0 N--CA 1.448 -1.189 0 C-N-CA 121.015 1.143 . . . . 0.0 111.386 -174.355 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 -57.92 -32.63 67.95 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 117.959 0.345 . . . . 0.0 111.098 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -88.15 -32.14 18.8 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.591 0.756 . . . . 0.0 109.98 177.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.5 -159.4 41.87 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.821 -0.911 . . . . 0.0 110.821 -167.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.58 61.05 14.96 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 125.441 1.496 . . . . 0.0 107.732 171.37 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -62.75 -32.4 78.18 Favored 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.438 2.092 . . . . 0.0 111.393 -169.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -59.68 -30.73 68.97 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 123.986 0.914 . . . . 0.0 110.642 178.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -94.34 -28.55 15.49 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 125.115 1.366 . . . . 0.0 110.515 -178.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.72 13.67 1.22 Allowed Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.413 1.006 . . . . 0.0 113.739 169.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 54.7 t -112.45 111.61 36.9 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.285 0 CA-C-N 118.45 1.125 . . . . 0.0 108.602 -174.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -64.12 155.15 80.1 Favored Pre-proline 0 CA--C 1.533 0.304 0 O-C-N 121.708 -0.62 . . . . 0.0 111.132 -176.156 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.2 149.5 80.08 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.127 1.218 . . . . 0.0 110.589 169.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 68.87 20.29 74.29 Favored Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.402 1.477 . . . . 0.0 112.885 -173.001 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 65.1 m -88.03 120.78 29.71 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 120.058 1.929 . . . . 0.0 107.558 174.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -59.75 134.08 56.7 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 172.312 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -42.2 -38.35 1.72 Allowed 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.126 0.57 . . . . 0.0 112.092 168.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 57.9 pttt -67.32 -41.72 84.81 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 117.579 -1.649 . . . . 0.0 110.185 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -71.83 -19.28 62.0 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 125.586 1.554 . . . . 0.0 110.577 -174.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 22.0 mt -52.52 133.11 44.86 Favored Pre-proline 0 N--CA 1.443 -0.802 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 173.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -65.17 141.48 69.59 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 122.275 1.984 . . . . 0.0 110.113 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.2 -15.95 60.98 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 124.198 0.999 . . . . 0.0 111.912 177.279 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -66.83 -22.83 65.99 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.268 1.027 . . . . 0.0 112.181 170.683 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 89.2 t90 -78.35 149.16 33.48 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-O 121.628 0.727 . . . . 0.0 111.102 -174.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 2.2 m -126.99 156.29 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 C-N-CA 125.847 1.659 . . . . 0.0 109.892 -174.03 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 7.7 t -63.36 137.09 96.98 Favored Pre-proline 0 CA--C 1.543 0.689 0 C-N-CA 122.958 0.503 . . . . 0.0 110.347 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -69.6 95.81 0.55 Allowed 'Trans proline' 0 N--CA 1.451 -1.022 0 C-N-CA 123.128 2.552 . . . . 0.0 110.66 -178.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 56.3 mt 85.42 59.11 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 126.813 2.045 . . . . 0.0 111.058 173.293 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 13.1 t -147.22 -94.67 0.09 Allowed 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -176.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 157.38 -41.85 0.53 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.4 t -70.5 148.0 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.97 177.7 49.8 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 176.321 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.9 ptmt -65.38 106.44 1.38 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 165.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -138.85 -65.84 0.49 Allowed 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 173.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -101.13 106.51 17.77 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 -178.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -142.29 128.7 20.07 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 51.7 mt-10 -104.2 141.88 35.49 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 124.443 1.097 . . . . 0.0 108.606 -175.221 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -75.49 142.69 42.85 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 119.913 1.233 . . . . 0.0 109.73 -179.354 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.2 t -112.38 106.56 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 C-N-CA 127.629 2.372 . . . . 0.0 106.737 177.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -82.93 53.74 2.52 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 124.968 1.307 . . . . 0.0 113.372 -173.261 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . 0.418 ' C ' ' HZ3' ' A' ' 3' ' ' LYS . 7.5 pt-20 . . . . . 0 C--O 1.25 1.095 0 C-N-CA 124.451 1.1 . . . . 0.0 110.256 179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.382 21.9 ptm . . . . . 0 N--CA 1.474 0.749 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.0 mttm 62.47 165.33 0.11 Allowed 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 126.544 1.937 . . . . 0.0 113.012 -172.131 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -78.0 163.13 26.22 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.595 -178.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -138.31 140.51 39.58 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 118.971 -0.538 . . . . 0.0 109.852 175.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.3 t -90.69 160.31 15.92 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 118.014 0.37 . . . . 0.0 111.151 173.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 51.5 t -81.37 -121.01 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 125.558 1.543 . . . . 0.0 107.452 175.435 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 12.6 t -160.49 -46.08 0.05 OUTLIER 'General case' 0 CA--C 1.535 0.368 0 O-C-N 121.427 -0.796 . . . . 0.0 110.415 -175.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.5 p -104.65 -66.75 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 C-N-CA 123.42 0.688 . . . . 0.0 111.271 179.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.5 p -67.59 -38.77 84.5 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 123.713 0.805 . . . . 0.0 110.626 -176.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.73 31.03 30.77 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 179.197 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 18.6 m-85 -65.76 87.21 0.09 Allowed 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 117.742 0.771 . . . . 0.0 109.439 168.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.4 mt -57.44 111.04 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 C-N-CA 123.293 0.637 . . . . 0.0 109.293 172.4 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 20.1 t80 -73.69 133.37 43.37 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 173.203 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 50.7 t-20 -121.45 112.78 32.52 Favored Pre-proline 0 N--CA 1.455 -0.191 0 C-N-CA 124.255 1.022 . . . . 0.0 109.753 177.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -62.85 -38.83 45.51 Favored 'Trans proline' 0 N--CA 1.45 -1.03 0 C-N-CA 121.474 1.449 . . . . 0.0 112.083 -171.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -58.75 -32.31 69.15 Favored 'General case' 0 N--CA 1.446 -0.625 0 O-C-N 123.151 0.282 . . . . 0.0 111.059 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -87.46 -31.38 20.05 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.494 0.717 . . . . 0.0 109.92 177.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.11 -157.36 43.32 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -166.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.31 61.57 12.08 Favored Pre-proline 0 CA--C 1.54 0.588 0 C-N-CA 125.457 1.503 . . . . 0.0 107.455 171.035 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -61.87 -33.86 83.43 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.62 2.213 . . . . 0.0 111.2 -169.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -56.1 -30.48 62.13 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 125.438 1.495 . . . . 0.0 110.66 178.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.0 m-80 -97.02 -32.84 11.79 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 125.531 1.533 . . . . 0.0 110.432 -177.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 139.39 11.24 0.77 Allowed Glycine 0 CA--C 1.53 1.013 0 C-N-CA 123.898 0.761 . . . . 0.0 114.015 171.106 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 68.6 t -109.31 112.18 39.36 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.215 0 CA-C-N 118.898 1.349 . . . . 0.0 108.791 -176.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.19 154.35 82.97 Favored Pre-proline 0 CA--C 1.533 0.306 0 O-C-N 121.91 -0.494 . . . . 0.0 110.904 -177.564 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -58.38 147.02 87.55 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 121.408 1.405 . . . . 0.0 110.947 170.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 77.04 15.39 81.69 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 125.051 1.31 . . . . 0.0 112.838 -176.326 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 98.7 m -87.78 117.48 26.65 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 119.956 1.878 . . . . 0.0 107.421 177.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -57.86 135.48 56.86 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 171.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -43.88 -36.95 2.59 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 123.389 0.676 . . . . 0.0 112.154 170.421 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.408 ' HZ1' ' CG ' ' A' ' 32' ' ' ASP . 19.7 pttp -66.51 -39.98 88.96 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 118.017 -1.473 . . . . 0.0 110.066 -178.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.408 ' CG ' ' HZ1' ' A' ' 31' ' ' LYS . 82.6 m-20 -80.04 -12.86 59.66 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 125.718 1.607 . . . . 0.0 110.741 -172.617 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 22.5 mt -56.36 132.8 76.24 Favored Pre-proline 0 N--CA 1.444 -0.752 0 CA-C-O 118.356 -0.831 . . . . 0.0 108.949 174.221 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -54.89 136.26 71.53 Favored 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 124.152 3.235 . . . . 0.0 110.551 176.555 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.73 -18.44 63.52 Favored 'General case' 0 CA--C 1.533 0.296 0 O-C-N 121.352 -0.843 . . . . 0.0 111.319 -179.482 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -76.55 -11.48 59.88 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 125.876 1.67 . . . . 0.0 112.104 171.092 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -71.65 149.77 45.24 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 119.07 0.85 . . . . 0.0 110.526 176.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 2.1 m -128.39 153.45 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 C-N-CA 126.082 1.753 . . . . 0.0 109.881 -175.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 8.2 t -73.71 138.48 77.05 Favored Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 123.658 0.783 . . . . 0.0 111.042 -175.079 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -58.64 127.53 24.88 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 123.416 2.744 . . . . 0.0 111.77 -177.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 24.5 mt 54.65 34.89 22.5 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.688 1.195 . . . . 0.0 111.857 -179.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.1 t -131.93 -176.22 3.99 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -139.01 47.57 0.91 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.036 -0.825 . . . . 0.0 111.036 -175.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -155.65 156.98 4.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 177.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.78 -179.6 50.03 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 178.405 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.8 ptmt -62.69 -19.56 64.0 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 170.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 29.26 -94.42 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 129.408 3.083 . . . . 0.0 111.529 -176.258 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.1 mm-40 -145.91 69.93 1.23 Allowed 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 164.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.4 m-30 -47.73 156.26 0.33 Allowed 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 125.656 1.582 . . . . 0.0 110.375 169.18 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -94.82 147.46 23.32 Favored 'General case' 0 C--O 1.225 -0.236 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -172.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -75.05 143.9 43.26 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 118.726 0.693 . . . . 0.0 109.198 -179.308 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 11.0 t -107.95 110.88 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 C-N-CA 126.121 1.768 . . . . 0.0 106.494 177.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -76.03 55.29 0.91 Allowed 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 125.454 1.502 . . . . 0.0 113.272 -177.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 117.231 -1.366 . . . . 0.0 108.085 158.569 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.376 26.5 ptm . . . . . 0 N--CA 1.472 0.657 0 N-CA-C 106.349 -1.723 . . . . 0.0 106.349 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 56.4 mttm 66.09 162.34 0.16 Allowed 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 126.64 1.976 . . . . 0.0 113.351 -176.079 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -77.71 163.65 25.97 Favored 'General case' 0 N--CA 1.447 -0.591 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.201 -179.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 23.6 m-85 -144.55 146.69 32.49 Favored 'General case' 0 CA--C 1.528 0.124 0 CA-C-O 119.046 -0.502 . . . . 0.0 110.732 176.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.5 t -99.0 143.48 29.24 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 174.251 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 48.9 t -82.65 120.23 25.3 Favored 'General case' 0 C--N 1.344 0.346 0 C-N-CA 126.678 1.991 . . . . 0.0 109.963 177.745 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 20.2 m -41.6 -76.18 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 127.617 2.367 . . . . 0.0 114.063 -175.256 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.2 p -99.7 48.5 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 O-C-N 121.233 -0.917 . . . . 0.0 109.653 -168.024 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 46.6 t -160.95 -60.95 0.06 Allowed 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -160.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.7 -13.48 63.9 Favored Glycine 0 CA--C 1.53 1.007 0 CA-C-O 119.025 -0.875 . . . . 0.0 113.137 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -59.19 143.32 49.33 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 119.42 1.61 . . . . 0.0 109.902 173.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 18.2 mt -112.04 121.22 64.07 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 123.89 0.876 . . . . 0.0 109.148 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 68.3 t80 -80.93 140.76 35.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 172.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 64.9 t-20 -124.68 120.1 25.79 Favored Pre-proline 0 C--O 1.224 -0.278 0 C-N-CA 124.252 1.021 . . . . 0.0 109.732 177.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -68.65 -40.49 7.35 Favored 'Trans proline' 0 N--CA 1.442 -1.507 0 C-N-CA 120.697 0.932 . . . . 0.0 112.122 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -60.4 -31.05 70.0 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 119.155 0.889 . . . . 0.0 110.95 -177.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.2 m-20 -90.11 -29.52 18.27 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.336 0.655 . . . . 0.0 109.967 177.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.48 -160.05 40.86 Favored Glycine 0 CA--C 1.529 0.951 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -165.615 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -139.64 62.43 23.17 Favored Pre-proline 0 CA--C 1.538 0.498 0 C-N-CA 125.181 1.393 . . . . 0.0 107.679 169.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -61.64 -32.12 86.99 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.345 2.03 . . . . 0.0 111.137 -171.244 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -57.05 -31.69 65.44 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.898 1.279 . . . . 0.0 110.587 178.39 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -95.43 -32.7 12.78 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.15 1.38 . . . . 0.0 110.483 -178.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.83 14.67 0.66 Allowed Glycine 0 CA--C 1.531 1.08 0 C-N-CA 124.053 0.835 . . . . 0.0 114.108 170.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.6 t -112.9 112.7 41.54 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.264 0 CA-C-N 118.808 1.304 . . . . 0.0 109.053 -176.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -64.58 155.94 79.62 Favored Pre-proline 0 C--N 1.328 -0.338 0 O-C-N 121.967 -0.458 . . . . 0.0 111.116 -177.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.64 148.29 88.27 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 121.569 1.513 . . . . 0.0 110.981 171.489 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.94 17.25 79.34 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 125.296 1.427 . . . . 0.0 112.662 -175.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 93.3 m -87.76 117.65 26.73 Favored 'General case' 0 N--CA 1.442 -0.875 0 CA-C-N 119.838 1.819 . . . . 0.0 107.59 176.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -58.1 134.35 56.37 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.401 171.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -40.47 -40.08 1.14 Allowed 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 123.901 0.88 . . . . 0.0 112.415 169.069 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.2 pttp -68.48 -38.29 80.9 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 118.295 -1.362 . . . . 0.0 109.973 -176.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -78.34 -15.62 58.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.805 1.642 . . . . 0.0 110.3 -174.358 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 19.4 mt -54.97 133.9 67.42 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-O 118.389 -0.815 . . . . 0.0 109.308 174.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_exo -57.69 137.3 80.53 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 123.597 2.865 . . . . 0.0 110.883 176.18 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -66.03 -18.43 65.33 Favored 'General case' 0 N--CA 1.45 -0.459 0 O-C-N 121.299 -0.875 . . . . 0.0 111.426 176.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -82.93 -6.21 59.37 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.563 1.545 . . . . 0.0 111.944 173.699 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 71.0 t90 -69.94 160.43 31.89 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 119.053 0.842 . . . . 0.0 110.093 172.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -139.5 150.17 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 C-N-CA 125.585 1.554 . . . . 0.0 108.465 176.656 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.4 p -83.68 165.27 40.75 Favored Pre-proline 0 CA--C 1.539 0.557 0 N-CA-C 108.785 -0.821 . . . . 0.0 108.785 -179.182 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.51 124.13 9.61 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 121.301 1.334 . . . . 0.0 110.842 -168.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 12.6 mt 66.29 44.17 2.56 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 125.258 1.423 . . . . 0.0 112.201 172.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.3 t -138.45 179.63 6.35 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.913 0.885 . . . . 0.0 108.818 -177.345 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -100.98 -87.81 1.99 Allowed Glycine 0 CA--C 1.526 0.72 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 178.047 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.6 p -82.99 102.2 8.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 178.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -108.54 145.82 16.44 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 108.751 -1.74 . . . . 0.0 108.751 176.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER 59.5 101.78 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.42 1.488 . . . . 0.0 111.749 -170.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -138.8 -75.73 0.37 Allowed 'General case' 0 CA--C 1.521 -0.139 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 160.341 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 10.3 tm0? -144.69 55.34 1.25 Allowed 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 124.739 1.216 . . . . 0.0 107.846 -174.575 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 4.1 m-30 -55.51 150.99 11.09 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 125.059 1.343 . . . . 0.0 108.894 175.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -87.39 150.86 23.53 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.491 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -78.83 145.84 34.04 Favored 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 123.676 0.791 . . . . 0.0 109.088 179.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 14.5 t -110.84 111.44 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 C-N-CA 126.622 1.969 . . . . 0.0 107.081 174.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -71.86 67.09 0.59 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.305 1.842 . . . . 0.0 113.116 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 . . . . . 0 C--O 1.255 1.372 0 CA-C-O 117.86 -1.067 . . . . 0.0 111.098 164.514 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.415 ' N ' ' OE2' ' A' ' 16' ' ' GLU . 0.7 OUTLIER . . . . . 0 N--CA 1.477 0.889 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 . . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 7.9 mttm -65.54 139.27 58.45 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.61 0.719 . . . . 0.0 111.586 178.093 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 78.7 mttt -73.9 174.6 8.29 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 124.907 1.283 . . . . 0.0 109.46 174.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -144.32 131.03 20.13 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-O 118.831 -0.604 . . . . 0.0 111.628 176.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.6 m -79.87 143.72 34.07 Favored 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 123.872 0.869 . . . . 0.0 110.811 174.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 9.0 t -70.43 -175.68 1.07 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.209 1.404 . . . . 0.0 109.569 168.014 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 63.5 m -82.29 -99.26 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 123.688 0.795 . . . . 0.0 110.06 -176.612 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.8 p -87.33 -30.69 5.76 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 O-C-N 120.967 -1.083 . . . . 0.0 110.85 -178.071 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 50.8 t -39.62 -55.48 1.86 Allowed 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 128.931 2.892 . . . . 0.0 112.365 175.247 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 100.91 -15.06 58.48 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-O 119.043 -0.865 . . . . 0.0 113.279 177.404 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -62.38 159.32 15.57 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.307 1.553 . . . . 0.0 111.574 176.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 28.7 mt -123.4 124.94 70.87 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 C-N-CA 125.227 1.411 . . . . 0.0 107.282 175.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 72.5 t80 -78.28 135.38 37.53 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 167.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -118.01 116.75 35.83 Favored Pre-proline 0 C--O 1.225 -0.204 0 C-N-CA 124.24 1.016 . . . . 0.0 109.948 175.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -64.82 -42.57 14.66 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 121.927 1.751 . . . . 0.0 111.793 -178.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . 0.415 ' OE2' ' N ' ' A' ' 1' ' ' MET . 45.3 mt-10 -61.98 -28.61 69.68 Favored 'General case' 0 N--CA 1.446 -0.658 0 O-C-N 123.27 0.356 . . . . 0.0 110.862 -174.34 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -90.63 -31.62 16.58 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.997 0.919 . . . . 0.0 110.399 174.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.98 -162.07 31.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.289 0.947 . . . . 0.0 110.984 -165.177 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -137.94 62.27 32.58 Favored Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 125.894 1.678 . . . . 0.0 107.485 171.878 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.1 -33.32 82.66 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 122.75 2.3 . . . . 0.0 111.28 -170.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -56.79 -28.99 62.25 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.674 1.189 . . . . 0.0 110.738 178.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.6 m-80 -102.11 -26.47 13.35 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 125.607 1.563 . . . . 0.0 110.684 -175.516 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.81 6.86 1.68 Allowed Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.167 0.889 . . . . 0.0 113.786 168.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 75.7 t -107.58 109.87 29.77 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.156 0 CA-C-N 118.595 1.198 . . . . 0.0 108.509 -174.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.87 155.97 81.25 Favored Pre-proline 0 C--N 1.329 -0.321 0 O-C-N 121.734 -0.604 . . . . 0.0 111.086 -176.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.32 147.68 89.91 Favored 'Trans proline' 0 N--CA 1.449 -1.102 0 C-N-CA 121.496 1.464 . . . . 0.0 111.032 171.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.28 14.98 81.8 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.682 -176.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 99.2 m -86.67 113.72 22.77 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 119.798 1.799 . . . . 0.0 107.546 178.042 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -53.4 133.26 40.44 Favored 'General case' 0 N--CA 1.446 -0.654 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 167.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 5.1 t80 -45.2 -31.84 1.64 Allowed 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 173.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 7.3 pttt -68.57 -45.65 71.49 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 118.398 -1.321 . . . . 0.0 110.065 179.538 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -67.58 -19.51 65.27 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 125.58 1.552 . . . . 0.0 111.222 -175.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 15.2 mt -53.29 131.37 52.27 Favored Pre-proline 0 N--CA 1.443 -0.812 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 176.089 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_endo -61.96 140.34 84.21 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 122.393 2.062 . . . . 0.0 109.455 -178.432 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -67.35 -14.38 62.87 Favored 'General case' 0 CA--C 1.535 0.373 0 O-C-N 121.968 -0.457 . . . . 0.0 111.87 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -75.34 -15.07 60.51 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.491 0.716 . . . . 0.0 112.204 171.545 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 85.5 t90 -73.7 151.8 40.62 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 176.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 12.1 p -141.29 164.61 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 C-N-CA 124.927 1.291 . . . . 0.0 107.777 -177.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.3 t -48.79 138.86 12.17 Favored Pre-proline 0 CA--C 1.54 0.561 0 C-N-CA 124.391 1.076 . . . . 0.0 110.111 176.606 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -59.89 -36.88 89.11 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.323 2.015 . . . . 0.0 112.881 -173.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 41.0 mt -136.95 42.11 2.45 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.301 0.641 . . . . 0.0 110.096 -175.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -164.71 173.68 11.59 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 -174.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -133.35 67.84 0.55 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 -174.14 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.7 p -128.92 141.42 46.66 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 172.289 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.38 147.84 49.18 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 6.2 ptmt -60.19 -38.52 83.52 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 117.226 0.513 . . . . 0.0 111.549 -179.472 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -72.35 71.63 0.91 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 124.295 1.038 . . . . 0.0 109.682 178.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 4.0 tp-100 -171.92 -38.66 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 125.728 1.611 . . . . 0.0 109.666 -175.524 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -57.84 137.21 56.86 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.048 0.939 . . . . 0.0 109.636 -176.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -96.01 149.49 21.52 Favored 'General case' 0 C--O 1.22 -0.496 0 C-N-CA 124.627 1.171 . . . . 0.0 109.364 -175.104 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -71.93 138.49 48.14 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 119.883 1.219 . . . . 0.0 110.039 -178.381 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.3 t -101.2 107.86 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 C-N-CA 125.467 1.507 . . . . 0.0 107.08 177.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -72.06 65.95 0.59 Allowed 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 126.348 1.859 . . . . 0.0 113.397 -177.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 . . . . . 0 C--O 1.257 1.467 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 150.768 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.422 ' N ' ' OE2' ' A' ' 16' ' ' GLU . 1.4 tmt? . . . . . 0 N--CA 1.476 0.852 0 N-CA-C 104.793 -2.299 . . . . 0.0 104.793 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 9.6 mttm -63.23 140.53 58.88 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 119.682 1.128 . . . . 0.0 111.494 177.337 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 58.2 mttt -71.02 171.33 11.05 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 124.678 1.191 . . . . 0.0 109.862 172.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -141.69 134.35 28.48 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 172.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.5 t -85.8 154.53 21.52 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 118.312 0.506 . . . . 0.0 111.282 174.281 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 19.9 t -75.01 170.2 16.48 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 125.15 1.38 . . . . 0.0 107.852 172.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 6.9 t -125.72 16.7 8.09 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.063 0.945 . . . . 0.0 110.497 177.248 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 74.1 t -132.5 -60.54 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.34 0.179 0 C-N-CA 123.932 0.893 . . . . 0.0 109.52 -179.1 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.6 p -95.92 -89.31 0.26 Allowed 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 176.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 164.12 28.95 0.02 OUTLIER Glycine 0 CA--C 1.529 0.94 0 C-N-CA 125.487 1.518 . . . . 0.0 110.638 176.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -80.73 73.66 7.69 Favored 'General case' 0 N--CA 1.453 -0.322 0 O-C-N 121.819 -0.812 . . . . 0.0 108.83 -170.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.0 mt -45.35 112.52 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 C-N-CA 123.33 0.652 . . . . 0.0 110.978 -178.484 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 35.7 t80 -73.53 134.44 43.82 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 173.041 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 46.3 t-20 -123.07 114.63 29.35 Favored Pre-proline 0 N--CA 1.446 -0.652 0 C-N-CA 123.437 0.695 . . . . 0.0 109.387 176.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -65.36 -43.77 10.21 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 122.317 2.012 . . . . 0.0 111.327 -177.256 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . 0.422 ' OE2' ' N ' ' A' ' 1' ' ' MET . 10.6 mt-10 -56.84 -29.39 62.79 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 123.636 0.774 . . . . 0.0 111.226 -176.679 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -100.45 -23.41 14.74 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.879 0.872 . . . . 0.0 110.455 179.033 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.11 -160.59 30.73 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 124.829 1.204 . . . . 0.0 110.983 -172.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -140.34 61.4 16.69 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 125.281 1.432 . . . . 0.0 107.497 171.719 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_endo -62.38 -30.86 81.14 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 122.199 1.933 . . . . 0.0 111.076 -172.009 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -59.02 -29.65 67.43 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 124.463 1.105 . . . . 0.0 110.337 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -98.81 -29.29 13.06 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 125.544 1.537 . . . . 0.0 110.964 -177.154 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.36 18.24 0.93 Allowed Glycine 0 CA--C 1.532 1.15 0 C-N-CA 124.249 0.928 . . . . 0.0 113.798 170.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.2 t -117.26 110.02 29.71 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.216 0 CA-C-N 118.334 1.067 . . . . 0.0 108.443 -175.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -63.36 155.76 73.14 Favored Pre-proline 0 CA--C 1.534 0.337 0 O-C-N 121.835 -0.541 . . . . 0.0 110.976 -177.253 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -60.54 149.37 87.16 Favored 'Trans proline' 0 N--CA 1.449 -1.129 0 C-N-CA 121.464 1.443 . . . . 0.0 110.717 171.509 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.04 14.93 81.76 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 125.129 1.347 . . . . 0.0 113.047 -175.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 97.8 m -89.34 114.89 26.36 Favored 'General case' 0 N--CA 1.443 -0.815 0 CA-C-N 119.919 1.86 . . . . 0.0 107.836 178.541 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -56.17 134.72 53.15 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 169.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -42.38 -35.6 1.06 Allowed 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 123.709 0.803 . . . . 0.0 112.881 171.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 51.0 pttt -69.69 -42.48 74.05 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.625 -178.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -68.08 -21.44 64.97 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 125.658 1.583 . . . . 0.0 110.438 -176.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 21.8 mt -53.63 130.6 55.08 Favored Pre-proline 0 N--CA 1.445 -0.688 0 CA-C-N 118.758 0.708 . . . . 0.0 109.216 175.331 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -63.94 140.52 73.3 Favored 'Trans proline' 0 N--CA 1.445 -1.335 0 C-N-CA 122.479 2.12 . . . . 0.0 109.758 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -57.84 -23.22 51.78 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.537 0.735 . . . . 0.0 111.522 175.225 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.57 -18.75 63.66 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 124.745 1.218 . . . . 0.0 112.057 177.633 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 80.1 t90 -75.55 154.54 36.76 Favored 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 121.629 -0.669 . . . . 0.0 110.095 -179.563 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.1 t -139.73 149.57 22.43 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 C-N-CA 124.905 1.282 . . . . 0.0 108.569 -169.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.1 t -73.41 127.39 88.98 Favored Pre-proline 0 CA--C 1.545 0.757 0 C-N-CA 122.974 0.509 . . . . 0.0 110.879 179.153 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.43 139.76 50.41 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 123.196 2.597 . . . . 0.0 111.646 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 57.6 mt 58.56 31.94 21.6 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.54 1.136 . . . . 0.0 111.706 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 43.5 t -147.76 -57.61 0.24 Allowed 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -173.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.94 26.8 63.75 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 111.946 -0.461 . . . . 0.0 111.946 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 95.6 t -111.35 155.99 12.6 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 C-N-CA 124.341 1.056 . . . . 0.0 109.182 177.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -67.91 155.69 52.94 Favored Glycine 0 CA--C 1.528 0.867 0 C-N-CA 124.469 1.033 . . . . 0.0 111.743 -176.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.1 ptmt -67.86 -42.89 80.62 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -175.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -76.87 77.65 3.46 Favored 'General case' 0 N--CA 1.456 -0.166 0 CA-C-O 122.426 1.108 . . . . 0.0 108.879 -170.874 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -179.37 -30.06 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 128.582 2.753 . . . . 0.0 108.97 -168.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -57.06 141.42 45.9 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.628 0.771 . . . . 0.0 110.888 169.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -111.66 145.16 39.74 Favored 'General case' 0 C--O 1.22 -0.458 0 C-N-CA 125.08 1.352 . . . . 0.0 109.551 -177.805 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -65.62 136.34 56.2 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-N 118.778 0.717 . . . . 0.0 110.415 -176.02 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.8 t -94.74 109.53 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 175.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -69.0 82.13 0.31 Allowed 'General case' 0 N--CA 1.443 -0.796 0 C-N-CA 125.503 1.521 . . . . 0.0 110.706 175.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 . . . . . 0 C--O 1.251 1.154 0 CA-C-O 117.229 -1.367 . . . . 0.0 110.471 169.387 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.415 25.1 ptm . . . . . 0 N--CA 1.47 0.534 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 22.6 mttm 55.83 174.82 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.431 0 O-C-N 125.473 1.733 . . . . 0.0 112.319 -172.416 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 66.2 mttt -73.61 170.65 14.76 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.439 -0.801 . . . . 0.0 109.836 -178.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.402 ' CE1' ' HB2' ' A' ' 30' ' ' PHE . 55.3 m-85 -142.07 141.64 32.77 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 122.501 0.32 . . . . 0.0 111.323 176.419 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 91.1 m -78.25 142.44 37.85 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 123.47 0.708 . . . . 0.0 109.605 172.108 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 24.8 t -79.58 135.48 36.61 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 125.071 1.348 . . . . 0.0 108.428 175.048 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.0 m -45.32 -56.79 4.55 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.496 1.519 . . . . 0.0 114.197 -168.135 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 14.5 p -153.35 35.91 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 120.939 0.399 . . . . 0.0 110.59 -173.321 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 2.8 m -121.79 -65.25 1.14 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.485 0.714 . . . . 0.0 109.188 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 116.78 56.33 0.31 Allowed Glycine 0 CA--C 1.53 0.995 0 C-N-CA 124.717 1.151 . . . . 0.0 111.948 176.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -139.18 87.66 2.22 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.457 1.103 . . . . 0.0 109.052 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.4 mt -57.23 127.13 15.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 O-C-N 121.439 -0.788 . . . . 0.0 111.035 -176.541 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.407 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 27.7 t80 -81.4 137.29 35.7 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 172.448 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 51.7 t-20 -122.55 112.44 31.02 Favored Pre-proline 0 C--N 1.339 0.136 0 C-N-CA 124.168 0.987 . . . . 0.0 109.841 175.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_endo -65.15 -37.44 32.23 Favored 'Trans proline' 0 N--CA 1.45 -1.086 0 C-N-CA 121.28 1.32 . . . . 0.0 111.51 -173.567 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -58.34 -32.09 68.2 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 117.726 0.239 . . . . 0.0 111.322 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -87.49 -32.8 19.26 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.489 0.716 . . . . 0.0 109.868 177.029 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.26 -156.41 45.16 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 -168.093 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -143.37 61.29 9.83 Favored Pre-proline 0 CA--C 1.542 0.669 0 C-N-CA 125.705 1.602 . . . . 0.0 107.442 172.26 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.01 -33.41 83.27 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.671 2.247 . . . . 0.0 111.618 -169.056 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -58.15 -30.99 66.79 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 124.688 1.195 . . . . 0.0 110.394 178.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -92.4 -29.42 16.31 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 125.245 1.418 . . . . 0.0 110.351 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.14 -4.01 3.13 Favored Glycine 0 CA--C 1.529 0.938 0 C-N-CA 124.477 1.037 . . . . 0.0 113.148 172.101 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 74.3 t -94.3 109.78 22.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -172.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -62.98 154.84 75.35 Favored Pre-proline 0 CA--C 1.534 0.354 0 O-C-N 121.767 -0.583 . . . . 0.0 110.488 -177.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -59.08 149.27 80.98 Favored 'Trans proline' 0 N--CA 1.449 -1.138 0 C-N-CA 121.123 1.215 . . . . 0.0 110.417 169.499 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.03 17.93 80.22 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 125.32 1.438 . . . . 0.0 113.3 -175.355 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 98.0 m -92.1 119.41 31.75 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-N 119.983 1.892 . . . . 0.0 107.312 177.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -65.2 142.99 58.13 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 173.168 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.402 ' HB2' ' CE1' ' A' ' 4' ' ' TYR . 2.2 t80 -49.22 -33.11 11.84 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 123.639 0.775 . . . . 0.0 112.366 175.106 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 10.4 pttm -67.27 -37.17 83.01 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 119.254 -0.978 . . . . 0.0 110.926 178.291 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 -77.43 -21.0 53.7 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 124.742 1.217 . . . . 0.0 110.09 -174.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.407 HD13 ' CZ ' ' A' ' 13' ' ' TYR . 22.4 mt -55.64 133.68 71.71 Favored Pre-proline 0 N--CA 1.445 -0.693 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.214 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -59.45 134.8 60.68 Favored 'Trans proline' 0 N--CA 1.449 -1.123 0 C-N-CA 122.746 2.297 . . . . 0.0 109.374 175.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.59 -3.84 33.48 Favored 'General case' 0 N--CA 1.447 -0.577 0 O-C-N 121.632 -0.667 . . . . 0.0 112.346 -176.489 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -76.23 -12.42 60.09 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.131 0.972 . . . . 0.0 112.596 164.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 80.6 t90 -67.15 148.92 51.21 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 118.981 0.81 . . . . 0.0 111.297 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 62.7 t -125.97 144.47 35.98 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 126.732 2.013 . . . . 0.0 108.718 -175.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.8 p -82.82 132.57 51.0 Favored Pre-proline 0 CA--C 1.543 0.695 0 CA-C-N 120.038 1.29 . . . . 0.0 110.06 177.064 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -79.12 139.84 15.32 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.617 2.211 . . . . 0.0 111.066 -175.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 18.1 tp 60.37 31.87 20.5 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 124.497 1.119 . . . . 0.0 111.262 -178.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 33.3 m -125.65 -97.83 0.42 Allowed 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.977 1.311 . . . . 0.0 109.357 -179.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 143.88 114.18 0.95 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 108.325 -1.91 . . . . 0.0 108.325 -164.628 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.265 0.4 OUTLIER 76.94 -173.2 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 125.151 1.38 . . . . 0.0 110.402 -171.721 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -129.53 -123.69 2.56 Favored Glycine 0 N--CA 1.449 -0.442 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 23.4 mtpt -82.23 167.86 18.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.429 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -159.45 -75.49 0.07 Allowed 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 124.656 1.183 . . . . 0.0 108.827 172.642 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -124.06 -38.65 2.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 127.268 2.227 . . . . 0.0 109.739 -177.626 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 25.2 p90 53.15 173.47 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.235 2.214 . . . . 0.0 112.882 -176.324 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -138.72 136.55 35.91 Favored 'General case' 0 CA--C 1.521 -0.155 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 172.491 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -74.22 137.27 42.95 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 176.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.6 t -97.59 113.97 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.823 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 175.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -74.09 51.56 0.42 Allowed 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.3 1.44 . . . . 0.0 114.113 -178.499 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 28.9 mt-10 . . . . . 0 C--O 1.253 1.288 0 C-N-CA 125.921 1.688 . . . . 0.0 107.587 157.143 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.396 13.4 ptt? . . . . . 0 N--CA 1.472 0.656 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 33.2 mttt 66.32 164.38 0.18 Allowed 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 126.93 2.092 . . . . 0.0 113.408 -173.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -70.67 162.61 28.69 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.54 178.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -144.99 137.18 25.92 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 124.248 1.019 . . . . 0.0 111.423 -178.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.8 m -75.92 155.59 35.01 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.232 1.013 . . . . 0.0 110.975 173.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 15.3 t -97.49 -37.49 9.95 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.236 1.814 . . . . 0.0 109.3 174.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 86.1 m 76.14 -62.46 0.43 Allowed 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 125.455 1.502 . . . . 0.0 112.016 166.407 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 31.2 m -78.79 43.72 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-N 119.284 0.947 . . . . 0.0 110.656 178.001 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 10.4 t 177.05 -102.49 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -156.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 121.21 64.77 0.24 Allowed Glycine 0 CA--C 1.53 0.974 0 C-N-CA 125.302 1.43 . . . . 0.0 111.035 -176.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -114.51 -57.55 2.26 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.301 1.04 . . . . 0.0 111.055 176.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . 0.251 57.8 mt 79.84 110.73 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 C-N-CA 127.548 2.339 . . . . 0.0 110.997 -170.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 51.6 t80 -74.23 141.6 45.4 Favored 'General case' 0 C--O 1.236 0.357 0 C-N-CA 124.203 1.001 . . . . 0.0 108.859 171.055 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 63.9 t-20 -126.57 116.57 22.88 Favored Pre-proline 0 C--O 1.224 -0.289 0 C-N-CA 123.488 0.715 . . . . 0.0 110.9 173.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -68.25 -41.46 6.97 Favored 'Trans proline' 0 N--CA 1.445 -1.369 0 C-N-CA 121.13 1.22 . . . . 0.0 112.042 -177.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -60.05 -30.9 69.5 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 118.706 0.684 . . . . 0.0 110.855 -178.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 -86.62 -32.71 20.45 Favored 'General case' 0 CA--C 1.53 0.192 0 C-N-CA 123.406 0.682 . . . . 0.0 109.512 176.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.89 -159.86 42.71 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -164.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -137.56 61.79 32.67 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 168.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -61.74 -38.22 62.12 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.11 2.54 . . . . 0.0 111.257 -167.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -51.02 -30.35 15.13 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.769 1.628 . . . . 0.0 110.825 177.145 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -101.48 -18.12 16.12 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 125.818 1.647 . . . . 0.0 110.976 -175.159 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 130.56 -5.18 5.87 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.583 1.087 . . . . 0.0 113.324 172.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 78.6 t -100.22 108.7 23.42 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.202 0 CA-C-N 118.2 1.0 . . . . 0.0 109.103 -171.658 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -64.73 155.16 83.31 Favored Pre-proline 0 CA--C 1.533 0.305 0 O-C-N 121.767 -0.583 . . . . 0.0 111.072 -175.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -57.95 147.64 80.81 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 121.322 1.348 . . . . 0.0 110.723 170.564 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 71.51 21.68 78.69 Favored Glycine 0 CA--C 1.525 0.714 0 C-N-CA 125.653 1.596 . . . . 0.0 112.945 -174.272 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.9 m -91.75 121.92 33.83 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 119.994 1.897 . . . . 0.0 107.818 174.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -63.87 137.87 58.23 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 174.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -42.95 -38.37 2.2 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.167 0.987 . . . . 0.0 111.733 170.277 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.445 ' HZ1' ' CG ' ' A' ' 32' ' ' ASP . 20.6 pttp -67.26 -39.73 86.14 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 118.572 -1.251 . . . . 0.0 110.493 -179.448 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.445 ' CG ' ' HZ1' ' A' ' 31' ' ' LYS . 81.9 m-20 -82.54 -11.45 58.43 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 125.906 1.683 . . . . 0.0 110.716 -172.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 19.6 mt -54.53 133.16 63.54 Favored Pre-proline 0 N--CA 1.441 -0.878 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 171.653 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 16.7 Cg_exo -53.83 134.53 59.42 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 123.785 2.99 . . . . 0.0 109.432 176.059 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.39 -11.2 60.0 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.146 -0.972 . . . . 0.0 111.705 -175.299 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -78.01 -10.1 59.44 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 126.493 1.917 . . . . 0.0 112.181 167.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 78.3 t90 -66.97 158.14 31.61 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 119.089 0.859 . . . . 0.0 109.971 173.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.8 p -136.52 155.09 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 124.712 1.205 . . . . 0.0 108.71 -176.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.6 t -56.4 136.02 76.26 Favored Pre-proline 0 CA--C 1.534 0.339 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -58.59 -28.98 87.73 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 123.045 2.496 . . . . 0.0 113.214 -174.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.6 tp -150.8 51.5 0.86 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 118.72 0.691 . . . . 0.0 111.075 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . 0.258 1.7 p -142.84 -64.68 0.4 Allowed 'General case' 0 N--CA 1.464 0.266 0 O-C-N 122.053 -0.405 . . . . 0.0 110.552 159.715 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 142.87 -136.33 7.04 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 -179.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.4 t 61.77 -83.65 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 C-N-CA 126.097 1.759 . . . . 0.0 112.352 173.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.58 -139.28 6.76 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -170.02 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 48.4 mtpt -113.77 93.75 4.52 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 124.925 1.29 . . . . 0.0 108.608 174.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 55.6 p-10 -144.72 169.73 17.45 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 170.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER 36.93 47.02 0.54 Allowed 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 127.218 2.207 . . . . 0.0 113.324 -177.377 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 21.3 p90 -95.29 113.79 25.51 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.372 0.669 . . . . 0.0 110.053 179.628 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -98.33 149.4 22.67 Favored 'General case' 0 C--O 1.223 -0.31 0 C-N-CA 125.77 1.628 . . . . 0.0 108.726 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -79.72 142.02 35.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 120.273 1.397 . . . . 0.0 110.031 -178.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.2 t -105.98 109.64 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 126.35 1.86 . . . . 0.0 107.376 176.248 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -72.63 66.55 0.73 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.994 1.718 . . . . 0.0 113.131 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 . . . . . 0 C--O 1.256 1.435 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.241 158.845 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.343 12.5 ptm . . . . . 0 CA--C 1.511 -0.529 0 N-CA-C 104.72 -2.326 . . . . 0.0 104.72 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.6 mttm 62.09 165.76 0.1 Allowed 'General case' 0 N--CA 1.451 -0.42 0 O-C-N 124.908 1.38 . . . . 0.0 112.432 -169.545 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -78.39 166.76 22.26 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.236 -174.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -151.62 150.39 30.23 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 123.367 0.667 . . . . 0.0 112.409 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.5 m -78.28 156.24 29.77 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 123.876 0.87 . . . . 0.0 112.355 171.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 34.0 t -70.93 166.71 20.62 Favored 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 125.026 1.33 . . . . 0.0 108.768 166.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 5.4 m -45.16 -41.88 8.51 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 126.463 1.905 . . . . 0.0 112.302 170.208 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.3 p -160.98 -32.74 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 113.53 0.937 . . . . 0.0 113.53 -172.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.9 p -77.58 172.46 13.33 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 120.213 1.369 . . . . 0.0 110.58 -177.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -89.5 51.69 3.65 Favored Glycine 0 CA--C 1.527 0.83 0 O-C-N 121.318 -0.864 . . . . 0.0 111.732 -176.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -125.84 86.73 2.57 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 118.25 1.025 . . . . 0.0 110.445 -177.557 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 15.9 mt -67.63 127.26 28.97 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 O-C-N 121.73 -0.607 . . . . 0.0 109.605 174.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 40.0 t80 -78.48 136.94 37.71 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 170.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.6 t-20 -122.19 113.11 31.24 Favored Pre-proline 0 C--O 1.227 -0.123 0 C-N-CA 124.312 1.045 . . . . 0.0 110.34 177.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -65.33 -38.98 24.24 Favored 'Trans proline' 0 N--CA 1.445 -1.359 0 C-N-CA 120.97 1.114 . . . . 0.0 112.246 -177.133 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -59.74 -32.13 70.28 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 118.562 0.619 . . . . 0.0 111.102 -178.054 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -88.06 -32.02 18.97 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 123.471 0.709 . . . . 0.0 109.75 178.083 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.1 -158.62 37.85 Favored Glycine 0 CA--C 1.529 0.952 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 -165.35 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.76 61.69 11.32 Favored Pre-proline 0 CA--C 1.54 0.595 0 C-N-CA 125.955 1.702 . . . . 0.0 107.113 171.831 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -61.11 -33.86 90.51 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.572 2.181 . . . . 0.0 111.045 -170.227 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -54.58 -30.61 54.83 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 125.294 1.437 . . . . 0.0 110.736 178.175 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -102.97 -23.03 13.73 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 125.432 1.493 . . . . 0.0 110.778 -174.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 132.42 11.05 2.02 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 124.287 0.946 . . . . 0.0 113.401 169.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 70.6 t -110.3 108.76 26.23 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 CA-C-N 118.544 1.172 . . . . 0.0 108.762 -175.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -63.1 155.04 75.25 Favored Pre-proline 0 CA--C 1.535 0.379 0 O-C-N 121.662 -0.649 . . . . 0.0 110.876 -178.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.79 148.78 86.8 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 121.118 1.212 . . . . 0.0 110.719 170.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.46 17.0 78.81 Favored Glycine 0 CA--C 1.526 0.73 0 C-N-CA 125.256 1.408 . . . . 0.0 112.963 -174.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 54.1 m -88.6 122.01 31.59 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 119.797 1.798 . . . . 0.0 107.977 178.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -63.88 135.56 56.66 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 171.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -40.39 -41.63 1.42 Allowed 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.4 0.68 . . . . 0.0 111.634 167.348 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.3 pttt -66.91 -34.74 78.44 Favored 'General case' 0 CA--C 1.536 0.429 0 O-C-N 120.241 -1.537 . . . . 0.0 110.823 -178.381 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -76.49 -22.1 54.94 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 125.13 1.372 . . . . 0.0 109.801 -177.64 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 15.8 mt -55.85 134.31 72.95 Favored Pre-proline 0 N--CA 1.445 -0.693 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_endo -62.05 137.3 66.0 Favored 'Trans proline' 0 N--CA 1.443 -1.443 0 C-N-CA 121.755 1.637 . . . . 0.0 108.889 176.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -72.46 -3.35 23.81 Favored 'General case' 0 N--CA 1.444 -0.741 0 O-C-N 121.914 -0.491 . . . . 0.0 111.908 -179.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.06 -23.16 64.01 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 125.509 1.524 . . . . 0.0 112.315 164.179 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 84.6 t90 -70.56 152.43 43.96 Favored 'General case' 0 CA--C 1.53 0.176 0 O-C-N 121.628 -0.67 . . . . 0.0 110.855 -176.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.6 t -139.24 151.8 23.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 C-N-CA 125.901 1.68 . . . . 0.0 107.441 -173.288 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 9.8 t -54.12 133.14 59.75 Favored Pre-proline 0 CA--C 1.541 0.632 0 C-N-CA 125.557 1.543 . . . . 0.0 110.119 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -59.19 -52.49 4.86 Favored 'Trans proline' 0 N--CA 1.459 -0.546 0 C-N-CA 123.674 2.916 . . . . 0.0 113.699 -166.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 96.1 mt -128.68 59.92 1.53 Allowed 'General case' 0 N--CA 1.462 0.135 0 C-N-CA 123.68 0.792 . . . . 0.0 109.541 -173.2 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -162.9 -66.79 0.05 OUTLIER 'General case' 0 CA--C 1.529 0.158 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 -171.637 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 101.1 51.76 1.13 Allowed Glycine 0 CA--C 1.528 0.879 0 C-N-CA 123.641 0.638 . . . . 0.0 112.493 175.21 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 34.7 m -125.56 152.92 32.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 C-N-CA 123.953 0.901 . . . . 0.0 108.91 168.002 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.12 -175.59 44.97 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 110.81 -0.916 . . . . 0.0 110.81 175.334 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 41.2 mtpt -78.41 84.43 4.57 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 122.931 0.492 . . . . 0.0 109.824 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -139.28 150.73 45.79 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.502 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.4 tp-100 48.32 55.82 8.3 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.993 2.117 . . . . 0.0 112.17 175.003 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -103.24 115.88 31.41 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.746 0.818 . . . . 0.0 110.077 -179.254 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -86.24 146.36 26.57 Favored 'General case' 0 C--O 1.226 -0.175 0 C-N-CA 125.431 1.492 . . . . 0.0 109.206 178.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -81.42 141.82 33.56 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 119.089 0.859 . . . . 0.0 109.36 -179.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.4 t -109.03 102.49 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.837 0 C-N-CA 127.109 2.164 . . . . 0.0 107.757 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -76.59 76.36 3.28 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 126.207 1.803 . . . . 0.0 112.682 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 51.2 mm-40 . . . . . 0 C--O 1.255 1.392 0 CA-C-O 116.671 -1.633 . . . . 0.0 108.414 153.42 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.475 0.801 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.3 mttm -82.52 149.09 27.73 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 119.757 1.162 . . . . 0.0 111.394 -178.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -75.33 168.27 20.32 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 124.213 1.005 . . . . 0.0 108.567 174.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 29.4 m-85 -144.62 139.12 27.86 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-O 118.899 -0.572 . . . . 0.0 112.306 -179.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.8 m -87.1 137.78 32.06 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 119.175 0.898 . . . . 0.0 111.298 178.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 40.8 t -62.73 149.7 43.14 Favored 'General case' 0 C--N 1.34 0.171 0 CA-C-N 118.699 0.682 . . . . 0.0 109.708 174.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 58.1 m -43.05 -36.67 1.68 Allowed 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 125.477 1.511 . . . . 0.0 112.113 172.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 m -129.71 -40.76 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 123.368 0.667 . . . . 0.0 112.46 178.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 m -76.79 160.65 29.11 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.346 0.976 . . . . 0.0 112.413 -171.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -99.38 12.59 61.67 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 119.222 -0.766 . . . . 0.0 112.406 174.106 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 38.8 m-85 -60.58 -43.91 96.81 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 118.873 1.336 . . . . 0.0 111.308 -175.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.7 mt 69.64 113.01 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 C-N-CA 126.137 1.775 . . . . 0.0 111.368 -177.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' TYR . . . . . 0.405 ' CZ ' HD13 ' A' ' 33' ' ' ILE . 80.4 t80 -69.62 132.49 46.28 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 171.109 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -120.35 113.23 33.88 Favored Pre-proline 0 N--CA 1.456 -0.168 0 C-N-CA 124.205 1.002 . . . . 0.0 109.685 177.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -59.67 -42.19 49.0 Favored 'Trans proline' 0 N--CA 1.45 -1.045 0 C-N-CA 122.017 1.811 . . . . 0.0 112.443 -176.561 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -59.64 -31.41 69.5 Favored 'General case' 0 N--CA 1.447 -0.606 0 O-C-N 123.108 0.255 . . . . 0.0 111.653 -178.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 -90.09 -29.59 18.24 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 123.304 0.641 . . . . 0.0 110.422 177.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.79 -154.99 42.38 Favored Glycine 0 CA--C 1.53 1.029 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -167.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -146.34 61.33 6.95 Favored Pre-proline 0 CA--C 1.543 0.702 0 C-N-CA 125.595 1.558 . . . . 0.0 107.842 173.558 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -61.33 -34.53 87.17 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 122.944 2.429 . . . . 0.0 111.599 -168.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -54.64 -29.88 53.55 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 125.253 1.421 . . . . 0.0 111.38 177.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -98.03 -33.98 10.97 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 125.493 1.517 . . . . 0.0 109.774 -177.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 141.27 11.51 0.56 Allowed Glycine 0 CA--C 1.532 1.132 0 C-N-CA 123.933 0.778 . . . . 0.0 114.06 169.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 52.2 t -107.61 112.73 41.35 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.245 0 CA-C-N 119.174 1.487 . . . . 0.0 108.947 -177.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -65.05 153.79 88.19 Favored Pre-proline 0 C--N 1.329 -0.283 0 O-C-N 122.016 -0.428 . . . . 0.0 110.406 -179.367 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -59.22 146.77 93.5 Favored 'Trans proline' 0 N--CA 1.449 -1.113 0 C-N-CA 121.631 1.554 . . . . 0.0 110.955 172.185 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 78.03 18.01 77.43 Favored Glycine 0 CA--C 1.524 0.642 0 CA-C-O 118.553 -1.137 . . . . 0.0 112.764 -177.159 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 83.0 m -89.96 120.84 31.52 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 119.577 1.689 . . . . 0.0 107.678 177.133 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -57.55 133.55 55.35 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 169.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -48.43 -32.27 7.45 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.753 174.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -68.73 -40.89 79.67 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 119.375 -0.93 . . . . 0.0 109.345 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -75.36 -15.32 60.48 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 125.546 1.539 . . . . 0.0 110.494 -172.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.405 HD13 ' CZ ' ' A' ' 13' ' ' TYR . 12.9 mt -55.94 132.17 73.59 Favored Pre-proline 0 N--CA 1.441 -0.891 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 172.427 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -63.41 140.2 75.09 Favored 'Trans proline' 0 N--CA 1.443 -1.486 0 C-N-CA 122.633 2.222 . . . . 0.0 109.042 178.083 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.37 -18.12 57.23 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 122.555 0.342 . . . . 0.0 111.224 177.243 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.25 -18.53 62.44 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.784 1.234 . . . . 0.0 112.076 176.357 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 73.3 t90 -68.76 159.47 32.24 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 121.668 0.747 . . . . 0.0 110.943 -178.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 15.9 m -136.51 151.4 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.796 0 C-N-CA 125.66 1.584 . . . . 0.0 109.279 -171.294 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.3 t -72.31 135.75 81.83 Favored Pre-proline 0 CA--C 1.537 0.472 0 C-N-CA 124.428 1.091 . . . . 0.0 108.886 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.58 131.7 30.55 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 122.173 1.916 . . . . 0.0 110.058 179.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 57.1 mt 56.97 49.46 13.89 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.544 0.738 . . . . 0.0 110.991 176.363 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 53.8 t -163.58 -176.62 4.77 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 127.877 2.471 . . . . 0.0 105.092 -174.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.71 -100.35 0.56 Allowed Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.161 0.886 . . . . 0.0 111.08 178.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.3 m -142.35 160.13 19.64 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.117 0 C-N-CA 123.93 0.892 . . . . 0.0 108.687 -177.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 142.84 149.05 5.06 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 177.165 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.8 ptmt -161.75 -177.58 5.96 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 125.291 1.436 . . . . 0.0 107.447 169.629 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 t0 69.59 -63.24 0.39 Allowed 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 126.992 2.117 . . . . 0.0 111.817 169.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 38.5 tt0 -56.73 -22.68 37.08 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.707 2.003 . . . . 0.0 113.188 174.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 6.0 m-30 -45.18 143.95 1.48 Allowed 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.865 1.666 . . . . 0.0 109.494 170.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -75.16 155.39 37.01 Favored 'General case' 0 C--O 1.224 -0.263 0 CA-C-N 119.429 1.013 . . . . 0.0 108.555 -177.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -83.03 133.87 35.06 Favored 'General case' 0 N--CA 1.442 -0.837 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 173.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 13.4 t -93.51 116.59 35.04 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.983 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 172.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -70.96 56.88 0.2 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.683 1.993 . . . . 0.0 114.491 -177.454 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 . . . . . 0 C--O 1.255 1.352 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 159.832 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 21.4 mttm . . . . . 0 N--CA 1.452 -0.35 0 CA-C-O 122.026 0.917 . . . . 0.0 112.77 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.4 mtpt -74.0 170.39 15.52 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.734 -178.73 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 38.2 m-85 -146.89 147.18 30.53 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 122.863 0.465 . . . . 0.0 110.648 -177.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 51.4 p -64.95 165.61 10.57 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 120.644 0.259 . . . . 0.0 111.075 167.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 4.4 t -68.77 -97.56 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 105.97 -1.863 . . . . 0.0 105.97 159.665 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.5 t -172.95 -41.65 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.578 1.951 . . . . 0.0 107.133 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 9.8 p -147.79 -38.62 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 114.495 1.294 . . . . 0.0 114.495 176.361 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 13.6 p -64.97 -41.47 95.41 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 120.345 1.43 . . . . 0.0 111.282 -170.305 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 109.39 47.67 0.85 Allowed Glycine 0 CA--C 1.527 0.793 0 C-N-CA 124.805 1.193 . . . . 0.0 111.779 175.362 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -114.87 89.4 3.09 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.129 0.972 . . . . 0.0 109.041 176.828 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 16.0 mt -63.82 125.52 20.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.509 -0.744 . . . . 0.0 109.601 176.838 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.557 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 39.9 t80 -81.56 138.89 35.35 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 173.077 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.1 t-20 -122.88 114.33 29.73 Favored Pre-proline 0 N--CA 1.456 -0.157 0 C-N-CA 123.862 0.865 . . . . 0.0 110.292 174.51 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -67.46 -38.89 13.61 Favored 'Trans proline' 0 N--CA 1.448 -1.196 0 C-N-CA 121.337 1.358 . . . . 0.0 111.777 -174.563 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -59.87 -30.86 69.27 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 118.141 0.428 . . . . 0.0 111.05 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -87.39 -31.73 19.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.477 0.711 . . . . 0.0 109.886 176.261 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.21 -159.4 37.05 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -166.504 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -139.91 61.16 17.31 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 125.485 1.514 . . . . 0.0 107.535 170.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -63.41 -30.65 72.59 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.527 2.151 . . . . 0.0 111.212 -170.825 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -59.9 -28.24 67.41 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 124.283 1.033 . . . . 0.0 109.858 179.155 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 21.6 m-80 -102.36 -26.22 13.36 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 125.73 1.612 . . . . 0.0 110.874 -175.322 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 135.83 10.96 1.31 Allowed Glycine 0 CA--C 1.531 1.077 0 C-N-CA 124.177 0.894 . . . . 0.0 113.86 169.632 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 70.7 t -112.95 110.22 31.41 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.294 0 CA-C-N 118.644 1.222 . . . . 0.0 108.709 -174.908 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -63.63 155.06 77.91 Favored Pre-proline 0 CA--C 1.535 0.366 0 O-C-N 121.631 -0.668 . . . . 0.0 111.073 -176.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.27 149.02 83.48 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 121.19 1.26 . . . . 0.0 110.665 170.497 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.26 15.76 80.98 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-O 118.368 -1.24 . . . . 0.0 112.616 -175.029 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 88.0 m -89.08 116.16 27.15 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 119.805 1.803 . . . . 0.0 107.073 177.066 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -57.84 136.06 56.93 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 170.641 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -44.18 -37.68 3.3 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 123.851 0.86 . . . . 0.0 111.79 171.255 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 56.9 pttt -67.22 -42.39 84.13 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 117.561 -1.656 . . . . 0.0 109.986 -178.549 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -71.36 -18.33 62.38 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 125.806 1.642 . . . . 0.0 111.138 -176.397 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.557 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.7 mt -53.38 133.4 52.87 Favored Pre-proline 0 N--CA 1.448 -0.569 0 CA-C-N 119.194 0.906 . . . . 0.0 108.941 174.252 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -64.9 142.17 74.35 Favored 'Trans proline' 0 N--CA 1.445 -1.331 0 C-N-CA 122.106 1.871 . . . . 0.0 109.946 179.472 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -68.47 -12.34 61.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 O-C-N 121.946 -0.471 . . . . 0.0 111.962 178.84 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -74.77 -17.18 60.68 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 118.275 0.489 . . . . 0.0 112.193 169.857 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 87.6 t90 -75.27 147.61 40.11 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 121.55 0.691 . . . . 0.0 109.529 179.532 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 59.3 t -131.51 161.22 41.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 125.097 1.359 . . . . 0.0 107.633 -177.467 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -43.79 144.49 1.42 Allowed Pre-proline 0 CA--C 1.537 0.475 0 C-N-CA 124.775 1.23 . . . . 0.0 110.031 170.406 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -64.34 -42.43 17.4 Favored 'Trans proline' 0 N--CA 1.452 -0.945 0 C-N-CA 122.271 1.981 . . . . 0.0 111.569 -176.448 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 88.9 mt -135.41 44.9 2.51 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 123.904 0.881 . . . . 0.0 109.983 -176.544 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -158.36 152.01 23.44 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 106.007 -1.849 . . . . 0.0 106.007 179.296 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -120.78 86.65 0.4 Allowed Glycine 0 C--N 1.335 0.506 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -169.417 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.8 p -145.46 -51.85 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 123.115 0.566 . . . . 0.0 110.699 -178.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 109.36 154.68 15.79 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -176.104 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -64.46 107.79 1.47 Allowed 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 118.153 0.976 . . . . 0.0 109.572 177.657 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -160.46 157.89 28.43 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 172.751 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 44.6 54.24 6.62 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.321 1.848 . . . . 0.0 111.549 173.649 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.6 p90 -100.28 117.86 35.37 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 126.507 1.923 . . . . 0.0 108.705 -179.261 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -85.17 148.11 26.27 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 123.526 0.73 . . . . 0.0 109.06 176.542 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -79.46 138.7 37.67 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.0 t -102.46 105.0 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 C-N-CA 125.419 1.488 . . . . 0.0 108.266 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -72.87 68.64 0.9 Allowed 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 126.348 1.859 . . . . 0.0 113.178 -179.205 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 43.3 mm-40 . . . . . 0 C--O 1.255 1.364 0 CA-C-O 116.78 -1.581 . . . . 0.0 108.332 154.843 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 12.1 mttm . . . . . 0 N--CA 1.446 -0.641 0 CA-C-O 121.72 0.772 . . . . 0.0 112.448 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt -76.76 174.29 10.66 Favored 'General case' 0 N--CA 1.442 -0.853 0 C-N-CA 125.617 1.567 . . . . 0.0 109.252 177.55 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -147.49 145.63 29.21 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 122.773 0.429 . . . . 0.0 110.167 -177.669 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 42.0 m -74.96 141.59 44.02 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 172.115 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 41.2 t -74.84 -112.08 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.494 0 N-CA-C 105.735 -1.95 . . . . 0.0 105.735 164.386 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 9.6 t -160.18 -158.2 0.61 Allowed 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 170.717 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 17.4 m -75.26 56.81 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 C-N-CA 124.079 0.952 . . . . 0.0 111.737 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 15.6 p -153.19 -55.85 0.12 Allowed 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.989 1.316 . . . . 0.0 109.452 177.24 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.71 -150.36 23.42 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 123.716 0.674 . . . . 0.0 113.248 -169.215 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 44.8 t80 -130.14 160.5 33.59 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 125.948 1.699 . . . . 0.0 107.666 179.525 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.6 mt -47.72 125.36 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 C-N-CA 124.6 1.16 . . . . 0.0 111.341 176.689 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.536 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 27.0 t80 -70.19 136.6 50.19 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 170.193 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.7 t-20 -120.02 113.02 34.46 Favored Pre-proline 0 N--CA 1.454 -0.232 0 C-N-CA 123.861 0.864 . . . . 0.0 109.707 175.349 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.74 -38.15 32.35 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 121.696 1.597 . . . . 0.0 111.342 -175.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -63.09 -28.81 70.33 Favored 'General case' 0 N--CA 1.444 -0.754 0 O-C-N 123.188 0.305 . . . . 0.0 111.333 -176.542 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -86.44 -32.97 20.57 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.807 0.843 . . . . 0.0 109.716 172.372 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.39 -158.86 42.23 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -166.748 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.3 61.59 17.41 Favored Pre-proline 0 C--O 1.237 0.435 0 C-N-CA 125.235 1.414 . . . . 0.0 107.891 171.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -64.24 -28.16 64.21 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 122.536 2.157 . . . . 0.0 111.222 -170.207 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -64.18 -30.25 71.32 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 123.24 0.616 . . . . 0.0 109.683 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 33.9 m-80 -93.0 -30.94 15.07 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 125.085 1.354 . . . . 0.0 110.747 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.15 5.88 1.52 Allowed Glycine 0 CA--C 1.531 1.06 0 C-N-CA 124.26 0.933 . . . . 0.0 113.915 170.5 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 50.2 t -103.44 112.1 35.64 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.266 0 CA-C-N 118.45 1.125 . . . . 0.0 108.559 -175.668 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -64.59 154.87 83.5 Favored Pre-proline 0 CA--C 1.533 0.32 0 O-C-N 121.784 -0.573 . . . . 0.0 110.416 -177.532 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.79 150.05 73.67 Favored 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 121.495 1.463 . . . . 0.0 110.851 170.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 79.33 14.44 81.55 Favored Glycine 0 CA--C 1.526 0.724 0 C-N-CA 125.708 1.623 . . . . 0.0 113.348 -176.332 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 93.9 m -94.35 114.77 26.88 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 120.149 1.974 . . . . 0.0 108.501 -178.27 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -56.42 135.24 54.15 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 169.423 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -42.69 -35.36 1.1 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 113.172 0.804 . . . . 0.0 113.172 171.206 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 53.8 pttt -68.3 -38.5 81.7 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 118.646 -1.221 . . . . 0.0 110.051 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -78.0 -16.9 57.73 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 125.005 1.322 . . . . 0.0 109.99 -173.807 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.536 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.7 mt -54.97 132.02 67.61 Favored Pre-proline 0 N--CA 1.442 -0.836 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 174.685 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 2.7 Cg_exo -57.64 134.69 64.72 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 123.162 2.575 . . . . 0.0 109.359 177.245 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -74.57 -7.4 53.0 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.298 -0.876 . . . . 0.0 111.966 -176.499 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -77.4 -10.23 59.34 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.491 1.116 . . . . 0.0 112.598 165.458 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 77.2 t90 -66.93 156.35 36.07 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 118.88 0.764 . . . . 0.0 110.516 177.661 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.4 p -123.91 154.57 30.6 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 125.886 1.675 . . . . 0.0 108.579 -177.255 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.0 m -34.57 148.55 0.1 Allowed Pre-proline 0 CA--C 1.541 0.609 0 C-N-CA 126.693 1.997 . . . . 0.0 113.715 172.676 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -76.49 -37.82 1.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 122.964 2.443 . . . . 0.0 113.057 -174.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 96.1 mt -132.3 30.7 4.16 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.908 0.883 . . . . 0.0 109.434 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -152.16 -173.9 4.7 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 -177.087 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -134.43 58.19 0.69 Allowed Glycine 0 C--N 1.339 0.714 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -176.247 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -133.86 158.74 42.55 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 C-N-CA 125.296 1.438 . . . . 0.0 107.947 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.5 -174.49 35.65 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 111.413 -0.675 . . . . 0.0 111.413 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 52.8 mtpt -71.03 -60.62 2.13 Favored 'General case' 0 CA--C 1.529 0.154 0 O-C-N 121.978 -0.719 . . . . 0.0 109.999 175.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 54.67 -68.53 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 129.357 3.063 . . . . 0.0 114.202 176.647 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -138.46 140.48 39.25 Favored 'General case' 0 CA--C 1.527 0.092 0 C-N-CA 125.26 1.424 . . . . 0.0 108.203 178.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 7.6 p90 -156.29 110.13 2.74 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -168.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -86.27 133.44 33.82 Favored 'General case' 0 C--O 1.225 -0.204 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -71.52 135.67 47.19 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 178.053 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.8 t -97.72 109.99 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 C-N-CA 126.39 1.876 . . . . 0.0 106.393 177.338 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -72.72 60.2 0.49 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.878 1.671 . . . . 0.0 114.308 -174.073 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 . . . . . 0 C--O 1.26 1.627 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 152.236 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 8.9 mttm . . . . . 0 CA--C 1.52 -0.21 0 CA-C-O 120.89 0.376 . . . . 0.0 111.109 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -71.37 171.35 11.37 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 123.557 0.743 . . . . 0.0 110.2 174.434 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -145.52 148.55 33.34 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.481 0.713 . . . . 0.0 111.253 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.5 m -80.07 122.16 26.43 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 123.294 0.638 . . . . 0.0 110.021 176.082 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 7.2 t -58.91 94.72 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.326 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 168.62 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 59.3 m -66.37 141.34 57.99 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -171.58 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . 0.305 12.7 p 54.37 20.5 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 125.845 1.658 . . . . 0.0 113.293 -171.565 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 66.9 m -139.03 -162.43 1.32 Allowed 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.591 1.557 . . . . 0.0 107.967 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.36 62.56 0.37 Allowed Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 178.066 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 6.1 t80 -150.82 66.13 0.92 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 124.069 0.947 . . . . 0.0 109.718 -173.152 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.1 mt -37.79 125.19 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 124.724 1.21 . . . . 0.0 112.791 -175.205 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.545 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 25.9 t80 -78.05 135.62 37.77 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 175.539 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 57.2 t-20 -120.11 111.52 35.38 Favored Pre-proline 0 N--CA 1.452 -0.338 0 C-N-CA 123.913 0.885 . . . . 0.0 109.807 176.103 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -64.98 -37.96 31.04 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.406 1.404 . . . . 0.0 111.479 -175.629 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -61.21 -29.91 70.11 Favored 'General case' 0 N--CA 1.446 -0.67 0 O-C-N 123.393 0.433 . . . . 0.0 111.074 -176.631 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -87.24 -33.17 19.4 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 123.962 0.905 . . . . 0.0 109.705 173.563 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.44 -158.14 39.83 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -167.632 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -142.54 62.36 12.81 Favored Pre-proline 0 CA--C 1.537 0.476 0 C-N-CA 125.503 1.521 . . . . 0.0 107.746 172.471 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.06 -33.98 81.25 Favored 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 122.558 2.172 . . . . 0.0 111.179 -170.215 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -57.41 -29.89 64.51 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.833 1.253 . . . . 0.0 110.35 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 21.3 m-80 -99.26 -23.4 15.21 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 125.554 1.541 . . . . 0.0 110.98 -176.79 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 131.52 7.42 3.1 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 124.571 1.081 . . . . 0.0 113.321 169.56 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.0 t -107.53 110.23 31.1 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.261 0 CA-C-N 118.313 1.057 . . . . 0.0 108.612 -174.816 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -64.08 155.16 79.86 Favored Pre-proline 0 CA--C 1.534 0.329 0 O-C-N 121.783 -0.573 . . . . 0.0 110.537 -177.744 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -59.58 149.9 79.42 Favored 'Trans proline' 0 N--CA 1.449 -1.127 0 C-N-CA 121.308 1.339 . . . . 0.0 110.679 170.269 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.65 23.45 76.79 Favored Glycine 0 CA--C 1.524 0.656 0 C-N-CA 125.469 1.509 . . . . 0.0 112.891 -175.16 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 94.2 m -97.81 117.66 32.63 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 119.514 1.657 . . . . 0.0 107.703 176.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -61.08 137.37 58.24 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 173.762 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -44.12 -35.11 2.03 Favored 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 113.588 0.959 . . . . 0.0 113.588 172.383 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 5.8 pttt -69.73 -37.89 76.66 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 120.813 -1.179 . . . . 0.0 110.144 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -73.64 -20.42 60.58 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 125.226 1.41 . . . . 0.0 109.799 -175.018 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.545 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.4 mt -54.36 131.07 62.03 Favored Pre-proline 0 N--CA 1.441 -0.882 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 176.317 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -60.66 135.84 62.99 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.094 1.863 . . . . 0.0 108.551 178.324 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -72.73 -5.41 37.56 Favored 'General case' 0 CA--C 1.54 0.567 0 O-C-N 121.89 -0.507 . . . . 0.0 111.744 -178.585 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.4 -26.41 66.42 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.98 1.312 . . . . 0.0 112.08 164.488 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 83.8 t90 -69.86 149.14 48.18 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.644 0.735 . . . . 0.0 110.639 -174.786 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 5.2 m -123.12 157.55 28.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 C-N-CA 125.913 1.685 . . . . 0.0 109.645 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.5 m -39.65 144.02 0.52 Allowed Pre-proline 0 CA--C 1.532 0.287 0 C-N-CA 126.351 1.861 . . . . 0.0 113.187 177.26 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -70.19 -31.94 17.71 Favored 'Trans proline' 0 N--CA 1.451 -1.003 0 C-N-CA 123.227 2.618 . . . . 0.0 112.832 -173.383 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 16.1 tp -149.32 35.87 0.73 Allowed 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.68 -0.637 . . . . 0.0 110.732 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.5 m -131.19 -47.41 1.0 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.625 0.77 . . . . 0.0 110.607 -178.306 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.43 62.32 1.65 Allowed Glycine 0 CA--C 1.531 1.057 0 C-N-CA 123.608 0.623 . . . . 0.0 112.254 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.1 p -151.69 159.18 4.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 172.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -68.04 167.56 42.39 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 54.9 mtpt -50.33 -58.13 6.35 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.757 0.823 . . . . 0.0 111.215 177.333 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.8 t0 21.11 85.83 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 128.275 2.63 . . . . 0.0 115.016 -172.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER 75.2 150.66 0.11 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.825 1.65 . . . . 0.0 110.228 178.54 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.3 p90 -171.02 109.44 0.31 Allowed 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -163.753 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 52.5 mt-10 -87.27 135.81 33.17 Favored 'General case' 0 CA--C 1.519 -0.228 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -176.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -76.88 137.55 39.21 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -178.64 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.1 t -98.47 109.91 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.042 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 176.77 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -74.69 59.62 0.87 Allowed 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 126.197 1.799 . . . . 0.0 113.914 -171.904 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 . . . . . 0 C--O 1.259 1.596 0 CA-C-N 114.845 -1.07 . . . . 0.0 108.372 156.286 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 38.1 mttm . . . . . 0 N--CA 1.449 -0.483 0 CA-C-O 122.012 0.91 . . . . 0.0 112.911 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 72.7 mttt -80.37 165.61 22.1 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 115.219 -0.9 . . . . 0.0 108.653 -176.385 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -144.92 136.25 25.17 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.04 -179.298 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.8 t -92.11 135.79 33.69 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 111.689 0.255 . . . . 0.0 111.689 172.884 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 48.0 t -77.56 47.45 0.6 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 127.223 2.209 . . . . 0.0 109.389 177.862 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 10.9 m 43.39 -124.27 0.81 Allowed 'General case' 0 CA--C 1.548 0.902 0 O-C-N 120.266 -1.521 . . . . 0.0 111.93 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 45.1 t -82.75 70.63 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 O-C-N 120.541 -1.35 . . . . 0.0 108.919 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 42.5 t -133.0 -70.04 0.55 Allowed 'General case' 0 CA--C 1.529 0.153 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 175.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.15 60.58 0.96 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -131.91 -57.63 0.98 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.904 0.882 . . . . 0.0 110.393 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 74.0 mt 75.17 119.15 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 C-N-CA 127.135 2.174 . . . . 0.0 111.683 -175.589 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.566 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 44.1 t80 -82.03 132.41 35.25 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 170.076 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 56.8 t-20 -118.87 112.64 36.46 Favored Pre-proline 0 C--O 1.227 -0.12 0 C-N-CA 124.348 1.059 . . . . 0.0 109.403 174.04 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -65.53 -38.23 26.27 Favored 'Trans proline' 0 N--CA 1.447 -1.265 0 C-N-CA 121.111 1.208 . . . . 0.0 111.573 -174.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -57.47 -32.22 66.74 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-N 117.97 0.35 . . . . 0.0 111.03 -179.007 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 60.1 m-20 -90.06 -29.83 18.11 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.705 0.802 . . . . 0.0 110.232 177.265 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.08 -158.67 41.35 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -168.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -141.87 60.82 11.71 Favored Pre-proline 0 CA--C 1.539 0.555 0 C-N-CA 125.373 1.469 . . . . 0.0 107.763 172.17 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -62.17 -33.64 81.16 Favored 'Trans proline' 0 N--CA 1.455 -0.767 0 C-N-CA 122.403 2.068 . . . . 0.0 111.173 -170.582 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -55.85 -31.35 62.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 125.011 1.324 . . . . 0.0 110.641 177.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.6 m-80 -97.83 -27.76 14.15 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 125.521 1.528 . . . . 0.0 110.663 -177.059 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.23 9.34 1.44 Allowed Glycine 0 CA--C 1.532 1.154 0 C-N-CA 124.345 0.974 . . . . 0.0 113.829 169.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 54.7 t -110.06 111.63 37.0 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.248 0 CA-C-N 118.579 1.189 . . . . 0.0 109.065 -174.219 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -63.62 154.8 78.79 Favored Pre-proline 0 C--N 1.328 -0.335 0 O-C-N 121.9 -0.5 . . . . 0.0 111.056 -177.566 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -59.94 150.15 79.84 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 121.423 1.416 . . . . 0.0 110.744 171.308 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 72.22 16.67 77.08 Favored Glycine 0 CA--C 1.525 0.704 0 CA-C-O 118.289 -1.284 . . . . 0.0 112.798 -174.511 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 92.4 m -87.75 117.6 26.69 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-N 119.951 1.875 . . . . 0.0 107.386 176.424 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -56.56 133.28 53.42 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.167 170.69 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -42.67 -38.31 2.0 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 123.326 0.65 . . . . 0.0 112.053 170.231 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.1 pttp -66.34 -39.08 88.97 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 118.181 -1.408 . . . . 0.0 109.945 -177.704 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -81.66 -11.37 59.11 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 126.108 1.763 . . . . 0.0 110.626 -172.304 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.566 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.8 mt -56.42 134.28 76.57 Favored Pre-proline 0 N--CA 1.443 -0.801 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 171.306 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 8.1 Cg_exo -58.08 138.35 85.5 Favored 'Trans proline' 0 N--CA 1.454 -0.796 0 C-N-CA 123.556 2.838 . . . . 0.0 110.932 176.476 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -69.92 -15.02 63.0 Favored 'General case' 0 N--CA 1.448 -0.55 0 O-C-N 121.071 -1.018 . . . . 0.0 111.822 177.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -78.96 -9.75 59.62 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.59 1.156 . . . . 0.0 112.065 169.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 76.9 t90 -72.22 156.12 39.49 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.086 0.857 . . . . 0.0 110.369 175.611 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 13.1 t -130.76 143.58 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 125.174 1.389 . . . . 0.0 108.227 -170.205 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 20.2 t -68.18 137.33 91.7 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 123.438 0.695 . . . . 0.0 109.629 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -68.15 127.85 16.59 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 122.749 2.299 . . . . 0.0 111.42 177.761 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 29.1 mt 61.26 44.73 9.5 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.759 1.223 . . . . 0.0 111.97 174.77 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 14.4 t -149.05 178.63 8.54 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -176.211 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -105.28 171.43 18.62 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 171.439 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.324 3.9 p 48.07 -149.39 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 CA-C-O 117.447 -1.263 . . . . 0.0 111.219 -173.421 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -146.13 -143.3 3.89 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-N 121.475 1.943 . . . . 0.0 111.131 -173.006 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.4 ptmt -78.11 115.53 17.9 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 172.15 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -158.43 -63.59 0.08 Allowed 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.029 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -105.0 97.53 7.37 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.638 1.175 . . . . 0.0 109.392 179.509 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.7 p90 -141.12 135.16 30.63 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.201 1.001 . . . . 0.0 109.189 -178.327 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 22.6 mt-10 -108.44 155.06 21.01 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 124.734 1.213 . . . . 0.0 109.519 178.615 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -78.96 143.22 35.98 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 123.635 0.774 . . . . 0.0 109.646 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.3 t -112.07 108.38 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 C-N-CA 126.679 1.991 . . . . 0.0 106.564 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -81.18 55.21 2.46 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 125.005 1.322 . . . . 0.0 113.098 -175.333 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 . . . . . 0 C--O 1.25 1.119 0 C-N-CA 124.911 1.285 . . . . 0.0 109.681 176.454 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 43.2 mttm . . . . . 0 N--CA 1.452 -0.366 0 CA-C-O 122.286 1.041 . . . . 0.0 112.618 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 3.7 mtpt -78.91 166.97 21.8 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.205 -177.28 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -147.68 149.31 32.23 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.068 0.547 . . . . 0.0 111.067 -179.53 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 57.4 p -74.38 170.82 14.87 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 123.281 0.633 . . . . 0.0 112.214 172.492 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 42.1 t -83.16 -53.06 6.07 Favored 'General case' 0 C--O 1.224 -0.254 0 C-N-CA 125.203 1.401 . . . . 0.0 109.074 162.601 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 85.9 m 61.25 22.74 13.04 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.017 0.927 . . . . 0.0 111.569 -173.607 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 66.1 t -123.34 -65.15 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 C-N-CA 124.421 1.088 . . . . 0.0 108.453 166.057 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 26.5 p -94.56 -60.53 1.69 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 118.633 0.651 . . . . 0.0 110.706 175.527 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 138.6 45.98 0.07 OUTLIER Glycine 0 CA--C 1.531 1.075 0 C-N-CA 124.873 1.225 . . . . 0.0 112.166 -176.208 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -111.13 103.27 11.69 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 125.122 1.369 . . . . 0.0 109.705 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.6 mt -72.52 123.73 27.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 O-C-N 120.919 -1.113 . . . . 0.0 110.085 178.034 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.55 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 48.4 t80 -79.38 138.59 37.71 Favored 'General case' 0 C--O 1.236 0.392 0 C-N-CA 124.396 1.078 . . . . 0.0 108.451 170.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -124.02 114.33 27.99 Favored Pre-proline 0 C--O 1.226 -0.141 0 C-N-CA 124.005 0.922 . . . . 0.0 109.995 174.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -65.95 -39.46 19.3 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 120.954 1.102 . . . . 0.0 111.969 -175.309 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -58.66 -31.4 68.14 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 118.318 0.508 . . . . 0.0 111.149 -178.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -88.91 -30.86 18.53 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.505 0.722 . . . . 0.0 109.954 177.569 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.52 -159.99 41.13 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 124.095 0.855 . . . . 0.0 110.997 -168.336 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.04 61.25 17.2 Favored Pre-proline 0 CA--C 1.539 0.532 0 C-N-CA 125.445 1.498 . . . . 0.0 107.712 170.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_endo -63.45 -28.3 70.93 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.237 1.958 . . . . 0.0 111.229 -171.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -61.56 -28.49 69.37 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 123.534 0.734 . . . . 0.0 110.076 178.687 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.4 m-80 -99.84 -26.93 13.86 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 125.236 1.414 . . . . 0.0 110.958 -177.821 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 133.2 17.12 1.15 Allowed Glycine 0 CA--C 1.531 1.052 0 C-N-CA 124.216 0.913 . . . . 0.0 113.635 170.238 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 78.5 t -115.43 109.59 28.87 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.272 0 CA-C-N 118.466 1.133 . . . . 0.0 108.381 -175.685 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -63.39 155.67 73.71 Favored Pre-proline 0 C--N 1.328 -0.327 0 O-C-N 121.671 -0.643 . . . . 0.0 111.23 -176.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.0 149.02 86.68 Favored 'Trans proline' 0 N--CA 1.448 -1.147 0 C-N-CA 121.279 1.32 . . . . 0.0 110.619 171.046 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.39 16.61 78.81 Favored Glycine 0 N--CA 1.445 -0.709 0 CA-C-O 118.307 -1.274 . . . . 0.0 112.693 -174.528 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 81.7 m -87.95 117.72 27.0 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 119.873 1.836 . . . . 0.0 106.942 176.483 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -58.58 136.51 57.61 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 171.38 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -45.76 -37.3 5.83 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 122.975 0.51 . . . . 0.0 111.337 171.526 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 48.0 pttt -66.41 -38.49 87.58 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 117.783 -1.567 . . . . 0.0 110.468 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -76.1 -18.88 58.98 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 125.012 1.325 . . . . 0.0 110.506 -174.414 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.55 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.7 mt -53.81 133.92 56.67 Favored Pre-proline 0 N--CA 1.446 -0.627 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 175.154 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -65.18 139.66 61.53 Favored 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 122.133 1.889 . . . . 0.0 109.7 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -66.3 -11.33 50.07 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 123.708 0.803 . . . . 0.0 111.54 177.378 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.4 -22.11 61.91 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.64 1.176 . . . . 0.0 112.11 170.285 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 84.9 t90 -73.39 155.7 39.08 Favored 'General case' 0 N--CA 1.455 -0.209 0 O-C-N 121.527 -0.733 . . . . 0.0 110.386 -177.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.72 159.68 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 C-N-CA 125.541 1.536 . . . . 0.0 109.232 -177.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 44.4 t -68.17 134.91 91.43 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 124.228 1.011 . . . . 0.0 109.668 -177.083 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -62.1 126.33 18.45 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.475 2.117 . . . . 0.0 110.883 178.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 41.0 mt 64.92 34.84 8.75 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.467 1.107 . . . . 0.0 111.615 174.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 41.5 t -151.61 160.95 43.44 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 106.399 -1.704 . . . . 0.0 106.399 -175.041 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -115.94 110.13 2.14 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 -174.125 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 36.0 t 78.84 123.35 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 C-N-CA 126.547 1.939 . . . . 0.0 108.785 -171.301 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -156.59 173.12 34.36 Favored Glycine 0 C--N 1.334 0.459 0 N-CA-C 107.696 -2.162 . . . . 0.0 107.696 178.04 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 53.87 74.05 0.35 Allowed 'General case' 0 CA--C 1.534 0.346 0 CA-C-O 122.941 1.353 . . . . 0.0 110.295 -170.773 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -152.59 -69.67 0.16 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 113.707 -1.588 . . . . 0.0 108.151 170.055 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -113.67 101.3 9.19 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 124.93 1.292 . . . . 0.0 108.453 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -140.27 131.93 27.25 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.092 1.357 . . . . 0.0 107.783 -175.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -96.63 149.35 21.89 Favored 'General case' 0 C--O 1.223 -0.297 0 C-N-CA 124.903 1.281 . . . . 0.0 109.28 -176.624 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -75.76 140.86 42.61 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-N 119.042 0.837 . . . . 0.0 109.218 178.897 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.2 t -106.63 107.57 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 C-N-CA 125.611 1.564 . . . . 0.0 106.8 176.814 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -76.85 57.03 1.25 Allowed 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 125.619 1.568 . . . . 0.0 113.075 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 . . . . . 0 C--O 1.251 1.144 0 CA-C-O 117.278 -1.344 . . . . 0.0 108.462 159.113 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.5 mmmt . . . . . 0 CA--C 1.52 -0.185 0 CA-C-O 121.391 0.615 . . . . 0.0 110.08 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 44.1 mtpt -74.12 169.75 16.89 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.568 -177.579 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -143.02 142.59 31.62 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 119.582 -0.247 . . . . 0.0 110.724 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.8 t -85.15 141.7 30.01 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 119.61 -0.836 . . . . 0.0 109.977 170.797 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 52.2 t -71.19 170.46 12.94 Favored 'General case' 0 CA--C 1.539 0.54 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 154.332 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.3 p -69.28 81.02 0.36 Allowed 'General case' 0 CA--C 1.533 0.32 0 O-C-N 120.97 -1.081 . . . . 0.0 110.725 -173.767 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 99.1 t 66.98 -74.88 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.456 -0.158 0 C-N-CA 126.014 1.725 . . . . 0.0 108.154 -170.436 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 48.1 t 43.05 -122.68 0.72 Allowed 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.77 1.228 . . . . 0.0 109.803 174.382 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -177.42 41.11 0.1 OUTLIER Glycine 0 CA--C 1.527 0.806 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 166.737 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -148.45 74.6 1.29 Allowed 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.748 0.785 . . . . 0.0 109.397 -169.443 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 12.6 mt -59.82 131.67 24.57 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 O-C-N 121.699 -0.626 . . . . 0.0 109.657 175.244 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.576 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 33.9 t80 -82.82 138.17 34.05 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 174.212 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -124.17 112.47 28.26 Favored Pre-proline 0 N--CA 1.454 -0.241 0 C-N-CA 124.229 1.011 . . . . 0.0 109.705 175.424 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -66.19 -35.19 33.78 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.076 1.184 . . . . 0.0 111.395 -174.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -65.13 -27.71 68.93 Favored 'General case' 0 N--CA 1.443 -0.792 0 O-C-N 123.313 0.383 . . . . 0.0 110.934 -176.112 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -87.37 -31.57 20.05 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.328 1.051 . . . . 0.0 109.788 171.498 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.27 -151.82 50.28 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -167.027 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 25.6 t0 -151.87 63.94 5.55 Favored Pre-proline 0 N--CA 1.443 -0.799 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 171.643 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -64.91 -28.28 58.49 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.701 2.267 . . . . 0.0 111.634 -166.214 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -62.37 -24.93 67.64 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 123.701 0.801 . . . . 0.0 109.727 -178.205 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.9 m-80 -111.37 17.12 20.47 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.062 1.345 . . . . 0.0 109.993 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 95.73 3.95 60.67 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.325 0.964 . . . . 0.0 114.63 170.861 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.9 t -104.16 107.84 23.28 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.23 0 CA-C-N 119.127 1.464 . . . . 0.0 109.345 -172.384 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -65.36 153.89 88.87 Favored Pre-proline 0 CA--C 1.536 0.44 0 O-C-N 121.614 -0.679 . . . . 0.0 110.697 -176.652 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_endo -58.38 149.11 76.24 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 121.575 1.517 . . . . 0.0 111.135 170.816 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.66 19.33 79.21 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 125.004 1.288 . . . . 0.0 112.47 -175.847 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 99.8 m -94.27 114.45 26.54 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 119.61 1.705 . . . . 0.0 106.811 176.084 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -59.72 138.24 57.82 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 170.778 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.434 ' CD1' ' CD2' ' A' ' 49' ' ' PHE . 2.1 t80 -42.14 -38.63 1.76 Allowed 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 113.194 0.813 . . . . 0.0 113.194 171.189 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 55.8 pttt -64.99 -40.13 94.51 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 118.345 -1.342 . . . . 0.0 110.224 -178.136 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -78.73 -12.45 60.02 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 125.057 1.343 . . . . 0.0 111.169 -175.025 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.576 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.8 mt -57.23 132.76 80.94 Favored Pre-proline 0 N--CA 1.442 -0.873 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 172.508 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -63.5 137.3 59.08 Favored 'Trans proline' 0 N--CA 1.442 -1.519 0 C-N-CA 121.641 1.56 . . . . 0.0 108.605 176.357 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -70.56 -3.47 18.25 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 123.543 0.737 . . . . 0.0 111.977 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -73.96 -24.71 59.67 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.968 1.707 . . . . 0.0 111.983 166.38 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 78.9 t90 -65.75 158.5 27.42 Favored 'General case' 0 CA--C 1.528 0.112 0 O-C-N 121.746 -0.596 . . . . 0.0 109.805 178.11 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.413 ' CG2' ' HA2' ' A' ' 43' ' ' GLY . 8.0 p -141.34 145.73 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 C-N-CA 123.895 0.878 . . . . 0.0 109.935 -173.637 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 53.2 t -66.92 125.12 90.33 Favored Pre-proline 0 C--O 1.24 0.597 0 C-N-CA 123.392 0.677 . . . . 0.0 110.029 178.472 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -66.04 133.7 34.27 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 123.26 2.64 . . . . 0.0 111.035 -175.85 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 48.4 mt 60.23 30.06 19.54 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 124.536 1.134 . . . . 0.0 112.042 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 8.4 t -142.67 -68.19 0.36 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.097 0.959 . . . . 0.0 108.841 -176.707 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLY . . . . . 0.413 ' HA2' ' CG2' ' A' ' 38' ' ' VAL . . . 85.71 17.98 60.8 Favored Glycine 0 CA--C 1.532 1.127 0 CA-C-O 118.613 -1.104 . . . . 0.0 114.737 177.464 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.8 p -72.17 -54.98 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 CA-C-N 119.761 1.781 . . . . 0.0 112.94 -176.394 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.95 -152.82 24.32 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 108.514 -1.834 . . . . 0.0 108.514 -170.634 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.55 33.89 0.78 Allowed 'General case' 0 CA--C 1.53 0.189 0 CA-C-N 118.217 1.009 . . . . 0.0 112.063 169.281 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -98.27 -49.66 4.62 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 125.086 1.354 . . . . 0.0 110.114 -161.406 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -94.23 67.23 3.53 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.057 1.343 . . . . 0.0 108.597 178.739 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.434 ' CD2' ' CD1' ' A' ' 30' ' ' PHE . 20.5 p90 -101.81 115.06 29.7 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 124.232 1.013 . . . . 0.0 109.214 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -99.27 142.92 30.13 Favored 'General case' 0 CA--C 1.519 -0.22 0 N-CA-C 108.164 -1.051 . . . . 0.0 108.164 174.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -73.04 134.78 44.75 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 15.3 t -93.29 108.86 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 174.808 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -78.64 51.28 1.06 Allowed 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 124.536 1.135 . . . . 0.0 113.489 -173.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 . . . . . 0 C--O 1.259 1.589 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 149.719 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 14.9 mttt . . . . . 0 N--CA 1.453 -0.31 0 CA-C-O 121.968 0.889 . . . . 0.0 112.672 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 58.9 mttt -75.02 167.07 22.63 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.241 -0.891 . . . . 0.0 109.492 -174.58 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -145.48 144.08 30.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.937 178.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 13.5 m -76.89 150.95 35.98 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-O 119.303 -0.379 . . . . 0.0 110.988 169.109 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 46.3 t -65.07 171.13 3.83 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-O 121.345 0.593 . . . . 0.0 110.136 170.003 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 1.9 t -71.52 -42.87 67.44 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 124.944 1.298 . . . . 0.0 111.402 -176.895 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 29.5 m -140.5 24.22 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -178.413 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 18.4 p -147.56 -166.37 2.5 Favored 'General case' 0 N--CA 1.455 -0.198 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 168.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.93 -82.0 0.99 Allowed Glycine 0 CA--C 1.525 0.705 0 N-CA-C 109.211 -1.556 . . . . 0.0 109.211 175.009 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 63.5 m-85 21.0 65.27 0.03 OUTLIER 'General case' 0 C--N 1.346 0.418 0 C-N-CA 128.452 2.701 . . . . 0.0 111.941 -175.588 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 23.4 mt -58.55 121.59 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.015 -173.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.554 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 35.2 t80 -73.29 138.12 45.27 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 173.282 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 62.1 t-20 -125.65 111.99 25.27 Favored Pre-proline 0 N--CA 1.454 -0.243 0 C-N-CA 123.975 0.91 . . . . 0.0 109.541 176.646 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -63.65 -39.69 33.73 Favored 'Trans proline' 0 N--CA 1.448 -1.204 0 C-N-CA 121.267 1.311 . . . . 0.0 111.355 -173.545 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -56.12 -32.82 64.57 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 117.977 0.353 . . . . 0.0 111.254 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -91.76 -29.84 16.57 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.453 0.701 . . . . 0.0 110.334 179.271 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 66.17 -159.0 47.63 Favored Glycine 0 CA--C 1.53 1.03 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -170.239 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.19 61.1 16.26 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 125.615 1.566 . . . . 0.0 107.393 171.062 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -61.59 -35.53 80.77 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.757 2.305 . . . . 0.0 111.451 -168.417 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -57.67 -31.38 66.28 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 124.875 1.27 . . . . 0.0 110.516 179.327 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 -92.21 -28.12 17.23 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 125.218 1.407 . . . . 0.0 110.469 -179.468 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.62 0.48 2.91 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.4 1.0 . . . . 0.0 113.205 171.406 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 75.2 t -100.97 111.08 29.52 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.206 0 CA-C-N 118.225 1.012 . . . . 0.0 109.002 -172.333 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -64.53 154.95 82.95 Favored Pre-proline 0 CA--C 1.533 0.308 0 O-C-N 121.765 -0.584 . . . . 0.0 110.929 -176.427 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -58.77 149.33 78.17 Favored 'Trans proline' 0 N--CA 1.449 -1.117 0 C-N-CA 121.425 1.416 . . . . 0.0 110.84 170.318 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.41 14.98 79.1 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 125.813 1.673 . . . . 0.0 113.082 -174.353 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.7 m -87.07 120.1 27.99 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 120.05 1.925 . . . . 0.0 107.871 178.343 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -59.81 134.45 57.04 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 172.406 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -43.04 -37.87 2.1 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 123.44 0.696 . . . . 0.0 112.176 169.356 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -68.13 -38.89 82.71 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 117.756 -1.578 . . . . 0.0 110.261 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -76.63 -17.57 59.09 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 124.989 1.316 . . . . 0.0 110.704 -175.764 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.554 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 23.0 mt -52.49 132.76 44.64 Favored Pre-proline 0 N--CA 1.445 -0.705 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.862 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -63.43 140.13 74.56 Favored 'Trans proline' 0 N--CA 1.445 -1.355 0 C-N-CA 122.234 1.956 . . . . 0.0 109.697 178.619 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 74.5 m-20 -69.98 -10.16 57.64 Favored 'General case' 0 N--CA 1.444 -0.772 0 C-N-CA 123.529 0.731 . . . . 0.0 111.914 -179.604 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -77.21 -12.02 59.89 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 124.232 1.013 . . . . 0.0 112.57 168.355 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -73.36 153.35 40.52 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 118.853 0.751 . . . . 0.0 110.303 177.646 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 97.4 t -137.02 150.01 26.44 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 125.573 1.549 . . . . 0.0 107.973 -171.209 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 13.2 t -79.48 130.63 67.61 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 124.854 1.262 . . . . 0.0 109.117 -176.407 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -64.98 147.91 89.37 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.461 2.108 . . . . 0.0 110.769 -178.441 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.2 mm? 68.8 -62.31 0.39 Allowed 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 126.323 1.849 . . . . 0.0 111.734 -179.495 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -59.03 -54.56 45.71 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 125.977 1.711 . . . . 0.0 110.787 178.354 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 106.84 -115.53 4.71 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -176.728 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.9 t -63.71 105.92 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 O-C-N 121.263 -1.139 . . . . 0.0 110.684 -167.437 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -130.74 -165.59 11.56 Favored Glycine 0 CA--C 1.527 0.809 0 C-N-CA 125.848 1.69 . . . . 0.0 109.323 178.348 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 55.22 61.74 2.78 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 123.112 1.434 . . . . 0.0 110.376 -173.723 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -156.19 157.49 35.98 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 156.839 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 45.09 37.83 2.79 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.117 1.767 . . . . 0.0 113.047 173.136 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 7.5 p90 -78.07 131.62 37.38 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 124.14 0.976 . . . . 0.0 110.335 -172.369 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -97.93 135.34 39.79 Favored 'General case' 0 C--O 1.227 -0.085 0 C-N-CA 123.929 0.892 . . . . 0.0 108.813 -179.051 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -72.66 138.18 46.52 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 176.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 32.2 t -105.53 105.81 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.054 0 C-N-CA 127.216 2.207 . . . . 0.0 105.418 176.579 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -81.91 54.17 2.39 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.427 1.091 . . . . 0.0 112.927 -173.574 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 . . . . . 0 C--O 1.251 1.143 0 C-N-CA 124.983 1.313 . . . . 0.0 109.617 176.508 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 21.9 mttm . . . . . 0 N--CA 1.454 -0.275 0 CA-C-O 122.438 1.113 . . . . 0.0 112.358 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 28.5 mtpt -72.57 170.27 14.76 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.824 -176.272 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 35.7 m-85 -149.12 145.69 27.33 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 -177.153 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 44.9 p -71.42 170.62 12.86 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.213 0.53 . . . . 0.0 112.152 170.087 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 2.2 t -108.26 166.63 10.61 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 126.998 2.119 . . . . 0.0 105.948 166.649 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 1.2 p -48.0 -50.3 28.01 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 124.683 1.193 . . . . 0.0 111.665 169.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 4.7 m -148.57 16.2 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 N-CA-C 114.111 1.152 . . . . 0.0 114.111 -173.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 79.7 m -109.18 119.6 40.02 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 119.945 1.248 . . . . 0.0 111.742 178.387 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -75.88 54.35 3.0 Favored Glycine 0 CA--C 1.532 1.137 0 O-C-N 121.55 -0.719 . . . . 0.0 111.411 172.104 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -111.54 -47.03 3.2 Favored 'General case' 0 N--CA 1.46 0.071 0 C-N-CA 124.556 1.142 . . . . 0.0 110.353 176.175 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 11.5 mt 71.32 128.06 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 C-N-CA 125.561 1.544 . . . . 0.0 111.491 -177.13 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.531 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 45.3 t80 -76.06 141.61 42.0 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 172.103 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 -125.77 115.58 24.6 Favored Pre-proline 0 N--CA 1.456 -0.174 0 C-N-CA 123.679 0.792 . . . . 0.0 110.421 175.354 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -67.48 -39.63 12.09 Favored 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 121.053 1.169 . . . . 0.0 111.695 -176.566 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -59.04 -31.08 68.53 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 118.585 0.63 . . . . 0.0 111.152 -178.382 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -88.47 -31.71 18.62 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 123.589 0.755 . . . . 0.0 110.023 176.654 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.9 -162.02 35.69 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -166.183 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -138.28 61.3 25.47 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 125.187 1.395 . . . . 0.0 107.735 171.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -62.8 -31.38 78.21 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 122.332 2.021 . . . . 0.0 111.154 -170.89 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -59.69 -30.65 68.93 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 123.864 0.866 . . . . 0.0 110.731 178.189 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -96.08 -28.07 14.78 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 124.87 1.268 . . . . 0.0 110.51 -178.5 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.71 16.96 0.97 Allowed Glycine 0 CA--C 1.531 1.081 0 C-N-CA 124.395 0.998 . . . . 0.0 113.992 169.641 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.1 t -116.72 112.29 38.72 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.304 0 CA-C-N 118.578 1.189 . . . . 0.0 109.006 -175.442 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.44 156.73 75.71 Favored Pre-proline 0 CA--C 1.533 0.316 0 O-C-N 121.898 -0.501 . . . . 0.0 111.136 -177.337 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -59.68 150.14 78.49 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 121.376 1.384 . . . . 0.0 110.802 170.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.57 16.32 79.06 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 125.816 1.674 . . . . 0.0 113.212 -175.187 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.9 m -89.48 118.56 29.22 Favored 'General case' 0 N--CA 1.445 -0.689 0 CA-C-N 119.923 1.862 . . . . 0.0 108.276 179.138 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -59.65 134.09 56.7 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 170.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -43.17 -37.04 1.92 Allowed 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 123.596 0.758 . . . . 0.0 112.731 170.149 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -68.76 -37.84 79.64 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 118.043 -1.463 . . . . 0.0 110.291 -178.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -77.29 -17.49 58.31 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 125.506 1.522 . . . . 0.0 110.462 -176.754 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.531 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.2 mt -55.81 133.56 72.77 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 173.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -62.97 137.1 60.44 Favored 'Trans proline' 0 N--CA 1.445 -1.359 0 C-N-CA 121.823 1.682 . . . . 0.0 108.98 175.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -71.43 -4.6 27.34 Favored 'General case' 0 N--CA 1.445 -0.683 0 O-C-N 121.95 -0.469 . . . . 0.0 111.728 -179.468 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.58 -22.65 63.51 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 125.034 1.333 . . . . 0.0 112.182 165.42 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 81.3 t90 -71.29 152.3 43.39 Favored 'General case' 0 N--CA 1.456 -0.174 0 O-C-N 121.484 -0.76 . . . . 0.0 111.237 -176.212 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.5 t -127.59 146.49 33.23 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 C-N-CA 125.72 1.608 . . . . 0.0 108.356 179.173 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -76.31 160.95 76.64 Favored Pre-proline 0 CA--C 1.538 0.519 0 C-N-CA 122.605 0.362 . . . . 0.0 110.158 -176.152 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -67.11 117.42 4.78 Favored 'Trans proline' 0 N--CA 1.45 -1.058 0 C-N-CA 121.9 1.733 . . . . 0.0 110.687 -170.75 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 50.5 mt 65.32 51.73 1.54 Allowed 'General case' 0 CA--C 1.534 0.33 0 C-N-CA 125.255 1.422 . . . . 0.0 111.623 177.667 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.0 t -142.9 -179.48 6.38 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 124.275 1.03 . . . . 0.0 108.539 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -107.19 -67.21 0.64 Allowed Glycine 0 CA--C 1.526 0.743 0 C-N-CA 124.504 1.05 . . . . 0.0 111.223 -175.829 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 25.2 m -72.66 164.03 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 CA-C-N 116.803 0.302 . . . . 0.0 110.201 -179.32 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -121.4 114.03 2.47 Favored Glycine 0 C--N 1.334 0.441 0 N-CA-C 110.396 -1.082 . . . . 0.0 110.396 -170.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mtpt 62.38 -88.02 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 125.412 1.485 . . . . 0.0 110.388 178.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 46.83 -72.48 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 128.799 2.84 . . . . 0.0 114.303 -172.219 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -127.92 116.78 20.63 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 126.014 1.725 . . . . 0.0 108.925 -176.225 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 4.9 p90 -149.99 112.68 4.77 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.194 1.397 . . . . 0.0 107.28 -171.697 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -82.91 145.53 29.35 Favored 'General case' 0 C--O 1.225 -0.225 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 44.9 tt0 -71.91 136.8 47.02 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 175.722 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.1 t -102.41 104.34 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 C-N-CA 126.248 1.819 . . . . 0.0 106.336 177.183 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -78.2 88.35 4.27 Favored 'General case' 0 N--CA 1.438 -1.03 0 CA-C-O 123.215 1.484 . . . . 0.0 109.125 172.182 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 . . . . . 0 C--O 1.257 1.483 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 158.701 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 51.2 mttm . . . . . 0 N--CA 1.453 -0.306 0 CA-C-O 121.877 0.846 . . . . 0.0 112.704 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -80.71 165.02 22.35 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -176.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -141.3 140.95 33.94 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 123.069 0.548 . . . . 0.0 111.069 178.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.3 t -99.4 140.88 32.92 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 113.084 0.772 . . . . 0.0 113.084 175.247 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.455 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 42.2 t -78.68 50.48 0.98 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.846 2.058 . . . . 0.0 109.399 177.458 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 5.7 m 53.84 -94.41 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.828 0 O-C-N 120.624 -1.297 . . . . 0.0 112.475 174.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.92 -28.93 5.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 125.246 1.418 . . . . 0.0 110.849 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.455 ' HB3' ' SG ' ' A' ' 6' ' ' CYS . 53.4 t -78.25 124.69 28.37 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 124.419 1.088 . . . . 0.0 109.44 -169.286 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -86.45 78.94 1.88 Allowed Glycine 0 CA--C 1.523 0.588 0 CA-C-O 119.211 -0.772 . . . . 0.0 111.283 -170.904 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -134.88 -57.76 0.82 Allowed 'General case' 0 CA--C 1.532 0.267 0 CA-C-N 117.796 0.798 . . . . 0.0 112.889 176.749 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 55.9 mt 75.22 121.25 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 126.637 1.975 . . . . 0.0 111.894 -173.717 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.548 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 77.2 t80 -83.22 138.23 33.7 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 169.482 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 55.1 t-20 -128.32 115.29 19.93 Favored Pre-proline 0 N--CA 1.454 -0.23 0 C-N-CA 124.582 1.153 . . . . 0.0 109.461 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.27 -39.48 17.55 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 121.779 1.653 . . . . 0.0 112.267 -172.858 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -55.13 -32.78 62.34 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 118.002 0.365 . . . . 0.0 110.749 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -95.06 -26.03 16.22 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 123.504 0.722 . . . . 0.0 109.9 -177.893 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.3 -157.46 36.58 Favored Glycine 0 CA--C 1.527 0.788 0 C-N-CA 124.684 1.135 . . . . 0.0 110.979 -170.442 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.76 62.31 12.23 Favored Pre-proline 0 CA--C 1.538 0.495 0 C-N-CA 125.062 1.345 . . . . 0.0 107.941 170.137 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -62.43 -33.34 79.65 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.697 2.264 . . . . 0.0 111.185 -170.264 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -56.76 -29.56 62.72 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 124.661 1.184 . . . . 0.0 110.728 178.376 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 -99.07 -30.8 12.11 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.267 1.427 . . . . 0.0 110.615 -177.307 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 140.15 7.49 0.95 Allowed Glycine 0 CA--C 1.531 1.077 0 C-N-CA 123.874 0.75 . . . . 0.0 114.061 169.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.48 HG23 ' CD1' ' A' ' 37' ' ' TRP . 45.6 t -106.58 112.52 40.02 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.217 0 CA-C-N 118.885 1.342 . . . . 0.0 109.04 -176.664 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -63.91 154.18 82.2 Favored Pre-proline 0 C--N 1.328 -0.351 0 O-C-N 121.982 -0.448 . . . . 0.0 110.585 -178.893 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -59.19 148.08 87.59 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 121.352 1.368 . . . . 0.0 110.771 170.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 77.77 15.59 81.09 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 124.819 1.2 . . . . 0.0 112.546 -176.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 97.2 m -89.18 118.87 29.19 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 119.698 1.749 . . . . 0.0 107.492 177.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -58.61 135.26 57.32 Favored 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 171.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.413 ' CD1' HD12 ' A' ' 33' ' ' ILE . 6.7 t80 -46.01 -34.66 4.18 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 123.173 0.589 . . . . 0.0 112.426 171.339 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.5 pttp -66.54 -40.02 88.86 Favored 'General case' 0 N--CA 1.453 -0.287 0 C-N-CA 118.076 -1.45 . . . . 0.0 110.083 179.69 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -80.62 -12.49 59.49 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.831 1.652 . . . . 0.0 110.588 -171.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.548 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 17.7 mt -57.2 132.67 80.82 Favored Pre-proline 0 N--CA 1.441 -0.877 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 172.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 1.2 Cg_endo -61.91 138.95 76.95 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 123.044 2.496 . . . . 0.0 109.904 178.072 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -64.66 -17.7 64.3 Favored 'General case' 0 N--CA 1.451 -0.397 0 O-C-N 121.819 -0.551 . . . . 0.0 112.024 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -75.54 -14.75 60.42 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 123.751 0.821 . . . . 0.0 112.696 173.363 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' TRP . . . . . 0.48 ' CD1' HG23 ' A' ' 24' ' ' VAL . 78.8 t90 -70.05 150.66 46.37 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.319 0.581 . . . . 0.0 111.2 -178.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 74.5 t -124.47 150.76 29.35 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 C-N-CA 125.656 1.582 . . . . 0.0 109.927 -173.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 49.8 t -57.86 136.66 83.41 Favored Pre-proline 0 CA--C 1.537 0.449 0 C-N-CA 125.844 1.658 . . . . 0.0 111.574 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -59.07 123.52 13.66 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 121.842 1.695 . . . . 0.0 110.14 173.592 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.2 mm? 66.71 21.79 10.5 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.701 1.201 . . . . 0.0 112.692 178.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -146.59 177.82 8.77 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 176.64 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -146.61 78.61 0.24 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -166.038 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.471 HG13 ' H ' ' A' ' 45' ' ' GLY . 7.2 p -143.58 -73.23 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 123.542 0.737 . . . . 0.0 109.928 179.163 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.471 ' H ' HG13 ' A' ' 44' ' ' VAL . . . 145.71 162.97 9.98 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 107.828 -2.109 . . . . 0.0 107.828 -173.547 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.5 ptmt -66.54 -18.7 65.51 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.836 1.318 . . . . 0.0 113.351 176.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 30.09 -93.74 0.01 OUTLIER 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 129.564 3.145 . . . . 0.0 111.964 -176.728 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.34 64.84 0.95 Allowed 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 166.034 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.3 m-30 -45.72 156.12 0.14 Allowed 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 125.093 1.357 . . . . 0.0 111.632 174.071 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -88.49 147.89 24.43 Favored 'General case' 0 C--O 1.225 -0.196 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 -175.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -74.55 141.49 44.79 Favored 'General case' 0 N--CA 1.442 -0.851 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.19 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.7 t -106.21 113.72 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.915 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 175.224 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -73.79 56.55 0.56 Allowed 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.546 1.539 . . . . 0.0 113.423 -178.658 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 . . . . . 0 C--O 1.254 1.338 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 158.363 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.4 mttm . . . . . 0 N--CA 1.452 -0.339 0 CA-C-O 122.039 0.923 . . . . 0.0 112.38 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 76.6 mttt -70.73 169.73 13.88 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.239 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 48.9 m-85 -147.65 142.74 27.09 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 118.636 -0.697 . . . . 0.0 110.815 -177.205 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.2 m -79.95 146.43 32.09 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 119.014 0.825 . . . . 0.0 109.811 172.072 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 46.6 t -67.45 176.01 2.53 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 166.642 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 90.0 m -76.4 -74.18 0.24 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.619 1.567 . . . . 0.0 112.297 -167.703 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 41.2 t -115.73 2.35 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 124.555 1.142 . . . . 0.0 110.557 177.547 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 10.4 t -80.58 -164.98 0.79 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.766 1.626 . . . . 0.0 108.725 -179.454 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -135.98 49.21 0.89 Allowed Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 44.3 m-85 -133.41 158.86 41.97 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.14 0.976 . . . . 0.0 110.168 179.176 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 13.8 mt -119.9 127.66 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 125.548 1.539 . . . . 0.0 108.224 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.535 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 25.0 t80 -78.39 140.21 38.73 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 124.807 1.243 . . . . 0.0 108.353 169.675 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 50.7 t-20 -124.81 111.87 27.29 Favored Pre-proline 0 N--CA 1.458 -0.072 0 C-N-CA 123.99 0.916 . . . . 0.0 109.963 176.521 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -63.73 -39.75 32.75 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 121.11 1.206 . . . . 0.0 111.59 -173.221 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -57.99 -31.92 67.39 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 118.052 0.387 . . . . 0.0 111.401 -179.065 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -86.88 -34.5 19.41 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 123.195 0.598 . . . . 0.0 109.787 177.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 58.43 -161.96 11.11 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -164.489 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -139.34 67.52 38.76 Favored Pre-proline 0 CA--C 1.535 0.396 0 C-N-CA 124.509 1.123 . . . . 0.0 108.299 169.582 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -58.63 -30.02 90.9 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.805 1.67 . . . . 0.0 110.855 -176.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 85.1 m-20 -60.2 -31.97 70.65 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 124.075 0.95 . . . . 0.0 110.753 178.259 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -98.8 -24.19 15.1 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 124.136 0.974 . . . . 0.0 110.292 -177.016 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 133.11 10.65 1.92 Allowed Glycine 0 CA--C 1.531 1.046 0 C-N-CA 124.484 1.04 . . . . 0.0 113.251 171.346 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.3 t -110.0 109.87 30.04 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.273 0 CA-C-N 118.593 1.197 . . . . 0.0 109.298 -175.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -64.04 154.06 83.14 Favored Pre-proline 0 C--N 1.328 -0.356 0 O-C-N 121.803 -0.561 . . . . 0.0 110.754 -178.505 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_endo -59.13 146.88 92.97 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.317 1.345 . . . . 0.0 110.659 171.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.53 20.18 77.08 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 125.329 1.442 . . . . 0.0 112.699 -177.091 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 96.9 m -91.87 121.36 33.41 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 119.443 1.622 . . . . 0.0 107.869 176.437 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.5 t0 -62.96 136.81 58.04 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 171.744 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -44.66 -35.7 2.75 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 123.332 0.653 . . . . 0.0 112.455 171.539 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.6 pttp -67.89 -36.68 80.64 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 118.482 -1.287 . . . . 0.0 110.369 -179.109 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -80.68 -16.74 53.2 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.485 1.514 . . . . 0.0 110.277 -174.269 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.535 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 20.9 mt -55.39 134.22 70.09 Favored Pre-proline 0 N--CA 1.445 -0.719 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 173.584 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_endo -64.33 138.27 59.91 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 122.425 2.083 . . . . 0.0 109.616 176.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -66.09 -12.63 56.85 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 123.054 0.541 . . . . 0.0 111.943 178.852 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.15 -19.6 64.02 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.782 1.233 . . . . 0.0 112.337 171.012 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 74.8 t90 -66.31 156.64 33.82 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 121.748 0.785 . . . . 0.0 111.985 -176.609 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -129.88 149.81 33.99 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 C-N-CA 126.904 2.082 . . . . 0.0 109.815 -178.668 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 14.6 t -73.64 138.38 77.27 Favored Pre-proline 0 C--O 1.236 0.351 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 -175.611 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -56.82 111.5 0.82 Allowed 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.1 1.866 . . . . 0.0 110.084 178.155 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 15.3 mt 79.15 16.63 0.94 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.352 1.861 . . . . 0.0 112.231 179.617 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.9 t -147.92 99.7 3.11 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-O 123.19 1.471 . . . . 0.0 108.786 -174.401 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -78.33 52.9 3.83 Favored Glycine 0 CA--C 1.528 0.859 0 O-C-N 120.878 -1.139 . . . . 0.0 111.754 -177.216 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 51.7 t -99.5 -71.2 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 175.068 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 127.73 -163.42 21.43 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 33.5 mtpt -86.61 168.72 13.38 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 169.149 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -163.54 -82.93 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 124.738 1.215 . . . . 0.0 108.288 168.265 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.1 mm-40 -99.55 -49.75 4.3 Favored 'General case' 0 C--O 1.226 -0.156 0 C-N-CA 125.22 1.408 . . . . 0.0 110.184 -171.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 29.8 p90 49.32 92.43 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.194 1.798 . . . . 0.0 112.7 177.89 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 50.2 mt-10 -74.6 137.26 42.2 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 62.8 tt0 -75.93 134.75 40.15 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.197 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 24.5 t -101.47 115.99 44.25 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.127 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 175.337 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -70.82 55.46 0.17 Allowed 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 125.893 1.677 . . . . 0.0 114.174 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 . . . . . 0 C--O 1.253 1.264 0 C-N-CA 126.698 1.999 . . . . 0.0 107.593 161.925 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 18.7 mttt . . . . . 0 N--CA 1.453 -0.295 0 CA-C-O 122.004 0.907 . . . . 0.0 112.979 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -76.27 167.98 20.87 Favored 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 115.085 -0.961 . . . . 0.0 109.649 -176.541 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -148.24 135.98 20.81 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 122.748 0.419 . . . . 0.0 112.11 -178.339 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 19.9 m -75.4 134.95 40.8 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 119.311 -0.376 . . . . 0.0 111.118 169.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 36.6 t -68.85 140.37 55.21 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.284 0.634 . . . . 0.0 110.187 170.795 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 75.1 p -25.84 -82.36 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 129.661 3.185 . . . . 0.0 114.899 -175.743 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.1 m -127.41 54.97 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 C-N-CA 125.347 1.459 . . . . 0.0 108.535 -172.613 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 37.3 t -141.09 -78.09 0.28 Allowed 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.3 -161.224 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 131.23 -33.11 2.85 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.334 -0.707 . . . . 0.0 111.334 -176.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 28.0 m-85 -57.09 139.79 51.3 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-N 118.352 1.076 . . . . 0.0 110.051 177.161 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.7 mt -106.1 120.01 56.38 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.242 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.518 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.542 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 44.9 t80 -72.49 138.38 46.97 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 169.714 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 53.8 t-20 -124.25 112.18 28.21 Favored Pre-proline 0 N--CA 1.455 -0.215 0 C-N-CA 124.08 0.952 . . . . 0.0 109.59 175.838 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -63.18 -39.2 40.13 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 C-N-CA 121.137 1.225 . . . . 0.0 112.082 -172.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -58.91 -31.56 68.75 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 117.751 0.251 . . . . 0.0 111.205 -179.522 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -87.76 -32.06 19.32 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.472 0.709 . . . . 0.0 109.877 177.77 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.32 -159.03 41.74 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -167.296 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.49 61.38 16.13 Favored Pre-proline 0 CA--C 1.539 0.544 0 C-N-CA 125.556 1.542 . . . . 0.0 107.763 171.31 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -62.7 -30.04 78.05 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 122.404 2.069 . . . . 0.0 111.329 -170.757 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -61.18 -29.6 69.9 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 123.922 0.889 . . . . 0.0 110.383 179.111 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -96.63 -28.32 14.4 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 125.232 1.413 . . . . 0.0 110.687 -178.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.52 12.78 1.35 Allowed Glycine 0 CA--C 1.531 1.092 0 C-N-CA 124.296 0.951 . . . . 0.0 113.673 169.843 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.3 t -110.02 111.01 34.25 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.208 0 CA-C-N 118.447 1.124 . . . . 0.0 108.464 -175.747 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -64.3 155.34 80.32 Favored Pre-proline 0 CA--C 1.535 0.382 0 O-C-N 121.787 -0.571 . . . . 0.0 110.981 -177.059 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.57 149.55 81.55 Favored 'Trans proline' 0 N--CA 1.449 -1.093 0 C-N-CA 121.399 1.399 . . . . 0.0 110.944 171.24 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 74.08 15.69 79.82 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 125.125 1.345 . . . . 0.0 112.848 -175.185 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 76.3 m -87.98 119.27 28.18 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 119.813 1.806 . . . . 0.0 107.183 177.56 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -61.07 137.65 58.23 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 172.653 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -46.33 -35.76 5.69 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 123.346 0.658 . . . . 0.0 111.71 172.622 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 54.2 pttt -68.2 -39.2 82.49 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 118.232 -1.387 . . . . 0.0 110.205 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -73.26 -21.16 60.68 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 125.126 1.37 . . . . 0.0 110.164 -175.193 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.542 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.3 mt -53.23 133.97 51.25 Favored Pre-proline 0 N--CA 1.446 -0.665 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 176.538 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -66.13 139.58 56.18 Favored 'Trans proline' 0 N--CA 1.444 -1.434 0 C-N-CA 122.093 1.862 . . . . 0.0 109.658 178.595 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -67.91 -9.17 42.85 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 123.806 0.843 . . . . 0.0 111.546 177.602 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -73.15 -22.69 60.47 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.779 1.232 . . . . 0.0 112.061 169.35 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 81.1 t90 -69.69 152.83 44.22 Favored 'General case' 0 N--CA 1.455 -0.221 0 O-C-N 121.628 -0.67 . . . . 0.0 110.464 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 99.2 t -131.87 152.69 37.34 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 C-N-CA 124.887 1.275 . . . . 0.0 108.862 -178.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 20.1 t -69.21 140.44 90.62 Favored Pre-proline 0 CA--C 1.54 0.568 0 C-N-CA 124.526 1.131 . . . . 0.0 110.425 -177.682 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -63.09 118.59 5.5 Favored 'Trans proline' 0 N--CA 1.452 -0.922 0 C-N-CA 122.575 2.183 . . . . 0.0 111.305 175.732 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 13.2 mt 70.19 43.54 0.85 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.85 1.26 . . . . 0.0 111.176 170.053 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 53.7 t -153.61 176.05 12.52 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 106.117 -1.808 . . . . 0.0 106.117 -171.791 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -80.42 -156.74 13.69 Favored Glycine 0 CA--C 1.528 0.867 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 173.542 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.9 m -51.98 126.93 8.2 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 O-C-N 122.099 -0.647 . . . . 0.0 109.632 171.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -126.2 -175.66 14.24 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 58.57 78.32 0.26 Allowed 'General case' 0 CA--C 1.537 0.446 0 CA-C-O 122.471 1.129 . . . . 0.0 110.444 -172.819 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -153.81 -99.68 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 114.174 -1.376 . . . . 0.0 107.653 168.635 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -76.39 60.74 1.6 Allowed 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 119.4 1.0 . . . . 0.0 111.493 178.836 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -75.93 146.1 39.93 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 121.441 -0.787 . . . . 0.0 109.911 173.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -114.38 141.53 47.52 Favored 'General case' 0 N--CA 1.464 0.232 0 C-N-CA 124.235 1.014 . . . . 0.0 108.592 175.409 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -77.54 138.58 39.26 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 29.9 t -103.65 104.5 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 C-N-CA 126.021 1.728 . . . . 0.0 107.039 178.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -77.12 57.72 1.44 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.639 1.576 . . . . 0.0 112.618 179.548 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 . . . . . 0 C--O 1.255 1.367 0 CA-C-O 117.349 -1.31 . . . . 0.0 108.446 156.776 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 40.4 mttm . . . . . 0 N--CA 1.455 -0.208 0 CA-C-O 122.056 0.931 . . . . 0.0 112.402 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 55.7 mttt -82.12 167.71 18.47 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.499 -171.425 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -146.92 136.17 22.64 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 113.411 0.893 . . . . 0.0 113.411 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.7 m -80.98 147.89 30.01 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 123.89 0.876 . . . . 0.0 111.695 169.81 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 36.1 t -79.31 14.65 1.46 Allowed 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 125.19 1.396 . . . . 0.0 112.631 175.573 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.8 m 65.64 -72.37 0.07 Allowed 'General case' 0 CA--C 1.538 0.511 0 O-C-N 119.413 -2.054 . . . . 0.0 112.588 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 69.4 t -70.54 -61.88 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 C-N-CA 123.968 0.907 . . . . 0.0 109.123 -174.341 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 8.1 p -95.41 173.58 7.45 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 172.541 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -72.74 -73.3 0.87 Allowed Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.141 -1.584 . . . . 0.0 109.141 177.174 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 22.19 63.88 0.03 OUTLIER 'General case' 0 C--N 1.345 0.408 0 C-N-CA 127.785 2.434 . . . . 0.0 111.93 -172.346 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.1 mt -62.38 115.05 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 CA-C-N 115.38 -0.827 . . . . 0.0 109.617 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.54 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 41.2 t80 -68.59 129.03 38.72 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 172.761 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 49.8 t-20 -117.36 111.25 40.2 Favored Pre-proline 0 N--CA 1.455 -0.176 0 C-N-CA 123.76 0.824 . . . . 0.0 109.212 175.044 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.11 -38.32 46.35 Favored 'Trans proline' 0 N--CA 1.448 -1.189 0 C-N-CA 121.015 1.143 . . . . 0.0 111.386 -174.355 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 -57.92 -32.63 67.95 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 117.959 0.345 . . . . 0.0 111.098 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -88.15 -32.14 18.8 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.591 0.756 . . . . 0.0 109.98 177.525 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.5 -159.4 41.87 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.821 -0.911 . . . . 0.0 110.821 -167.326 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.58 61.05 14.96 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 125.441 1.496 . . . . 0.0 107.732 171.37 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -62.75 -32.4 78.18 Favored 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.438 2.092 . . . . 0.0 111.393 -169.672 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -59.68 -30.73 68.97 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 123.986 0.914 . . . . 0.0 110.642 178.714 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -94.34 -28.55 15.49 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 125.115 1.366 . . . . 0.0 110.515 -178.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.72 13.67 1.22 Allowed Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.413 1.006 . . . . 0.0 113.739 169.443 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 54.7 t -112.45 111.61 36.9 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.285 0 CA-C-N 118.45 1.125 . . . . 0.0 108.602 -174.778 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -64.12 155.15 80.1 Favored Pre-proline 0 CA--C 1.533 0.304 0 O-C-N 121.708 -0.62 . . . . 0.0 111.132 -176.156 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.2 149.5 80.08 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.127 1.218 . . . . 0.0 110.589 169.686 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 68.87 20.29 74.29 Favored Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.402 1.477 . . . . 0.0 112.885 -173.001 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 65.1 m -88.03 120.78 29.71 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 120.058 1.929 . . . . 0.0 107.558 174.686 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -59.75 134.08 56.7 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 172.312 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -42.2 -38.35 1.72 Allowed 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.126 0.57 . . . . 0.0 112.092 168.733 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 57.9 pttt -67.32 -41.72 84.81 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 117.579 -1.649 . . . . 0.0 110.185 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -71.83 -19.28 62.0 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 125.586 1.554 . . . . 0.0 110.577 -174.448 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.54 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.0 mt -52.52 133.11 44.86 Favored Pre-proline 0 N--CA 1.443 -0.802 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 173.663 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -65.17 141.48 69.59 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 122.275 1.984 . . . . 0.0 110.113 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.2 -15.95 60.98 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 124.198 0.999 . . . . 0.0 111.912 177.279 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -66.83 -22.83 65.99 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.268 1.027 . . . . 0.0 112.181 170.683 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 89.2 t90 -78.35 149.16 33.48 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-O 121.628 0.727 . . . . 0.0 111.102 -174.555 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 2.2 m -126.99 156.29 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 C-N-CA 125.847 1.659 . . . . 0.0 109.892 -174.03 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 7.7 t -63.36 137.09 96.98 Favored Pre-proline 0 CA--C 1.543 0.689 0 C-N-CA 122.958 0.503 . . . . 0.0 110.347 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -69.6 95.81 0.55 Allowed 'Trans proline' 0 N--CA 1.451 -1.022 0 C-N-CA 123.128 2.552 . . . . 0.0 110.66 -178.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 56.3 mt 85.42 59.11 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 126.813 2.045 . . . . 0.0 111.058 173.293 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 13.1 t -147.22 -94.67 0.09 Allowed 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -176.49 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 157.38 -41.85 0.53 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.4 t -70.5 148.0 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.97 177.7 49.8 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 176.321 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.9 ptmt -65.38 106.44 1.38 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 165.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -138.85 -65.84 0.49 Allowed 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 173.708 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -101.13 106.51 17.77 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 -178.68 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -142.29 128.7 20.07 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 51.7 mt-10 -104.2 141.88 35.49 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 124.443 1.097 . . . . 0.0 108.606 -175.221 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -75.49 142.69 42.85 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 119.913 1.233 . . . . 0.0 109.73 -179.354 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.2 t -112.38 106.56 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 C-N-CA 127.629 2.372 . . . . 0.0 106.737 177.377 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -82.93 53.74 2.52 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 124.968 1.307 . . . . 0.0 113.372 -173.261 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 . . . . . 0 C--O 1.25 1.095 0 C-N-CA 124.451 1.1 . . . . 0.0 110.256 179.762 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.0 mttm . . . . . 0 N--CA 1.451 -0.378 0 CA-C-O 122.121 0.962 . . . . 0.0 113.012 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -78.0 163.13 26.22 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.595 -178.372 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -138.31 140.51 39.58 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 118.971 -0.538 . . . . 0.0 109.852 175.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.3 t -90.69 160.31 15.92 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 118.014 0.37 . . . . 0.0 111.151 173.587 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 51.5 t -81.37 -121.01 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 125.558 1.543 . . . . 0.0 107.452 175.435 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 12.6 t -160.49 -46.08 0.05 OUTLIER 'General case' 0 CA--C 1.535 0.368 0 O-C-N 121.427 -0.796 . . . . 0.0 110.415 -175.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.5 p -104.65 -66.75 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 C-N-CA 123.42 0.688 . . . . 0.0 111.271 179.81 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.5 p -67.59 -38.77 84.5 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 123.713 0.805 . . . . 0.0 110.626 -176.604 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.73 31.03 30.77 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 179.197 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 18.6 m-85 -65.76 87.21 0.09 Allowed 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 117.742 0.771 . . . . 0.0 109.439 168.581 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.4 mt -57.44 111.04 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 C-N-CA 123.293 0.637 . . . . 0.0 109.293 172.4 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.544 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 20.1 t80 -73.69 133.37 43.37 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 173.203 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 50.7 t-20 -121.45 112.78 32.52 Favored Pre-proline 0 N--CA 1.455 -0.191 0 C-N-CA 124.255 1.022 . . . . 0.0 109.753 177.613 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -62.85 -38.83 45.51 Favored 'Trans proline' 0 N--CA 1.45 -1.03 0 C-N-CA 121.474 1.449 . . . . 0.0 112.083 -171.87 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -58.75 -32.31 69.15 Favored 'General case' 0 N--CA 1.446 -0.625 0 O-C-N 123.151 0.282 . . . . 0.0 111.059 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -87.46 -31.38 20.05 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.494 0.717 . . . . 0.0 109.92 177.584 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.11 -157.36 43.32 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -166.641 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.31 61.57 12.08 Favored Pre-proline 0 CA--C 1.54 0.588 0 C-N-CA 125.457 1.503 . . . . 0.0 107.455 171.035 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -61.87 -33.86 83.43 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.62 2.213 . . . . 0.0 111.2 -169.751 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -56.1 -30.48 62.13 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 125.438 1.495 . . . . 0.0 110.66 178.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.0 m-80 -97.02 -32.84 11.79 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 125.531 1.533 . . . . 0.0 110.432 -177.829 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 139.39 11.24 0.77 Allowed Glycine 0 CA--C 1.53 1.013 0 C-N-CA 123.898 0.761 . . . . 0.0 114.015 171.106 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 68.6 t -109.31 112.18 39.36 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.215 0 CA-C-N 118.898 1.349 . . . . 0.0 108.791 -176.608 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.19 154.35 82.97 Favored Pre-proline 0 CA--C 1.533 0.306 0 O-C-N 121.91 -0.494 . . . . 0.0 110.904 -177.564 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -58.38 147.02 87.55 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 121.408 1.405 . . . . 0.0 110.947 170.716 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 77.04 15.39 81.69 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 125.051 1.31 . . . . 0.0 112.838 -176.326 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 98.7 m -87.78 117.48 26.65 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 119.956 1.878 . . . . 0.0 107.421 177.663 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -57.86 135.48 56.86 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 171.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -43.88 -36.95 2.59 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 123.389 0.676 . . . . 0.0 112.154 170.421 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -66.51 -39.98 88.96 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 118.017 -1.473 . . . . 0.0 110.066 -178.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -80.04 -12.86 59.66 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 125.718 1.607 . . . . 0.0 110.741 -172.617 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.544 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.5 mt -56.36 132.8 76.24 Favored Pre-proline 0 N--CA 1.444 -0.752 0 CA-C-O 118.356 -0.831 . . . . 0.0 108.949 174.221 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -54.89 136.26 71.53 Favored 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 124.152 3.235 . . . . 0.0 110.551 176.555 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.73 -18.44 63.52 Favored 'General case' 0 CA--C 1.533 0.296 0 O-C-N 121.352 -0.843 . . . . 0.0 111.319 -179.482 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -76.55 -11.48 59.88 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 125.876 1.67 . . . . 0.0 112.104 171.092 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -71.65 149.77 45.24 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 119.07 0.85 . . . . 0.0 110.526 176.648 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 2.1 m -128.39 153.45 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 C-N-CA 126.082 1.753 . . . . 0.0 109.881 -175.315 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 8.2 t -73.71 138.48 77.05 Favored Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 123.658 0.783 . . . . 0.0 111.042 -175.079 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -58.64 127.53 24.88 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 123.416 2.744 . . . . 0.0 111.77 -177.23 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 24.5 mt 54.65 34.89 22.5 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.688 1.195 . . . . 0.0 111.857 -179.427 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.1 t -131.93 -176.22 3.99 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -139.01 47.57 0.91 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.036 -0.825 . . . . 0.0 111.036 -175.519 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -155.65 156.98 4.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 177.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.78 -179.6 50.03 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 178.405 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.8 ptmt -62.69 -19.56 64.0 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 170.859 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 29.26 -94.42 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 129.408 3.083 . . . . 0.0 111.529 -176.258 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.1 mm-40 -145.91 69.93 1.23 Allowed 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 164.57 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.4 m-30 -47.73 156.26 0.33 Allowed 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 125.656 1.582 . . . . 0.0 110.375 169.18 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -94.82 147.46 23.32 Favored 'General case' 0 C--O 1.225 -0.236 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -172.86 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -75.05 143.9 43.26 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 118.726 0.693 . . . . 0.0 109.198 -179.308 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 11.0 t -107.95 110.88 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 C-N-CA 126.121 1.768 . . . . 0.0 106.494 177.574 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -76.03 55.29 0.91 Allowed 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 125.454 1.502 . . . . 0.0 113.272 -177.396 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 117.231 -1.366 . . . . 0.0 108.085 158.569 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 56.4 mttm . . . . . 0 N--CA 1.451 -0.399 0 N-CA-C 113.351 0.871 . . . . 0.0 113.351 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -77.71 163.65 25.97 Favored 'General case' 0 N--CA 1.447 -0.591 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.201 -179.514 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 23.6 m-85 -144.55 146.69 32.49 Favored 'General case' 0 CA--C 1.528 0.124 0 CA-C-O 119.046 -0.502 . . . . 0.0 110.732 176.895 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.5 t -99.0 143.48 29.24 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 174.251 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.452 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 48.9 t -82.65 120.23 25.3 Favored 'General case' 0 C--N 1.344 0.346 0 C-N-CA 126.678 1.991 . . . . 0.0 109.963 177.745 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 20.2 m -41.6 -76.18 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 127.617 2.367 . . . . 0.0 114.063 -175.256 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.2 p -99.7 48.5 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 O-C-N 121.233 -0.917 . . . . 0.0 109.653 -168.024 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.452 ' HB3' ' SG ' ' A' ' 6' ' ' CYS . 46.6 t -160.95 -60.95 0.06 Allowed 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -160.595 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.7 -13.48 63.9 Favored Glycine 0 CA--C 1.53 1.007 0 CA-C-O 119.025 -0.875 . . . . 0.0 113.137 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -59.19 143.32 49.33 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 119.42 1.61 . . . . 0.0 109.902 173.22 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 18.2 mt -112.04 121.22 64.07 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 123.89 0.876 . . . . 0.0 109.148 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.494 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 68.3 t80 -80.93 140.76 35.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 172.751 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 64.9 t-20 -124.68 120.1 25.79 Favored Pre-proline 0 C--O 1.224 -0.278 0 C-N-CA 124.252 1.021 . . . . 0.0 109.732 177.853 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -68.65 -40.49 7.35 Favored 'Trans proline' 0 N--CA 1.442 -1.507 0 C-N-CA 120.697 0.932 . . . . 0.0 112.122 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -60.4 -31.05 70.0 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 119.155 0.889 . . . . 0.0 110.95 -177.363 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.2 m-20 -90.11 -29.52 18.27 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.336 0.655 . . . . 0.0 109.967 177.513 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.48 -160.05 40.86 Favored Glycine 0 CA--C 1.529 0.951 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -165.615 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -139.64 62.43 23.17 Favored Pre-proline 0 CA--C 1.538 0.498 0 C-N-CA 125.181 1.393 . . . . 0.0 107.679 169.884 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -61.64 -32.12 86.99 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.345 2.03 . . . . 0.0 111.137 -171.244 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -57.05 -31.69 65.44 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.898 1.279 . . . . 0.0 110.587 178.39 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -95.43 -32.7 12.78 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.15 1.38 . . . . 0.0 110.483 -178.572 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.83 14.67 0.66 Allowed Glycine 0 CA--C 1.531 1.08 0 C-N-CA 124.053 0.835 . . . . 0.0 114.108 170.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.438 HG23 ' CD1' ' A' ' 37' ' ' TRP . 46.6 t -112.9 112.7 41.54 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.264 0 CA-C-N 118.808 1.304 . . . . 0.0 109.053 -176.037 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -64.58 155.94 79.62 Favored Pre-proline 0 C--N 1.328 -0.338 0 O-C-N 121.967 -0.458 . . . . 0.0 111.116 -177.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.64 148.29 88.27 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 121.569 1.513 . . . . 0.0 110.981 171.489 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.94 17.25 79.34 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 125.296 1.427 . . . . 0.0 112.662 -175.869 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 93.3 m -87.76 117.65 26.73 Favored 'General case' 0 N--CA 1.442 -0.875 0 CA-C-N 119.838 1.819 . . . . 0.0 107.59 176.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -58.1 134.35 56.37 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.401 171.842 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -40.47 -40.08 1.14 Allowed 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 123.901 0.88 . . . . 0.0 112.415 169.069 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.2 pttp -68.48 -38.29 80.9 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 118.295 -1.362 . . . . 0.0 109.973 -176.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -78.34 -15.62 58.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.805 1.642 . . . . 0.0 110.3 -174.358 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.494 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.4 mt -54.97 133.9 67.42 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-O 118.389 -0.815 . . . . 0.0 109.308 174.727 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 10.2 Cg_exo -57.69 137.3 80.53 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 123.597 2.865 . . . . 0.0 110.883 176.18 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -66.03 -18.43 65.33 Favored 'General case' 0 N--CA 1.45 -0.459 0 O-C-N 121.299 -0.875 . . . . 0.0 111.426 176.635 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -82.93 -6.21 59.37 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.563 1.545 . . . . 0.0 111.944 173.699 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' TRP . . . . . 0.438 ' CD1' HG23 ' A' ' 24' ' ' VAL . 71.0 t90 -69.94 160.43 31.89 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 119.053 0.842 . . . . 0.0 110.093 172.474 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -139.5 150.17 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 C-N-CA 125.585 1.554 . . . . 0.0 108.465 176.656 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.4 p -83.68 165.27 40.75 Favored Pre-proline 0 CA--C 1.539 0.557 0 N-CA-C 108.785 -0.821 . . . . 0.0 108.785 -179.182 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.51 124.13 9.61 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 121.301 1.334 . . . . 0.0 110.842 -168.702 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 12.6 mt 66.29 44.17 2.56 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 125.258 1.423 . . . . 0.0 112.201 172.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.3 t -138.45 179.63 6.35 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.913 0.885 . . . . 0.0 108.818 -177.345 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -100.98 -87.81 1.99 Allowed Glycine 0 CA--C 1.526 0.72 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 178.047 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.6 p -82.99 102.2 8.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 178.458 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -108.54 145.82 16.44 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 108.751 -1.74 . . . . 0.0 108.751 176.717 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER 59.5 101.78 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.42 1.488 . . . . 0.0 111.749 -170.652 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -138.8 -75.73 0.37 Allowed 'General case' 0 CA--C 1.521 -0.139 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 160.341 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 10.3 tm0? -144.69 55.34 1.25 Allowed 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 124.739 1.216 . . . . 0.0 107.846 -174.575 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 4.1 m-30 -55.51 150.99 11.09 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 125.059 1.343 . . . . 0.0 108.894 175.556 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -87.39 150.86 23.53 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.491 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -78.83 145.84 34.04 Favored 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 123.676 0.791 . . . . 0.0 109.088 179.301 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 14.5 t -110.84 111.44 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 C-N-CA 126.622 1.969 . . . . 0.0 107.081 174.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -71.86 67.09 0.59 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.305 1.842 . . . . 0.0 113.116 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 . . . . . 0 C--O 1.255 1.372 0 CA-C-O 117.86 -1.067 . . . . 0.0 111.098 164.514 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 7.9 mttm . . . . . 0 N--CA 1.449 -0.519 0 CA-C-O 121.61 0.719 . . . . 0.0 111.586 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 78.7 mttt -73.9 174.6 8.29 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 124.907 1.283 . . . . 0.0 109.46 174.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -144.32 131.03 20.13 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-O 118.831 -0.604 . . . . 0.0 111.628 176.419 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.6 m -79.87 143.72 34.07 Favored 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 123.872 0.869 . . . . 0.0 110.811 174.429 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.406 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 9.0 t -70.43 -175.68 1.07 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.209 1.404 . . . . 0.0 109.569 168.014 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 63.5 m -82.29 -99.26 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 123.688 0.795 . . . . 0.0 110.06 -176.612 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.8 p -87.33 -30.69 5.76 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 O-C-N 120.967 -1.083 . . . . 0.0 110.85 -178.071 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' CYS . . . . . 0.406 ' HB3' ' SG ' ' A' ' 6' ' ' CYS . 50.8 t -39.62 -55.48 1.86 Allowed 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 128.931 2.892 . . . . 0.0 112.365 175.247 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 100.91 -15.06 58.48 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-O 119.043 -0.865 . . . . 0.0 113.279 177.404 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -62.38 159.32 15.57 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.307 1.553 . . . . 0.0 111.574 176.843 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 28.7 mt -123.4 124.94 70.87 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 C-N-CA 125.227 1.411 . . . . 0.0 107.282 175.376 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.504 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 72.5 t80 -78.28 135.38 37.53 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 167.872 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -118.01 116.75 35.83 Favored Pre-proline 0 C--O 1.225 -0.204 0 C-N-CA 124.24 1.016 . . . . 0.0 109.948 175.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -64.82 -42.57 14.66 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 121.927 1.751 . . . . 0.0 111.793 -178.65 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -61.98 -28.61 69.68 Favored 'General case' 0 N--CA 1.446 -0.658 0 O-C-N 123.27 0.356 . . . . 0.0 110.862 -174.34 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -90.63 -31.62 16.58 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.997 0.919 . . . . 0.0 110.399 174.776 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.98 -162.07 31.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.289 0.947 . . . . 0.0 110.984 -165.177 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -137.94 62.27 32.58 Favored Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 125.894 1.678 . . . . 0.0 107.485 171.878 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.1 -33.32 82.66 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 122.75 2.3 . . . . 0.0 111.28 -170.618 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -56.79 -28.99 62.25 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.674 1.189 . . . . 0.0 110.738 178.634 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.6 m-80 -102.11 -26.47 13.35 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 125.607 1.563 . . . . 0.0 110.684 -175.516 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.81 6.86 1.68 Allowed Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.167 0.889 . . . . 0.0 113.786 168.841 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 75.7 t -107.58 109.87 29.77 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.156 0 CA-C-N 118.595 1.198 . . . . 0.0 108.509 -174.332 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.87 155.97 81.25 Favored Pre-proline 0 C--N 1.329 -0.321 0 O-C-N 121.734 -0.604 . . . . 0.0 111.086 -176.622 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.32 147.68 89.91 Favored 'Trans proline' 0 N--CA 1.449 -1.102 0 C-N-CA 121.496 1.464 . . . . 0.0 111.032 171.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.28 14.98 81.8 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.682 -176.857 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 99.2 m -86.67 113.72 22.77 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 119.798 1.799 . . . . 0.0 107.546 178.042 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -53.4 133.26 40.44 Favored 'General case' 0 N--CA 1.446 -0.654 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 167.838 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.425 ' CD1' HD12 ' A' ' 33' ' ' ILE . 5.1 t80 -45.2 -31.84 1.64 Allowed 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 173.758 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 7.3 pttt -68.57 -45.65 71.49 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 118.398 -1.321 . . . . 0.0 110.065 179.538 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -67.58 -19.51 65.27 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 125.58 1.552 . . . . 0.0 111.222 -175.59 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.504 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 15.2 mt -53.29 131.37 52.27 Favored Pre-proline 0 N--CA 1.443 -0.812 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 176.089 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_endo -61.96 140.34 84.21 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 122.393 2.062 . . . . 0.0 109.455 -178.432 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -67.35 -14.38 62.87 Favored 'General case' 0 CA--C 1.535 0.373 0 O-C-N 121.968 -0.457 . . . . 0.0 111.87 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -75.34 -15.07 60.51 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.491 0.716 . . . . 0.0 112.204 171.545 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 85.5 t90 -73.7 151.8 40.62 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 176.842 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 12.1 p -141.29 164.61 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 C-N-CA 124.927 1.291 . . . . 0.0 107.777 -177.345 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' CYS . . . . . 0.416 ' SG ' ' HD2' ' A' ' 40' ' ' PRO . 4.3 t -48.79 138.86 12.17 Favored Pre-proline 0 CA--C 1.54 0.561 0 C-N-CA 124.391 1.076 . . . . 0.0 110.111 176.606 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' PRO . . . . . 0.416 ' HD2' ' SG ' ' A' ' 39' ' ' CYS . 39.2 Cg_endo -59.89 -36.88 89.11 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.323 2.015 . . . . 0.0 112.881 -173.391 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 41.0 mt -136.95 42.11 2.45 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.301 0.641 . . . . 0.0 110.096 -175.197 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -164.71 173.68 11.59 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 -174.765 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -133.35 67.84 0.55 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 -174.14 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.7 p -128.92 141.42 46.66 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 172.289 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.38 147.84 49.18 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 6.2 ptmt -60.19 -38.52 83.52 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 117.226 0.513 . . . . 0.0 111.549 -179.472 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -72.35 71.63 0.91 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 124.295 1.038 . . . . 0.0 109.682 178.397 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 4.0 tp-100 -171.92 -38.66 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 125.728 1.611 . . . . 0.0 109.666 -175.524 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -57.84 137.21 56.86 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.048 0.939 . . . . 0.0 109.636 -176.777 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -96.01 149.49 21.52 Favored 'General case' 0 C--O 1.22 -0.496 0 C-N-CA 124.627 1.171 . . . . 0.0 109.364 -175.104 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -71.93 138.49 48.14 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 119.883 1.219 . . . . 0.0 110.039 -178.381 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.3 t -101.2 107.86 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 C-N-CA 125.467 1.507 . . . . 0.0 107.08 177.25 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -72.06 65.95 0.59 Allowed 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 126.348 1.859 . . . . 0.0 113.397 -177.703 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 . . . . . 0 C--O 1.257 1.467 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 150.768 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 9.6 mttm . . . . . 0 N--CA 1.448 -0.531 0 CA-C-O 121.449 0.643 . . . . 0.0 111.494 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 58.2 mttt -71.02 171.33 11.05 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 124.678 1.191 . . . . 0.0 109.862 172.881 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -141.69 134.35 28.48 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 172.77 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.5 t -85.8 154.53 21.52 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 118.312 0.506 . . . . 0.0 111.282 174.281 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 19.9 t -75.01 170.2 16.48 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 125.15 1.38 . . . . 0.0 107.852 172.639 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 6.9 t -125.72 16.7 8.09 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.063 0.945 . . . . 0.0 110.497 177.248 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 74.1 t -132.5 -60.54 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.34 0.179 0 C-N-CA 123.932 0.893 . . . . 0.0 109.52 -179.1 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.6 p -95.92 -89.31 0.26 Allowed 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 176.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 164.12 28.95 0.02 OUTLIER Glycine 0 CA--C 1.529 0.94 0 C-N-CA 125.487 1.518 . . . . 0.0 110.638 176.448 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -80.73 73.66 7.69 Favored 'General case' 0 N--CA 1.453 -0.322 0 O-C-N 121.819 -0.812 . . . . 0.0 108.83 -170.55 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.0 mt -45.35 112.52 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 C-N-CA 123.33 0.652 . . . . 0.0 110.978 -178.484 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.538 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 35.7 t80 -73.53 134.44 43.82 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 173.041 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 46.3 t-20 -123.07 114.63 29.35 Favored Pre-proline 0 N--CA 1.446 -0.652 0 C-N-CA 123.437 0.695 . . . . 0.0 109.387 176.585 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -65.36 -43.77 10.21 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 122.317 2.012 . . . . 0.0 111.327 -177.256 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -56.84 -29.39 62.79 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 123.636 0.774 . . . . 0.0 111.226 -176.679 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -100.45 -23.41 14.74 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.879 0.872 . . . . 0.0 110.455 179.033 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.11 -160.59 30.73 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 124.829 1.204 . . . . 0.0 110.983 -172.333 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -140.34 61.4 16.69 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 125.281 1.432 . . . . 0.0 107.497 171.719 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_endo -62.38 -30.86 81.14 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 122.199 1.933 . . . . 0.0 111.076 -172.009 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -59.02 -29.65 67.43 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 124.463 1.105 . . . . 0.0 110.337 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -98.81 -29.29 13.06 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 125.544 1.537 . . . . 0.0 110.964 -177.154 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.36 18.24 0.93 Allowed Glycine 0 CA--C 1.532 1.15 0 C-N-CA 124.249 0.928 . . . . 0.0 113.798 170.469 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.2 t -117.26 110.02 29.71 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.216 0 CA-C-N 118.334 1.067 . . . . 0.0 108.443 -175.552 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -63.36 155.76 73.14 Favored Pre-proline 0 CA--C 1.534 0.337 0 O-C-N 121.835 -0.541 . . . . 0.0 110.976 -177.253 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -60.54 149.37 87.16 Favored 'Trans proline' 0 N--CA 1.449 -1.129 0 C-N-CA 121.464 1.443 . . . . 0.0 110.717 171.509 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.04 14.93 81.76 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 125.129 1.347 . . . . 0.0 113.047 -175.6 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 97.8 m -89.34 114.89 26.36 Favored 'General case' 0 N--CA 1.443 -0.815 0 CA-C-N 119.919 1.86 . . . . 0.0 107.836 178.541 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -56.17 134.72 53.15 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 169.732 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -42.38 -35.6 1.06 Allowed 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 123.709 0.803 . . . . 0.0 112.881 171.217 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 51.0 pttt -69.69 -42.48 74.05 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.625 -178.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -68.08 -21.44 64.97 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 125.658 1.583 . . . . 0.0 110.438 -176.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.538 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.8 mt -53.63 130.6 55.08 Favored Pre-proline 0 N--CA 1.445 -0.688 0 CA-C-N 118.758 0.708 . . . . 0.0 109.216 175.331 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -63.94 140.52 73.3 Favored 'Trans proline' 0 N--CA 1.445 -1.335 0 C-N-CA 122.479 2.12 . . . . 0.0 109.758 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -57.84 -23.22 51.78 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.537 0.735 . . . . 0.0 111.522 175.225 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.57 -18.75 63.66 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 124.745 1.218 . . . . 0.0 112.057 177.633 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 80.1 t90 -75.55 154.54 36.76 Favored 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 121.629 -0.669 . . . . 0.0 110.095 -179.563 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.1 t -139.73 149.57 22.43 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 C-N-CA 124.905 1.282 . . . . 0.0 108.569 -169.011 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.1 t -73.41 127.39 88.98 Favored Pre-proline 0 CA--C 1.545 0.757 0 C-N-CA 122.974 0.509 . . . . 0.0 110.879 179.153 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.43 139.76 50.41 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 123.196 2.597 . . . . 0.0 111.646 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 57.6 mt 58.56 31.94 21.6 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.54 1.136 . . . . 0.0 111.706 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 43.5 t -147.76 -57.61 0.24 Allowed 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -173.469 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.94 26.8 63.75 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 111.946 -0.461 . . . . 0.0 111.946 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 95.6 t -111.35 155.99 12.6 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 C-N-CA 124.341 1.056 . . . . 0.0 109.182 177.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -67.91 155.69 52.94 Favored Glycine 0 CA--C 1.528 0.867 0 C-N-CA 124.469 1.033 . . . . 0.0 111.743 -176.675 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.1 ptmt -67.86 -42.89 80.62 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -175.643 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -76.87 77.65 3.46 Favored 'General case' 0 N--CA 1.456 -0.166 0 CA-C-O 122.426 1.108 . . . . 0.0 108.879 -170.874 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -179.37 -30.06 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 128.582 2.753 . . . . 0.0 108.97 -168.706 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -57.06 141.42 45.9 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.628 0.771 . . . . 0.0 110.888 169.629 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -111.66 145.16 39.74 Favored 'General case' 0 C--O 1.22 -0.458 0 C-N-CA 125.08 1.352 . . . . 0.0 109.551 -177.805 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -65.62 136.34 56.2 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-N 118.778 0.717 . . . . 0.0 110.415 -176.02 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.8 t -94.74 109.53 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 175.859 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -69.0 82.13 0.31 Allowed 'General case' 0 N--CA 1.443 -0.796 0 C-N-CA 125.503 1.521 . . . . 0.0 110.706 175.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 . . . . . 0 C--O 1.251 1.154 0 CA-C-O 117.229 -1.367 . . . . 0.0 110.471 169.387 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 22.6 mttm . . . . . 0 N--CA 1.45 -0.431 0 CA-C-O 122.674 1.226 . . . . 0.0 112.319 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 66.2 mttt -73.61 170.65 14.76 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.439 -0.801 . . . . 0.0 109.836 -178.749 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.482 ' CE1' ' HB2' ' A' ' 30' ' ' PHE . 55.3 m-85 -142.07 141.64 32.77 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 122.501 0.32 . . . . 0.0 111.323 176.419 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 91.1 m -78.25 142.44 37.85 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 123.47 0.708 . . . . 0.0 109.605 172.108 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 24.8 t -79.58 135.48 36.61 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 125.071 1.348 . . . . 0.0 108.428 175.048 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.0 m -45.32 -56.79 4.55 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.496 1.519 . . . . 0.0 114.197 -168.135 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 14.5 p -153.35 35.91 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 120.939 0.399 . . . . 0.0 110.59 -173.321 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 2.8 m -121.79 -65.25 1.14 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.485 0.714 . . . . 0.0 109.188 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 116.78 56.33 0.31 Allowed Glycine 0 CA--C 1.53 0.995 0 C-N-CA 124.717 1.151 . . . . 0.0 111.948 176.907 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -139.18 87.66 2.22 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.457 1.103 . . . . 0.0 109.052 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.4 mt -57.23 127.13 15.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 O-C-N 121.439 -0.788 . . . . 0.0 111.035 -176.541 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.566 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 27.7 t80 -81.4 137.29 35.7 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 172.448 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 51.7 t-20 -122.55 112.44 31.02 Favored Pre-proline 0 C--N 1.339 0.136 0 C-N-CA 124.168 0.987 . . . . 0.0 109.841 175.809 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_endo -65.15 -37.44 32.23 Favored 'Trans proline' 0 N--CA 1.45 -1.086 0 C-N-CA 121.28 1.32 . . . . 0.0 111.51 -173.567 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -58.34 -32.09 68.2 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 117.726 0.239 . . . . 0.0 111.322 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -87.49 -32.8 19.26 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.489 0.716 . . . . 0.0 109.868 177.029 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.26 -156.41 45.16 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 -168.093 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -143.37 61.29 9.83 Favored Pre-proline 0 CA--C 1.542 0.669 0 C-N-CA 125.705 1.602 . . . . 0.0 107.442 172.26 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.01 -33.41 83.27 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.671 2.247 . . . . 0.0 111.618 -169.056 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -58.15 -30.99 66.79 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 124.688 1.195 . . . . 0.0 110.394 178.738 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -92.4 -29.42 16.31 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 125.245 1.418 . . . . 0.0 110.351 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.14 -4.01 3.13 Favored Glycine 0 CA--C 1.529 0.938 0 C-N-CA 124.477 1.037 . . . . 0.0 113.148 172.101 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 74.3 t -94.3 109.78 22.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -172.633 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -62.98 154.84 75.35 Favored Pre-proline 0 CA--C 1.534 0.354 0 O-C-N 121.767 -0.583 . . . . 0.0 110.488 -177.565 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -59.08 149.27 80.98 Favored 'Trans proline' 0 N--CA 1.449 -1.138 0 C-N-CA 121.123 1.215 . . . . 0.0 110.417 169.499 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.03 17.93 80.22 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 125.32 1.438 . . . . 0.0 113.3 -175.355 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 98.0 m -92.1 119.41 31.75 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-N 119.983 1.892 . . . . 0.0 107.312 177.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -65.2 142.99 58.13 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 173.168 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' PHE . . . . . 0.482 ' HB2' ' CE1' ' A' ' 4' ' ' TYR . 2.2 t80 -49.22 -33.11 11.84 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 123.639 0.775 . . . . 0.0 112.366 175.106 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 10.4 pttm -67.27 -37.17 83.01 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 119.254 -0.978 . . . . 0.0 110.926 178.291 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 -77.43 -21.0 53.7 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 124.742 1.217 . . . . 0.0 110.09 -174.878 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.566 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.4 mt -55.64 133.68 71.71 Favored Pre-proline 0 N--CA 1.445 -0.693 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.214 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 5.9 Cg_exo -59.45 134.8 60.68 Favored 'Trans proline' 0 N--CA 1.449 -1.123 0 C-N-CA 122.746 2.297 . . . . 0.0 109.374 175.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.59 -3.84 33.48 Favored 'General case' 0 N--CA 1.447 -0.577 0 O-C-N 121.632 -0.667 . . . . 0.0 112.346 -176.489 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -76.23 -12.42 60.09 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.131 0.972 . . . . 0.0 112.596 164.735 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 80.6 t90 -67.15 148.92 51.21 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 118.981 0.81 . . . . 0.0 111.297 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 62.7 t -125.97 144.47 35.98 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 126.732 2.013 . . . . 0.0 108.718 -175.079 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.8 p -82.82 132.57 51.0 Favored Pre-proline 0 CA--C 1.543 0.695 0 CA-C-N 120.038 1.29 . . . . 0.0 110.06 177.064 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -79.12 139.84 15.32 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.617 2.211 . . . . 0.0 111.066 -175.39 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 18.1 tp 60.37 31.87 20.5 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 124.497 1.119 . . . . 0.0 111.262 -178.971 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 33.3 m -125.65 -97.83 0.42 Allowed 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.977 1.311 . . . . 0.0 109.357 -179.612 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 143.88 114.18 0.95 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 108.325 -1.91 . . . . 0.0 108.325 -164.628 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.427 HG13 ' N ' ' A' ' 45' ' ' GLY 0.265 0.4 OUTLIER 76.94 -173.2 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 125.151 1.38 . . . . 0.0 110.402 -171.721 . . . . . . . . 4 4 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLY . . . . . 0.427 ' N ' HG13 ' A' ' 44' ' ' VAL . . . -129.53 -123.69 2.56 Favored Glycine 0 N--CA 1.449 -0.442 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 179.854 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 23.4 mtpt -82.23 167.86 18.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.429 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -159.45 -75.49 0.07 Allowed 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 124.656 1.183 . . . . 0.0 108.827 172.642 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -124.06 -38.65 2.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 127.268 2.227 . . . . 0.0 109.739 -177.626 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 25.2 p90 53.15 173.47 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.235 2.214 . . . . 0.0 112.882 -176.324 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -138.72 136.55 35.91 Favored 'General case' 0 CA--C 1.521 -0.155 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 172.491 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -74.22 137.27 42.95 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 176.806 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.6 t -97.59 113.97 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.823 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 175.348 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -74.09 51.56 0.42 Allowed 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.3 1.44 . . . . 0.0 114.113 -178.499 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 28.9 mt-10 . . . . . 0 C--O 1.253 1.288 0 C-N-CA 125.921 1.688 . . . . 0.0 107.587 157.143 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 33.2 mttt . . . . . 0 N--CA 1.451 -0.403 0 N-CA-C 113.408 0.892 . . . . 0.0 113.408 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -70.67 162.61 28.69 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.54 178.777 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -144.99 137.18 25.92 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 124.248 1.019 . . . . 0.0 111.423 -178.847 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.8 m -75.92 155.59 35.01 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.232 1.013 . . . . 0.0 110.975 173.684 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 15.3 t -97.49 -37.49 9.95 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.236 1.814 . . . . 0.0 109.3 174.281 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 86.1 m 76.14 -62.46 0.43 Allowed 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 125.455 1.502 . . . . 0.0 112.016 166.407 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 31.2 m -78.79 43.72 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-N 119.284 0.947 . . . . 0.0 110.656 178.001 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 10.4 t 177.05 -102.49 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -156.27 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 121.21 64.77 0.24 Allowed Glycine 0 CA--C 1.53 0.974 0 C-N-CA 125.302 1.43 . . . . 0.0 111.035 -176.808 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -114.51 -57.55 2.26 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.301 1.04 . . . . 0.0 111.055 176.722 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . 0.251 57.8 mt 79.84 110.73 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 C-N-CA 127.548 2.339 . . . . 0.0 110.997 -170.921 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.535 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 51.6 t80 -74.23 141.6 45.4 Favored 'General case' 0 C--O 1.236 0.357 0 C-N-CA 124.203 1.001 . . . . 0.0 108.859 171.055 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 63.9 t-20 -126.57 116.57 22.88 Favored Pre-proline 0 C--O 1.224 -0.289 0 C-N-CA 123.488 0.715 . . . . 0.0 110.9 173.463 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -68.25 -41.46 6.97 Favored 'Trans proline' 0 N--CA 1.445 -1.369 0 C-N-CA 121.13 1.22 . . . . 0.0 112.042 -177.54 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -60.05 -30.9 69.5 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 118.706 0.684 . . . . 0.0 110.855 -178.005 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 -86.62 -32.71 20.45 Favored 'General case' 0 CA--C 1.53 0.192 0 C-N-CA 123.406 0.682 . . . . 0.0 109.512 176.629 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.89 -159.86 42.71 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -164.122 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -137.56 61.79 32.67 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 168.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -61.74 -38.22 62.12 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.11 2.54 . . . . 0.0 111.257 -167.886 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -51.02 -30.35 15.13 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.769 1.628 . . . . 0.0 110.825 177.145 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -101.48 -18.12 16.12 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 125.818 1.647 . . . . 0.0 110.976 -175.159 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 130.56 -5.18 5.87 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.583 1.087 . . . . 0.0 113.324 172.281 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 78.6 t -100.22 108.7 23.42 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.202 0 CA-C-N 118.2 1.0 . . . . 0.0 109.103 -171.658 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -64.73 155.16 83.31 Favored Pre-proline 0 CA--C 1.533 0.305 0 O-C-N 121.767 -0.583 . . . . 0.0 111.072 -175.634 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -57.95 147.64 80.81 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 121.322 1.348 . . . . 0.0 110.723 170.564 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 71.51 21.68 78.69 Favored Glycine 0 CA--C 1.525 0.714 0 C-N-CA 125.653 1.596 . . . . 0.0 112.945 -174.272 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.9 m -91.75 121.92 33.83 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 119.994 1.897 . . . . 0.0 107.818 174.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -63.87 137.87 58.23 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 174.325 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -42.95 -38.37 2.2 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.167 0.987 . . . . 0.0 111.733 170.277 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -67.26 -39.73 86.14 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 118.572 -1.251 . . . . 0.0 110.493 -179.448 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -82.54 -11.45 58.43 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 125.906 1.683 . . . . 0.0 110.716 -172.594 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.535 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.6 mt -54.53 133.16 63.54 Favored Pre-proline 0 N--CA 1.441 -0.878 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 171.653 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 16.7 Cg_exo -53.83 134.53 59.42 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 123.785 2.99 . . . . 0.0 109.432 176.059 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.39 -11.2 60.0 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.146 -0.972 . . . . 0.0 111.705 -175.299 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -78.01 -10.1 59.44 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 126.493 1.917 . . . . 0.0 112.181 167.027 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 78.3 t90 -66.97 158.14 31.61 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 119.089 0.859 . . . . 0.0 109.971 173.391 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.8 p -136.52 155.09 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 124.712 1.205 . . . . 0.0 108.71 -176.684 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.6 t -56.4 136.02 76.26 Favored Pre-proline 0 CA--C 1.534 0.339 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.89 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -58.59 -28.98 87.73 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 123.045 2.496 . . . . 0.0 113.214 -174.701 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.6 tp -150.8 51.5 0.86 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 118.72 0.691 . . . . 0.0 111.075 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . 0.258 1.7 p -142.84 -64.68 0.4 Allowed 'General case' 0 N--CA 1.464 0.266 0 O-C-N 122.053 -0.405 . . . . 0.0 110.552 159.715 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 142.87 -136.33 7.04 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 -179.408 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.4 t 61.77 -83.65 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 C-N-CA 126.097 1.759 . . . . 0.0 112.352 173.77 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.58 -139.28 6.76 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -170.02 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 48.4 mtpt -113.77 93.75 4.52 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 124.925 1.29 . . . . 0.0 108.608 174.778 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 55.6 p-10 -144.72 169.73 17.45 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 170.875 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER 36.93 47.02 0.54 Allowed 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 127.218 2.207 . . . . 0.0 113.324 -177.377 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 21.3 p90 -95.29 113.79 25.51 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.372 0.669 . . . . 0.0 110.053 179.628 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -98.33 149.4 22.67 Favored 'General case' 0 C--O 1.223 -0.31 0 C-N-CA 125.77 1.628 . . . . 0.0 108.726 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -79.72 142.02 35.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 120.273 1.397 . . . . 0.0 110.031 -178.441 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.2 t -105.98 109.64 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 126.35 1.86 . . . . 0.0 107.376 176.248 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -72.63 66.55 0.73 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.994 1.718 . . . . 0.0 113.131 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 . . . . . 0 C--O 1.256 1.435 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.241 158.845 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.6 mttm . . . . . 0 N--CA 1.451 -0.42 0 CA-C-O 122.072 0.939 . . . . 0.0 112.432 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -78.39 166.76 22.26 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.236 -174.719 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -151.62 150.39 30.23 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 123.367 0.667 . . . . 0.0 112.409 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.5 m -78.28 156.24 29.77 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 123.876 0.87 . . . . 0.0 112.355 171.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 34.0 t -70.93 166.71 20.62 Favored 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 125.026 1.33 . . . . 0.0 108.768 166.03 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 5.4 m -45.16 -41.88 8.51 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 126.463 1.905 . . . . 0.0 112.302 170.208 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.3 p -160.98 -32.74 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 113.53 0.937 . . . . 0.0 113.53 -172.669 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.9 p -77.58 172.46 13.33 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 120.213 1.369 . . . . 0.0 110.58 -177.764 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -89.5 51.69 3.65 Favored Glycine 0 CA--C 1.527 0.83 0 O-C-N 121.318 -0.864 . . . . 0.0 111.732 -176.914 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -125.84 86.73 2.57 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 118.25 1.025 . . . . 0.0 110.445 -177.557 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 15.9 mt -67.63 127.26 28.97 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 O-C-N 121.73 -0.607 . . . . 0.0 109.605 174.914 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 40.0 t80 -78.48 136.94 37.71 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 170.899 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.6 t-20 -122.19 113.11 31.24 Favored Pre-proline 0 C--O 1.227 -0.123 0 C-N-CA 124.312 1.045 . . . . 0.0 110.34 177.698 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -65.33 -38.98 24.24 Favored 'Trans proline' 0 N--CA 1.445 -1.359 0 C-N-CA 120.97 1.114 . . . . 0.0 112.246 -177.133 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -59.74 -32.13 70.28 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 118.562 0.619 . . . . 0.0 111.102 -178.054 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -88.06 -32.02 18.97 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 123.471 0.709 . . . . 0.0 109.75 178.083 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.1 -158.62 37.85 Favored Glycine 0 CA--C 1.529 0.952 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 -165.35 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.76 61.69 11.32 Favored Pre-proline 0 CA--C 1.54 0.595 0 C-N-CA 125.955 1.702 . . . . 0.0 107.113 171.831 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -61.11 -33.86 90.51 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.572 2.181 . . . . 0.0 111.045 -170.227 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -54.58 -30.61 54.83 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 125.294 1.437 . . . . 0.0 110.736 178.175 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -102.97 -23.03 13.73 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 125.432 1.493 . . . . 0.0 110.778 -174.815 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 132.42 11.05 2.02 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 124.287 0.946 . . . . 0.0 113.401 169.645 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 70.6 t -110.3 108.76 26.23 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 CA-C-N 118.544 1.172 . . . . 0.0 108.762 -175.732 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -63.1 155.04 75.25 Favored Pre-proline 0 CA--C 1.535 0.379 0 O-C-N 121.662 -0.649 . . . . 0.0 110.876 -178.319 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.79 148.78 86.8 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 121.118 1.212 . . . . 0.0 110.719 170.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.46 17.0 78.81 Favored Glycine 0 CA--C 1.526 0.73 0 C-N-CA 125.256 1.408 . . . . 0.0 112.963 -174.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 54.1 m -88.6 122.01 31.59 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 119.797 1.798 . . . . 0.0 107.977 178.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -63.88 135.56 56.66 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 171.672 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -40.39 -41.63 1.42 Allowed 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.4 0.68 . . . . 0.0 111.634 167.348 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.3 pttt -66.91 -34.74 78.44 Favored 'General case' 0 CA--C 1.536 0.429 0 O-C-N 120.241 -1.537 . . . . 0.0 110.823 -178.381 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -76.49 -22.1 54.94 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 125.13 1.372 . . . . 0.0 109.801 -177.64 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 15.8 mt -55.85 134.31 72.95 Favored Pre-proline 0 N--CA 1.445 -0.693 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.757 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_endo -62.05 137.3 66.0 Favored 'Trans proline' 0 N--CA 1.443 -1.443 0 C-N-CA 121.755 1.637 . . . . 0.0 108.889 176.482 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -72.46 -3.35 23.81 Favored 'General case' 0 N--CA 1.444 -0.741 0 O-C-N 121.914 -0.491 . . . . 0.0 111.908 -179.443 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.06 -23.16 64.01 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 125.509 1.524 . . . . 0.0 112.315 164.179 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 84.6 t90 -70.56 152.43 43.96 Favored 'General case' 0 CA--C 1.53 0.176 0 O-C-N 121.628 -0.67 . . . . 0.0 110.855 -176.447 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.6 t -139.24 151.8 23.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 C-N-CA 125.901 1.68 . . . . 0.0 107.441 -173.288 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 9.8 t -54.12 133.14 59.75 Favored Pre-proline 0 CA--C 1.541 0.632 0 C-N-CA 125.557 1.543 . . . . 0.0 110.119 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -59.19 -52.49 4.86 Favored 'Trans proline' 0 N--CA 1.459 -0.546 0 C-N-CA 123.674 2.916 . . . . 0.0 113.699 -166.383 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 96.1 mt -128.68 59.92 1.53 Allowed 'General case' 0 N--CA 1.462 0.135 0 C-N-CA 123.68 0.792 . . . . 0.0 109.541 -173.2 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -162.9 -66.79 0.05 OUTLIER 'General case' 0 CA--C 1.529 0.158 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 -171.637 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 101.1 51.76 1.13 Allowed Glycine 0 CA--C 1.528 0.879 0 C-N-CA 123.641 0.638 . . . . 0.0 112.493 175.21 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 34.7 m -125.56 152.92 32.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 C-N-CA 123.953 0.901 . . . . 0.0 108.91 168.002 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.12 -175.59 44.97 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 110.81 -0.916 . . . . 0.0 110.81 175.334 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 41.2 mtpt -78.41 84.43 4.57 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 122.931 0.492 . . . . 0.0 109.824 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -139.28 150.73 45.79 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.502 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.4 tp-100 48.32 55.82 8.3 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.993 2.117 . . . . 0.0 112.17 175.003 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -103.24 115.88 31.41 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.746 0.818 . . . . 0.0 110.077 -179.254 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -86.24 146.36 26.57 Favored 'General case' 0 C--O 1.226 -0.175 0 C-N-CA 125.431 1.492 . . . . 0.0 109.206 178.495 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -81.42 141.82 33.56 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 119.089 0.859 . . . . 0.0 109.36 -179.848 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.4 t -109.03 102.49 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.837 0 C-N-CA 127.109 2.164 . . . . 0.0 107.757 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -76.59 76.36 3.28 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 126.207 1.803 . . . . 0.0 112.682 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 51.2 mm-40 . . . . . 0 C--O 1.255 1.392 0 CA-C-O 116.671 -1.633 . . . . 0.0 108.414 153.42 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.3 mttm . . . . . 0 N--CA 1.455 -0.203 0 CA-C-O 121.568 0.699 . . . . 0.0 111.394 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -75.33 168.27 20.32 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 124.213 1.005 . . . . 0.0 108.567 174.045 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 29.4 m-85 -144.62 139.12 27.86 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-O 118.899 -0.572 . . . . 0.0 112.306 -179.045 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.8 m -87.1 137.78 32.06 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 119.175 0.898 . . . . 0.0 111.298 178.154 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 40.8 t -62.73 149.7 43.14 Favored 'General case' 0 C--N 1.34 0.171 0 CA-C-N 118.699 0.682 . . . . 0.0 109.708 174.075 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 58.1 m -43.05 -36.67 1.68 Allowed 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 125.477 1.511 . . . . 0.0 112.113 172.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 m -129.71 -40.76 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 123.368 0.667 . . . . 0.0 112.46 178.677 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 m -76.79 160.65 29.11 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.346 0.976 . . . . 0.0 112.413 -171.558 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -99.38 12.59 61.67 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 119.222 -0.766 . . . . 0.0 112.406 174.106 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 38.8 m-85 -60.58 -43.91 96.81 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 118.873 1.336 . . . . 0.0 111.308 -175.696 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.7 mt 69.64 113.01 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 C-N-CA 126.137 1.775 . . . . 0.0 111.368 -177.155 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' TYR . . . . . 0.504 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 80.4 t80 -69.62 132.49 46.28 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 171.109 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -120.35 113.23 33.88 Favored Pre-proline 0 N--CA 1.456 -0.168 0 C-N-CA 124.205 1.002 . . . . 0.0 109.685 177.429 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -59.67 -42.19 49.0 Favored 'Trans proline' 0 N--CA 1.45 -1.045 0 C-N-CA 122.017 1.811 . . . . 0.0 112.443 -176.561 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -59.64 -31.41 69.5 Favored 'General case' 0 N--CA 1.447 -0.606 0 O-C-N 123.108 0.255 . . . . 0.0 111.653 -178.266 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 -90.09 -29.59 18.24 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 123.304 0.641 . . . . 0.0 110.422 177.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.79 -154.99 42.38 Favored Glycine 0 CA--C 1.53 1.029 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -167.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -146.34 61.33 6.95 Favored Pre-proline 0 CA--C 1.543 0.702 0 C-N-CA 125.595 1.558 . . . . 0.0 107.842 173.558 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -61.33 -34.53 87.17 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 122.944 2.429 . . . . 0.0 111.599 -168.879 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -54.64 -29.88 53.55 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 125.253 1.421 . . . . 0.0 111.38 177.84 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -98.03 -33.98 10.97 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 125.493 1.517 . . . . 0.0 109.774 -177.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 141.27 11.51 0.56 Allowed Glycine 0 CA--C 1.532 1.132 0 C-N-CA 123.933 0.778 . . . . 0.0 114.06 169.829 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.462 HG23 ' CD1' ' A' ' 37' ' ' TRP . 52.2 t -107.61 112.73 41.35 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.245 0 CA-C-N 119.174 1.487 . . . . 0.0 108.947 -177.379 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -65.05 153.79 88.19 Favored Pre-proline 0 C--N 1.329 -0.283 0 O-C-N 122.016 -0.428 . . . . 0.0 110.406 -179.367 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -59.22 146.77 93.5 Favored 'Trans proline' 0 N--CA 1.449 -1.113 0 C-N-CA 121.631 1.554 . . . . 0.0 110.955 172.185 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 78.03 18.01 77.43 Favored Glycine 0 CA--C 1.524 0.642 0 CA-C-O 118.553 -1.137 . . . . 0.0 112.764 -177.159 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 83.0 m -89.96 120.84 31.52 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 119.577 1.689 . . . . 0.0 107.678 177.133 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -57.55 133.55 55.35 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 169.523 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -48.43 -32.27 7.45 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.753 174.48 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -68.73 -40.89 79.67 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 119.375 -0.93 . . . . 0.0 109.345 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -75.36 -15.32 60.48 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 125.546 1.539 . . . . 0.0 110.494 -172.689 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.504 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 12.9 mt -55.94 132.17 73.59 Favored Pre-proline 0 N--CA 1.441 -0.891 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 172.427 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -63.41 140.2 75.09 Favored 'Trans proline' 0 N--CA 1.443 -1.486 0 C-N-CA 122.633 2.222 . . . . 0.0 109.042 178.083 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.37 -18.12 57.23 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 122.555 0.342 . . . . 0.0 111.224 177.243 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.25 -18.53 62.44 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.784 1.234 . . . . 0.0 112.076 176.357 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' TRP . . . . . 0.462 ' CD1' HG23 ' A' ' 24' ' ' VAL . 73.3 t90 -68.76 159.47 32.24 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 121.668 0.747 . . . . 0.0 110.943 -178.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 15.9 m -136.51 151.4 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.796 0 C-N-CA 125.66 1.584 . . . . 0.0 109.279 -171.294 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.3 t -72.31 135.75 81.83 Favored Pre-proline 0 CA--C 1.537 0.472 0 C-N-CA 124.428 1.091 . . . . 0.0 108.886 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.58 131.7 30.55 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 122.173 1.916 . . . . 0.0 110.058 179.318 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 57.1 mt 56.97 49.46 13.89 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.544 0.738 . . . . 0.0 110.991 176.363 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 53.8 t -163.58 -176.62 4.77 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 127.877 2.471 . . . . 0.0 105.092 -174.873 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.71 -100.35 0.56 Allowed Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.161 0.886 . . . . 0.0 111.08 178.025 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.3 m -142.35 160.13 19.64 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.117 0 C-N-CA 123.93 0.892 . . . . 0.0 108.687 -177.754 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 142.84 149.05 5.06 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 177.165 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.8 ptmt -161.75 -177.58 5.96 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 125.291 1.436 . . . . 0.0 107.447 169.629 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 t0 69.59 -63.24 0.39 Allowed 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 126.992 2.117 . . . . 0.0 111.817 169.535 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 38.5 tt0 -56.73 -22.68 37.08 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.707 2.003 . . . . 0.0 113.188 174.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 6.0 m-30 -45.18 143.95 1.48 Allowed 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.865 1.666 . . . . 0.0 109.494 170.825 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -75.16 155.39 37.01 Favored 'General case' 0 C--O 1.224 -0.263 0 CA-C-N 119.429 1.013 . . . . 0.0 108.555 -177.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -83.03 133.87 35.06 Favored 'General case' 0 N--CA 1.442 -0.837 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 173.644 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 13.4 t -93.51 116.59 35.04 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.983 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 172.842 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -70.96 56.88 0.2 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.683 1.993 . . . . 0.0 114.491 -177.454 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 . . . . . 0 C--O 1.255 1.352 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 159.832 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.379 20.6 ptm . . . . . 0 N--CA 1.475 0.813 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 21.4 mttm 58.72 167.41 0.05 Allowed 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 125.885 1.674 . . . . 0.0 112.77 -165.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.4 mtpt -74.0 170.39 15.52 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.734 -178.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 38.2 m-85 -146.89 147.18 30.53 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 122.863 0.465 . . . . 0.0 110.648 -177.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 51.4 p -64.95 165.61 10.57 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 120.644 0.259 . . . . 0.0 111.075 167.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 4.4 t -68.77 -97.56 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 105.97 -1.863 . . . . 0.0 105.97 159.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.5 t -172.95 -41.65 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.578 1.951 . . . . 0.0 107.133 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 9.8 p -147.79 -38.62 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 114.495 1.294 . . . . 0.0 114.495 176.361 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 13.6 p -64.97 -41.47 95.41 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 120.345 1.43 . . . . 0.0 111.282 -170.305 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 109.39 47.67 0.85 Allowed Glycine 0 CA--C 1.527 0.793 0 C-N-CA 124.805 1.193 . . . . 0.0 111.779 175.362 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -114.87 89.4 3.09 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.129 0.972 . . . . 0.0 109.041 176.828 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 16.0 mt -63.82 125.52 20.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.509 -0.744 . . . . 0.0 109.601 176.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.557 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 39.9 t80 -81.56 138.89 35.35 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 173.077 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.1 t-20 -122.88 114.33 29.73 Favored Pre-proline 0 N--CA 1.456 -0.157 0 C-N-CA 123.862 0.865 . . . . 0.0 110.292 174.51 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -67.46 -38.89 13.61 Favored 'Trans proline' 0 N--CA 1.448 -1.196 0 C-N-CA 121.337 1.358 . . . . 0.0 111.777 -174.563 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -59.87 -30.86 69.27 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 118.141 0.428 . . . . 0.0 111.05 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -87.39 -31.73 19.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.477 0.711 . . . . 0.0 109.886 176.261 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.21 -159.4 37.05 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -166.504 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -139.91 61.16 17.31 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 125.485 1.514 . . . . 0.0 107.535 170.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -63.41 -30.65 72.59 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.527 2.151 . . . . 0.0 111.212 -170.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -59.9 -28.24 67.41 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 124.283 1.033 . . . . 0.0 109.858 179.155 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 21.6 m-80 -102.36 -26.22 13.36 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 125.73 1.612 . . . . 0.0 110.874 -175.322 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 135.83 10.96 1.31 Allowed Glycine 0 CA--C 1.531 1.077 0 C-N-CA 124.177 0.894 . . . . 0.0 113.86 169.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 70.7 t -112.95 110.22 31.41 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.294 0 CA-C-N 118.644 1.222 . . . . 0.0 108.709 -174.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -63.63 155.06 77.91 Favored Pre-proline 0 CA--C 1.535 0.366 0 O-C-N 121.631 -0.668 . . . . 0.0 111.073 -176.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.27 149.02 83.48 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 121.19 1.26 . . . . 0.0 110.665 170.497 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.26 15.76 80.98 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-O 118.368 -1.24 . . . . 0.0 112.616 -175.029 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 88.0 m -89.08 116.16 27.15 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 119.805 1.803 . . . . 0.0 107.073 177.066 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -57.84 136.06 56.93 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 170.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -44.18 -37.68 3.3 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 123.851 0.86 . . . . 0.0 111.79 171.255 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 56.9 pttt -67.22 -42.39 84.13 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 117.561 -1.656 . . . . 0.0 109.986 -178.549 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -71.36 -18.33 62.38 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 125.806 1.642 . . . . 0.0 111.138 -176.397 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.557 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.7 mt -53.38 133.4 52.87 Favored Pre-proline 0 N--CA 1.448 -0.569 0 CA-C-N 119.194 0.906 . . . . 0.0 108.941 174.252 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -64.9 142.17 74.35 Favored 'Trans proline' 0 N--CA 1.445 -1.331 0 C-N-CA 122.106 1.871 . . . . 0.0 109.946 179.472 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -68.47 -12.34 61.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 O-C-N 121.946 -0.471 . . . . 0.0 111.962 178.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -74.77 -17.18 60.68 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 118.275 0.489 . . . . 0.0 112.193 169.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 87.6 t90 -75.27 147.61 40.11 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 121.55 0.691 . . . . 0.0 109.529 179.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 59.3 t -131.51 161.22 41.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 125.097 1.359 . . . . 0.0 107.633 -177.467 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -43.79 144.49 1.42 Allowed Pre-proline 0 CA--C 1.537 0.475 0 C-N-CA 124.775 1.23 . . . . 0.0 110.031 170.406 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -64.34 -42.43 17.4 Favored 'Trans proline' 0 N--CA 1.452 -0.945 0 C-N-CA 122.271 1.981 . . . . 0.0 111.569 -176.448 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 88.9 mt -135.41 44.9 2.51 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 123.904 0.881 . . . . 0.0 109.983 -176.544 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -158.36 152.01 23.44 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 106.007 -1.849 . . . . 0.0 106.007 179.296 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -120.78 86.65 0.4 Allowed Glycine 0 C--N 1.335 0.506 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -169.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.8 p -145.46 -51.85 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 123.115 0.566 . . . . 0.0 110.699 -178.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 109.36 154.68 15.79 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -176.104 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -64.46 107.79 1.47 Allowed 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 118.153 0.976 . . . . 0.0 109.572 177.657 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -160.46 157.89 28.43 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 172.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 44.6 54.24 6.62 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.321 1.848 . . . . 0.0 111.549 173.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.6 p90 -100.28 117.86 35.37 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 126.507 1.923 . . . . 0.0 108.705 -179.261 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -85.17 148.11 26.27 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 123.526 0.73 . . . . 0.0 109.06 176.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -79.46 138.7 37.67 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.0 t -102.46 105.0 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 C-N-CA 125.419 1.488 . . . . 0.0 108.266 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -72.87 68.64 0.9 Allowed 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 126.348 1.859 . . . . 0.0 113.178 -179.205 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 43.3 mm-40 . . . . . 0 C--O 1.255 1.364 0 CA-C-O 116.78 -1.581 . . . . 0.0 108.332 154.843 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.476 0.86 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 12.1 mttm -59.83 144.91 47.33 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-O 121.72 0.772 . . . . 0.0 112.448 172.703 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt -76.76 174.29 10.66 Favored 'General case' 0 N--CA 1.442 -0.853 0 C-N-CA 125.617 1.567 . . . . 0.0 109.252 177.55 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -147.49 145.63 29.21 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 122.773 0.429 . . . . 0.0 110.167 -177.669 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 42.0 m -74.96 141.59 44.02 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 172.115 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 41.2 t -74.84 -112.08 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.494 0 N-CA-C 105.735 -1.95 . . . . 0.0 105.735 164.386 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 9.6 t -160.18 -158.2 0.61 Allowed 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 170.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 17.4 m -75.26 56.81 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 C-N-CA 124.079 0.952 . . . . 0.0 111.737 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 15.6 p -153.19 -55.85 0.12 Allowed 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.989 1.316 . . . . 0.0 109.452 177.24 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.71 -150.36 23.42 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 123.716 0.674 . . . . 0.0 113.248 -169.215 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 44.8 t80 -130.14 160.5 33.59 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 125.948 1.699 . . . . 0.0 107.666 179.525 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.6 mt -47.72 125.36 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 C-N-CA 124.6 1.16 . . . . 0.0 111.341 176.689 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.536 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 27.0 t80 -70.19 136.6 50.19 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 170.193 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.7 t-20 -120.02 113.02 34.46 Favored Pre-proline 0 N--CA 1.454 -0.232 0 C-N-CA 123.861 0.864 . . . . 0.0 109.707 175.349 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.74 -38.15 32.35 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 121.696 1.597 . . . . 0.0 111.342 -175.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -63.09 -28.81 70.33 Favored 'General case' 0 N--CA 1.444 -0.754 0 O-C-N 123.188 0.305 . . . . 0.0 111.333 -176.542 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -86.44 -32.97 20.57 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.807 0.843 . . . . 0.0 109.716 172.372 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.39 -158.86 42.23 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -166.748 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.3 61.59 17.41 Favored Pre-proline 0 C--O 1.237 0.435 0 C-N-CA 125.235 1.414 . . . . 0.0 107.891 171.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -64.24 -28.16 64.21 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 122.536 2.157 . . . . 0.0 111.222 -170.207 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -64.18 -30.25 71.32 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 123.24 0.616 . . . . 0.0 109.683 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 33.9 m-80 -93.0 -30.94 15.07 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 125.085 1.354 . . . . 0.0 110.747 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.15 5.88 1.52 Allowed Glycine 0 CA--C 1.531 1.06 0 C-N-CA 124.26 0.933 . . . . 0.0 113.915 170.5 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 50.2 t -103.44 112.1 35.64 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.266 0 CA-C-N 118.45 1.125 . . . . 0.0 108.559 -175.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -64.59 154.87 83.5 Favored Pre-proline 0 CA--C 1.533 0.32 0 O-C-N 121.784 -0.573 . . . . 0.0 110.416 -177.532 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.79 150.05 73.67 Favored 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 121.495 1.463 . . . . 0.0 110.851 170.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 79.33 14.44 81.55 Favored Glycine 0 CA--C 1.526 0.724 0 C-N-CA 125.708 1.623 . . . . 0.0 113.348 -176.332 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 93.9 m -94.35 114.77 26.88 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 120.149 1.974 . . . . 0.0 108.501 -178.27 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -56.42 135.24 54.15 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 169.423 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -42.69 -35.36 1.1 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 113.172 0.804 . . . . 0.0 113.172 171.206 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 53.8 pttt -68.3 -38.5 81.7 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 118.646 -1.221 . . . . 0.0 110.051 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -78.0 -16.9 57.73 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 125.005 1.322 . . . . 0.0 109.99 -173.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.536 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.7 mt -54.97 132.02 67.61 Favored Pre-proline 0 N--CA 1.442 -0.836 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 174.685 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 2.7 Cg_exo -57.64 134.69 64.72 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 123.162 2.575 . . . . 0.0 109.359 177.245 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -74.57 -7.4 53.0 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.298 -0.876 . . . . 0.0 111.966 -176.499 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -77.4 -10.23 59.34 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.491 1.116 . . . . 0.0 112.598 165.458 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 77.2 t90 -66.93 156.35 36.07 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 118.88 0.764 . . . . 0.0 110.516 177.661 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.4 p -123.91 154.57 30.6 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 125.886 1.675 . . . . 0.0 108.579 -177.255 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.0 m -34.57 148.55 0.1 Allowed Pre-proline 0 CA--C 1.541 0.609 0 C-N-CA 126.693 1.997 . . . . 0.0 113.715 172.676 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -76.49 -37.82 1.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 122.964 2.443 . . . . 0.0 113.057 -174.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 96.1 mt -132.3 30.7 4.16 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.908 0.883 . . . . 0.0 109.434 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -152.16 -173.9 4.7 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 -177.087 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -134.43 58.19 0.69 Allowed Glycine 0 C--N 1.339 0.714 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -176.247 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -133.86 158.74 42.55 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 C-N-CA 125.296 1.438 . . . . 0.0 107.947 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.5 -174.49 35.65 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 111.413 -0.675 . . . . 0.0 111.413 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 52.8 mtpt -71.03 -60.62 2.13 Favored 'General case' 0 CA--C 1.529 0.154 0 O-C-N 121.978 -0.719 . . . . 0.0 109.999 175.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 54.67 -68.53 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 129.357 3.063 . . . . 0.0 114.202 176.647 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -138.46 140.48 39.25 Favored 'General case' 0 CA--C 1.527 0.092 0 C-N-CA 125.26 1.424 . . . . 0.0 108.203 178.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 7.6 p90 -156.29 110.13 2.74 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -168.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -86.27 133.44 33.82 Favored 'General case' 0 C--O 1.225 -0.204 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -71.52 135.67 47.19 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 178.053 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.8 t -97.72 109.99 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 C-N-CA 126.39 1.876 . . . . 0.0 106.393 177.338 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -72.72 60.2 0.49 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.878 1.671 . . . . 0.0 114.308 -174.073 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 . . . . . 0 C--O 1.26 1.627 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 152.236 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 49.7 mtt . . . . . 0 N--CA 1.476 0.844 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 8.9 mttm -87.25 142.91 27.54 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-O 120.89 0.376 . . . . 0.0 111.109 -178.055 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -71.37 171.35 11.37 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 123.557 0.743 . . . . 0.0 110.2 174.434 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -145.52 148.55 33.34 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.481 0.713 . . . . 0.0 111.253 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.5 m -80.07 122.16 26.43 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 123.294 0.638 . . . . 0.0 110.021 176.082 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 7.2 t -58.91 94.72 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.326 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 168.62 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 59.3 m -66.37 141.34 57.99 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -171.58 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . 0.305 12.7 p 54.37 20.5 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 125.845 1.658 . . . . 0.0 113.293 -171.565 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 66.9 m -139.03 -162.43 1.32 Allowed 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.591 1.557 . . . . 0.0 107.967 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.36 62.56 0.37 Allowed Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 178.066 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 6.1 t80 -150.82 66.13 0.92 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 124.069 0.947 . . . . 0.0 109.718 -173.152 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.1 mt -37.79 125.19 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 124.724 1.21 . . . . 0.0 112.791 -175.205 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.545 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 25.9 t80 -78.05 135.62 37.77 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 175.539 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 57.2 t-20 -120.11 111.52 35.38 Favored Pre-proline 0 N--CA 1.452 -0.338 0 C-N-CA 123.913 0.885 . . . . 0.0 109.807 176.103 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -64.98 -37.96 31.04 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.406 1.404 . . . . 0.0 111.479 -175.629 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -61.21 -29.91 70.11 Favored 'General case' 0 N--CA 1.446 -0.67 0 O-C-N 123.393 0.433 . . . . 0.0 111.074 -176.631 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -87.24 -33.17 19.4 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 123.962 0.905 . . . . 0.0 109.705 173.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.44 -158.14 39.83 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -167.632 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -142.54 62.36 12.81 Favored Pre-proline 0 CA--C 1.537 0.476 0 C-N-CA 125.503 1.521 . . . . 0.0 107.746 172.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.06 -33.98 81.25 Favored 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 122.558 2.172 . . . . 0.0 111.179 -170.215 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -57.41 -29.89 64.51 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.833 1.253 . . . . 0.0 110.35 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 21.3 m-80 -99.26 -23.4 15.21 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 125.554 1.541 . . . . 0.0 110.98 -176.79 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 131.52 7.42 3.1 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 124.571 1.081 . . . . 0.0 113.321 169.56 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.0 t -107.53 110.23 31.1 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.261 0 CA-C-N 118.313 1.057 . . . . 0.0 108.612 -174.816 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -64.08 155.16 79.86 Favored Pre-proline 0 CA--C 1.534 0.329 0 O-C-N 121.783 -0.573 . . . . 0.0 110.537 -177.744 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -59.58 149.9 79.42 Favored 'Trans proline' 0 N--CA 1.449 -1.127 0 C-N-CA 121.308 1.339 . . . . 0.0 110.679 170.269 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.65 23.45 76.79 Favored Glycine 0 CA--C 1.524 0.656 0 C-N-CA 125.469 1.509 . . . . 0.0 112.891 -175.16 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 94.2 m -97.81 117.66 32.63 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 119.514 1.657 . . . . 0.0 107.703 176.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -61.08 137.37 58.24 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 173.762 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -44.12 -35.11 2.03 Favored 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 113.588 0.959 . . . . 0.0 113.588 172.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 5.8 pttt -69.73 -37.89 76.66 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 120.813 -1.179 . . . . 0.0 110.144 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -73.64 -20.42 60.58 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 125.226 1.41 . . . . 0.0 109.799 -175.018 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.545 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.4 mt -54.36 131.07 62.03 Favored Pre-proline 0 N--CA 1.441 -0.882 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 176.317 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -60.66 135.84 62.99 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.094 1.863 . . . . 0.0 108.551 178.324 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -72.73 -5.41 37.56 Favored 'General case' 0 CA--C 1.54 0.567 0 O-C-N 121.89 -0.507 . . . . 0.0 111.744 -178.585 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.4 -26.41 66.42 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.98 1.312 . . . . 0.0 112.08 164.488 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 83.8 t90 -69.86 149.14 48.18 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.644 0.735 . . . . 0.0 110.639 -174.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 5.2 m -123.12 157.55 28.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 C-N-CA 125.913 1.685 . . . . 0.0 109.645 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.5 m -39.65 144.02 0.52 Allowed Pre-proline 0 CA--C 1.532 0.287 0 C-N-CA 126.351 1.861 . . . . 0.0 113.187 177.26 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -70.19 -31.94 17.71 Favored 'Trans proline' 0 N--CA 1.451 -1.003 0 C-N-CA 123.227 2.618 . . . . 0.0 112.832 -173.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 16.1 tp -149.32 35.87 0.73 Allowed 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.68 -0.637 . . . . 0.0 110.732 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.5 m -131.19 -47.41 1.0 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.625 0.77 . . . . 0.0 110.607 -178.306 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.43 62.32 1.65 Allowed Glycine 0 CA--C 1.531 1.057 0 C-N-CA 123.608 0.623 . . . . 0.0 112.254 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.1 p -151.69 159.18 4.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 172.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -68.04 167.56 42.39 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 54.9 mtpt -50.33 -58.13 6.35 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.757 0.823 . . . . 0.0 111.215 177.333 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.8 t0 21.11 85.83 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 128.275 2.63 . . . . 0.0 115.016 -172.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER 75.2 150.66 0.11 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.825 1.65 . . . . 0.0 110.228 178.54 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.3 p90 -171.02 109.44 0.31 Allowed 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -163.753 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 52.5 mt-10 -87.27 135.81 33.17 Favored 'General case' 0 CA--C 1.519 -0.228 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -176.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -76.88 137.55 39.21 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -178.64 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.1 t -98.47 109.91 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.042 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 176.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -74.69 59.62 0.87 Allowed 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 126.197 1.799 . . . . 0.0 113.914 -171.904 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 . . . . . 0 C--O 1.259 1.596 0 CA-C-N 114.845 -1.07 . . . . 0.0 108.372 156.286 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.408 4.9 ptt? . . . . . 0 N--CA 1.469 0.503 0 N-CA-C 104.824 -2.287 . . . . 0.0 104.824 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 38.1 mttm 62.54 162.0 0.09 Allowed 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 126.278 1.831 . . . . 0.0 112.911 -171.061 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 72.7 mttt -80.37 165.61 22.1 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 115.219 -0.9 . . . . 0.0 108.653 -176.385 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -144.92 136.25 25.17 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.04 -179.298 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.8 t -92.11 135.79 33.69 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 111.689 0.255 . . . . 0.0 111.689 172.884 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 48.0 t -77.56 47.45 0.6 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 127.223 2.209 . . . . 0.0 109.389 177.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 10.9 m 43.39 -124.27 0.81 Allowed 'General case' 0 CA--C 1.548 0.902 0 O-C-N 120.266 -1.521 . . . . 0.0 111.93 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 45.1 t -82.75 70.63 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 O-C-N 120.541 -1.35 . . . . 0.0 108.919 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 42.5 t -133.0 -70.04 0.55 Allowed 'General case' 0 CA--C 1.529 0.153 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 175.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.15 60.58 0.96 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -131.91 -57.63 0.98 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.904 0.882 . . . . 0.0 110.393 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 74.0 mt 75.17 119.15 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 C-N-CA 127.135 2.174 . . . . 0.0 111.683 -175.589 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.566 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 44.1 t80 -82.03 132.41 35.25 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 170.076 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 56.8 t-20 -118.87 112.64 36.46 Favored Pre-proline 0 C--O 1.227 -0.12 0 C-N-CA 124.348 1.059 . . . . 0.0 109.403 174.04 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -65.53 -38.23 26.27 Favored 'Trans proline' 0 N--CA 1.447 -1.265 0 C-N-CA 121.111 1.208 . . . . 0.0 111.573 -174.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -57.47 -32.22 66.74 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-N 117.97 0.35 . . . . 0.0 111.03 -179.007 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 60.1 m-20 -90.06 -29.83 18.11 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.705 0.802 . . . . 0.0 110.232 177.265 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.08 -158.67 41.35 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -168.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -141.87 60.82 11.71 Favored Pre-proline 0 CA--C 1.539 0.555 0 C-N-CA 125.373 1.469 . . . . 0.0 107.763 172.17 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -62.17 -33.64 81.16 Favored 'Trans proline' 0 N--CA 1.455 -0.767 0 C-N-CA 122.403 2.068 . . . . 0.0 111.173 -170.582 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -55.85 -31.35 62.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 125.011 1.324 . . . . 0.0 110.641 177.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.6 m-80 -97.83 -27.76 14.15 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 125.521 1.528 . . . . 0.0 110.663 -177.059 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.23 9.34 1.44 Allowed Glycine 0 CA--C 1.532 1.154 0 C-N-CA 124.345 0.974 . . . . 0.0 113.829 169.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 54.7 t -110.06 111.63 37.0 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.248 0 CA-C-N 118.579 1.189 . . . . 0.0 109.065 -174.219 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -63.62 154.8 78.79 Favored Pre-proline 0 C--N 1.328 -0.335 0 O-C-N 121.9 -0.5 . . . . 0.0 111.056 -177.566 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -59.94 150.15 79.84 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 121.423 1.416 . . . . 0.0 110.744 171.308 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 72.22 16.67 77.08 Favored Glycine 0 CA--C 1.525 0.704 0 CA-C-O 118.289 -1.284 . . . . 0.0 112.798 -174.511 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 92.4 m -87.75 117.6 26.69 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-N 119.951 1.875 . . . . 0.0 107.386 176.424 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -56.56 133.28 53.42 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.167 170.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -42.67 -38.31 2.0 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 123.326 0.65 . . . . 0.0 112.053 170.231 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.1 pttp -66.34 -39.08 88.97 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 118.181 -1.408 . . . . 0.0 109.945 -177.704 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -81.66 -11.37 59.11 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 126.108 1.763 . . . . 0.0 110.626 -172.304 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.566 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.8 mt -56.42 134.28 76.57 Favored Pre-proline 0 N--CA 1.443 -0.801 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 171.306 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 8.1 Cg_exo -58.08 138.35 85.5 Favored 'Trans proline' 0 N--CA 1.454 -0.796 0 C-N-CA 123.556 2.838 . . . . 0.0 110.932 176.476 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -69.92 -15.02 63.0 Favored 'General case' 0 N--CA 1.448 -0.55 0 O-C-N 121.071 -1.018 . . . . 0.0 111.822 177.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -78.96 -9.75 59.62 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.59 1.156 . . . . 0.0 112.065 169.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 76.9 t90 -72.22 156.12 39.49 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.086 0.857 . . . . 0.0 110.369 175.611 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 13.1 t -130.76 143.58 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 125.174 1.389 . . . . 0.0 108.227 -170.205 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 20.2 t -68.18 137.33 91.7 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 123.438 0.695 . . . . 0.0 109.629 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -68.15 127.85 16.59 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 122.749 2.299 . . . . 0.0 111.42 177.761 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 29.1 mt 61.26 44.73 9.5 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.759 1.223 . . . . 0.0 111.97 174.77 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 14.4 t -149.05 178.63 8.54 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -176.211 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -105.28 171.43 18.62 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 171.439 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.324 3.9 p 48.07 -149.39 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 CA-C-O 117.447 -1.263 . . . . 0.0 111.219 -173.421 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -146.13 -143.3 3.89 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-N 121.475 1.943 . . . . 0.0 111.131 -173.006 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.4 ptmt -78.11 115.53 17.9 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 172.15 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -158.43 -63.59 0.08 Allowed 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.029 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -105.0 97.53 7.37 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.638 1.175 . . . . 0.0 109.392 179.509 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.7 p90 -141.12 135.16 30.63 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.201 1.001 . . . . 0.0 109.189 -178.327 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 22.6 mt-10 -108.44 155.06 21.01 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 124.734 1.213 . . . . 0.0 109.519 178.615 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -78.96 143.22 35.98 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 123.635 0.774 . . . . 0.0 109.646 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.3 t -112.07 108.38 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 C-N-CA 126.679 1.991 . . . . 0.0 106.564 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -81.18 55.21 2.46 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 125.005 1.322 . . . . 0.0 113.098 -175.333 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 . . . . . 0 C--O 1.25 1.119 0 C-N-CA 124.911 1.285 . . . . 0.0 109.681 176.454 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.378 23.2 ptm . . . . . 0 N--CA 1.473 0.7 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 43.2 mttm 60.15 168.36 0.08 Allowed 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 126.013 1.725 . . . . 0.0 112.618 -170.251 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 3.7 mtpt -78.91 166.97 21.8 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.205 -177.28 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -147.68 149.31 32.23 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.068 0.547 . . . . 0.0 111.067 -179.53 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 57.4 p -74.38 170.82 14.87 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 123.281 0.633 . . . . 0.0 112.214 172.492 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 42.1 t -83.16 -53.06 6.07 Favored 'General case' 0 C--O 1.224 -0.254 0 C-N-CA 125.203 1.401 . . . . 0.0 109.074 162.601 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 85.9 m 61.25 22.74 13.04 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.017 0.927 . . . . 0.0 111.569 -173.607 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 66.1 t -123.34 -65.15 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 C-N-CA 124.421 1.088 . . . . 0.0 108.453 166.057 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 26.5 p -94.56 -60.53 1.69 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 118.633 0.651 . . . . 0.0 110.706 175.527 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 138.6 45.98 0.07 OUTLIER Glycine 0 CA--C 1.531 1.075 0 C-N-CA 124.873 1.225 . . . . 0.0 112.166 -176.208 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -111.13 103.27 11.69 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 125.122 1.369 . . . . 0.0 109.705 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.6 mt -72.52 123.73 27.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 O-C-N 120.919 -1.113 . . . . 0.0 110.085 178.034 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.55 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 48.4 t80 -79.38 138.59 37.71 Favored 'General case' 0 C--O 1.236 0.392 0 C-N-CA 124.396 1.078 . . . . 0.0 108.451 170.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -124.02 114.33 27.99 Favored Pre-proline 0 C--O 1.226 -0.141 0 C-N-CA 124.005 0.922 . . . . 0.0 109.995 174.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -65.95 -39.46 19.3 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 120.954 1.102 . . . . 0.0 111.969 -175.309 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -58.66 -31.4 68.14 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 118.318 0.508 . . . . 0.0 111.149 -178.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -88.91 -30.86 18.53 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.505 0.722 . . . . 0.0 109.954 177.569 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.52 -159.99 41.13 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 124.095 0.855 . . . . 0.0 110.997 -168.336 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.04 61.25 17.2 Favored Pre-proline 0 CA--C 1.539 0.532 0 C-N-CA 125.445 1.498 . . . . 0.0 107.712 170.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_endo -63.45 -28.3 70.93 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.237 1.958 . . . . 0.0 111.229 -171.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -61.56 -28.49 69.37 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 123.534 0.734 . . . . 0.0 110.076 178.687 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.4 m-80 -99.84 -26.93 13.86 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 125.236 1.414 . . . . 0.0 110.958 -177.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 133.2 17.12 1.15 Allowed Glycine 0 CA--C 1.531 1.052 0 C-N-CA 124.216 0.913 . . . . 0.0 113.635 170.238 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 78.5 t -115.43 109.59 28.87 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.272 0 CA-C-N 118.466 1.133 . . . . 0.0 108.381 -175.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -63.39 155.67 73.71 Favored Pre-proline 0 C--N 1.328 -0.327 0 O-C-N 121.671 -0.643 . . . . 0.0 111.23 -176.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.0 149.02 86.68 Favored 'Trans proline' 0 N--CA 1.448 -1.147 0 C-N-CA 121.279 1.32 . . . . 0.0 110.619 171.046 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.39 16.61 78.81 Favored Glycine 0 N--CA 1.445 -0.709 0 CA-C-O 118.307 -1.274 . . . . 0.0 112.693 -174.528 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 81.7 m -87.95 117.72 27.0 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 119.873 1.836 . . . . 0.0 106.942 176.483 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -58.58 136.51 57.61 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 171.38 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -45.76 -37.3 5.83 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 122.975 0.51 . . . . 0.0 111.337 171.526 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 48.0 pttt -66.41 -38.49 87.58 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 117.783 -1.567 . . . . 0.0 110.468 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -76.1 -18.88 58.98 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 125.012 1.325 . . . . 0.0 110.506 -174.414 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.55 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.7 mt -53.81 133.92 56.67 Favored Pre-proline 0 N--CA 1.446 -0.627 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 175.154 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -65.18 139.66 61.53 Favored 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 122.133 1.889 . . . . 0.0 109.7 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -66.3 -11.33 50.07 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 123.708 0.803 . . . . 0.0 111.54 177.378 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.4 -22.11 61.91 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.64 1.176 . . . . 0.0 112.11 170.285 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 84.9 t90 -73.39 155.7 39.08 Favored 'General case' 0 N--CA 1.455 -0.209 0 O-C-N 121.527 -0.733 . . . . 0.0 110.386 -177.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.72 159.68 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 C-N-CA 125.541 1.536 . . . . 0.0 109.232 -177.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 44.4 t -68.17 134.91 91.43 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 124.228 1.011 . . . . 0.0 109.668 -177.083 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -62.1 126.33 18.45 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.475 2.117 . . . . 0.0 110.883 178.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 41.0 mt 64.92 34.84 8.75 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.467 1.107 . . . . 0.0 111.615 174.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 41.5 t -151.61 160.95 43.44 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 106.399 -1.704 . . . . 0.0 106.399 -175.041 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -115.94 110.13 2.14 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 -174.125 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 36.0 t 78.84 123.35 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 C-N-CA 126.547 1.939 . . . . 0.0 108.785 -171.301 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -156.59 173.12 34.36 Favored Glycine 0 C--N 1.334 0.459 0 N-CA-C 107.696 -2.162 . . . . 0.0 107.696 178.04 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 53.87 74.05 0.35 Allowed 'General case' 0 CA--C 1.534 0.346 0 CA-C-O 122.941 1.353 . . . . 0.0 110.295 -170.773 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -152.59 -69.67 0.16 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 113.707 -1.588 . . . . 0.0 108.151 170.055 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -113.67 101.3 9.19 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 124.93 1.292 . . . . 0.0 108.453 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -140.27 131.93 27.25 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.092 1.357 . . . . 0.0 107.783 -175.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -96.63 149.35 21.89 Favored 'General case' 0 C--O 1.223 -0.297 0 C-N-CA 124.903 1.281 . . . . 0.0 109.28 -176.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -75.76 140.86 42.61 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-N 119.042 0.837 . . . . 0.0 109.218 178.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.2 t -106.63 107.57 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 C-N-CA 125.611 1.564 . . . . 0.0 106.8 176.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -76.85 57.03 1.25 Allowed 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 125.619 1.568 . . . . 0.0 113.075 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 . . . . . 0 C--O 1.251 1.144 0 CA-C-O 117.278 -1.344 . . . . 0.0 108.462 159.113 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.404 ' N ' ' OE2' ' A' ' 16' ' ' GLU . 8.1 mtt . . . . . 0 N--CA 1.478 0.932 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.5 mmmt -91.67 149.56 21.57 Favored 'General case' 0 CA--C 1.52 -0.185 0 CA-C-O 121.391 0.615 . . . . 0.0 110.08 -175.606 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 44.1 mtpt -74.12 169.75 16.89 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.568 -177.579 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -143.02 142.59 31.62 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 119.582 -0.247 . . . . 0.0 110.724 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.8 t -85.15 141.7 30.01 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 119.61 -0.836 . . . . 0.0 109.977 170.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 52.2 t -71.19 170.46 12.94 Favored 'General case' 0 CA--C 1.539 0.54 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 154.332 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.3 p -69.28 81.02 0.36 Allowed 'General case' 0 CA--C 1.533 0.32 0 O-C-N 120.97 -1.081 . . . . 0.0 110.725 -173.767 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 99.1 t 66.98 -74.88 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.456 -0.158 0 C-N-CA 126.014 1.725 . . . . 0.0 108.154 -170.436 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 48.1 t 43.05 -122.68 0.72 Allowed 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.77 1.228 . . . . 0.0 109.803 174.382 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -177.42 41.11 0.1 OUTLIER Glycine 0 CA--C 1.527 0.806 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 166.737 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -148.45 74.6 1.29 Allowed 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.748 0.785 . . . . 0.0 109.397 -169.443 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 12.6 mt -59.82 131.67 24.57 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 O-C-N 121.699 -0.626 . . . . 0.0 109.657 175.244 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.576 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 33.9 t80 -82.82 138.17 34.05 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 174.212 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -124.17 112.47 28.26 Favored Pre-proline 0 N--CA 1.454 -0.241 0 C-N-CA 124.229 1.011 . . . . 0.0 109.705 175.424 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -66.19 -35.19 33.78 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.076 1.184 . . . . 0.0 111.395 -174.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLU . . . . . 0.404 ' OE2' ' N ' ' A' ' 1' ' ' MET . 20.1 mt-10 -65.13 -27.71 68.93 Favored 'General case' 0 N--CA 1.443 -0.792 0 O-C-N 123.313 0.383 . . . . 0.0 110.934 -176.112 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -87.37 -31.57 20.05 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.328 1.051 . . . . 0.0 109.788 171.498 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.27 -151.82 50.28 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -167.027 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 25.6 t0 -151.87 63.94 5.55 Favored Pre-proline 0 N--CA 1.443 -0.799 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 171.643 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -64.91 -28.28 58.49 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.701 2.267 . . . . 0.0 111.634 -166.214 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -62.37 -24.93 67.64 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 123.701 0.801 . . . . 0.0 109.727 -178.205 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.9 m-80 -111.37 17.12 20.47 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.062 1.345 . . . . 0.0 109.993 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 95.73 3.95 60.67 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.325 0.964 . . . . 0.0 114.63 170.861 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.9 t -104.16 107.84 23.28 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.23 0 CA-C-N 119.127 1.464 . . . . 0.0 109.345 -172.384 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -65.36 153.89 88.87 Favored Pre-proline 0 CA--C 1.536 0.44 0 O-C-N 121.614 -0.679 . . . . 0.0 110.697 -176.652 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_endo -58.38 149.11 76.24 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 121.575 1.517 . . . . 0.0 111.135 170.816 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.66 19.33 79.21 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 125.004 1.288 . . . . 0.0 112.47 -175.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 99.8 m -94.27 114.45 26.54 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 119.61 1.705 . . . . 0.0 106.811 176.084 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -59.72 138.24 57.82 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 170.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.434 ' CD1' ' CD2' ' A' ' 49' ' ' PHE . 2.1 t80 -42.14 -38.63 1.76 Allowed 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 113.194 0.813 . . . . 0.0 113.194 171.189 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 55.8 pttt -64.99 -40.13 94.51 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 118.345 -1.342 . . . . 0.0 110.224 -178.136 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -78.73 -12.45 60.02 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 125.057 1.343 . . . . 0.0 111.169 -175.025 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.576 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.8 mt -57.23 132.76 80.94 Favored Pre-proline 0 N--CA 1.442 -0.873 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 172.508 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -63.5 137.3 59.08 Favored 'Trans proline' 0 N--CA 1.442 -1.519 0 C-N-CA 121.641 1.56 . . . . 0.0 108.605 176.357 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -70.56 -3.47 18.25 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 123.543 0.737 . . . . 0.0 111.977 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -73.96 -24.71 59.67 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.968 1.707 . . . . 0.0 111.983 166.38 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 78.9 t90 -65.75 158.5 27.42 Favored 'General case' 0 CA--C 1.528 0.112 0 O-C-N 121.746 -0.596 . . . . 0.0 109.805 178.11 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.413 ' CG2' ' HA2' ' A' ' 43' ' ' GLY . 8.0 p -141.34 145.73 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 C-N-CA 123.895 0.878 . . . . 0.0 109.935 -173.637 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 53.2 t -66.92 125.12 90.33 Favored Pre-proline 0 C--O 1.24 0.597 0 C-N-CA 123.392 0.677 . . . . 0.0 110.029 178.472 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -66.04 133.7 34.27 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 123.26 2.64 . . . . 0.0 111.035 -175.85 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 48.4 mt 60.23 30.06 19.54 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 124.536 1.134 . . . . 0.0 112.042 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 8.4 t -142.67 -68.19 0.36 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.097 0.959 . . . . 0.0 108.841 -176.707 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLY . . . . . 0.413 ' HA2' ' CG2' ' A' ' 38' ' ' VAL . . . 85.71 17.98 60.8 Favored Glycine 0 CA--C 1.532 1.127 0 CA-C-O 118.613 -1.104 . . . . 0.0 114.737 177.464 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.8 p -72.17 -54.98 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 CA-C-N 119.761 1.781 . . . . 0.0 112.94 -176.394 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.95 -152.82 24.32 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 108.514 -1.834 . . . . 0.0 108.514 -170.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.55 33.89 0.78 Allowed 'General case' 0 CA--C 1.53 0.189 0 CA-C-N 118.217 1.009 . . . . 0.0 112.063 169.281 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -98.27 -49.66 4.62 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 125.086 1.354 . . . . 0.0 110.114 -161.406 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -94.23 67.23 3.53 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.057 1.343 . . . . 0.0 108.597 178.739 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.434 ' CD2' ' CD1' ' A' ' 30' ' ' PHE . 20.5 p90 -101.81 115.06 29.7 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 124.232 1.013 . . . . 0.0 109.214 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -99.27 142.92 30.13 Favored 'General case' 0 CA--C 1.519 -0.22 0 N-CA-C 108.164 -1.051 . . . . 0.0 108.164 174.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -73.04 134.78 44.75 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 15.3 t -93.29 108.86 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 174.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -78.64 51.28 1.06 Allowed 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 124.536 1.135 . . . . 0.0 113.489 -173.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 . . . . . 0 C--O 1.259 1.589 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 149.719 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.357 20.7 ptm . . . . . 0 N--CA 1.476 0.837 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 14.9 mttt 62.18 171.6 0.13 Allowed 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 125.867 1.667 . . . . 0.0 112.672 -171.155 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 58.9 mttt -75.02 167.07 22.63 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.241 -0.891 . . . . 0.0 109.492 -174.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -145.48 144.08 30.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.937 178.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 13.5 m -76.89 150.95 35.98 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-O 119.303 -0.379 . . . . 0.0 110.988 169.109 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 46.3 t -65.07 171.13 3.83 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-O 121.345 0.593 . . . . 0.0 110.136 170.003 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 1.9 t -71.52 -42.87 67.44 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 124.944 1.298 . . . . 0.0 111.402 -176.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 29.5 m -140.5 24.22 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -178.413 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 18.4 p -147.56 -166.37 2.5 Favored 'General case' 0 N--CA 1.455 -0.198 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 168.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.93 -82.0 0.99 Allowed Glycine 0 CA--C 1.525 0.705 0 N-CA-C 109.211 -1.556 . . . . 0.0 109.211 175.009 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 63.5 m-85 21.0 65.27 0.03 OUTLIER 'General case' 0 C--N 1.346 0.418 0 C-N-CA 128.452 2.701 . . . . 0.0 111.941 -175.588 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 23.4 mt -58.55 121.59 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.015 -173.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.554 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 35.2 t80 -73.29 138.12 45.27 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 173.282 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 62.1 t-20 -125.65 111.99 25.27 Favored Pre-proline 0 N--CA 1.454 -0.243 0 C-N-CA 123.975 0.91 . . . . 0.0 109.541 176.646 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -63.65 -39.69 33.73 Favored 'Trans proline' 0 N--CA 1.448 -1.204 0 C-N-CA 121.267 1.311 . . . . 0.0 111.355 -173.545 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -56.12 -32.82 64.57 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 117.977 0.353 . . . . 0.0 111.254 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -91.76 -29.84 16.57 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.453 0.701 . . . . 0.0 110.334 179.271 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 66.17 -159.0 47.63 Favored Glycine 0 CA--C 1.53 1.03 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -170.239 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.19 61.1 16.26 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 125.615 1.566 . . . . 0.0 107.393 171.062 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -61.59 -35.53 80.77 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.757 2.305 . . . . 0.0 111.451 -168.417 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -57.67 -31.38 66.28 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 124.875 1.27 . . . . 0.0 110.516 179.327 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 -92.21 -28.12 17.23 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 125.218 1.407 . . . . 0.0 110.469 -179.468 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.62 0.48 2.91 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.4 1.0 . . . . 0.0 113.205 171.406 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 75.2 t -100.97 111.08 29.52 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.206 0 CA-C-N 118.225 1.012 . . . . 0.0 109.002 -172.333 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -64.53 154.95 82.95 Favored Pre-proline 0 CA--C 1.533 0.308 0 O-C-N 121.765 -0.584 . . . . 0.0 110.929 -176.427 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -58.77 149.33 78.17 Favored 'Trans proline' 0 N--CA 1.449 -1.117 0 C-N-CA 121.425 1.416 . . . . 0.0 110.84 170.318 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.41 14.98 79.1 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 125.813 1.673 . . . . 0.0 113.082 -174.353 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.7 m -87.07 120.1 27.99 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 120.05 1.925 . . . . 0.0 107.871 178.343 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -59.81 134.45 57.04 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 172.406 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -43.04 -37.87 2.1 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 123.44 0.696 . . . . 0.0 112.176 169.356 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -68.13 -38.89 82.71 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 117.756 -1.578 . . . . 0.0 110.261 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -76.63 -17.57 59.09 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 124.989 1.316 . . . . 0.0 110.704 -175.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.554 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 23.0 mt -52.49 132.76 44.64 Favored Pre-proline 0 N--CA 1.445 -0.705 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.862 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -63.43 140.13 74.56 Favored 'Trans proline' 0 N--CA 1.445 -1.355 0 C-N-CA 122.234 1.956 . . . . 0.0 109.697 178.619 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 74.5 m-20 -69.98 -10.16 57.64 Favored 'General case' 0 N--CA 1.444 -0.772 0 C-N-CA 123.529 0.731 . . . . 0.0 111.914 -179.604 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -77.21 -12.02 59.89 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 124.232 1.013 . . . . 0.0 112.57 168.355 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -73.36 153.35 40.52 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 118.853 0.751 . . . . 0.0 110.303 177.646 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 97.4 t -137.02 150.01 26.44 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 125.573 1.549 . . . . 0.0 107.973 -171.209 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 13.2 t -79.48 130.63 67.61 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 124.854 1.262 . . . . 0.0 109.117 -176.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -64.98 147.91 89.37 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.461 2.108 . . . . 0.0 110.769 -178.441 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.2 mm? 68.8 -62.31 0.39 Allowed 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 126.323 1.849 . . . . 0.0 111.734 -179.495 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -59.03 -54.56 45.71 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 125.977 1.711 . . . . 0.0 110.787 178.354 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 106.84 -115.53 4.71 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -176.728 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.9 t -63.71 105.92 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 O-C-N 121.263 -1.139 . . . . 0.0 110.684 -167.437 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -130.74 -165.59 11.56 Favored Glycine 0 CA--C 1.527 0.809 0 C-N-CA 125.848 1.69 . . . . 0.0 109.323 178.348 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 55.22 61.74 2.78 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 123.112 1.434 . . . . 0.0 110.376 -173.723 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -156.19 157.49 35.98 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 156.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 45.09 37.83 2.79 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.117 1.767 . . . . 0.0 113.047 173.136 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 7.5 p90 -78.07 131.62 37.38 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 124.14 0.976 . . . . 0.0 110.335 -172.369 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -97.93 135.34 39.79 Favored 'General case' 0 C--O 1.227 -0.085 0 C-N-CA 123.929 0.892 . . . . 0.0 108.813 -179.051 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -72.66 138.18 46.52 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 176.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 32.2 t -105.53 105.81 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.054 0 C-N-CA 127.216 2.207 . . . . 0.0 105.418 176.579 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -81.91 54.17 2.39 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.427 1.091 . . . . 0.0 112.927 -173.574 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 . . . . . 0 C--O 1.251 1.143 0 C-N-CA 124.983 1.313 . . . . 0.0 109.617 176.508 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.352 5.9 ptt? . . . . . 0 N--CA 1.474 0.741 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 21.9 mttm 54.64 173.38 0.02 OUTLIER 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 125.102 1.361 . . . . 0.0 112.358 -168.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 28.5 mtpt -72.57 170.27 14.76 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.824 -176.272 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 35.7 m-85 -149.12 145.69 27.33 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 -177.153 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 44.9 p -71.42 170.62 12.86 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.213 0.53 . . . . 0.0 112.152 170.087 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 2.2 t -108.26 166.63 10.61 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 126.998 2.119 . . . . 0.0 105.948 166.649 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 1.2 p -48.0 -50.3 28.01 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 124.683 1.193 . . . . 0.0 111.665 169.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 4.7 m -148.57 16.2 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 N-CA-C 114.111 1.152 . . . . 0.0 114.111 -173.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 79.7 m -109.18 119.6 40.02 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 119.945 1.248 . . . . 0.0 111.742 178.387 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -75.88 54.35 3.0 Favored Glycine 0 CA--C 1.532 1.137 0 O-C-N 121.55 -0.719 . . . . 0.0 111.411 172.104 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -111.54 -47.03 3.2 Favored 'General case' 0 N--CA 1.46 0.071 0 C-N-CA 124.556 1.142 . . . . 0.0 110.353 176.175 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 11.5 mt 71.32 128.06 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 C-N-CA 125.561 1.544 . . . . 0.0 111.491 -177.13 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.531 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 45.3 t80 -76.06 141.61 42.0 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 172.103 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 -125.77 115.58 24.6 Favored Pre-proline 0 N--CA 1.456 -0.174 0 C-N-CA 123.679 0.792 . . . . 0.0 110.421 175.354 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -67.48 -39.63 12.09 Favored 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 121.053 1.169 . . . . 0.0 111.695 -176.566 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -59.04 -31.08 68.53 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 118.585 0.63 . . . . 0.0 111.152 -178.382 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -88.47 -31.71 18.62 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 123.589 0.755 . . . . 0.0 110.023 176.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.9 -162.02 35.69 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -166.183 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -138.28 61.3 25.47 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 125.187 1.395 . . . . 0.0 107.735 171.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -62.8 -31.38 78.21 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 122.332 2.021 . . . . 0.0 111.154 -170.89 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -59.69 -30.65 68.93 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 123.864 0.866 . . . . 0.0 110.731 178.189 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -96.08 -28.07 14.78 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 124.87 1.268 . . . . 0.0 110.51 -178.5 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.71 16.96 0.97 Allowed Glycine 0 CA--C 1.531 1.081 0 C-N-CA 124.395 0.998 . . . . 0.0 113.992 169.641 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.1 t -116.72 112.29 38.72 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.304 0 CA-C-N 118.578 1.189 . . . . 0.0 109.006 -175.442 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.44 156.73 75.71 Favored Pre-proline 0 CA--C 1.533 0.316 0 O-C-N 121.898 -0.501 . . . . 0.0 111.136 -177.337 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -59.68 150.14 78.49 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 121.376 1.384 . . . . 0.0 110.802 170.839 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.57 16.32 79.06 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 125.816 1.674 . . . . 0.0 113.212 -175.187 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.9 m -89.48 118.56 29.22 Favored 'General case' 0 N--CA 1.445 -0.689 0 CA-C-N 119.923 1.862 . . . . 0.0 108.276 179.138 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -59.65 134.09 56.7 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 170.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -43.17 -37.04 1.92 Allowed 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 123.596 0.758 . . . . 0.0 112.731 170.149 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -68.76 -37.84 79.64 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 118.043 -1.463 . . . . 0.0 110.291 -178.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -77.29 -17.49 58.31 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 125.506 1.522 . . . . 0.0 110.462 -176.754 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.531 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.2 mt -55.81 133.56 72.77 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 173.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -62.97 137.1 60.44 Favored 'Trans proline' 0 N--CA 1.445 -1.359 0 C-N-CA 121.823 1.682 . . . . 0.0 108.98 175.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -71.43 -4.6 27.34 Favored 'General case' 0 N--CA 1.445 -0.683 0 O-C-N 121.95 -0.469 . . . . 0.0 111.728 -179.468 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.58 -22.65 63.51 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 125.034 1.333 . . . . 0.0 112.182 165.42 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 81.3 t90 -71.29 152.3 43.39 Favored 'General case' 0 N--CA 1.456 -0.174 0 O-C-N 121.484 -0.76 . . . . 0.0 111.237 -176.212 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.5 t -127.59 146.49 33.23 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 C-N-CA 125.72 1.608 . . . . 0.0 108.356 179.173 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -76.31 160.95 76.64 Favored Pre-proline 0 CA--C 1.538 0.519 0 C-N-CA 122.605 0.362 . . . . 0.0 110.158 -176.152 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -67.11 117.42 4.78 Favored 'Trans proline' 0 N--CA 1.45 -1.058 0 C-N-CA 121.9 1.733 . . . . 0.0 110.687 -170.75 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 50.5 mt 65.32 51.73 1.54 Allowed 'General case' 0 CA--C 1.534 0.33 0 C-N-CA 125.255 1.422 . . . . 0.0 111.623 177.667 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.0 t -142.9 -179.48 6.38 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 124.275 1.03 . . . . 0.0 108.539 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -107.19 -67.21 0.64 Allowed Glycine 0 CA--C 1.526 0.743 0 C-N-CA 124.504 1.05 . . . . 0.0 111.223 -175.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 25.2 m -72.66 164.03 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 CA-C-N 116.803 0.302 . . . . 0.0 110.201 -179.32 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -121.4 114.03 2.47 Favored Glycine 0 C--N 1.334 0.441 0 N-CA-C 110.396 -1.082 . . . . 0.0 110.396 -170.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mtpt 62.38 -88.02 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 125.412 1.485 . . . . 0.0 110.388 178.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 46.83 -72.48 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 128.799 2.84 . . . . 0.0 114.303 -172.219 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -127.92 116.78 20.63 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 126.014 1.725 . . . . 0.0 108.925 -176.225 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 4.9 p90 -149.99 112.68 4.77 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.194 1.397 . . . . 0.0 107.28 -171.697 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -82.91 145.53 29.35 Favored 'General case' 0 C--O 1.225 -0.225 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 44.9 tt0 -71.91 136.8 47.02 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 175.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.1 t -102.41 104.34 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 C-N-CA 126.248 1.819 . . . . 0.0 106.336 177.183 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -78.2 88.35 4.27 Favored 'General case' 0 N--CA 1.438 -1.03 0 CA-C-O 123.215 1.484 . . . . 0.0 109.125 172.182 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 . . . . . 0 C--O 1.257 1.483 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 158.701 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.387 24.9 ptm . . . . . 0 N--CA 1.474 0.75 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 51.2 mttm 64.04 167.82 0.16 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 126.65 1.98 . . . . 0.0 112.704 -172.877 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -80.71 165.02 22.35 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -176.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -141.3 140.95 33.94 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 123.069 0.548 . . . . 0.0 111.069 178.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.3 t -99.4 140.88 32.92 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 113.084 0.772 . . . . 0.0 113.084 175.247 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.455 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 42.2 t -78.68 50.48 0.98 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.846 2.058 . . . . 0.0 109.399 177.458 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 5.7 m 53.84 -94.41 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.828 0 O-C-N 120.624 -1.297 . . . . 0.0 112.475 174.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.92 -28.93 5.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 125.246 1.418 . . . . 0.0 110.849 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.455 ' HB3' ' SG ' ' A' ' 6' ' ' CYS . 53.4 t -78.25 124.69 28.37 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 124.419 1.088 . . . . 0.0 109.44 -169.286 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -86.45 78.94 1.88 Allowed Glycine 0 CA--C 1.523 0.588 0 CA-C-O 119.211 -0.772 . . . . 0.0 111.283 -170.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -134.88 -57.76 0.82 Allowed 'General case' 0 CA--C 1.532 0.267 0 CA-C-N 117.796 0.798 . . . . 0.0 112.889 176.749 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 55.9 mt 75.22 121.25 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 126.637 1.975 . . . . 0.0 111.894 -173.717 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.548 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 77.2 t80 -83.22 138.23 33.7 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 169.482 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 55.1 t-20 -128.32 115.29 19.93 Favored Pre-proline 0 N--CA 1.454 -0.23 0 C-N-CA 124.582 1.153 . . . . 0.0 109.461 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.27 -39.48 17.55 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 121.779 1.653 . . . . 0.0 112.267 -172.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -55.13 -32.78 62.34 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 118.002 0.365 . . . . 0.0 110.749 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -95.06 -26.03 16.22 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 123.504 0.722 . . . . 0.0 109.9 -177.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.3 -157.46 36.58 Favored Glycine 0 CA--C 1.527 0.788 0 C-N-CA 124.684 1.135 . . . . 0.0 110.979 -170.442 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.76 62.31 12.23 Favored Pre-proline 0 CA--C 1.538 0.495 0 C-N-CA 125.062 1.345 . . . . 0.0 107.941 170.137 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -62.43 -33.34 79.65 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.697 2.264 . . . . 0.0 111.185 -170.264 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -56.76 -29.56 62.72 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 124.661 1.184 . . . . 0.0 110.728 178.376 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 -99.07 -30.8 12.11 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.267 1.427 . . . . 0.0 110.615 -177.307 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 140.15 7.49 0.95 Allowed Glycine 0 CA--C 1.531 1.077 0 C-N-CA 123.874 0.75 . . . . 0.0 114.061 169.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.48 HG23 ' CD1' ' A' ' 37' ' ' TRP . 45.6 t -106.58 112.52 40.02 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.217 0 CA-C-N 118.885 1.342 . . . . 0.0 109.04 -176.664 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -63.91 154.18 82.2 Favored Pre-proline 0 C--N 1.328 -0.351 0 O-C-N 121.982 -0.448 . . . . 0.0 110.585 -178.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -59.19 148.08 87.59 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 121.352 1.368 . . . . 0.0 110.771 170.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 77.77 15.59 81.09 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 124.819 1.2 . . . . 0.0 112.546 -176.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 97.2 m -89.18 118.87 29.19 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 119.698 1.749 . . . . 0.0 107.492 177.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -58.61 135.26 57.32 Favored 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 171.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.413 ' CD1' HD12 ' A' ' 33' ' ' ILE . 6.7 t80 -46.01 -34.66 4.18 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 123.173 0.589 . . . . 0.0 112.426 171.339 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.5 pttp -66.54 -40.02 88.86 Favored 'General case' 0 N--CA 1.453 -0.287 0 C-N-CA 118.076 -1.45 . . . . 0.0 110.083 179.69 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -80.62 -12.49 59.49 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.831 1.652 . . . . 0.0 110.588 -171.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.548 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 17.7 mt -57.2 132.67 80.82 Favored Pre-proline 0 N--CA 1.441 -0.877 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 172.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 1.2 Cg_endo -61.91 138.95 76.95 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 123.044 2.496 . . . . 0.0 109.904 178.072 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -64.66 -17.7 64.3 Favored 'General case' 0 N--CA 1.451 -0.397 0 O-C-N 121.819 -0.551 . . . . 0.0 112.024 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -75.54 -14.75 60.42 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 123.751 0.821 . . . . 0.0 112.696 173.363 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' TRP . . . . . 0.48 ' CD1' HG23 ' A' ' 24' ' ' VAL . 78.8 t90 -70.05 150.66 46.37 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.319 0.581 . . . . 0.0 111.2 -178.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 74.5 t -124.47 150.76 29.35 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 C-N-CA 125.656 1.582 . . . . 0.0 109.927 -173.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 49.8 t -57.86 136.66 83.41 Favored Pre-proline 0 CA--C 1.537 0.449 0 C-N-CA 125.844 1.658 . . . . 0.0 111.574 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -59.07 123.52 13.66 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 121.842 1.695 . . . . 0.0 110.14 173.592 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.2 mm? 66.71 21.79 10.5 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.701 1.201 . . . . 0.0 112.692 178.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -146.59 177.82 8.77 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 176.64 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -146.61 78.61 0.24 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -166.038 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.471 HG13 ' H ' ' A' ' 45' ' ' GLY . 7.2 p -143.58 -73.23 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 123.542 0.737 . . . . 0.0 109.928 179.163 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.471 ' H ' HG13 ' A' ' 44' ' ' VAL . . . 145.71 162.97 9.98 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 107.828 -2.109 . . . . 0.0 107.828 -173.547 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.5 ptmt -66.54 -18.7 65.51 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.836 1.318 . . . . 0.0 113.351 176.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 30.09 -93.74 0.01 OUTLIER 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 129.564 3.145 . . . . 0.0 111.964 -176.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.34 64.84 0.95 Allowed 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 166.034 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.3 m-30 -45.72 156.12 0.14 Allowed 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 125.093 1.357 . . . . 0.0 111.632 174.071 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -88.49 147.89 24.43 Favored 'General case' 0 C--O 1.225 -0.196 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 -175.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -74.55 141.49 44.79 Favored 'General case' 0 N--CA 1.442 -0.851 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.19 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.7 t -106.21 113.72 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.915 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 175.224 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -73.79 56.55 0.56 Allowed 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.546 1.539 . . . . 0.0 113.423 -178.658 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 . . . . . 0 C--O 1.254 1.338 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 158.363 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.411 13.5 ptt? . . . . . 0 N--CA 1.476 0.865 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.4 mttm 57.79 174.94 0.05 Allowed 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 126.343 1.857 . . . . 0.0 112.38 -166.718 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 76.6 mttt -70.73 169.73 13.88 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.239 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 48.9 m-85 -147.65 142.74 27.09 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 118.636 -0.697 . . . . 0.0 110.815 -177.205 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.2 m -79.95 146.43 32.09 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 119.014 0.825 . . . . 0.0 109.811 172.072 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 46.6 t -67.45 176.01 2.53 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 166.642 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 90.0 m -76.4 -74.18 0.24 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.619 1.567 . . . . 0.0 112.297 -167.703 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 41.2 t -115.73 2.35 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 124.555 1.142 . . . . 0.0 110.557 177.547 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 10.4 t -80.58 -164.98 0.79 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.766 1.626 . . . . 0.0 108.725 -179.454 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -135.98 49.21 0.89 Allowed Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 44.3 m-85 -133.41 158.86 41.97 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.14 0.976 . . . . 0.0 110.168 179.176 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 13.8 mt -119.9 127.66 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 125.548 1.539 . . . . 0.0 108.224 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.535 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 25.0 t80 -78.39 140.21 38.73 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 124.807 1.243 . . . . 0.0 108.353 169.675 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 50.7 t-20 -124.81 111.87 27.29 Favored Pre-proline 0 N--CA 1.458 -0.072 0 C-N-CA 123.99 0.916 . . . . 0.0 109.963 176.521 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -63.73 -39.75 32.75 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 121.11 1.206 . . . . 0.0 111.59 -173.221 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -57.99 -31.92 67.39 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 118.052 0.387 . . . . 0.0 111.401 -179.065 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -86.88 -34.5 19.41 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 123.195 0.598 . . . . 0.0 109.787 177.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 58.43 -161.96 11.11 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -164.489 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -139.34 67.52 38.76 Favored Pre-proline 0 CA--C 1.535 0.396 0 C-N-CA 124.509 1.123 . . . . 0.0 108.299 169.582 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -58.63 -30.02 90.9 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.805 1.67 . . . . 0.0 110.855 -176.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 85.1 m-20 -60.2 -31.97 70.65 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 124.075 0.95 . . . . 0.0 110.753 178.259 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -98.8 -24.19 15.1 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 124.136 0.974 . . . . 0.0 110.292 -177.016 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 133.11 10.65 1.92 Allowed Glycine 0 CA--C 1.531 1.046 0 C-N-CA 124.484 1.04 . . . . 0.0 113.251 171.346 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.3 t -110.0 109.87 30.04 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.273 0 CA-C-N 118.593 1.197 . . . . 0.0 109.298 -175.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -64.04 154.06 83.14 Favored Pre-proline 0 C--N 1.328 -0.356 0 O-C-N 121.803 -0.561 . . . . 0.0 110.754 -178.505 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_endo -59.13 146.88 92.97 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.317 1.345 . . . . 0.0 110.659 171.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.53 20.18 77.08 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 125.329 1.442 . . . . 0.0 112.699 -177.091 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 96.9 m -91.87 121.36 33.41 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 119.443 1.622 . . . . 0.0 107.869 176.437 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.5 t0 -62.96 136.81 58.04 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 171.744 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -44.66 -35.7 2.75 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 123.332 0.653 . . . . 0.0 112.455 171.539 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.6 pttp -67.89 -36.68 80.64 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 118.482 -1.287 . . . . 0.0 110.369 -179.109 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -80.68 -16.74 53.2 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.485 1.514 . . . . 0.0 110.277 -174.269 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.535 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 20.9 mt -55.39 134.22 70.09 Favored Pre-proline 0 N--CA 1.445 -0.719 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 173.584 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_endo -64.33 138.27 59.91 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 122.425 2.083 . . . . 0.0 109.616 176.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -66.09 -12.63 56.85 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 123.054 0.541 . . . . 0.0 111.943 178.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.15 -19.6 64.02 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.782 1.233 . . . . 0.0 112.337 171.012 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 74.8 t90 -66.31 156.64 33.82 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 121.748 0.785 . . . . 0.0 111.985 -176.609 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -129.88 149.81 33.99 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 C-N-CA 126.904 2.082 . . . . 0.0 109.815 -178.668 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 14.6 t -73.64 138.38 77.27 Favored Pre-proline 0 C--O 1.236 0.351 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 -175.611 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -56.82 111.5 0.82 Allowed 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.1 1.866 . . . . 0.0 110.084 178.155 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 15.3 mt 79.15 16.63 0.94 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.352 1.861 . . . . 0.0 112.231 179.617 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.9 t -147.92 99.7 3.11 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-O 123.19 1.471 . . . . 0.0 108.786 -174.401 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -78.33 52.9 3.83 Favored Glycine 0 CA--C 1.528 0.859 0 O-C-N 120.878 -1.139 . . . . 0.0 111.754 -177.216 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 51.7 t -99.5 -71.2 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 175.068 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 127.73 -163.42 21.43 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 33.5 mtpt -86.61 168.72 13.38 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 169.149 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -163.54 -82.93 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 124.738 1.215 . . . . 0.0 108.288 168.265 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.1 mm-40 -99.55 -49.75 4.3 Favored 'General case' 0 C--O 1.226 -0.156 0 C-N-CA 125.22 1.408 . . . . 0.0 110.184 -171.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 29.8 p90 49.32 92.43 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.194 1.798 . . . . 0.0 112.7 177.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 50.2 mt-10 -74.6 137.26 42.2 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 62.8 tt0 -75.93 134.75 40.15 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.197 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 24.5 t -101.47 115.99 44.25 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.127 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 175.337 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -70.82 55.46 0.17 Allowed 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 125.893 1.677 . . . . 0.0 114.174 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 . . . . . 0 C--O 1.253 1.264 0 C-N-CA 126.698 1.999 . . . . 0.0 107.593 161.925 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.366 19.2 ptm . . . . . 0 N--CA 1.473 0.713 0 N-CA-C 106.819 -1.549 . . . . 0.0 106.819 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 18.7 mttt 62.6 167.47 0.12 Allowed 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 126.228 1.811 . . . . 0.0 112.979 -171.051 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -76.27 167.98 20.87 Favored 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 115.085 -0.961 . . . . 0.0 109.649 -176.541 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -148.24 135.98 20.81 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 122.748 0.419 . . . . 0.0 112.11 -178.339 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 19.9 m -75.4 134.95 40.8 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 119.311 -0.376 . . . . 0.0 111.118 169.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 36.6 t -68.85 140.37 55.21 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.284 0.634 . . . . 0.0 110.187 170.795 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 75.1 p -25.84 -82.36 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 129.661 3.185 . . . . 0.0 114.899 -175.743 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.1 m -127.41 54.97 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 C-N-CA 125.347 1.459 . . . . 0.0 108.535 -172.613 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 37.3 t -141.09 -78.09 0.28 Allowed 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.3 -161.224 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 131.23 -33.11 2.85 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.334 -0.707 . . . . 0.0 111.334 -176.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 28.0 m-85 -57.09 139.79 51.3 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-N 118.352 1.076 . . . . 0.0 110.051 177.161 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.7 mt -106.1 120.01 56.38 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.242 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.518 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.542 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 44.9 t80 -72.49 138.38 46.97 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 169.714 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 53.8 t-20 -124.25 112.18 28.21 Favored Pre-proline 0 N--CA 1.455 -0.215 0 C-N-CA 124.08 0.952 . . . . 0.0 109.59 175.838 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -63.18 -39.2 40.13 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 C-N-CA 121.137 1.225 . . . . 0.0 112.082 -172.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -58.91 -31.56 68.75 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 117.751 0.251 . . . . 0.0 111.205 -179.522 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -87.76 -32.06 19.32 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.472 0.709 . . . . 0.0 109.877 177.77 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.32 -159.03 41.74 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -167.296 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.49 61.38 16.13 Favored Pre-proline 0 CA--C 1.539 0.544 0 C-N-CA 125.556 1.542 . . . . 0.0 107.763 171.31 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -62.7 -30.04 78.05 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 122.404 2.069 . . . . 0.0 111.329 -170.757 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -61.18 -29.6 69.9 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 123.922 0.889 . . . . 0.0 110.383 179.111 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -96.63 -28.32 14.4 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 125.232 1.413 . . . . 0.0 110.687 -178.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.52 12.78 1.35 Allowed Glycine 0 CA--C 1.531 1.092 0 C-N-CA 124.296 0.951 . . . . 0.0 113.673 169.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.3 t -110.02 111.01 34.25 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.208 0 CA-C-N 118.447 1.124 . . . . 0.0 108.464 -175.747 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -64.3 155.34 80.32 Favored Pre-proline 0 CA--C 1.535 0.382 0 O-C-N 121.787 -0.571 . . . . 0.0 110.981 -177.059 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.57 149.55 81.55 Favored 'Trans proline' 0 N--CA 1.449 -1.093 0 C-N-CA 121.399 1.399 . . . . 0.0 110.944 171.24 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 74.08 15.69 79.82 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 125.125 1.345 . . . . 0.0 112.848 -175.185 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 76.3 m -87.98 119.27 28.18 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 119.813 1.806 . . . . 0.0 107.183 177.56 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -61.07 137.65 58.23 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 172.653 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -46.33 -35.76 5.69 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 123.346 0.658 . . . . 0.0 111.71 172.622 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 54.2 pttt -68.2 -39.2 82.49 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 118.232 -1.387 . . . . 0.0 110.205 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -73.26 -21.16 60.68 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 125.126 1.37 . . . . 0.0 110.164 -175.193 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.542 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.3 mt -53.23 133.97 51.25 Favored Pre-proline 0 N--CA 1.446 -0.665 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 176.538 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -66.13 139.58 56.18 Favored 'Trans proline' 0 N--CA 1.444 -1.434 0 C-N-CA 122.093 1.862 . . . . 0.0 109.658 178.595 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -67.91 -9.17 42.85 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 123.806 0.843 . . . . 0.0 111.546 177.602 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -73.15 -22.69 60.47 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.779 1.232 . . . . 0.0 112.061 169.35 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 81.1 t90 -69.69 152.83 44.22 Favored 'General case' 0 N--CA 1.455 -0.221 0 O-C-N 121.628 -0.67 . . . . 0.0 110.464 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 99.2 t -131.87 152.69 37.34 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 C-N-CA 124.887 1.275 . . . . 0.0 108.862 -178.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 20.1 t -69.21 140.44 90.62 Favored Pre-proline 0 CA--C 1.54 0.568 0 C-N-CA 124.526 1.131 . . . . 0.0 110.425 -177.682 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -63.09 118.59 5.5 Favored 'Trans proline' 0 N--CA 1.452 -0.922 0 C-N-CA 122.575 2.183 . . . . 0.0 111.305 175.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 13.2 mt 70.19 43.54 0.85 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.85 1.26 . . . . 0.0 111.176 170.053 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 53.7 t -153.61 176.05 12.52 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 106.117 -1.808 . . . . 0.0 106.117 -171.791 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -80.42 -156.74 13.69 Favored Glycine 0 CA--C 1.528 0.867 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 173.542 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.9 m -51.98 126.93 8.2 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 O-C-N 122.099 -0.647 . . . . 0.0 109.632 171.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -126.2 -175.66 14.24 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 58.57 78.32 0.26 Allowed 'General case' 0 CA--C 1.537 0.446 0 CA-C-O 122.471 1.129 . . . . 0.0 110.444 -172.819 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -153.81 -99.68 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 114.174 -1.376 . . . . 0.0 107.653 168.635 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -76.39 60.74 1.6 Allowed 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 119.4 1.0 . . . . 0.0 111.493 178.836 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -75.93 146.1 39.93 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 121.441 -0.787 . . . . 0.0 109.911 173.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -114.38 141.53 47.52 Favored 'General case' 0 N--CA 1.464 0.232 0 C-N-CA 124.235 1.014 . . . . 0.0 108.592 175.409 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -77.54 138.58 39.26 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 29.9 t -103.65 104.5 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 C-N-CA 126.021 1.728 . . . . 0.0 107.039 178.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -77.12 57.72 1.44 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.639 1.576 . . . . 0.0 112.618 179.548 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 . . . . . 0 C--O 1.255 1.367 0 CA-C-O 117.349 -1.31 . . . . 0.0 108.446 156.776 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.373 20.4 ptt? . . . . . 0 N--CA 1.472 0.668 0 N-CA-C 105.561 -2.014 . . . . 0.0 105.561 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 40.4 mttm 59.73 170.29 0.08 Allowed 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 125.47 1.508 . . . . 0.0 112.402 -172.81 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 55.7 mttt -82.12 167.71 18.47 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.499 -171.425 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -146.92 136.17 22.64 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 113.411 0.893 . . . . 0.0 113.411 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.7 m -80.98 147.89 30.01 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 123.89 0.876 . . . . 0.0 111.695 169.81 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 36.1 t -79.31 14.65 1.46 Allowed 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 125.19 1.396 . . . . 0.0 112.631 175.573 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.8 m 65.64 -72.37 0.07 Allowed 'General case' 0 CA--C 1.538 0.511 0 O-C-N 119.413 -2.054 . . . . 0.0 112.588 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 69.4 t -70.54 -61.88 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 C-N-CA 123.968 0.907 . . . . 0.0 109.123 -174.341 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 8.1 p -95.41 173.58 7.45 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 172.541 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -72.74 -73.3 0.87 Allowed Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.141 -1.584 . . . . 0.0 109.141 177.174 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 22.19 63.88 0.03 OUTLIER 'General case' 0 C--N 1.345 0.408 0 C-N-CA 127.785 2.434 . . . . 0.0 111.93 -172.346 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.1 mt -62.38 115.05 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 CA-C-N 115.38 -0.827 . . . . 0.0 109.617 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.54 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 41.2 t80 -68.59 129.03 38.72 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 172.761 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 49.8 t-20 -117.36 111.25 40.2 Favored Pre-proline 0 N--CA 1.455 -0.176 0 C-N-CA 123.76 0.824 . . . . 0.0 109.212 175.044 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.11 -38.32 46.35 Favored 'Trans proline' 0 N--CA 1.448 -1.189 0 C-N-CA 121.015 1.143 . . . . 0.0 111.386 -174.355 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 -57.92 -32.63 67.95 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 117.959 0.345 . . . . 0.0 111.098 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -88.15 -32.14 18.8 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.591 0.756 . . . . 0.0 109.98 177.525 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.5 -159.4 41.87 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.821 -0.911 . . . . 0.0 110.821 -167.326 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.58 61.05 14.96 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 125.441 1.496 . . . . 0.0 107.732 171.37 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -62.75 -32.4 78.18 Favored 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.438 2.092 . . . . 0.0 111.393 -169.672 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -59.68 -30.73 68.97 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 123.986 0.914 . . . . 0.0 110.642 178.714 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -94.34 -28.55 15.49 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 125.115 1.366 . . . . 0.0 110.515 -178.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.72 13.67 1.22 Allowed Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.413 1.006 . . . . 0.0 113.739 169.443 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 54.7 t -112.45 111.61 36.9 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.285 0 CA-C-N 118.45 1.125 . . . . 0.0 108.602 -174.778 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -64.12 155.15 80.1 Favored Pre-proline 0 CA--C 1.533 0.304 0 O-C-N 121.708 -0.62 . . . . 0.0 111.132 -176.156 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.2 149.5 80.08 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.127 1.218 . . . . 0.0 110.589 169.686 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 68.87 20.29 74.29 Favored Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.402 1.477 . . . . 0.0 112.885 -173.001 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 65.1 m -88.03 120.78 29.71 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 120.058 1.929 . . . . 0.0 107.558 174.686 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -59.75 134.08 56.7 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 172.312 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -42.2 -38.35 1.72 Allowed 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.126 0.57 . . . . 0.0 112.092 168.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 57.9 pttt -67.32 -41.72 84.81 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 117.579 -1.649 . . . . 0.0 110.185 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -71.83 -19.28 62.0 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 125.586 1.554 . . . . 0.0 110.577 -174.448 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.54 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.0 mt -52.52 133.11 44.86 Favored Pre-proline 0 N--CA 1.443 -0.802 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 173.663 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -65.17 141.48 69.59 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 122.275 1.984 . . . . 0.0 110.113 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.2 -15.95 60.98 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 124.198 0.999 . . . . 0.0 111.912 177.279 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -66.83 -22.83 65.99 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.268 1.027 . . . . 0.0 112.181 170.683 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 89.2 t90 -78.35 149.16 33.48 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-O 121.628 0.727 . . . . 0.0 111.102 -174.555 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 2.2 m -126.99 156.29 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 C-N-CA 125.847 1.659 . . . . 0.0 109.892 -174.03 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 7.7 t -63.36 137.09 96.98 Favored Pre-proline 0 CA--C 1.543 0.689 0 C-N-CA 122.958 0.503 . . . . 0.0 110.347 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -69.6 95.81 0.55 Allowed 'Trans proline' 0 N--CA 1.451 -1.022 0 C-N-CA 123.128 2.552 . . . . 0.0 110.66 -178.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 56.3 mt 85.42 59.11 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 126.813 2.045 . . . . 0.0 111.058 173.293 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 13.1 t -147.22 -94.67 0.09 Allowed 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -176.49 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 157.38 -41.85 0.53 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.4 t -70.5 148.0 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.97 177.7 49.8 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 176.321 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.9 ptmt -65.38 106.44 1.38 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 165.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -138.85 -65.84 0.49 Allowed 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 173.708 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -101.13 106.51 17.77 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 -178.68 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -142.29 128.7 20.07 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 51.7 mt-10 -104.2 141.88 35.49 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 124.443 1.097 . . . . 0.0 108.606 -175.221 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -75.49 142.69 42.85 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 119.913 1.233 . . . . 0.0 109.73 -179.354 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.2 t -112.38 106.56 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 C-N-CA 127.629 2.372 . . . . 0.0 106.737 177.377 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -82.93 53.74 2.52 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 124.968 1.307 . . . . 0.0 113.372 -173.261 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 . . . . . 0 C--O 1.25 1.095 0 C-N-CA 124.451 1.1 . . . . 0.0 110.256 179.762 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.382 21.9 ptm . . . . . 0 N--CA 1.474 0.749 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.0 mttm 62.47 165.33 0.11 Allowed 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 126.544 1.937 . . . . 0.0 113.012 -172.131 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -78.0 163.13 26.22 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.595 -178.372 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -138.31 140.51 39.58 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 118.971 -0.538 . . . . 0.0 109.852 175.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.3 t -90.69 160.31 15.92 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 118.014 0.37 . . . . 0.0 111.151 173.587 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 51.5 t -81.37 -121.01 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 125.558 1.543 . . . . 0.0 107.452 175.435 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 12.6 t -160.49 -46.08 0.05 OUTLIER 'General case' 0 CA--C 1.535 0.368 0 O-C-N 121.427 -0.796 . . . . 0.0 110.415 -175.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.5 p -104.65 -66.75 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 C-N-CA 123.42 0.688 . . . . 0.0 111.271 179.81 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.5 p -67.59 -38.77 84.5 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 123.713 0.805 . . . . 0.0 110.626 -176.604 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.73 31.03 30.77 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 179.197 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 18.6 m-85 -65.76 87.21 0.09 Allowed 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 117.742 0.771 . . . . 0.0 109.439 168.581 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.4 mt -57.44 111.04 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 C-N-CA 123.293 0.637 . . . . 0.0 109.293 172.4 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.544 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 20.1 t80 -73.69 133.37 43.37 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 173.203 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 50.7 t-20 -121.45 112.78 32.52 Favored Pre-proline 0 N--CA 1.455 -0.191 0 C-N-CA 124.255 1.022 . . . . 0.0 109.753 177.613 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -62.85 -38.83 45.51 Favored 'Trans proline' 0 N--CA 1.45 -1.03 0 C-N-CA 121.474 1.449 . . . . 0.0 112.083 -171.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -58.75 -32.31 69.15 Favored 'General case' 0 N--CA 1.446 -0.625 0 O-C-N 123.151 0.282 . . . . 0.0 111.059 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -87.46 -31.38 20.05 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.494 0.717 . . . . 0.0 109.92 177.584 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.11 -157.36 43.32 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -166.641 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.31 61.57 12.08 Favored Pre-proline 0 CA--C 1.54 0.588 0 C-N-CA 125.457 1.503 . . . . 0.0 107.455 171.035 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -61.87 -33.86 83.43 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.62 2.213 . . . . 0.0 111.2 -169.751 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -56.1 -30.48 62.13 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 125.438 1.495 . . . . 0.0 110.66 178.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.0 m-80 -97.02 -32.84 11.79 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 125.531 1.533 . . . . 0.0 110.432 -177.829 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 139.39 11.24 0.77 Allowed Glycine 0 CA--C 1.53 1.013 0 C-N-CA 123.898 0.761 . . . . 0.0 114.015 171.106 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 68.6 t -109.31 112.18 39.36 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.215 0 CA-C-N 118.898 1.349 . . . . 0.0 108.791 -176.608 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.19 154.35 82.97 Favored Pre-proline 0 CA--C 1.533 0.306 0 O-C-N 121.91 -0.494 . . . . 0.0 110.904 -177.564 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -58.38 147.02 87.55 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 121.408 1.405 . . . . 0.0 110.947 170.716 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 77.04 15.39 81.69 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 125.051 1.31 . . . . 0.0 112.838 -176.326 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 98.7 m -87.78 117.48 26.65 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 119.956 1.878 . . . . 0.0 107.421 177.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -57.86 135.48 56.86 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 171.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -43.88 -36.95 2.59 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 123.389 0.676 . . . . 0.0 112.154 170.421 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -66.51 -39.98 88.96 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 118.017 -1.473 . . . . 0.0 110.066 -178.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -80.04 -12.86 59.66 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 125.718 1.607 . . . . 0.0 110.741 -172.617 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.544 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.5 mt -56.36 132.8 76.24 Favored Pre-proline 0 N--CA 1.444 -0.752 0 CA-C-O 118.356 -0.831 . . . . 0.0 108.949 174.221 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -54.89 136.26 71.53 Favored 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 124.152 3.235 . . . . 0.0 110.551 176.555 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.73 -18.44 63.52 Favored 'General case' 0 CA--C 1.533 0.296 0 O-C-N 121.352 -0.843 . . . . 0.0 111.319 -179.482 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -76.55 -11.48 59.88 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 125.876 1.67 . . . . 0.0 112.104 171.092 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -71.65 149.77 45.24 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 119.07 0.85 . . . . 0.0 110.526 176.648 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 2.1 m -128.39 153.45 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 C-N-CA 126.082 1.753 . . . . 0.0 109.881 -175.315 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 8.2 t -73.71 138.48 77.05 Favored Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 123.658 0.783 . . . . 0.0 111.042 -175.079 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -58.64 127.53 24.88 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 123.416 2.744 . . . . 0.0 111.77 -177.23 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 24.5 mt 54.65 34.89 22.5 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.688 1.195 . . . . 0.0 111.857 -179.427 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.1 t -131.93 -176.22 3.99 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -139.01 47.57 0.91 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.036 -0.825 . . . . 0.0 111.036 -175.519 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -155.65 156.98 4.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 177.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.78 -179.6 50.03 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 178.405 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.8 ptmt -62.69 -19.56 64.0 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 170.859 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 29.26 -94.42 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 129.408 3.083 . . . . 0.0 111.529 -176.258 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.1 mm-40 -145.91 69.93 1.23 Allowed 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 164.57 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.4 m-30 -47.73 156.26 0.33 Allowed 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 125.656 1.582 . . . . 0.0 110.375 169.18 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -94.82 147.46 23.32 Favored 'General case' 0 C--O 1.225 -0.236 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -172.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -75.05 143.9 43.26 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 118.726 0.693 . . . . 0.0 109.198 -179.308 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 11.0 t -107.95 110.88 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 C-N-CA 126.121 1.768 . . . . 0.0 106.494 177.574 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -76.03 55.29 0.91 Allowed 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 125.454 1.502 . . . . 0.0 113.272 -177.396 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 117.231 -1.366 . . . . 0.0 108.085 158.569 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.376 26.5 ptm . . . . . 0 N--CA 1.472 0.657 0 N-CA-C 106.349 -1.723 . . . . 0.0 106.349 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 56.4 mttm 66.09 162.34 0.16 Allowed 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 126.64 1.976 . . . . 0.0 113.351 -176.079 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -77.71 163.65 25.97 Favored 'General case' 0 N--CA 1.447 -0.591 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.201 -179.514 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 23.6 m-85 -144.55 146.69 32.49 Favored 'General case' 0 CA--C 1.528 0.124 0 CA-C-O 119.046 -0.502 . . . . 0.0 110.732 176.895 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.5 t -99.0 143.48 29.24 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 174.251 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.452 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 48.9 t -82.65 120.23 25.3 Favored 'General case' 0 C--N 1.344 0.346 0 C-N-CA 126.678 1.991 . . . . 0.0 109.963 177.745 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 20.2 m -41.6 -76.18 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 127.617 2.367 . . . . 0.0 114.063 -175.256 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.2 p -99.7 48.5 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 O-C-N 121.233 -0.917 . . . . 0.0 109.653 -168.024 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.452 ' HB3' ' SG ' ' A' ' 6' ' ' CYS . 46.6 t -160.95 -60.95 0.06 Allowed 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -160.595 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.7 -13.48 63.9 Favored Glycine 0 CA--C 1.53 1.007 0 CA-C-O 119.025 -0.875 . . . . 0.0 113.137 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -59.19 143.32 49.33 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 119.42 1.61 . . . . 0.0 109.902 173.22 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 18.2 mt -112.04 121.22 64.07 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 123.89 0.876 . . . . 0.0 109.148 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.494 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 68.3 t80 -80.93 140.76 35.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 172.751 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 64.9 t-20 -124.68 120.1 25.79 Favored Pre-proline 0 C--O 1.224 -0.278 0 C-N-CA 124.252 1.021 . . . . 0.0 109.732 177.853 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -68.65 -40.49 7.35 Favored 'Trans proline' 0 N--CA 1.442 -1.507 0 C-N-CA 120.697 0.932 . . . . 0.0 112.122 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -60.4 -31.05 70.0 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 119.155 0.889 . . . . 0.0 110.95 -177.363 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.2 m-20 -90.11 -29.52 18.27 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.336 0.655 . . . . 0.0 109.967 177.513 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.48 -160.05 40.86 Favored Glycine 0 CA--C 1.529 0.951 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -165.615 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -139.64 62.43 23.17 Favored Pre-proline 0 CA--C 1.538 0.498 0 C-N-CA 125.181 1.393 . . . . 0.0 107.679 169.884 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -61.64 -32.12 86.99 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.345 2.03 . . . . 0.0 111.137 -171.244 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -57.05 -31.69 65.44 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.898 1.279 . . . . 0.0 110.587 178.39 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -95.43 -32.7 12.78 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.15 1.38 . . . . 0.0 110.483 -178.572 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.83 14.67 0.66 Allowed Glycine 0 CA--C 1.531 1.08 0 C-N-CA 124.053 0.835 . . . . 0.0 114.108 170.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.438 HG23 ' CD1' ' A' ' 37' ' ' TRP . 46.6 t -112.9 112.7 41.54 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.264 0 CA-C-N 118.808 1.304 . . . . 0.0 109.053 -176.037 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -64.58 155.94 79.62 Favored Pre-proline 0 C--N 1.328 -0.338 0 O-C-N 121.967 -0.458 . . . . 0.0 111.116 -177.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.64 148.29 88.27 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 121.569 1.513 . . . . 0.0 110.981 171.489 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.94 17.25 79.34 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 125.296 1.427 . . . . 0.0 112.662 -175.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 93.3 m -87.76 117.65 26.73 Favored 'General case' 0 N--CA 1.442 -0.875 0 CA-C-N 119.838 1.819 . . . . 0.0 107.59 176.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -58.1 134.35 56.37 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.401 171.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -40.47 -40.08 1.14 Allowed 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 123.901 0.88 . . . . 0.0 112.415 169.069 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.2 pttp -68.48 -38.29 80.9 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 118.295 -1.362 . . . . 0.0 109.973 -176.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -78.34 -15.62 58.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.805 1.642 . . . . 0.0 110.3 -174.358 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.494 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.4 mt -54.97 133.9 67.42 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-O 118.389 -0.815 . . . . 0.0 109.308 174.727 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 10.2 Cg_exo -57.69 137.3 80.53 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 123.597 2.865 . . . . 0.0 110.883 176.18 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -66.03 -18.43 65.33 Favored 'General case' 0 N--CA 1.45 -0.459 0 O-C-N 121.299 -0.875 . . . . 0.0 111.426 176.635 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -82.93 -6.21 59.37 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.563 1.545 . . . . 0.0 111.944 173.699 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' TRP . . . . . 0.438 ' CD1' HG23 ' A' ' 24' ' ' VAL . 71.0 t90 -69.94 160.43 31.89 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 119.053 0.842 . . . . 0.0 110.093 172.474 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -139.5 150.17 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 C-N-CA 125.585 1.554 . . . . 0.0 108.465 176.656 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.4 p -83.68 165.27 40.75 Favored Pre-proline 0 CA--C 1.539 0.557 0 N-CA-C 108.785 -0.821 . . . . 0.0 108.785 -179.182 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.51 124.13 9.61 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 121.301 1.334 . . . . 0.0 110.842 -168.702 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 12.6 mt 66.29 44.17 2.56 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 125.258 1.423 . . . . 0.0 112.201 172.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.3 t -138.45 179.63 6.35 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.913 0.885 . . . . 0.0 108.818 -177.345 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -100.98 -87.81 1.99 Allowed Glycine 0 CA--C 1.526 0.72 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 178.047 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.6 p -82.99 102.2 8.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 178.458 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -108.54 145.82 16.44 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 108.751 -1.74 . . . . 0.0 108.751 176.717 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER 59.5 101.78 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.42 1.488 . . . . 0.0 111.749 -170.652 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -138.8 -75.73 0.37 Allowed 'General case' 0 CA--C 1.521 -0.139 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 160.341 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 10.3 tm0? -144.69 55.34 1.25 Allowed 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 124.739 1.216 . . . . 0.0 107.846 -174.575 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 4.1 m-30 -55.51 150.99 11.09 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 125.059 1.343 . . . . 0.0 108.894 175.556 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -87.39 150.86 23.53 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.491 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -78.83 145.84 34.04 Favored 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 123.676 0.791 . . . . 0.0 109.088 179.301 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 14.5 t -110.84 111.44 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 C-N-CA 126.622 1.969 . . . . 0.0 107.081 174.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -71.86 67.09 0.59 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.305 1.842 . . . . 0.0 113.116 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 . . . . . 0 C--O 1.255 1.372 0 CA-C-O 117.86 -1.067 . . . . 0.0 111.098 164.514 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.415 ' N ' ' OE2' ' A' ' 16' ' ' GLU . 0.7 OUTLIER . . . . . 0 N--CA 1.477 0.889 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 . . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 7.9 mttm -65.54 139.27 58.45 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.61 0.719 . . . . 0.0 111.586 178.093 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 78.7 mttt -73.9 174.6 8.29 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 124.907 1.283 . . . . 0.0 109.46 174.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -144.32 131.03 20.13 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-O 118.831 -0.604 . . . . 0.0 111.628 176.419 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.6 m -79.87 143.72 34.07 Favored 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 123.872 0.869 . . . . 0.0 110.811 174.429 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.406 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 9.0 t -70.43 -175.68 1.07 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.209 1.404 . . . . 0.0 109.569 168.014 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 63.5 m -82.29 -99.26 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 123.688 0.795 . . . . 0.0 110.06 -176.612 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.8 p -87.33 -30.69 5.76 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 O-C-N 120.967 -1.083 . . . . 0.0 110.85 -178.071 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' CYS . . . . . 0.406 ' HB3' ' SG ' ' A' ' 6' ' ' CYS . 50.8 t -39.62 -55.48 1.86 Allowed 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 128.931 2.892 . . . . 0.0 112.365 175.247 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 100.91 -15.06 58.48 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-O 119.043 -0.865 . . . . 0.0 113.279 177.404 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -62.38 159.32 15.57 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.307 1.553 . . . . 0.0 111.574 176.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 28.7 mt -123.4 124.94 70.87 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 C-N-CA 125.227 1.411 . . . . 0.0 107.282 175.376 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.504 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 72.5 t80 -78.28 135.38 37.53 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 167.872 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -118.01 116.75 35.83 Favored Pre-proline 0 C--O 1.225 -0.204 0 C-N-CA 124.24 1.016 . . . . 0.0 109.948 175.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -64.82 -42.57 14.66 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 121.927 1.751 . . . . 0.0 111.793 -178.65 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLU . . . . . 0.415 ' OE2' ' N ' ' A' ' 1' ' ' MET . 45.3 mt-10 -61.98 -28.61 69.68 Favored 'General case' 0 N--CA 1.446 -0.658 0 O-C-N 123.27 0.356 . . . . 0.0 110.862 -174.34 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -90.63 -31.62 16.58 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.997 0.919 . . . . 0.0 110.399 174.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.98 -162.07 31.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.289 0.947 . . . . 0.0 110.984 -165.177 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -137.94 62.27 32.58 Favored Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 125.894 1.678 . . . . 0.0 107.485 171.878 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.1 -33.32 82.66 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 122.75 2.3 . . . . 0.0 111.28 -170.618 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -56.79 -28.99 62.25 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.674 1.189 . . . . 0.0 110.738 178.634 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.6 m-80 -102.11 -26.47 13.35 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 125.607 1.563 . . . . 0.0 110.684 -175.516 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.81 6.86 1.68 Allowed Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.167 0.889 . . . . 0.0 113.786 168.841 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 75.7 t -107.58 109.87 29.77 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.156 0 CA-C-N 118.595 1.198 . . . . 0.0 108.509 -174.332 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.87 155.97 81.25 Favored Pre-proline 0 C--N 1.329 -0.321 0 O-C-N 121.734 -0.604 . . . . 0.0 111.086 -176.622 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.32 147.68 89.91 Favored 'Trans proline' 0 N--CA 1.449 -1.102 0 C-N-CA 121.496 1.464 . . . . 0.0 111.032 171.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.28 14.98 81.8 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.682 -176.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 99.2 m -86.67 113.72 22.77 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 119.798 1.799 . . . . 0.0 107.546 178.042 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -53.4 133.26 40.44 Favored 'General case' 0 N--CA 1.446 -0.654 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 167.838 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.425 ' CD1' HD12 ' A' ' 33' ' ' ILE . 5.1 t80 -45.2 -31.84 1.64 Allowed 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 173.758 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 7.3 pttt -68.57 -45.65 71.49 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 118.398 -1.321 . . . . 0.0 110.065 179.538 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -67.58 -19.51 65.27 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 125.58 1.552 . . . . 0.0 111.222 -175.59 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.504 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 15.2 mt -53.29 131.37 52.27 Favored Pre-proline 0 N--CA 1.443 -0.812 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 176.089 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_endo -61.96 140.34 84.21 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 122.393 2.062 . . . . 0.0 109.455 -178.432 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -67.35 -14.38 62.87 Favored 'General case' 0 CA--C 1.535 0.373 0 O-C-N 121.968 -0.457 . . . . 0.0 111.87 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -75.34 -15.07 60.51 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.491 0.716 . . . . 0.0 112.204 171.545 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 85.5 t90 -73.7 151.8 40.62 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 176.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 12.1 p -141.29 164.61 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 C-N-CA 124.927 1.291 . . . . 0.0 107.777 -177.345 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' CYS . . . . . 0.416 ' SG ' ' HD2' ' A' ' 40' ' ' PRO . 4.3 t -48.79 138.86 12.17 Favored Pre-proline 0 CA--C 1.54 0.561 0 C-N-CA 124.391 1.076 . . . . 0.0 110.111 176.606 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' PRO . . . . . 0.416 ' HD2' ' SG ' ' A' ' 39' ' ' CYS . 39.2 Cg_endo -59.89 -36.88 89.11 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.323 2.015 . . . . 0.0 112.881 -173.391 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 41.0 mt -136.95 42.11 2.45 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.301 0.641 . . . . 0.0 110.096 -175.197 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -164.71 173.68 11.59 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 -174.765 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -133.35 67.84 0.55 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 -174.14 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.7 p -128.92 141.42 46.66 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 172.289 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.38 147.84 49.18 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 6.2 ptmt -60.19 -38.52 83.52 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 117.226 0.513 . . . . 0.0 111.549 -179.472 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -72.35 71.63 0.91 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 124.295 1.038 . . . . 0.0 109.682 178.397 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 4.0 tp-100 -171.92 -38.66 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 125.728 1.611 . . . . 0.0 109.666 -175.524 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -57.84 137.21 56.86 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.048 0.939 . . . . 0.0 109.636 -176.777 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -96.01 149.49 21.52 Favored 'General case' 0 C--O 1.22 -0.496 0 C-N-CA 124.627 1.171 . . . . 0.0 109.364 -175.104 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -71.93 138.49 48.14 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 119.883 1.219 . . . . 0.0 110.039 -178.381 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.3 t -101.2 107.86 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 C-N-CA 125.467 1.507 . . . . 0.0 107.08 177.25 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -72.06 65.95 0.59 Allowed 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 126.348 1.859 . . . . 0.0 113.397 -177.703 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 . . . . . 0 C--O 1.257 1.467 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 150.768 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.422 ' N ' ' OE2' ' A' ' 16' ' ' GLU . 1.4 tmt? . . . . . 0 N--CA 1.476 0.852 0 N-CA-C 104.793 -2.299 . . . . 0.0 104.793 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 9.6 mttm -63.23 140.53 58.88 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 119.682 1.128 . . . . 0.0 111.494 177.337 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 58.2 mttt -71.02 171.33 11.05 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 124.678 1.191 . . . . 0.0 109.862 172.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -141.69 134.35 28.48 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 172.77 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.5 t -85.8 154.53 21.52 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 118.312 0.506 . . . . 0.0 111.282 174.281 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 19.9 t -75.01 170.2 16.48 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 125.15 1.38 . . . . 0.0 107.852 172.639 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 6.9 t -125.72 16.7 8.09 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.063 0.945 . . . . 0.0 110.497 177.248 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 74.1 t -132.5 -60.54 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.34 0.179 0 C-N-CA 123.932 0.893 . . . . 0.0 109.52 -179.1 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.6 p -95.92 -89.31 0.26 Allowed 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 176.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 164.12 28.95 0.02 OUTLIER Glycine 0 CA--C 1.529 0.94 0 C-N-CA 125.487 1.518 . . . . 0.0 110.638 176.448 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -80.73 73.66 7.69 Favored 'General case' 0 N--CA 1.453 -0.322 0 O-C-N 121.819 -0.812 . . . . 0.0 108.83 -170.55 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.0 mt -45.35 112.52 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 C-N-CA 123.33 0.652 . . . . 0.0 110.978 -178.484 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.538 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 35.7 t80 -73.53 134.44 43.82 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 173.041 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 46.3 t-20 -123.07 114.63 29.35 Favored Pre-proline 0 N--CA 1.446 -0.652 0 C-N-CA 123.437 0.695 . . . . 0.0 109.387 176.585 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -65.36 -43.77 10.21 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 122.317 2.012 . . . . 0.0 111.327 -177.256 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLU . . . . . 0.422 ' OE2' ' N ' ' A' ' 1' ' ' MET . 10.6 mt-10 -56.84 -29.39 62.79 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 123.636 0.774 . . . . 0.0 111.226 -176.679 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -100.45 -23.41 14.74 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.879 0.872 . . . . 0.0 110.455 179.033 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.11 -160.59 30.73 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 124.829 1.204 . . . . 0.0 110.983 -172.333 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -140.34 61.4 16.69 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 125.281 1.432 . . . . 0.0 107.497 171.719 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_endo -62.38 -30.86 81.14 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 122.199 1.933 . . . . 0.0 111.076 -172.009 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -59.02 -29.65 67.43 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 124.463 1.105 . . . . 0.0 110.337 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -98.81 -29.29 13.06 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 125.544 1.537 . . . . 0.0 110.964 -177.154 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.36 18.24 0.93 Allowed Glycine 0 CA--C 1.532 1.15 0 C-N-CA 124.249 0.928 . . . . 0.0 113.798 170.469 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.2 t -117.26 110.02 29.71 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.216 0 CA-C-N 118.334 1.067 . . . . 0.0 108.443 -175.552 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -63.36 155.76 73.14 Favored Pre-proline 0 CA--C 1.534 0.337 0 O-C-N 121.835 -0.541 . . . . 0.0 110.976 -177.253 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -60.54 149.37 87.16 Favored 'Trans proline' 0 N--CA 1.449 -1.129 0 C-N-CA 121.464 1.443 . . . . 0.0 110.717 171.509 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.04 14.93 81.76 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 125.129 1.347 . . . . 0.0 113.047 -175.6 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 97.8 m -89.34 114.89 26.36 Favored 'General case' 0 N--CA 1.443 -0.815 0 CA-C-N 119.919 1.86 . . . . 0.0 107.836 178.541 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -56.17 134.72 53.15 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 169.732 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -42.38 -35.6 1.06 Allowed 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 123.709 0.803 . . . . 0.0 112.881 171.217 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 51.0 pttt -69.69 -42.48 74.05 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.625 -178.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -68.08 -21.44 64.97 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 125.658 1.583 . . . . 0.0 110.438 -176.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.538 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.8 mt -53.63 130.6 55.08 Favored Pre-proline 0 N--CA 1.445 -0.688 0 CA-C-N 118.758 0.708 . . . . 0.0 109.216 175.331 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -63.94 140.52 73.3 Favored 'Trans proline' 0 N--CA 1.445 -1.335 0 C-N-CA 122.479 2.12 . . . . 0.0 109.758 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -57.84 -23.22 51.78 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.537 0.735 . . . . 0.0 111.522 175.225 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.57 -18.75 63.66 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 124.745 1.218 . . . . 0.0 112.057 177.633 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 80.1 t90 -75.55 154.54 36.76 Favored 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 121.629 -0.669 . . . . 0.0 110.095 -179.563 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.1 t -139.73 149.57 22.43 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 C-N-CA 124.905 1.282 . . . . 0.0 108.569 -169.011 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.1 t -73.41 127.39 88.98 Favored Pre-proline 0 CA--C 1.545 0.757 0 C-N-CA 122.974 0.509 . . . . 0.0 110.879 179.153 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.43 139.76 50.41 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 123.196 2.597 . . . . 0.0 111.646 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 57.6 mt 58.56 31.94 21.6 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.54 1.136 . . . . 0.0 111.706 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 43.5 t -147.76 -57.61 0.24 Allowed 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -173.469 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.94 26.8 63.75 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 111.946 -0.461 . . . . 0.0 111.946 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 95.6 t -111.35 155.99 12.6 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 C-N-CA 124.341 1.056 . . . . 0.0 109.182 177.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -67.91 155.69 52.94 Favored Glycine 0 CA--C 1.528 0.867 0 C-N-CA 124.469 1.033 . . . . 0.0 111.743 -176.675 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.1 ptmt -67.86 -42.89 80.62 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -175.643 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -76.87 77.65 3.46 Favored 'General case' 0 N--CA 1.456 -0.166 0 CA-C-O 122.426 1.108 . . . . 0.0 108.879 -170.874 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -179.37 -30.06 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 128.582 2.753 . . . . 0.0 108.97 -168.706 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -57.06 141.42 45.9 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.628 0.771 . . . . 0.0 110.888 169.629 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -111.66 145.16 39.74 Favored 'General case' 0 C--O 1.22 -0.458 0 C-N-CA 125.08 1.352 . . . . 0.0 109.551 -177.805 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -65.62 136.34 56.2 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-N 118.778 0.717 . . . . 0.0 110.415 -176.02 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.8 t -94.74 109.53 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 175.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -69.0 82.13 0.31 Allowed 'General case' 0 N--CA 1.443 -0.796 0 C-N-CA 125.503 1.521 . . . . 0.0 110.706 175.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 . . . . . 0 C--O 1.251 1.154 0 CA-C-O 117.229 -1.367 . . . . 0.0 110.471 169.387 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.415 25.1 ptm . . . . . 0 N--CA 1.47 0.534 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 22.6 mttm 55.83 174.82 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.431 0 O-C-N 125.473 1.733 . . . . 0.0 112.319 -172.416 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 66.2 mttt -73.61 170.65 14.76 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.439 -0.801 . . . . 0.0 109.836 -178.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.482 ' CE1' ' HB2' ' A' ' 30' ' ' PHE . 55.3 m-85 -142.07 141.64 32.77 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 122.501 0.32 . . . . 0.0 111.323 176.419 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 91.1 m -78.25 142.44 37.85 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 123.47 0.708 . . . . 0.0 109.605 172.108 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 24.8 t -79.58 135.48 36.61 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 125.071 1.348 . . . . 0.0 108.428 175.048 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.0 m -45.32 -56.79 4.55 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.496 1.519 . . . . 0.0 114.197 -168.135 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 14.5 p -153.35 35.91 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 120.939 0.399 . . . . 0.0 110.59 -173.321 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 2.8 m -121.79 -65.25 1.14 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.485 0.714 . . . . 0.0 109.188 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 116.78 56.33 0.31 Allowed Glycine 0 CA--C 1.53 0.995 0 C-N-CA 124.717 1.151 . . . . 0.0 111.948 176.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -139.18 87.66 2.22 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.457 1.103 . . . . 0.0 109.052 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.4 mt -57.23 127.13 15.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 O-C-N 121.439 -0.788 . . . . 0.0 111.035 -176.541 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.566 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 27.7 t80 -81.4 137.29 35.7 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 172.448 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 51.7 t-20 -122.55 112.44 31.02 Favored Pre-proline 0 C--N 1.339 0.136 0 C-N-CA 124.168 0.987 . . . . 0.0 109.841 175.809 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_endo -65.15 -37.44 32.23 Favored 'Trans proline' 0 N--CA 1.45 -1.086 0 C-N-CA 121.28 1.32 . . . . 0.0 111.51 -173.567 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -58.34 -32.09 68.2 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 117.726 0.239 . . . . 0.0 111.322 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -87.49 -32.8 19.26 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.489 0.716 . . . . 0.0 109.868 177.029 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.26 -156.41 45.16 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 -168.093 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -143.37 61.29 9.83 Favored Pre-proline 0 CA--C 1.542 0.669 0 C-N-CA 125.705 1.602 . . . . 0.0 107.442 172.26 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.01 -33.41 83.27 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.671 2.247 . . . . 0.0 111.618 -169.056 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -58.15 -30.99 66.79 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 124.688 1.195 . . . . 0.0 110.394 178.738 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -92.4 -29.42 16.31 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 125.245 1.418 . . . . 0.0 110.351 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.14 -4.01 3.13 Favored Glycine 0 CA--C 1.529 0.938 0 C-N-CA 124.477 1.037 . . . . 0.0 113.148 172.101 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 74.3 t -94.3 109.78 22.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -172.633 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -62.98 154.84 75.35 Favored Pre-proline 0 CA--C 1.534 0.354 0 O-C-N 121.767 -0.583 . . . . 0.0 110.488 -177.565 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -59.08 149.27 80.98 Favored 'Trans proline' 0 N--CA 1.449 -1.138 0 C-N-CA 121.123 1.215 . . . . 0.0 110.417 169.499 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.03 17.93 80.22 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 125.32 1.438 . . . . 0.0 113.3 -175.355 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 98.0 m -92.1 119.41 31.75 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-N 119.983 1.892 . . . . 0.0 107.312 177.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -65.2 142.99 58.13 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 173.168 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.482 ' HB2' ' CE1' ' A' ' 4' ' ' TYR . 2.2 t80 -49.22 -33.11 11.84 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 123.639 0.775 . . . . 0.0 112.366 175.106 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 10.4 pttm -67.27 -37.17 83.01 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 119.254 -0.978 . . . . 0.0 110.926 178.291 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 -77.43 -21.0 53.7 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 124.742 1.217 . . . . 0.0 110.09 -174.878 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.566 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.4 mt -55.64 133.68 71.71 Favored Pre-proline 0 N--CA 1.445 -0.693 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.214 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 5.9 Cg_exo -59.45 134.8 60.68 Favored 'Trans proline' 0 N--CA 1.449 -1.123 0 C-N-CA 122.746 2.297 . . . . 0.0 109.374 175.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.59 -3.84 33.48 Favored 'General case' 0 N--CA 1.447 -0.577 0 O-C-N 121.632 -0.667 . . . . 0.0 112.346 -176.489 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -76.23 -12.42 60.09 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.131 0.972 . . . . 0.0 112.596 164.735 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 80.6 t90 -67.15 148.92 51.21 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 118.981 0.81 . . . . 0.0 111.297 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 62.7 t -125.97 144.47 35.98 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 126.732 2.013 . . . . 0.0 108.718 -175.079 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.8 p -82.82 132.57 51.0 Favored Pre-proline 0 CA--C 1.543 0.695 0 CA-C-N 120.038 1.29 . . . . 0.0 110.06 177.064 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -79.12 139.84 15.32 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.617 2.211 . . . . 0.0 111.066 -175.39 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 18.1 tp 60.37 31.87 20.5 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 124.497 1.119 . . . . 0.0 111.262 -178.971 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 33.3 m -125.65 -97.83 0.42 Allowed 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.977 1.311 . . . . 0.0 109.357 -179.612 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 143.88 114.18 0.95 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 108.325 -1.91 . . . . 0.0 108.325 -164.628 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.427 HG13 ' N ' ' A' ' 45' ' ' GLY 0.265 0.4 OUTLIER 76.94 -173.2 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 125.151 1.38 . . . . 0.0 110.402 -171.721 . . . . . . . . 4 4 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.427 ' N ' HG13 ' A' ' 44' ' ' VAL . . . -129.53 -123.69 2.56 Favored Glycine 0 N--CA 1.449 -0.442 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 179.854 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 23.4 mtpt -82.23 167.86 18.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.429 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -159.45 -75.49 0.07 Allowed 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 124.656 1.183 . . . . 0.0 108.827 172.642 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -124.06 -38.65 2.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 127.268 2.227 . . . . 0.0 109.739 -177.626 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 25.2 p90 53.15 173.47 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.235 2.214 . . . . 0.0 112.882 -176.324 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -138.72 136.55 35.91 Favored 'General case' 0 CA--C 1.521 -0.155 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 172.491 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -74.22 137.27 42.95 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 176.806 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.6 t -97.59 113.97 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.823 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 175.348 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -74.09 51.56 0.42 Allowed 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.3 1.44 . . . . 0.0 114.113 -178.499 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 28.9 mt-10 . . . . . 0 C--O 1.253 1.288 0 C-N-CA 125.921 1.688 . . . . 0.0 107.587 157.143 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.396 13.4 ptt? . . . . . 0 N--CA 1.472 0.656 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 33.2 mttt 66.32 164.38 0.18 Allowed 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 126.93 2.092 . . . . 0.0 113.408 -173.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -70.67 162.61 28.69 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.54 178.777 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -144.99 137.18 25.92 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 124.248 1.019 . . . . 0.0 111.423 -178.847 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.8 m -75.92 155.59 35.01 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.232 1.013 . . . . 0.0 110.975 173.684 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 15.3 t -97.49 -37.49 9.95 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.236 1.814 . . . . 0.0 109.3 174.281 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 86.1 m 76.14 -62.46 0.43 Allowed 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 125.455 1.502 . . . . 0.0 112.016 166.407 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 31.2 m -78.79 43.72 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-N 119.284 0.947 . . . . 0.0 110.656 178.001 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 10.4 t 177.05 -102.49 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -156.27 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 121.21 64.77 0.24 Allowed Glycine 0 CA--C 1.53 0.974 0 C-N-CA 125.302 1.43 . . . . 0.0 111.035 -176.808 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -114.51 -57.55 2.26 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.301 1.04 . . . . 0.0 111.055 176.722 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . 0.251 57.8 mt 79.84 110.73 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 C-N-CA 127.548 2.339 . . . . 0.0 110.997 -170.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.535 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 51.6 t80 -74.23 141.6 45.4 Favored 'General case' 0 C--O 1.236 0.357 0 C-N-CA 124.203 1.001 . . . . 0.0 108.859 171.055 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 63.9 t-20 -126.57 116.57 22.88 Favored Pre-proline 0 C--O 1.224 -0.289 0 C-N-CA 123.488 0.715 . . . . 0.0 110.9 173.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -68.25 -41.46 6.97 Favored 'Trans proline' 0 N--CA 1.445 -1.369 0 C-N-CA 121.13 1.22 . . . . 0.0 112.042 -177.54 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -60.05 -30.9 69.5 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 118.706 0.684 . . . . 0.0 110.855 -178.005 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 -86.62 -32.71 20.45 Favored 'General case' 0 CA--C 1.53 0.192 0 C-N-CA 123.406 0.682 . . . . 0.0 109.512 176.629 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.89 -159.86 42.71 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -164.122 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -137.56 61.79 32.67 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 168.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -61.74 -38.22 62.12 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.11 2.54 . . . . 0.0 111.257 -167.886 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -51.02 -30.35 15.13 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.769 1.628 . . . . 0.0 110.825 177.145 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -101.48 -18.12 16.12 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 125.818 1.647 . . . . 0.0 110.976 -175.159 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 130.56 -5.18 5.87 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.583 1.087 . . . . 0.0 113.324 172.281 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 78.6 t -100.22 108.7 23.42 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.202 0 CA-C-N 118.2 1.0 . . . . 0.0 109.103 -171.658 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -64.73 155.16 83.31 Favored Pre-proline 0 CA--C 1.533 0.305 0 O-C-N 121.767 -0.583 . . . . 0.0 111.072 -175.634 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -57.95 147.64 80.81 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 121.322 1.348 . . . . 0.0 110.723 170.564 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 71.51 21.68 78.69 Favored Glycine 0 CA--C 1.525 0.714 0 C-N-CA 125.653 1.596 . . . . 0.0 112.945 -174.272 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.9 m -91.75 121.92 33.83 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 119.994 1.897 . . . . 0.0 107.818 174.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -63.87 137.87 58.23 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 174.325 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -42.95 -38.37 2.2 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.167 0.987 . . . . 0.0 111.733 170.277 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -67.26 -39.73 86.14 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 118.572 -1.251 . . . . 0.0 110.493 -179.448 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -82.54 -11.45 58.43 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 125.906 1.683 . . . . 0.0 110.716 -172.594 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.535 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.6 mt -54.53 133.16 63.54 Favored Pre-proline 0 N--CA 1.441 -0.878 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 171.653 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 16.7 Cg_exo -53.83 134.53 59.42 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 123.785 2.99 . . . . 0.0 109.432 176.059 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.39 -11.2 60.0 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.146 -0.972 . . . . 0.0 111.705 -175.299 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -78.01 -10.1 59.44 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 126.493 1.917 . . . . 0.0 112.181 167.027 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 78.3 t90 -66.97 158.14 31.61 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 119.089 0.859 . . . . 0.0 109.971 173.391 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.8 p -136.52 155.09 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 124.712 1.205 . . . . 0.0 108.71 -176.684 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.6 t -56.4 136.02 76.26 Favored Pre-proline 0 CA--C 1.534 0.339 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.89 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -58.59 -28.98 87.73 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 123.045 2.496 . . . . 0.0 113.214 -174.701 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.6 tp -150.8 51.5 0.86 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 118.72 0.691 . . . . 0.0 111.075 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . 0.258 1.7 p -142.84 -64.68 0.4 Allowed 'General case' 0 N--CA 1.464 0.266 0 O-C-N 122.053 -0.405 . . . . 0.0 110.552 159.715 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 142.87 -136.33 7.04 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 -179.408 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.4 t 61.77 -83.65 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 C-N-CA 126.097 1.759 . . . . 0.0 112.352 173.77 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.58 -139.28 6.76 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -170.02 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 48.4 mtpt -113.77 93.75 4.52 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 124.925 1.29 . . . . 0.0 108.608 174.778 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 55.6 p-10 -144.72 169.73 17.45 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 170.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER 36.93 47.02 0.54 Allowed 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 127.218 2.207 . . . . 0.0 113.324 -177.377 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 21.3 p90 -95.29 113.79 25.51 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.372 0.669 . . . . 0.0 110.053 179.628 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -98.33 149.4 22.67 Favored 'General case' 0 C--O 1.223 -0.31 0 C-N-CA 125.77 1.628 . . . . 0.0 108.726 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -79.72 142.02 35.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 120.273 1.397 . . . . 0.0 110.031 -178.441 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.2 t -105.98 109.64 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 126.35 1.86 . . . . 0.0 107.376 176.248 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -72.63 66.55 0.73 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.994 1.718 . . . . 0.0 113.131 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 . . . . . 0 C--O 1.256 1.435 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.241 158.845 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.343 12.5 ptm . . . . . 0 CA--C 1.511 -0.529 0 N-CA-C 104.72 -2.326 . . . . 0.0 104.72 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.6 mttm 62.09 165.76 0.1 Allowed 'General case' 0 N--CA 1.451 -0.42 0 O-C-N 124.908 1.38 . . . . 0.0 112.432 -169.545 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -78.39 166.76 22.26 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.236 -174.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -151.62 150.39 30.23 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 123.367 0.667 . . . . 0.0 112.409 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.5 m -78.28 156.24 29.77 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 123.876 0.87 . . . . 0.0 112.355 171.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 34.0 t -70.93 166.71 20.62 Favored 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 125.026 1.33 . . . . 0.0 108.768 166.03 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 5.4 m -45.16 -41.88 8.51 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 126.463 1.905 . . . . 0.0 112.302 170.208 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.3 p -160.98 -32.74 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 113.53 0.937 . . . . 0.0 113.53 -172.669 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.9 p -77.58 172.46 13.33 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 120.213 1.369 . . . . 0.0 110.58 -177.764 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -89.5 51.69 3.65 Favored Glycine 0 CA--C 1.527 0.83 0 O-C-N 121.318 -0.864 . . . . 0.0 111.732 -176.914 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -125.84 86.73 2.57 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 118.25 1.025 . . . . 0.0 110.445 -177.557 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 15.9 mt -67.63 127.26 28.97 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 O-C-N 121.73 -0.607 . . . . 0.0 109.605 174.914 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 40.0 t80 -78.48 136.94 37.71 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 170.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.6 t-20 -122.19 113.11 31.24 Favored Pre-proline 0 C--O 1.227 -0.123 0 C-N-CA 124.312 1.045 . . . . 0.0 110.34 177.698 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -65.33 -38.98 24.24 Favored 'Trans proline' 0 N--CA 1.445 -1.359 0 C-N-CA 120.97 1.114 . . . . 0.0 112.246 -177.133 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -59.74 -32.13 70.28 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 118.562 0.619 . . . . 0.0 111.102 -178.054 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -88.06 -32.02 18.97 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 123.471 0.709 . . . . 0.0 109.75 178.083 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.1 -158.62 37.85 Favored Glycine 0 CA--C 1.529 0.952 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 -165.35 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.76 61.69 11.32 Favored Pre-proline 0 CA--C 1.54 0.595 0 C-N-CA 125.955 1.702 . . . . 0.0 107.113 171.831 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -61.11 -33.86 90.51 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.572 2.181 . . . . 0.0 111.045 -170.227 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -54.58 -30.61 54.83 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 125.294 1.437 . . . . 0.0 110.736 178.175 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -102.97 -23.03 13.73 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 125.432 1.493 . . . . 0.0 110.778 -174.815 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 132.42 11.05 2.02 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 124.287 0.946 . . . . 0.0 113.401 169.645 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 70.6 t -110.3 108.76 26.23 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 CA-C-N 118.544 1.172 . . . . 0.0 108.762 -175.732 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -63.1 155.04 75.25 Favored Pre-proline 0 CA--C 1.535 0.379 0 O-C-N 121.662 -0.649 . . . . 0.0 110.876 -178.319 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.79 148.78 86.8 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 121.118 1.212 . . . . 0.0 110.719 170.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.46 17.0 78.81 Favored Glycine 0 CA--C 1.526 0.73 0 C-N-CA 125.256 1.408 . . . . 0.0 112.963 -174.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 54.1 m -88.6 122.01 31.59 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 119.797 1.798 . . . . 0.0 107.977 178.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -63.88 135.56 56.66 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 171.672 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -40.39 -41.63 1.42 Allowed 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.4 0.68 . . . . 0.0 111.634 167.348 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.3 pttt -66.91 -34.74 78.44 Favored 'General case' 0 CA--C 1.536 0.429 0 O-C-N 120.241 -1.537 . . . . 0.0 110.823 -178.381 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -76.49 -22.1 54.94 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 125.13 1.372 . . . . 0.0 109.801 -177.64 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 15.8 mt -55.85 134.31 72.95 Favored Pre-proline 0 N--CA 1.445 -0.693 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.757 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_endo -62.05 137.3 66.0 Favored 'Trans proline' 0 N--CA 1.443 -1.443 0 C-N-CA 121.755 1.637 . . . . 0.0 108.889 176.482 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -72.46 -3.35 23.81 Favored 'General case' 0 N--CA 1.444 -0.741 0 O-C-N 121.914 -0.491 . . . . 0.0 111.908 -179.443 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.06 -23.16 64.01 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 125.509 1.524 . . . . 0.0 112.315 164.179 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 84.6 t90 -70.56 152.43 43.96 Favored 'General case' 0 CA--C 1.53 0.176 0 O-C-N 121.628 -0.67 . . . . 0.0 110.855 -176.447 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.6 t -139.24 151.8 23.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 C-N-CA 125.901 1.68 . . . . 0.0 107.441 -173.288 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 9.8 t -54.12 133.14 59.75 Favored Pre-proline 0 CA--C 1.541 0.632 0 C-N-CA 125.557 1.543 . . . . 0.0 110.119 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -59.19 -52.49 4.86 Favored 'Trans proline' 0 N--CA 1.459 -0.546 0 C-N-CA 123.674 2.916 . . . . 0.0 113.699 -166.383 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 96.1 mt -128.68 59.92 1.53 Allowed 'General case' 0 N--CA 1.462 0.135 0 C-N-CA 123.68 0.792 . . . . 0.0 109.541 -173.2 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -162.9 -66.79 0.05 OUTLIER 'General case' 0 CA--C 1.529 0.158 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 -171.637 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 101.1 51.76 1.13 Allowed Glycine 0 CA--C 1.528 0.879 0 C-N-CA 123.641 0.638 . . . . 0.0 112.493 175.21 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 34.7 m -125.56 152.92 32.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 C-N-CA 123.953 0.901 . . . . 0.0 108.91 168.002 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.12 -175.59 44.97 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 110.81 -0.916 . . . . 0.0 110.81 175.334 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 41.2 mtpt -78.41 84.43 4.57 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 122.931 0.492 . . . . 0.0 109.824 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -139.28 150.73 45.79 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.502 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.4 tp-100 48.32 55.82 8.3 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.993 2.117 . . . . 0.0 112.17 175.003 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -103.24 115.88 31.41 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.746 0.818 . . . . 0.0 110.077 -179.254 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -86.24 146.36 26.57 Favored 'General case' 0 C--O 1.226 -0.175 0 C-N-CA 125.431 1.492 . . . . 0.0 109.206 178.495 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -81.42 141.82 33.56 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 119.089 0.859 . . . . 0.0 109.36 -179.848 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.4 t -109.03 102.49 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.837 0 C-N-CA 127.109 2.164 . . . . 0.0 107.757 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -76.59 76.36 3.28 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 126.207 1.803 . . . . 0.0 112.682 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 51.2 mm-40 . . . . . 0 C--O 1.255 1.392 0 CA-C-O 116.671 -1.633 . . . . 0.0 108.414 153.42 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.475 0.801 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.3 mttm -82.52 149.09 27.73 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 119.757 1.162 . . . . 0.0 111.394 -178.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -75.33 168.27 20.32 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 124.213 1.005 . . . . 0.0 108.567 174.045 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 29.4 m-85 -144.62 139.12 27.86 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-O 118.899 -0.572 . . . . 0.0 112.306 -179.045 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.8 m -87.1 137.78 32.06 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 119.175 0.898 . . . . 0.0 111.298 178.154 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 40.8 t -62.73 149.7 43.14 Favored 'General case' 0 C--N 1.34 0.171 0 CA-C-N 118.699 0.682 . . . . 0.0 109.708 174.075 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 58.1 m -43.05 -36.67 1.68 Allowed 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 125.477 1.511 . . . . 0.0 112.113 172.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 m -129.71 -40.76 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 123.368 0.667 . . . . 0.0 112.46 178.677 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 m -76.79 160.65 29.11 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.346 0.976 . . . . 0.0 112.413 -171.558 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -99.38 12.59 61.67 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 119.222 -0.766 . . . . 0.0 112.406 174.106 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 38.8 m-85 -60.58 -43.91 96.81 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 118.873 1.336 . . . . 0.0 111.308 -175.696 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.7 mt 69.64 113.01 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 C-N-CA 126.137 1.775 . . . . 0.0 111.368 -177.155 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' TYR . . . . . 0.504 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 80.4 t80 -69.62 132.49 46.28 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 171.109 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -120.35 113.23 33.88 Favored Pre-proline 0 N--CA 1.456 -0.168 0 C-N-CA 124.205 1.002 . . . . 0.0 109.685 177.429 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -59.67 -42.19 49.0 Favored 'Trans proline' 0 N--CA 1.45 -1.045 0 C-N-CA 122.017 1.811 . . . . 0.0 112.443 -176.561 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -59.64 -31.41 69.5 Favored 'General case' 0 N--CA 1.447 -0.606 0 O-C-N 123.108 0.255 . . . . 0.0 111.653 -178.266 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 -90.09 -29.59 18.24 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 123.304 0.641 . . . . 0.0 110.422 177.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.79 -154.99 42.38 Favored Glycine 0 CA--C 1.53 1.029 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -167.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -146.34 61.33 6.95 Favored Pre-proline 0 CA--C 1.543 0.702 0 C-N-CA 125.595 1.558 . . . . 0.0 107.842 173.558 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -61.33 -34.53 87.17 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 122.944 2.429 . . . . 0.0 111.599 -168.879 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -54.64 -29.88 53.55 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 125.253 1.421 . . . . 0.0 111.38 177.84 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -98.03 -33.98 10.97 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 125.493 1.517 . . . . 0.0 109.774 -177.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 141.27 11.51 0.56 Allowed Glycine 0 CA--C 1.532 1.132 0 C-N-CA 123.933 0.778 . . . . 0.0 114.06 169.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.462 HG23 ' CD1' ' A' ' 37' ' ' TRP . 52.2 t -107.61 112.73 41.35 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.245 0 CA-C-N 119.174 1.487 . . . . 0.0 108.947 -177.379 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -65.05 153.79 88.19 Favored Pre-proline 0 C--N 1.329 -0.283 0 O-C-N 122.016 -0.428 . . . . 0.0 110.406 -179.367 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -59.22 146.77 93.5 Favored 'Trans proline' 0 N--CA 1.449 -1.113 0 C-N-CA 121.631 1.554 . . . . 0.0 110.955 172.185 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 78.03 18.01 77.43 Favored Glycine 0 CA--C 1.524 0.642 0 CA-C-O 118.553 -1.137 . . . . 0.0 112.764 -177.159 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 83.0 m -89.96 120.84 31.52 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 119.577 1.689 . . . . 0.0 107.678 177.133 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -57.55 133.55 55.35 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 169.523 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -48.43 -32.27 7.45 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.753 174.48 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -68.73 -40.89 79.67 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 119.375 -0.93 . . . . 0.0 109.345 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -75.36 -15.32 60.48 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 125.546 1.539 . . . . 0.0 110.494 -172.689 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.504 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 12.9 mt -55.94 132.17 73.59 Favored Pre-proline 0 N--CA 1.441 -0.891 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 172.427 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -63.41 140.2 75.09 Favored 'Trans proline' 0 N--CA 1.443 -1.486 0 C-N-CA 122.633 2.222 . . . . 0.0 109.042 178.083 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.37 -18.12 57.23 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 122.555 0.342 . . . . 0.0 111.224 177.243 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.25 -18.53 62.44 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.784 1.234 . . . . 0.0 112.076 176.357 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' TRP . . . . . 0.462 ' CD1' HG23 ' A' ' 24' ' ' VAL . 73.3 t90 -68.76 159.47 32.24 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 121.668 0.747 . . . . 0.0 110.943 -178.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 15.9 m -136.51 151.4 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.796 0 C-N-CA 125.66 1.584 . . . . 0.0 109.279 -171.294 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.3 t -72.31 135.75 81.83 Favored Pre-proline 0 CA--C 1.537 0.472 0 C-N-CA 124.428 1.091 . . . . 0.0 108.886 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.58 131.7 30.55 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 122.173 1.916 . . . . 0.0 110.058 179.318 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 57.1 mt 56.97 49.46 13.89 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.544 0.738 . . . . 0.0 110.991 176.363 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 53.8 t -163.58 -176.62 4.77 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 127.877 2.471 . . . . 0.0 105.092 -174.873 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.71 -100.35 0.56 Allowed Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.161 0.886 . . . . 0.0 111.08 178.025 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.3 m -142.35 160.13 19.64 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.117 0 C-N-CA 123.93 0.892 . . . . 0.0 108.687 -177.754 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 142.84 149.05 5.06 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 177.165 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.8 ptmt -161.75 -177.58 5.96 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 125.291 1.436 . . . . 0.0 107.447 169.629 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 t0 69.59 -63.24 0.39 Allowed 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 126.992 2.117 . . . . 0.0 111.817 169.535 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 38.5 tt0 -56.73 -22.68 37.08 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.707 2.003 . . . . 0.0 113.188 174.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 6.0 m-30 -45.18 143.95 1.48 Allowed 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.865 1.666 . . . . 0.0 109.494 170.825 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -75.16 155.39 37.01 Favored 'General case' 0 C--O 1.224 -0.263 0 CA-C-N 119.429 1.013 . . . . 0.0 108.555 -177.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -83.03 133.87 35.06 Favored 'General case' 0 N--CA 1.442 -0.837 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 173.644 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 13.4 t -93.51 116.59 35.04 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.983 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 172.842 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -70.96 56.88 0.2 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.683 1.993 . . . . 0.0 114.491 -177.454 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 . . . . . 0 C--O 1.255 1.352 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 159.832 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 21.4 mttm . . . . . 0 N--CA 1.452 -0.35 0 CA-C-O 122.026 0.917 . . . . 0.0 112.77 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.4 mtpt -74.0 170.39 15.52 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.734 -178.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 38.2 m-85 -146.89 147.18 30.53 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 122.863 0.465 . . . . 0.0 110.648 -177.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 51.4 p -64.95 165.61 10.57 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 120.644 0.259 . . . . 0.0 111.075 167.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 4.4 t -68.77 -97.56 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 105.97 -1.863 . . . . 0.0 105.97 159.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.5 t -172.95 -41.65 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.578 1.951 . . . . 0.0 107.133 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 9.8 p -147.79 -38.62 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 114.495 1.294 . . . . 0.0 114.495 176.361 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 13.6 p -64.97 -41.47 95.41 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 120.345 1.43 . . . . 0.0 111.282 -170.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 109.39 47.67 0.85 Allowed Glycine 0 CA--C 1.527 0.793 0 C-N-CA 124.805 1.193 . . . . 0.0 111.779 175.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -114.87 89.4 3.09 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.129 0.972 . . . . 0.0 109.041 176.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 16.0 mt -63.82 125.52 20.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.509 -0.744 . . . . 0.0 109.601 176.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.557 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 39.9 t80 -81.56 138.89 35.35 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 173.077 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.1 t-20 -122.88 114.33 29.73 Favored Pre-proline 0 N--CA 1.456 -0.157 0 C-N-CA 123.862 0.865 . . . . 0.0 110.292 174.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -67.46 -38.89 13.61 Favored 'Trans proline' 0 N--CA 1.448 -1.196 0 C-N-CA 121.337 1.358 . . . . 0.0 111.777 -174.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -59.87 -30.86 69.27 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 118.141 0.428 . . . . 0.0 111.05 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -87.39 -31.73 19.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.477 0.711 . . . . 0.0 109.886 176.261 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.21 -159.4 37.05 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -166.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -139.91 61.16 17.31 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 125.485 1.514 . . . . 0.0 107.535 170.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -63.41 -30.65 72.59 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.527 2.151 . . . . 0.0 111.212 -170.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -59.9 -28.24 67.41 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 124.283 1.033 . . . . 0.0 109.858 179.155 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 21.6 m-80 -102.36 -26.22 13.36 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 125.73 1.612 . . . . 0.0 110.874 -175.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 135.83 10.96 1.31 Allowed Glycine 0 CA--C 1.531 1.077 0 C-N-CA 124.177 0.894 . . . . 0.0 113.86 169.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 70.7 t -112.95 110.22 31.41 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.294 0 CA-C-N 118.644 1.222 . . . . 0.0 108.709 -174.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -63.63 155.06 77.91 Favored Pre-proline 0 CA--C 1.535 0.366 0 O-C-N 121.631 -0.668 . . . . 0.0 111.073 -176.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.27 149.02 83.48 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 121.19 1.26 . . . . 0.0 110.665 170.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.26 15.76 80.98 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-O 118.368 -1.24 . . . . 0.0 112.616 -175.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 88.0 m -89.08 116.16 27.15 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 119.805 1.803 . . . . 0.0 107.073 177.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -57.84 136.06 56.93 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 170.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -44.18 -37.68 3.3 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 123.851 0.86 . . . . 0.0 111.79 171.255 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 56.9 pttt -67.22 -42.39 84.13 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 117.561 -1.656 . . . . 0.0 109.986 -178.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -71.36 -18.33 62.38 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 125.806 1.642 . . . . 0.0 111.138 -176.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.557 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.7 mt -53.38 133.4 52.87 Favored Pre-proline 0 N--CA 1.448 -0.569 0 CA-C-N 119.194 0.906 . . . . 0.0 108.941 174.252 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -64.9 142.17 74.35 Favored 'Trans proline' 0 N--CA 1.445 -1.331 0 C-N-CA 122.106 1.871 . . . . 0.0 109.946 179.472 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -68.47 -12.34 61.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 O-C-N 121.946 -0.471 . . . . 0.0 111.962 178.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -74.77 -17.18 60.68 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 118.275 0.489 . . . . 0.0 112.193 169.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 87.6 t90 -75.27 147.61 40.11 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 121.55 0.691 . . . . 0.0 109.529 179.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 59.3 t -131.51 161.22 41.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 125.097 1.359 . . . . 0.0 107.633 -177.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -43.79 144.49 1.42 Allowed Pre-proline 0 CA--C 1.537 0.475 0 C-N-CA 124.775 1.23 . . . . 0.0 110.031 170.406 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -64.34 -42.43 17.4 Favored 'Trans proline' 0 N--CA 1.452 -0.945 0 C-N-CA 122.271 1.981 . . . . 0.0 111.569 -176.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 88.9 mt -135.41 44.9 2.51 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 123.904 0.881 . . . . 0.0 109.983 -176.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -158.36 152.01 23.44 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 106.007 -1.849 . . . . 0.0 106.007 179.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -120.78 86.65 0.4 Allowed Glycine 0 C--N 1.335 0.506 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -169.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.8 p -145.46 -51.85 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 123.115 0.566 . . . . 0.0 110.699 -178.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 109.36 154.68 15.79 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -176.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -64.46 107.79 1.47 Allowed 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 118.153 0.976 . . . . 0.0 109.572 177.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -160.46 157.89 28.43 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 172.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 44.6 54.24 6.62 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.321 1.848 . . . . 0.0 111.549 173.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.6 p90 -100.28 117.86 35.37 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 126.507 1.923 . . . . 0.0 108.705 -179.261 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -85.17 148.11 26.27 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 123.526 0.73 . . . . 0.0 109.06 176.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -79.46 138.7 37.67 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.0 t -102.46 105.0 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 C-N-CA 125.419 1.488 . . . . 0.0 108.266 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -72.87 68.64 0.9 Allowed 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 126.348 1.859 . . . . 0.0 113.178 -179.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 43.3 mm-40 . . . . . 0 C--O 1.255 1.364 0 CA-C-O 116.78 -1.581 . . . . 0.0 108.332 154.843 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 12.1 mttm . . . . . 0 N--CA 1.446 -0.641 0 CA-C-O 121.72 0.772 . . . . 0.0 112.448 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt -76.76 174.29 10.66 Favored 'General case' 0 N--CA 1.442 -0.853 0 C-N-CA 125.617 1.567 . . . . 0.0 109.252 177.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -147.49 145.63 29.21 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 122.773 0.429 . . . . 0.0 110.167 -177.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 42.0 m -74.96 141.59 44.02 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 172.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 41.2 t -74.84 -112.08 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.494 0 N-CA-C 105.735 -1.95 . . . . 0.0 105.735 164.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 9.6 t -160.18 -158.2 0.61 Allowed 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 170.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 17.4 m -75.26 56.81 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 C-N-CA 124.079 0.952 . . . . 0.0 111.737 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 15.6 p -153.19 -55.85 0.12 Allowed 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.989 1.316 . . . . 0.0 109.452 177.24 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.71 -150.36 23.42 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 123.716 0.674 . . . . 0.0 113.248 -169.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 44.8 t80 -130.14 160.5 33.59 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 125.948 1.699 . . . . 0.0 107.666 179.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.6 mt -47.72 125.36 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 C-N-CA 124.6 1.16 . . . . 0.0 111.341 176.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.536 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 27.0 t80 -70.19 136.6 50.19 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 170.193 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.7 t-20 -120.02 113.02 34.46 Favored Pre-proline 0 N--CA 1.454 -0.232 0 C-N-CA 123.861 0.864 . . . . 0.0 109.707 175.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.74 -38.15 32.35 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 121.696 1.597 . . . . 0.0 111.342 -175.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -63.09 -28.81 70.33 Favored 'General case' 0 N--CA 1.444 -0.754 0 O-C-N 123.188 0.305 . . . . 0.0 111.333 -176.542 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -86.44 -32.97 20.57 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.807 0.843 . . . . 0.0 109.716 172.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.39 -158.86 42.23 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -166.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.3 61.59 17.41 Favored Pre-proline 0 C--O 1.237 0.435 0 C-N-CA 125.235 1.414 . . . . 0.0 107.891 171.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -64.24 -28.16 64.21 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 122.536 2.157 . . . . 0.0 111.222 -170.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -64.18 -30.25 71.32 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 123.24 0.616 . . . . 0.0 109.683 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 33.9 m-80 -93.0 -30.94 15.07 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 125.085 1.354 . . . . 0.0 110.747 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.15 5.88 1.52 Allowed Glycine 0 CA--C 1.531 1.06 0 C-N-CA 124.26 0.933 . . . . 0.0 113.915 170.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 50.2 t -103.44 112.1 35.64 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.266 0 CA-C-N 118.45 1.125 . . . . 0.0 108.559 -175.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -64.59 154.87 83.5 Favored Pre-proline 0 CA--C 1.533 0.32 0 O-C-N 121.784 -0.573 . . . . 0.0 110.416 -177.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.79 150.05 73.67 Favored 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 121.495 1.463 . . . . 0.0 110.851 170.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 79.33 14.44 81.55 Favored Glycine 0 CA--C 1.526 0.724 0 C-N-CA 125.708 1.623 . . . . 0.0 113.348 -176.332 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 93.9 m -94.35 114.77 26.88 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 120.149 1.974 . . . . 0.0 108.501 -178.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -56.42 135.24 54.15 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 169.423 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -42.69 -35.36 1.1 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 113.172 0.804 . . . . 0.0 113.172 171.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 53.8 pttt -68.3 -38.5 81.7 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 118.646 -1.221 . . . . 0.0 110.051 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -78.0 -16.9 57.73 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 125.005 1.322 . . . . 0.0 109.99 -173.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.536 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.7 mt -54.97 132.02 67.61 Favored Pre-proline 0 N--CA 1.442 -0.836 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 174.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 2.7 Cg_exo -57.64 134.69 64.72 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 123.162 2.575 . . . . 0.0 109.359 177.245 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -74.57 -7.4 53.0 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.298 -0.876 . . . . 0.0 111.966 -176.499 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -77.4 -10.23 59.34 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.491 1.116 . . . . 0.0 112.598 165.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 77.2 t90 -66.93 156.35 36.07 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 118.88 0.764 . . . . 0.0 110.516 177.661 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.4 p -123.91 154.57 30.6 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 125.886 1.675 . . . . 0.0 108.579 -177.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.0 m -34.57 148.55 0.1 Allowed Pre-proline 0 CA--C 1.541 0.609 0 C-N-CA 126.693 1.997 . . . . 0.0 113.715 172.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -76.49 -37.82 1.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 122.964 2.443 . . . . 0.0 113.057 -174.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 96.1 mt -132.3 30.7 4.16 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.908 0.883 . . . . 0.0 109.434 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -152.16 -173.9 4.7 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 -177.087 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -134.43 58.19 0.69 Allowed Glycine 0 C--N 1.339 0.714 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -176.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -133.86 158.74 42.55 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 C-N-CA 125.296 1.438 . . . . 0.0 107.947 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.5 -174.49 35.65 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 111.413 -0.675 . . . . 0.0 111.413 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 52.8 mtpt -71.03 -60.62 2.13 Favored 'General case' 0 CA--C 1.529 0.154 0 O-C-N 121.978 -0.719 . . . . 0.0 109.999 175.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 54.67 -68.53 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 129.357 3.063 . . . . 0.0 114.202 176.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -138.46 140.48 39.25 Favored 'General case' 0 CA--C 1.527 0.092 0 C-N-CA 125.26 1.424 . . . . 0.0 108.203 178.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 7.6 p90 -156.29 110.13 2.74 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -168.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -86.27 133.44 33.82 Favored 'General case' 0 C--O 1.225 -0.204 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -71.52 135.67 47.19 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 178.053 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.8 t -97.72 109.99 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 C-N-CA 126.39 1.876 . . . . 0.0 106.393 177.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -72.72 60.2 0.49 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.878 1.671 . . . . 0.0 114.308 -174.073 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 . . . . . 0 C--O 1.26 1.627 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 152.236 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 8.9 mttm . . . . . 0 CA--C 1.52 -0.21 0 CA-C-O 120.89 0.376 . . . . 0.0 111.109 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -71.37 171.35 11.37 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 123.557 0.743 . . . . 0.0 110.2 174.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -145.52 148.55 33.34 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.481 0.713 . . . . 0.0 111.253 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.5 m -80.07 122.16 26.43 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 123.294 0.638 . . . . 0.0 110.021 176.082 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 7.2 t -58.91 94.72 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.326 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 168.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 59.3 m -66.37 141.34 57.99 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -171.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . 0.305 12.7 p 54.37 20.5 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 125.845 1.658 . . . . 0.0 113.293 -171.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 66.9 m -139.03 -162.43 1.32 Allowed 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.591 1.557 . . . . 0.0 107.967 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.36 62.56 0.37 Allowed Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 178.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 6.1 t80 -150.82 66.13 0.92 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 124.069 0.947 . . . . 0.0 109.718 -173.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.1 mt -37.79 125.19 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 124.724 1.21 . . . . 0.0 112.791 -175.205 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.545 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 25.9 t80 -78.05 135.62 37.77 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 175.539 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 57.2 t-20 -120.11 111.52 35.38 Favored Pre-proline 0 N--CA 1.452 -0.338 0 C-N-CA 123.913 0.885 . . . . 0.0 109.807 176.103 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -64.98 -37.96 31.04 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.406 1.404 . . . . 0.0 111.479 -175.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -61.21 -29.91 70.11 Favored 'General case' 0 N--CA 1.446 -0.67 0 O-C-N 123.393 0.433 . . . . 0.0 111.074 -176.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -87.24 -33.17 19.4 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 123.962 0.905 . . . . 0.0 109.705 173.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.44 -158.14 39.83 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -167.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -142.54 62.36 12.81 Favored Pre-proline 0 CA--C 1.537 0.476 0 C-N-CA 125.503 1.521 . . . . 0.0 107.746 172.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.06 -33.98 81.25 Favored 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 122.558 2.172 . . . . 0.0 111.179 -170.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -57.41 -29.89 64.51 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.833 1.253 . . . . 0.0 110.35 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 21.3 m-80 -99.26 -23.4 15.21 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 125.554 1.541 . . . . 0.0 110.98 -176.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 131.52 7.42 3.1 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 124.571 1.081 . . . . 0.0 113.321 169.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.0 t -107.53 110.23 31.1 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.261 0 CA-C-N 118.313 1.057 . . . . 0.0 108.612 -174.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -64.08 155.16 79.86 Favored Pre-proline 0 CA--C 1.534 0.329 0 O-C-N 121.783 -0.573 . . . . 0.0 110.537 -177.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -59.58 149.9 79.42 Favored 'Trans proline' 0 N--CA 1.449 -1.127 0 C-N-CA 121.308 1.339 . . . . 0.0 110.679 170.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.65 23.45 76.79 Favored Glycine 0 CA--C 1.524 0.656 0 C-N-CA 125.469 1.509 . . . . 0.0 112.891 -175.16 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 94.2 m -97.81 117.66 32.63 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 119.514 1.657 . . . . 0.0 107.703 176.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -61.08 137.37 58.24 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 173.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -44.12 -35.11 2.03 Favored 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 113.588 0.959 . . . . 0.0 113.588 172.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 5.8 pttt -69.73 -37.89 76.66 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 120.813 -1.179 . . . . 0.0 110.144 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -73.64 -20.42 60.58 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 125.226 1.41 . . . . 0.0 109.799 -175.018 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.545 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.4 mt -54.36 131.07 62.03 Favored Pre-proline 0 N--CA 1.441 -0.882 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 176.317 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -60.66 135.84 62.99 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.094 1.863 . . . . 0.0 108.551 178.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -72.73 -5.41 37.56 Favored 'General case' 0 CA--C 1.54 0.567 0 O-C-N 121.89 -0.507 . . . . 0.0 111.744 -178.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.4 -26.41 66.42 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.98 1.312 . . . . 0.0 112.08 164.488 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 83.8 t90 -69.86 149.14 48.18 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.644 0.735 . . . . 0.0 110.639 -174.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 5.2 m -123.12 157.55 28.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 C-N-CA 125.913 1.685 . . . . 0.0 109.645 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.5 m -39.65 144.02 0.52 Allowed Pre-proline 0 CA--C 1.532 0.287 0 C-N-CA 126.351 1.861 . . . . 0.0 113.187 177.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -70.19 -31.94 17.71 Favored 'Trans proline' 0 N--CA 1.451 -1.003 0 C-N-CA 123.227 2.618 . . . . 0.0 112.832 -173.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 16.1 tp -149.32 35.87 0.73 Allowed 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.68 -0.637 . . . . 0.0 110.732 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.5 m -131.19 -47.41 1.0 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.625 0.77 . . . . 0.0 110.607 -178.306 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.43 62.32 1.65 Allowed Glycine 0 CA--C 1.531 1.057 0 C-N-CA 123.608 0.623 . . . . 0.0 112.254 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.1 p -151.69 159.18 4.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 172.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -68.04 167.56 42.39 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 54.9 mtpt -50.33 -58.13 6.35 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.757 0.823 . . . . 0.0 111.215 177.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.8 t0 21.11 85.83 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 128.275 2.63 . . . . 0.0 115.016 -172.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER 75.2 150.66 0.11 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.825 1.65 . . . . 0.0 110.228 178.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.3 p90 -171.02 109.44 0.31 Allowed 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -163.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 52.5 mt-10 -87.27 135.81 33.17 Favored 'General case' 0 CA--C 1.519 -0.228 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -176.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -76.88 137.55 39.21 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -178.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.1 t -98.47 109.91 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.042 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 176.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -74.69 59.62 0.87 Allowed 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 126.197 1.799 . . . . 0.0 113.914 -171.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 . . . . . 0 C--O 1.259 1.596 0 CA-C-N 114.845 -1.07 . . . . 0.0 108.372 156.286 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 38.1 mttm . . . . . 0 N--CA 1.449 -0.483 0 CA-C-O 122.012 0.91 . . . . 0.0 112.911 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 72.7 mttt -80.37 165.61 22.1 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 115.219 -0.9 . . . . 0.0 108.653 -176.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -144.92 136.25 25.17 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.04 -179.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.8 t -92.11 135.79 33.69 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 111.689 0.255 . . . . 0.0 111.689 172.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 48.0 t -77.56 47.45 0.6 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 127.223 2.209 . . . . 0.0 109.389 177.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 10.9 m 43.39 -124.27 0.81 Allowed 'General case' 0 CA--C 1.548 0.902 0 O-C-N 120.266 -1.521 . . . . 0.0 111.93 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 45.1 t -82.75 70.63 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 O-C-N 120.541 -1.35 . . . . 0.0 108.919 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 42.5 t -133.0 -70.04 0.55 Allowed 'General case' 0 CA--C 1.529 0.153 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 175.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.15 60.58 0.96 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -131.91 -57.63 0.98 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.904 0.882 . . . . 0.0 110.393 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 74.0 mt 75.17 119.15 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 C-N-CA 127.135 2.174 . . . . 0.0 111.683 -175.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.566 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 44.1 t80 -82.03 132.41 35.25 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 170.076 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 56.8 t-20 -118.87 112.64 36.46 Favored Pre-proline 0 C--O 1.227 -0.12 0 C-N-CA 124.348 1.059 . . . . 0.0 109.403 174.04 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -65.53 -38.23 26.27 Favored 'Trans proline' 0 N--CA 1.447 -1.265 0 C-N-CA 121.111 1.208 . . . . 0.0 111.573 -174.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -57.47 -32.22 66.74 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-N 117.97 0.35 . . . . 0.0 111.03 -179.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 60.1 m-20 -90.06 -29.83 18.11 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.705 0.802 . . . . 0.0 110.232 177.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.08 -158.67 41.35 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -168.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -141.87 60.82 11.71 Favored Pre-proline 0 CA--C 1.539 0.555 0 C-N-CA 125.373 1.469 . . . . 0.0 107.763 172.17 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -62.17 -33.64 81.16 Favored 'Trans proline' 0 N--CA 1.455 -0.767 0 C-N-CA 122.403 2.068 . . . . 0.0 111.173 -170.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -55.85 -31.35 62.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 125.011 1.324 . . . . 0.0 110.641 177.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.6 m-80 -97.83 -27.76 14.15 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 125.521 1.528 . . . . 0.0 110.663 -177.059 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.23 9.34 1.44 Allowed Glycine 0 CA--C 1.532 1.154 0 C-N-CA 124.345 0.974 . . . . 0.0 113.829 169.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 54.7 t -110.06 111.63 37.0 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.248 0 CA-C-N 118.579 1.189 . . . . 0.0 109.065 -174.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -63.62 154.8 78.79 Favored Pre-proline 0 C--N 1.328 -0.335 0 O-C-N 121.9 -0.5 . . . . 0.0 111.056 -177.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -59.94 150.15 79.84 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 121.423 1.416 . . . . 0.0 110.744 171.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 72.22 16.67 77.08 Favored Glycine 0 CA--C 1.525 0.704 0 CA-C-O 118.289 -1.284 . . . . 0.0 112.798 -174.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 92.4 m -87.75 117.6 26.69 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-N 119.951 1.875 . . . . 0.0 107.386 176.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -56.56 133.28 53.42 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.167 170.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -42.67 -38.31 2.0 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 123.326 0.65 . . . . 0.0 112.053 170.231 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.1 pttp -66.34 -39.08 88.97 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 118.181 -1.408 . . . . 0.0 109.945 -177.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -81.66 -11.37 59.11 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 126.108 1.763 . . . . 0.0 110.626 -172.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.566 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.8 mt -56.42 134.28 76.57 Favored Pre-proline 0 N--CA 1.443 -0.801 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 171.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 8.1 Cg_exo -58.08 138.35 85.5 Favored 'Trans proline' 0 N--CA 1.454 -0.796 0 C-N-CA 123.556 2.838 . . . . 0.0 110.932 176.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -69.92 -15.02 63.0 Favored 'General case' 0 N--CA 1.448 -0.55 0 O-C-N 121.071 -1.018 . . . . 0.0 111.822 177.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -78.96 -9.75 59.62 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.59 1.156 . . . . 0.0 112.065 169.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 76.9 t90 -72.22 156.12 39.49 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.086 0.857 . . . . 0.0 110.369 175.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 13.1 t -130.76 143.58 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 125.174 1.389 . . . . 0.0 108.227 -170.205 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 20.2 t -68.18 137.33 91.7 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 123.438 0.695 . . . . 0.0 109.629 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -68.15 127.85 16.59 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 122.749 2.299 . . . . 0.0 111.42 177.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 29.1 mt 61.26 44.73 9.5 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.759 1.223 . . . . 0.0 111.97 174.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 14.4 t -149.05 178.63 8.54 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -176.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -105.28 171.43 18.62 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 171.439 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.324 3.9 p 48.07 -149.39 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 CA-C-O 117.447 -1.263 . . . . 0.0 111.219 -173.421 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -146.13 -143.3 3.89 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-N 121.475 1.943 . . . . 0.0 111.131 -173.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.4 ptmt -78.11 115.53 17.9 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 172.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -158.43 -63.59 0.08 Allowed 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.029 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -105.0 97.53 7.37 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.638 1.175 . . . . 0.0 109.392 179.509 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.7 p90 -141.12 135.16 30.63 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.201 1.001 . . . . 0.0 109.189 -178.327 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 22.6 mt-10 -108.44 155.06 21.01 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 124.734 1.213 . . . . 0.0 109.519 178.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -78.96 143.22 35.98 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 123.635 0.774 . . . . 0.0 109.646 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.3 t -112.07 108.38 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 C-N-CA 126.679 1.991 . . . . 0.0 106.564 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -81.18 55.21 2.46 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 125.005 1.322 . . . . 0.0 113.098 -175.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 . . . . . 0 C--O 1.25 1.119 0 C-N-CA 124.911 1.285 . . . . 0.0 109.681 176.454 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 43.2 mttm . . . . . 0 N--CA 1.452 -0.366 0 CA-C-O 122.286 1.041 . . . . 0.0 112.618 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 3.7 mtpt -78.91 166.97 21.8 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.205 -177.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -147.68 149.31 32.23 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.068 0.547 . . . . 0.0 111.067 -179.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 57.4 p -74.38 170.82 14.87 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 123.281 0.633 . . . . 0.0 112.214 172.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 42.1 t -83.16 -53.06 6.07 Favored 'General case' 0 C--O 1.224 -0.254 0 C-N-CA 125.203 1.401 . . . . 0.0 109.074 162.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 85.9 m 61.25 22.74 13.04 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.017 0.927 . . . . 0.0 111.569 -173.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 66.1 t -123.34 -65.15 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 C-N-CA 124.421 1.088 . . . . 0.0 108.453 166.057 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 26.5 p -94.56 -60.53 1.69 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 118.633 0.651 . . . . 0.0 110.706 175.527 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 138.6 45.98 0.07 OUTLIER Glycine 0 CA--C 1.531 1.075 0 C-N-CA 124.873 1.225 . . . . 0.0 112.166 -176.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -111.13 103.27 11.69 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 125.122 1.369 . . . . 0.0 109.705 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.6 mt -72.52 123.73 27.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 O-C-N 120.919 -1.113 . . . . 0.0 110.085 178.034 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.55 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 48.4 t80 -79.38 138.59 37.71 Favored 'General case' 0 C--O 1.236 0.392 0 C-N-CA 124.396 1.078 . . . . 0.0 108.451 170.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -124.02 114.33 27.99 Favored Pre-proline 0 C--O 1.226 -0.141 0 C-N-CA 124.005 0.922 . . . . 0.0 109.995 174.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -65.95 -39.46 19.3 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 120.954 1.102 . . . . 0.0 111.969 -175.309 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -58.66 -31.4 68.14 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 118.318 0.508 . . . . 0.0 111.149 -178.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -88.91 -30.86 18.53 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.505 0.722 . . . . 0.0 109.954 177.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.52 -159.99 41.13 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 124.095 0.855 . . . . 0.0 110.997 -168.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.04 61.25 17.2 Favored Pre-proline 0 CA--C 1.539 0.532 0 C-N-CA 125.445 1.498 . . . . 0.0 107.712 170.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_endo -63.45 -28.3 70.93 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.237 1.958 . . . . 0.0 111.229 -171.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -61.56 -28.49 69.37 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 123.534 0.734 . . . . 0.0 110.076 178.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.4 m-80 -99.84 -26.93 13.86 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 125.236 1.414 . . . . 0.0 110.958 -177.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 133.2 17.12 1.15 Allowed Glycine 0 CA--C 1.531 1.052 0 C-N-CA 124.216 0.913 . . . . 0.0 113.635 170.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 78.5 t -115.43 109.59 28.87 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.272 0 CA-C-N 118.466 1.133 . . . . 0.0 108.381 -175.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -63.39 155.67 73.71 Favored Pre-proline 0 C--N 1.328 -0.327 0 O-C-N 121.671 -0.643 . . . . 0.0 111.23 -176.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.0 149.02 86.68 Favored 'Trans proline' 0 N--CA 1.448 -1.147 0 C-N-CA 121.279 1.32 . . . . 0.0 110.619 171.046 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.39 16.61 78.81 Favored Glycine 0 N--CA 1.445 -0.709 0 CA-C-O 118.307 -1.274 . . . . 0.0 112.693 -174.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 81.7 m -87.95 117.72 27.0 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 119.873 1.836 . . . . 0.0 106.942 176.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -58.58 136.51 57.61 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 171.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -45.76 -37.3 5.83 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 122.975 0.51 . . . . 0.0 111.337 171.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 48.0 pttt -66.41 -38.49 87.58 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 117.783 -1.567 . . . . 0.0 110.468 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -76.1 -18.88 58.98 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 125.012 1.325 . . . . 0.0 110.506 -174.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.55 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.7 mt -53.81 133.92 56.67 Favored Pre-proline 0 N--CA 1.446 -0.627 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 175.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -65.18 139.66 61.53 Favored 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 122.133 1.889 . . . . 0.0 109.7 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -66.3 -11.33 50.07 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 123.708 0.803 . . . . 0.0 111.54 177.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.4 -22.11 61.91 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.64 1.176 . . . . 0.0 112.11 170.285 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 84.9 t90 -73.39 155.7 39.08 Favored 'General case' 0 N--CA 1.455 -0.209 0 O-C-N 121.527 -0.733 . . . . 0.0 110.386 -177.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.72 159.68 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 C-N-CA 125.541 1.536 . . . . 0.0 109.232 -177.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 44.4 t -68.17 134.91 91.43 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 124.228 1.011 . . . . 0.0 109.668 -177.083 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -62.1 126.33 18.45 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.475 2.117 . . . . 0.0 110.883 178.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 41.0 mt 64.92 34.84 8.75 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.467 1.107 . . . . 0.0 111.615 174.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 41.5 t -151.61 160.95 43.44 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 106.399 -1.704 . . . . 0.0 106.399 -175.041 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -115.94 110.13 2.14 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 -174.125 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 36.0 t 78.84 123.35 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 C-N-CA 126.547 1.939 . . . . 0.0 108.785 -171.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -156.59 173.12 34.36 Favored Glycine 0 C--N 1.334 0.459 0 N-CA-C 107.696 -2.162 . . . . 0.0 107.696 178.04 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 53.87 74.05 0.35 Allowed 'General case' 0 CA--C 1.534 0.346 0 CA-C-O 122.941 1.353 . . . . 0.0 110.295 -170.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -152.59 -69.67 0.16 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 113.707 -1.588 . . . . 0.0 108.151 170.055 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -113.67 101.3 9.19 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 124.93 1.292 . . . . 0.0 108.453 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -140.27 131.93 27.25 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.092 1.357 . . . . 0.0 107.783 -175.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -96.63 149.35 21.89 Favored 'General case' 0 C--O 1.223 -0.297 0 C-N-CA 124.903 1.281 . . . . 0.0 109.28 -176.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -75.76 140.86 42.61 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-N 119.042 0.837 . . . . 0.0 109.218 178.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.2 t -106.63 107.57 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 C-N-CA 125.611 1.564 . . . . 0.0 106.8 176.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -76.85 57.03 1.25 Allowed 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 125.619 1.568 . . . . 0.0 113.075 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 . . . . . 0 C--O 1.251 1.144 0 CA-C-O 117.278 -1.344 . . . . 0.0 108.462 159.113 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.5 mmmt . . . . . 0 CA--C 1.52 -0.185 0 CA-C-O 121.391 0.615 . . . . 0.0 110.08 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 44.1 mtpt -74.12 169.75 16.89 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.568 -177.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -143.02 142.59 31.62 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 119.582 -0.247 . . . . 0.0 110.724 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.8 t -85.15 141.7 30.01 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 119.61 -0.836 . . . . 0.0 109.977 170.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 52.2 t -71.19 170.46 12.94 Favored 'General case' 0 CA--C 1.539 0.54 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 154.332 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.3 p -69.28 81.02 0.36 Allowed 'General case' 0 CA--C 1.533 0.32 0 O-C-N 120.97 -1.081 . . . . 0.0 110.725 -173.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 99.1 t 66.98 -74.88 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.456 -0.158 0 C-N-CA 126.014 1.725 . . . . 0.0 108.154 -170.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 48.1 t 43.05 -122.68 0.72 Allowed 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.77 1.228 . . . . 0.0 109.803 174.382 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -177.42 41.11 0.1 OUTLIER Glycine 0 CA--C 1.527 0.806 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 166.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -148.45 74.6 1.29 Allowed 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.748 0.785 . . . . 0.0 109.397 -169.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 12.6 mt -59.82 131.67 24.57 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 O-C-N 121.699 -0.626 . . . . 0.0 109.657 175.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.576 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 33.9 t80 -82.82 138.17 34.05 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 174.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -124.17 112.47 28.26 Favored Pre-proline 0 N--CA 1.454 -0.241 0 C-N-CA 124.229 1.011 . . . . 0.0 109.705 175.424 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -66.19 -35.19 33.78 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.076 1.184 . . . . 0.0 111.395 -174.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.1 mt-10 -65.13 -27.71 68.93 Favored 'General case' 0 N--CA 1.443 -0.792 0 O-C-N 123.313 0.383 . . . . 0.0 110.934 -176.112 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -87.37 -31.57 20.05 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.328 1.051 . . . . 0.0 109.788 171.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.27 -151.82 50.28 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -167.027 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 25.6 t0 -151.87 63.94 5.55 Favored Pre-proline 0 N--CA 1.443 -0.799 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 171.643 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -64.91 -28.28 58.49 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.701 2.267 . . . . 0.0 111.634 -166.214 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -62.37 -24.93 67.64 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 123.701 0.801 . . . . 0.0 109.727 -178.205 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.9 m-80 -111.37 17.12 20.47 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.062 1.345 . . . . 0.0 109.993 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 95.73 3.95 60.67 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.325 0.964 . . . . 0.0 114.63 170.861 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.9 t -104.16 107.84 23.28 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.23 0 CA-C-N 119.127 1.464 . . . . 0.0 109.345 -172.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -65.36 153.89 88.87 Favored Pre-proline 0 CA--C 1.536 0.44 0 O-C-N 121.614 -0.679 . . . . 0.0 110.697 -176.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_endo -58.38 149.11 76.24 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 121.575 1.517 . . . . 0.0 111.135 170.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.66 19.33 79.21 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 125.004 1.288 . . . . 0.0 112.47 -175.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 99.8 m -94.27 114.45 26.54 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 119.61 1.705 . . . . 0.0 106.811 176.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -59.72 138.24 57.82 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 170.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.434 ' CD1' ' CD2' ' A' ' 49' ' ' PHE . 2.1 t80 -42.14 -38.63 1.76 Allowed 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 113.194 0.813 . . . . 0.0 113.194 171.189 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 55.8 pttt -64.99 -40.13 94.51 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 118.345 -1.342 . . . . 0.0 110.224 -178.136 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -78.73 -12.45 60.02 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 125.057 1.343 . . . . 0.0 111.169 -175.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.576 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.8 mt -57.23 132.76 80.94 Favored Pre-proline 0 N--CA 1.442 -0.873 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 172.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -63.5 137.3 59.08 Favored 'Trans proline' 0 N--CA 1.442 -1.519 0 C-N-CA 121.641 1.56 . . . . 0.0 108.605 176.357 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -70.56 -3.47 18.25 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 123.543 0.737 . . . . 0.0 111.977 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -73.96 -24.71 59.67 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.968 1.707 . . . . 0.0 111.983 166.38 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 78.9 t90 -65.75 158.5 27.42 Favored 'General case' 0 CA--C 1.528 0.112 0 O-C-N 121.746 -0.596 . . . . 0.0 109.805 178.11 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.413 ' CG2' ' HA2' ' A' ' 43' ' ' GLY . 8.0 p -141.34 145.73 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 C-N-CA 123.895 0.878 . . . . 0.0 109.935 -173.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 53.2 t -66.92 125.12 90.33 Favored Pre-proline 0 C--O 1.24 0.597 0 C-N-CA 123.392 0.677 . . . . 0.0 110.029 178.472 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -66.04 133.7 34.27 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 123.26 2.64 . . . . 0.0 111.035 -175.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 48.4 mt 60.23 30.06 19.54 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 124.536 1.134 . . . . 0.0 112.042 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 8.4 t -142.67 -68.19 0.36 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.097 0.959 . . . . 0.0 108.841 -176.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . 0.413 ' HA2' ' CG2' ' A' ' 38' ' ' VAL . . . 85.71 17.98 60.8 Favored Glycine 0 CA--C 1.532 1.127 0 CA-C-O 118.613 -1.104 . . . . 0.0 114.737 177.464 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.8 p -72.17 -54.98 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 CA-C-N 119.761 1.781 . . . . 0.0 112.94 -176.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.95 -152.82 24.32 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 108.514 -1.834 . . . . 0.0 108.514 -170.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.55 33.89 0.78 Allowed 'General case' 0 CA--C 1.53 0.189 0 CA-C-N 118.217 1.009 . . . . 0.0 112.063 169.281 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -98.27 -49.66 4.62 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 125.086 1.354 . . . . 0.0 110.114 -161.406 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -94.23 67.23 3.53 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.057 1.343 . . . . 0.0 108.597 178.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.434 ' CD2' ' CD1' ' A' ' 30' ' ' PHE . 20.5 p90 -101.81 115.06 29.7 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 124.232 1.013 . . . . 0.0 109.214 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -99.27 142.92 30.13 Favored 'General case' 0 CA--C 1.519 -0.22 0 N-CA-C 108.164 -1.051 . . . . 0.0 108.164 174.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -73.04 134.78 44.75 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 15.3 t -93.29 108.86 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 174.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -78.64 51.28 1.06 Allowed 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 124.536 1.135 . . . . 0.0 113.489 -173.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 . . . . . 0 C--O 1.259 1.589 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 149.719 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 14.9 mttt . . . . . 0 N--CA 1.453 -0.31 0 CA-C-O 121.968 0.889 . . . . 0.0 112.672 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 58.9 mttt -75.02 167.07 22.63 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.241 -0.891 . . . . 0.0 109.492 -174.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -145.48 144.08 30.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.937 178.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 13.5 m -76.89 150.95 35.98 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-O 119.303 -0.379 . . . . 0.0 110.988 169.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 46.3 t -65.07 171.13 3.83 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-O 121.345 0.593 . . . . 0.0 110.136 170.003 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 1.9 t -71.52 -42.87 67.44 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 124.944 1.298 . . . . 0.0 111.402 -176.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 29.5 m -140.5 24.22 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -178.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 18.4 p -147.56 -166.37 2.5 Favored 'General case' 0 N--CA 1.455 -0.198 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 168.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.93 -82.0 0.99 Allowed Glycine 0 CA--C 1.525 0.705 0 N-CA-C 109.211 -1.556 . . . . 0.0 109.211 175.009 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 63.5 m-85 21.0 65.27 0.03 OUTLIER 'General case' 0 C--N 1.346 0.418 0 C-N-CA 128.452 2.701 . . . . 0.0 111.941 -175.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 23.4 mt -58.55 121.59 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.015 -173.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.554 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 35.2 t80 -73.29 138.12 45.27 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 173.282 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 62.1 t-20 -125.65 111.99 25.27 Favored Pre-proline 0 N--CA 1.454 -0.243 0 C-N-CA 123.975 0.91 . . . . 0.0 109.541 176.646 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -63.65 -39.69 33.73 Favored 'Trans proline' 0 N--CA 1.448 -1.204 0 C-N-CA 121.267 1.311 . . . . 0.0 111.355 -173.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -56.12 -32.82 64.57 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 117.977 0.353 . . . . 0.0 111.254 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -91.76 -29.84 16.57 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.453 0.701 . . . . 0.0 110.334 179.271 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 66.17 -159.0 47.63 Favored Glycine 0 CA--C 1.53 1.03 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -170.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.19 61.1 16.26 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 125.615 1.566 . . . . 0.0 107.393 171.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -61.59 -35.53 80.77 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.757 2.305 . . . . 0.0 111.451 -168.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -57.67 -31.38 66.28 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 124.875 1.27 . . . . 0.0 110.516 179.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 -92.21 -28.12 17.23 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 125.218 1.407 . . . . 0.0 110.469 -179.468 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.62 0.48 2.91 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.4 1.0 . . . . 0.0 113.205 171.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 75.2 t -100.97 111.08 29.52 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.206 0 CA-C-N 118.225 1.012 . . . . 0.0 109.002 -172.333 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -64.53 154.95 82.95 Favored Pre-proline 0 CA--C 1.533 0.308 0 O-C-N 121.765 -0.584 . . . . 0.0 110.929 -176.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -58.77 149.33 78.17 Favored 'Trans proline' 0 N--CA 1.449 -1.117 0 C-N-CA 121.425 1.416 . . . . 0.0 110.84 170.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.41 14.98 79.1 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 125.813 1.673 . . . . 0.0 113.082 -174.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.7 m -87.07 120.1 27.99 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 120.05 1.925 . . . . 0.0 107.871 178.343 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -59.81 134.45 57.04 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 172.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -43.04 -37.87 2.1 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 123.44 0.696 . . . . 0.0 112.176 169.356 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -68.13 -38.89 82.71 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 117.756 -1.578 . . . . 0.0 110.261 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -76.63 -17.57 59.09 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 124.989 1.316 . . . . 0.0 110.704 -175.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.554 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 23.0 mt -52.49 132.76 44.64 Favored Pre-proline 0 N--CA 1.445 -0.705 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -63.43 140.13 74.56 Favored 'Trans proline' 0 N--CA 1.445 -1.355 0 C-N-CA 122.234 1.956 . . . . 0.0 109.697 178.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 74.5 m-20 -69.98 -10.16 57.64 Favored 'General case' 0 N--CA 1.444 -0.772 0 C-N-CA 123.529 0.731 . . . . 0.0 111.914 -179.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -77.21 -12.02 59.89 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 124.232 1.013 . . . . 0.0 112.57 168.355 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -73.36 153.35 40.52 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 118.853 0.751 . . . . 0.0 110.303 177.646 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 97.4 t -137.02 150.01 26.44 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 125.573 1.549 . . . . 0.0 107.973 -171.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 13.2 t -79.48 130.63 67.61 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 124.854 1.262 . . . . 0.0 109.117 -176.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -64.98 147.91 89.37 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.461 2.108 . . . . 0.0 110.769 -178.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.2 mm? 68.8 -62.31 0.39 Allowed 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 126.323 1.849 . . . . 0.0 111.734 -179.495 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -59.03 -54.56 45.71 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 125.977 1.711 . . . . 0.0 110.787 178.354 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 106.84 -115.53 4.71 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -176.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.9 t -63.71 105.92 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 O-C-N 121.263 -1.139 . . . . 0.0 110.684 -167.437 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -130.74 -165.59 11.56 Favored Glycine 0 CA--C 1.527 0.809 0 C-N-CA 125.848 1.69 . . . . 0.0 109.323 178.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 55.22 61.74 2.78 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 123.112 1.434 . . . . 0.0 110.376 -173.723 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -156.19 157.49 35.98 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 156.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 45.09 37.83 2.79 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.117 1.767 . . . . 0.0 113.047 173.136 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 7.5 p90 -78.07 131.62 37.38 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 124.14 0.976 . . . . 0.0 110.335 -172.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -97.93 135.34 39.79 Favored 'General case' 0 C--O 1.227 -0.085 0 C-N-CA 123.929 0.892 . . . . 0.0 108.813 -179.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -72.66 138.18 46.52 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 176.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 32.2 t -105.53 105.81 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.054 0 C-N-CA 127.216 2.207 . . . . 0.0 105.418 176.579 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -81.91 54.17 2.39 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.427 1.091 . . . . 0.0 112.927 -173.574 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 . . . . . 0 C--O 1.251 1.143 0 C-N-CA 124.983 1.313 . . . . 0.0 109.617 176.508 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 21.9 mttm . . . . . 0 N--CA 1.454 -0.275 0 CA-C-O 122.438 1.113 . . . . 0.0 112.358 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 28.5 mtpt -72.57 170.27 14.76 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.824 -176.272 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 35.7 m-85 -149.12 145.69 27.33 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 -177.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 44.9 p -71.42 170.62 12.86 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.213 0.53 . . . . 0.0 112.152 170.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 2.2 t -108.26 166.63 10.61 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 126.998 2.119 . . . . 0.0 105.948 166.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 1.2 p -48.0 -50.3 28.01 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 124.683 1.193 . . . . 0.0 111.665 169.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 4.7 m -148.57 16.2 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 N-CA-C 114.111 1.152 . . . . 0.0 114.111 -173.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 79.7 m -109.18 119.6 40.02 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 119.945 1.248 . . . . 0.0 111.742 178.387 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -75.88 54.35 3.0 Favored Glycine 0 CA--C 1.532 1.137 0 O-C-N 121.55 -0.719 . . . . 0.0 111.411 172.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -111.54 -47.03 3.2 Favored 'General case' 0 N--CA 1.46 0.071 0 C-N-CA 124.556 1.142 . . . . 0.0 110.353 176.175 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 11.5 mt 71.32 128.06 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 C-N-CA 125.561 1.544 . . . . 0.0 111.491 -177.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.531 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 45.3 t80 -76.06 141.61 42.0 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 172.103 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 -125.77 115.58 24.6 Favored Pre-proline 0 N--CA 1.456 -0.174 0 C-N-CA 123.679 0.792 . . . . 0.0 110.421 175.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -67.48 -39.63 12.09 Favored 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 121.053 1.169 . . . . 0.0 111.695 -176.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -59.04 -31.08 68.53 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 118.585 0.63 . . . . 0.0 111.152 -178.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -88.47 -31.71 18.62 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 123.589 0.755 . . . . 0.0 110.023 176.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.9 -162.02 35.69 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -166.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -138.28 61.3 25.47 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 125.187 1.395 . . . . 0.0 107.735 171.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -62.8 -31.38 78.21 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 122.332 2.021 . . . . 0.0 111.154 -170.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -59.69 -30.65 68.93 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 123.864 0.866 . . . . 0.0 110.731 178.189 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -96.08 -28.07 14.78 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 124.87 1.268 . . . . 0.0 110.51 -178.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.71 16.96 0.97 Allowed Glycine 0 CA--C 1.531 1.081 0 C-N-CA 124.395 0.998 . . . . 0.0 113.992 169.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.1 t -116.72 112.29 38.72 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.304 0 CA-C-N 118.578 1.189 . . . . 0.0 109.006 -175.442 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.44 156.73 75.71 Favored Pre-proline 0 CA--C 1.533 0.316 0 O-C-N 121.898 -0.501 . . . . 0.0 111.136 -177.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -59.68 150.14 78.49 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 121.376 1.384 . . . . 0.0 110.802 170.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.57 16.32 79.06 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 125.816 1.674 . . . . 0.0 113.212 -175.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.9 m -89.48 118.56 29.22 Favored 'General case' 0 N--CA 1.445 -0.689 0 CA-C-N 119.923 1.862 . . . . 0.0 108.276 179.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -59.65 134.09 56.7 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 170.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -43.17 -37.04 1.92 Allowed 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 123.596 0.758 . . . . 0.0 112.731 170.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -68.76 -37.84 79.64 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 118.043 -1.463 . . . . 0.0 110.291 -178.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -77.29 -17.49 58.31 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 125.506 1.522 . . . . 0.0 110.462 -176.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.531 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.2 mt -55.81 133.56 72.77 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 173.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -62.97 137.1 60.44 Favored 'Trans proline' 0 N--CA 1.445 -1.359 0 C-N-CA 121.823 1.682 . . . . 0.0 108.98 175.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -71.43 -4.6 27.34 Favored 'General case' 0 N--CA 1.445 -0.683 0 O-C-N 121.95 -0.469 . . . . 0.0 111.728 -179.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.58 -22.65 63.51 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 125.034 1.333 . . . . 0.0 112.182 165.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 81.3 t90 -71.29 152.3 43.39 Favored 'General case' 0 N--CA 1.456 -0.174 0 O-C-N 121.484 -0.76 . . . . 0.0 111.237 -176.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.5 t -127.59 146.49 33.23 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 C-N-CA 125.72 1.608 . . . . 0.0 108.356 179.173 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -76.31 160.95 76.64 Favored Pre-proline 0 CA--C 1.538 0.519 0 C-N-CA 122.605 0.362 . . . . 0.0 110.158 -176.152 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -67.11 117.42 4.78 Favored 'Trans proline' 0 N--CA 1.45 -1.058 0 C-N-CA 121.9 1.733 . . . . 0.0 110.687 -170.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 50.5 mt 65.32 51.73 1.54 Allowed 'General case' 0 CA--C 1.534 0.33 0 C-N-CA 125.255 1.422 . . . . 0.0 111.623 177.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.0 t -142.9 -179.48 6.38 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 124.275 1.03 . . . . 0.0 108.539 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -107.19 -67.21 0.64 Allowed Glycine 0 CA--C 1.526 0.743 0 C-N-CA 124.504 1.05 . . . . 0.0 111.223 -175.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 25.2 m -72.66 164.03 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 CA-C-N 116.803 0.302 . . . . 0.0 110.201 -179.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -121.4 114.03 2.47 Favored Glycine 0 C--N 1.334 0.441 0 N-CA-C 110.396 -1.082 . . . . 0.0 110.396 -170.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mtpt 62.38 -88.02 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 125.412 1.485 . . . . 0.0 110.388 178.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 46.83 -72.48 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 128.799 2.84 . . . . 0.0 114.303 -172.219 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -127.92 116.78 20.63 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 126.014 1.725 . . . . 0.0 108.925 -176.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 4.9 p90 -149.99 112.68 4.77 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.194 1.397 . . . . 0.0 107.28 -171.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -82.91 145.53 29.35 Favored 'General case' 0 C--O 1.225 -0.225 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 44.9 tt0 -71.91 136.8 47.02 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 175.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.1 t -102.41 104.34 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 C-N-CA 126.248 1.819 . . . . 0.0 106.336 177.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -78.2 88.35 4.27 Favored 'General case' 0 N--CA 1.438 -1.03 0 CA-C-O 123.215 1.484 . . . . 0.0 109.125 172.182 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 . . . . . 0 C--O 1.257 1.483 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 158.701 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 51.2 mttm . . . . . 0 N--CA 1.453 -0.306 0 CA-C-O 121.877 0.846 . . . . 0.0 112.704 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -80.71 165.02 22.35 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -176.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -141.3 140.95 33.94 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 123.069 0.548 . . . . 0.0 111.069 178.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.3 t -99.4 140.88 32.92 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 113.084 0.772 . . . . 0.0 113.084 175.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.455 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 42.2 t -78.68 50.48 0.98 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.846 2.058 . . . . 0.0 109.399 177.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 5.7 m 53.84 -94.41 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.828 0 O-C-N 120.624 -1.297 . . . . 0.0 112.475 174.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.92 -28.93 5.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 125.246 1.418 . . . . 0.0 110.849 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.455 ' HB3' ' SG ' ' A' ' 6' ' ' CYS . 53.4 t -78.25 124.69 28.37 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 124.419 1.088 . . . . 0.0 109.44 -169.286 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -86.45 78.94 1.88 Allowed Glycine 0 CA--C 1.523 0.588 0 CA-C-O 119.211 -0.772 . . . . 0.0 111.283 -170.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -134.88 -57.76 0.82 Allowed 'General case' 0 CA--C 1.532 0.267 0 CA-C-N 117.796 0.798 . . . . 0.0 112.889 176.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 55.9 mt 75.22 121.25 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 126.637 1.975 . . . . 0.0 111.894 -173.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.548 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 77.2 t80 -83.22 138.23 33.7 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 169.482 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 55.1 t-20 -128.32 115.29 19.93 Favored Pre-proline 0 N--CA 1.454 -0.23 0 C-N-CA 124.582 1.153 . . . . 0.0 109.461 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.27 -39.48 17.55 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 121.779 1.653 . . . . 0.0 112.267 -172.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -55.13 -32.78 62.34 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 118.002 0.365 . . . . 0.0 110.749 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -95.06 -26.03 16.22 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 123.504 0.722 . . . . 0.0 109.9 -177.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.3 -157.46 36.58 Favored Glycine 0 CA--C 1.527 0.788 0 C-N-CA 124.684 1.135 . . . . 0.0 110.979 -170.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.76 62.31 12.23 Favored Pre-proline 0 CA--C 1.538 0.495 0 C-N-CA 125.062 1.345 . . . . 0.0 107.941 170.137 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -62.43 -33.34 79.65 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.697 2.264 . . . . 0.0 111.185 -170.264 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -56.76 -29.56 62.72 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 124.661 1.184 . . . . 0.0 110.728 178.376 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 -99.07 -30.8 12.11 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.267 1.427 . . . . 0.0 110.615 -177.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 140.15 7.49 0.95 Allowed Glycine 0 CA--C 1.531 1.077 0 C-N-CA 123.874 0.75 . . . . 0.0 114.061 169.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.48 HG23 ' CD1' ' A' ' 37' ' ' TRP . 45.6 t -106.58 112.52 40.02 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.217 0 CA-C-N 118.885 1.342 . . . . 0.0 109.04 -176.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -63.91 154.18 82.2 Favored Pre-proline 0 C--N 1.328 -0.351 0 O-C-N 121.982 -0.448 . . . . 0.0 110.585 -178.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -59.19 148.08 87.59 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 121.352 1.368 . . . . 0.0 110.771 170.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 77.77 15.59 81.09 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 124.819 1.2 . . . . 0.0 112.546 -176.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 97.2 m -89.18 118.87 29.19 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 119.698 1.749 . . . . 0.0 107.492 177.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -58.61 135.26 57.32 Favored 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 171.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.413 ' CD1' HD12 ' A' ' 33' ' ' ILE . 6.7 t80 -46.01 -34.66 4.18 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 123.173 0.589 . . . . 0.0 112.426 171.339 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.5 pttp -66.54 -40.02 88.86 Favored 'General case' 0 N--CA 1.453 -0.287 0 C-N-CA 118.076 -1.45 . . . . 0.0 110.083 179.69 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -80.62 -12.49 59.49 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.831 1.652 . . . . 0.0 110.588 -171.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.548 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 17.7 mt -57.2 132.67 80.82 Favored Pre-proline 0 N--CA 1.441 -0.877 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 172.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 1.2 Cg_endo -61.91 138.95 76.95 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 123.044 2.496 . . . . 0.0 109.904 178.072 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -64.66 -17.7 64.3 Favored 'General case' 0 N--CA 1.451 -0.397 0 O-C-N 121.819 -0.551 . . . . 0.0 112.024 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -75.54 -14.75 60.42 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 123.751 0.821 . . . . 0.0 112.696 173.363 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . 0.48 ' CD1' HG23 ' A' ' 24' ' ' VAL . 78.8 t90 -70.05 150.66 46.37 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.319 0.581 . . . . 0.0 111.2 -178.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 74.5 t -124.47 150.76 29.35 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 C-N-CA 125.656 1.582 . . . . 0.0 109.927 -173.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 49.8 t -57.86 136.66 83.41 Favored Pre-proline 0 CA--C 1.537 0.449 0 C-N-CA 125.844 1.658 . . . . 0.0 111.574 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -59.07 123.52 13.66 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 121.842 1.695 . . . . 0.0 110.14 173.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.2 mm? 66.71 21.79 10.5 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.701 1.201 . . . . 0.0 112.692 178.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -146.59 177.82 8.77 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 176.64 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -146.61 78.61 0.24 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -166.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.471 HG13 ' H ' ' A' ' 45' ' ' GLY . 7.2 p -143.58 -73.23 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 123.542 0.737 . . . . 0.0 109.928 179.163 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.471 ' H ' HG13 ' A' ' 44' ' ' VAL . . . 145.71 162.97 9.98 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 107.828 -2.109 . . . . 0.0 107.828 -173.547 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.5 ptmt -66.54 -18.7 65.51 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.836 1.318 . . . . 0.0 113.351 176.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 30.09 -93.74 0.01 OUTLIER 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 129.564 3.145 . . . . 0.0 111.964 -176.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.34 64.84 0.95 Allowed 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 166.034 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.3 m-30 -45.72 156.12 0.14 Allowed 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 125.093 1.357 . . . . 0.0 111.632 174.071 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -88.49 147.89 24.43 Favored 'General case' 0 C--O 1.225 -0.196 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 -175.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -74.55 141.49 44.79 Favored 'General case' 0 N--CA 1.442 -0.851 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.7 t -106.21 113.72 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.915 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 175.224 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -73.79 56.55 0.56 Allowed 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.546 1.539 . . . . 0.0 113.423 -178.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 . . . . . 0 C--O 1.254 1.338 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 158.363 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.4 mttm . . . . . 0 N--CA 1.452 -0.339 0 CA-C-O 122.039 0.923 . . . . 0.0 112.38 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 76.6 mttt -70.73 169.73 13.88 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.239 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 48.9 m-85 -147.65 142.74 27.09 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 118.636 -0.697 . . . . 0.0 110.815 -177.205 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.2 m -79.95 146.43 32.09 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 119.014 0.825 . . . . 0.0 109.811 172.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 46.6 t -67.45 176.01 2.53 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 166.642 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 90.0 m -76.4 -74.18 0.24 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.619 1.567 . . . . 0.0 112.297 -167.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 41.2 t -115.73 2.35 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 124.555 1.142 . . . . 0.0 110.557 177.547 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 10.4 t -80.58 -164.98 0.79 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.766 1.626 . . . . 0.0 108.725 -179.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -135.98 49.21 0.89 Allowed Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 44.3 m-85 -133.41 158.86 41.97 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.14 0.976 . . . . 0.0 110.168 179.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 13.8 mt -119.9 127.66 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 125.548 1.539 . . . . 0.0 108.224 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.535 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 25.0 t80 -78.39 140.21 38.73 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 124.807 1.243 . . . . 0.0 108.353 169.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 50.7 t-20 -124.81 111.87 27.29 Favored Pre-proline 0 N--CA 1.458 -0.072 0 C-N-CA 123.99 0.916 . . . . 0.0 109.963 176.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -63.73 -39.75 32.75 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 121.11 1.206 . . . . 0.0 111.59 -173.221 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -57.99 -31.92 67.39 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 118.052 0.387 . . . . 0.0 111.401 -179.065 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -86.88 -34.5 19.41 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 123.195 0.598 . . . . 0.0 109.787 177.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 58.43 -161.96 11.11 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -164.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -139.34 67.52 38.76 Favored Pre-proline 0 CA--C 1.535 0.396 0 C-N-CA 124.509 1.123 . . . . 0.0 108.299 169.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -58.63 -30.02 90.9 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.805 1.67 . . . . 0.0 110.855 -176.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 85.1 m-20 -60.2 -31.97 70.65 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 124.075 0.95 . . . . 0.0 110.753 178.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.2 m-80 -98.8 -24.19 15.1 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 124.136 0.974 . . . . 0.0 110.292 -177.016 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 133.11 10.65 1.92 Allowed Glycine 0 CA--C 1.531 1.046 0 C-N-CA 124.484 1.04 . . . . 0.0 113.251 171.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.3 t -110.0 109.87 30.04 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.273 0 CA-C-N 118.593 1.197 . . . . 0.0 109.298 -175.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -64.04 154.06 83.14 Favored Pre-proline 0 C--N 1.328 -0.356 0 O-C-N 121.803 -0.561 . . . . 0.0 110.754 -178.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_endo -59.13 146.88 92.97 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.317 1.345 . . . . 0.0 110.659 171.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.53 20.18 77.08 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 125.329 1.442 . . . . 0.0 112.699 -177.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 96.9 m -91.87 121.36 33.41 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 119.443 1.622 . . . . 0.0 107.869 176.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.5 t0 -62.96 136.81 58.04 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 171.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -44.66 -35.7 2.75 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 123.332 0.653 . . . . 0.0 112.455 171.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.6 pttp -67.89 -36.68 80.64 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 118.482 -1.287 . . . . 0.0 110.369 -179.109 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -80.68 -16.74 53.2 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.485 1.514 . . . . 0.0 110.277 -174.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.535 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 20.9 mt -55.39 134.22 70.09 Favored Pre-proline 0 N--CA 1.445 -0.719 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 173.584 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_endo -64.33 138.27 59.91 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 122.425 2.083 . . . . 0.0 109.616 176.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -66.09 -12.63 56.85 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 123.054 0.541 . . . . 0.0 111.943 178.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.15 -19.6 64.02 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.782 1.233 . . . . 0.0 112.337 171.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 74.8 t90 -66.31 156.64 33.82 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 121.748 0.785 . . . . 0.0 111.985 -176.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -129.88 149.81 33.99 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 C-N-CA 126.904 2.082 . . . . 0.0 109.815 -178.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 14.6 t -73.64 138.38 77.27 Favored Pre-proline 0 C--O 1.236 0.351 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 -175.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -56.82 111.5 0.82 Allowed 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.1 1.866 . . . . 0.0 110.084 178.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 15.3 mt 79.15 16.63 0.94 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.352 1.861 . . . . 0.0 112.231 179.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.9 t -147.92 99.7 3.11 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-O 123.19 1.471 . . . . 0.0 108.786 -174.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -78.33 52.9 3.83 Favored Glycine 0 CA--C 1.528 0.859 0 O-C-N 120.878 -1.139 . . . . 0.0 111.754 -177.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 51.7 t -99.5 -71.2 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 175.068 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 127.73 -163.42 21.43 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 33.5 mtpt -86.61 168.72 13.38 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 169.149 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -163.54 -82.93 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 124.738 1.215 . . . . 0.0 108.288 168.265 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.1 mm-40 -99.55 -49.75 4.3 Favored 'General case' 0 C--O 1.226 -0.156 0 C-N-CA 125.22 1.408 . . . . 0.0 110.184 -171.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 29.8 p90 49.32 92.43 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.194 1.798 . . . . 0.0 112.7 177.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 50.2 mt-10 -74.6 137.26 42.2 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 62.8 tt0 -75.93 134.75 40.15 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.197 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 24.5 t -101.47 115.99 44.25 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.127 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 175.337 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -70.82 55.46 0.17 Allowed 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 125.893 1.677 . . . . 0.0 114.174 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 . . . . . 0 C--O 1.253 1.264 0 C-N-CA 126.698 1.999 . . . . 0.0 107.593 161.925 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 18.7 mttt . . . . . 0 N--CA 1.453 -0.295 0 CA-C-O 122.004 0.907 . . . . 0.0 112.979 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -76.27 167.98 20.87 Favored 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 115.085 -0.961 . . . . 0.0 109.649 -176.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -148.24 135.98 20.81 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 122.748 0.419 . . . . 0.0 112.11 -178.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 19.9 m -75.4 134.95 40.8 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 119.311 -0.376 . . . . 0.0 111.118 169.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 36.6 t -68.85 140.37 55.21 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.284 0.634 . . . . 0.0 110.187 170.795 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 75.1 p -25.84 -82.36 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 129.661 3.185 . . . . 0.0 114.899 -175.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.1 m -127.41 54.97 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 C-N-CA 125.347 1.459 . . . . 0.0 108.535 -172.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 37.3 t -141.09 -78.09 0.28 Allowed 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.3 -161.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 131.23 -33.11 2.85 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.334 -0.707 . . . . 0.0 111.334 -176.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 28.0 m-85 -57.09 139.79 51.3 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-N 118.352 1.076 . . . . 0.0 110.051 177.161 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.7 mt -106.1 120.01 56.38 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.242 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.518 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.542 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 44.9 t80 -72.49 138.38 46.97 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 169.714 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 53.8 t-20 -124.25 112.18 28.21 Favored Pre-proline 0 N--CA 1.455 -0.215 0 C-N-CA 124.08 0.952 . . . . 0.0 109.59 175.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -63.18 -39.2 40.13 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 C-N-CA 121.137 1.225 . . . . 0.0 112.082 -172.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -58.91 -31.56 68.75 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 117.751 0.251 . . . . 0.0 111.205 -179.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -87.76 -32.06 19.32 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.472 0.709 . . . . 0.0 109.877 177.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.32 -159.03 41.74 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -167.296 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.49 61.38 16.13 Favored Pre-proline 0 CA--C 1.539 0.544 0 C-N-CA 125.556 1.542 . . . . 0.0 107.763 171.31 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -62.7 -30.04 78.05 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 122.404 2.069 . . . . 0.0 111.329 -170.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -61.18 -29.6 69.9 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 123.922 0.889 . . . . 0.0 110.383 179.111 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -96.63 -28.32 14.4 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 125.232 1.413 . . . . 0.0 110.687 -178.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.52 12.78 1.35 Allowed Glycine 0 CA--C 1.531 1.092 0 C-N-CA 124.296 0.951 . . . . 0.0 113.673 169.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.3 t -110.02 111.01 34.25 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.208 0 CA-C-N 118.447 1.124 . . . . 0.0 108.464 -175.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -64.3 155.34 80.32 Favored Pre-proline 0 CA--C 1.535 0.382 0 O-C-N 121.787 -0.571 . . . . 0.0 110.981 -177.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.57 149.55 81.55 Favored 'Trans proline' 0 N--CA 1.449 -1.093 0 C-N-CA 121.399 1.399 . . . . 0.0 110.944 171.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 74.08 15.69 79.82 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 125.125 1.345 . . . . 0.0 112.848 -175.185 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 76.3 m -87.98 119.27 28.18 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 119.813 1.806 . . . . 0.0 107.183 177.56 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -61.07 137.65 58.23 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 172.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -46.33 -35.76 5.69 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 123.346 0.658 . . . . 0.0 111.71 172.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 54.2 pttt -68.2 -39.2 82.49 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 118.232 -1.387 . . . . 0.0 110.205 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -73.26 -21.16 60.68 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 125.126 1.37 . . . . 0.0 110.164 -175.193 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.542 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.3 mt -53.23 133.97 51.25 Favored Pre-proline 0 N--CA 1.446 -0.665 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 176.538 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -66.13 139.58 56.18 Favored 'Trans proline' 0 N--CA 1.444 -1.434 0 C-N-CA 122.093 1.862 . . . . 0.0 109.658 178.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -67.91 -9.17 42.85 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 123.806 0.843 . . . . 0.0 111.546 177.602 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -73.15 -22.69 60.47 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.779 1.232 . . . . 0.0 112.061 169.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 81.1 t90 -69.69 152.83 44.22 Favored 'General case' 0 N--CA 1.455 -0.221 0 O-C-N 121.628 -0.67 . . . . 0.0 110.464 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 99.2 t -131.87 152.69 37.34 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 C-N-CA 124.887 1.275 . . . . 0.0 108.862 -178.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 20.1 t -69.21 140.44 90.62 Favored Pre-proline 0 CA--C 1.54 0.568 0 C-N-CA 124.526 1.131 . . . . 0.0 110.425 -177.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -63.09 118.59 5.5 Favored 'Trans proline' 0 N--CA 1.452 -0.922 0 C-N-CA 122.575 2.183 . . . . 0.0 111.305 175.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 13.2 mt 70.19 43.54 0.85 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.85 1.26 . . . . 0.0 111.176 170.053 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 53.7 t -153.61 176.05 12.52 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 106.117 -1.808 . . . . 0.0 106.117 -171.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -80.42 -156.74 13.69 Favored Glycine 0 CA--C 1.528 0.867 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 173.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.9 m -51.98 126.93 8.2 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 O-C-N 122.099 -0.647 . . . . 0.0 109.632 171.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -126.2 -175.66 14.24 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 58.57 78.32 0.26 Allowed 'General case' 0 CA--C 1.537 0.446 0 CA-C-O 122.471 1.129 . . . . 0.0 110.444 -172.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -153.81 -99.68 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 114.174 -1.376 . . . . 0.0 107.653 168.635 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -76.39 60.74 1.6 Allowed 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 119.4 1.0 . . . . 0.0 111.493 178.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -75.93 146.1 39.93 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 121.441 -0.787 . . . . 0.0 109.911 173.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -114.38 141.53 47.52 Favored 'General case' 0 N--CA 1.464 0.232 0 C-N-CA 124.235 1.014 . . . . 0.0 108.592 175.409 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -77.54 138.58 39.26 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 29.9 t -103.65 104.5 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 C-N-CA 126.021 1.728 . . . . 0.0 107.039 178.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -77.12 57.72 1.44 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.639 1.576 . . . . 0.0 112.618 179.548 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 . . . . . 0 C--O 1.255 1.367 0 CA-C-O 117.349 -1.31 . . . . 0.0 108.446 156.776 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 40.4 mttm . . . . . 0 N--CA 1.455 -0.208 0 CA-C-O 122.056 0.931 . . . . 0.0 112.402 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 55.7 mttt -82.12 167.71 18.47 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.499 -171.425 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -146.92 136.17 22.64 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 113.411 0.893 . . . . 0.0 113.411 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.7 m -80.98 147.89 30.01 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 123.89 0.876 . . . . 0.0 111.695 169.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 36.1 t -79.31 14.65 1.46 Allowed 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 125.19 1.396 . . . . 0.0 112.631 175.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.8 m 65.64 -72.37 0.07 Allowed 'General case' 0 CA--C 1.538 0.511 0 O-C-N 119.413 -2.054 . . . . 0.0 112.588 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 69.4 t -70.54 -61.88 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 C-N-CA 123.968 0.907 . . . . 0.0 109.123 -174.341 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 8.1 p -95.41 173.58 7.45 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 172.541 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -72.74 -73.3 0.87 Allowed Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.141 -1.584 . . . . 0.0 109.141 177.174 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 22.19 63.88 0.03 OUTLIER 'General case' 0 C--N 1.345 0.408 0 C-N-CA 127.785 2.434 . . . . 0.0 111.93 -172.346 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.1 mt -62.38 115.05 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 CA-C-N 115.38 -0.827 . . . . 0.0 109.617 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.54 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 41.2 t80 -68.59 129.03 38.72 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 172.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 49.8 t-20 -117.36 111.25 40.2 Favored Pre-proline 0 N--CA 1.455 -0.176 0 C-N-CA 123.76 0.824 . . . . 0.0 109.212 175.044 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.11 -38.32 46.35 Favored 'Trans proline' 0 N--CA 1.448 -1.189 0 C-N-CA 121.015 1.143 . . . . 0.0 111.386 -174.355 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 -57.92 -32.63 67.95 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 117.959 0.345 . . . . 0.0 111.098 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -88.15 -32.14 18.8 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.591 0.756 . . . . 0.0 109.98 177.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.5 -159.4 41.87 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.821 -0.911 . . . . 0.0 110.821 -167.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.58 61.05 14.96 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 125.441 1.496 . . . . 0.0 107.732 171.37 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -62.75 -32.4 78.18 Favored 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.438 2.092 . . . . 0.0 111.393 -169.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -59.68 -30.73 68.97 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 123.986 0.914 . . . . 0.0 110.642 178.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -94.34 -28.55 15.49 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 125.115 1.366 . . . . 0.0 110.515 -178.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.72 13.67 1.22 Allowed Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.413 1.006 . . . . 0.0 113.739 169.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 54.7 t -112.45 111.61 36.9 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.285 0 CA-C-N 118.45 1.125 . . . . 0.0 108.602 -174.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -64.12 155.15 80.1 Favored Pre-proline 0 CA--C 1.533 0.304 0 O-C-N 121.708 -0.62 . . . . 0.0 111.132 -176.156 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.2 149.5 80.08 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.127 1.218 . . . . 0.0 110.589 169.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 68.87 20.29 74.29 Favored Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.402 1.477 . . . . 0.0 112.885 -173.001 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 65.1 m -88.03 120.78 29.71 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 120.058 1.929 . . . . 0.0 107.558 174.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -59.75 134.08 56.7 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 172.312 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -42.2 -38.35 1.72 Allowed 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.126 0.57 . . . . 0.0 112.092 168.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 57.9 pttt -67.32 -41.72 84.81 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 117.579 -1.649 . . . . 0.0 110.185 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -71.83 -19.28 62.0 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 125.586 1.554 . . . . 0.0 110.577 -174.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.54 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.0 mt -52.52 133.11 44.86 Favored Pre-proline 0 N--CA 1.443 -0.802 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 173.663 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -65.17 141.48 69.59 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 122.275 1.984 . . . . 0.0 110.113 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.2 -15.95 60.98 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 124.198 0.999 . . . . 0.0 111.912 177.279 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -66.83 -22.83 65.99 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.268 1.027 . . . . 0.0 112.181 170.683 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 89.2 t90 -78.35 149.16 33.48 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-O 121.628 0.727 . . . . 0.0 111.102 -174.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 2.2 m -126.99 156.29 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 C-N-CA 125.847 1.659 . . . . 0.0 109.892 -174.03 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 7.7 t -63.36 137.09 96.98 Favored Pre-proline 0 CA--C 1.543 0.689 0 C-N-CA 122.958 0.503 . . . . 0.0 110.347 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -69.6 95.81 0.55 Allowed 'Trans proline' 0 N--CA 1.451 -1.022 0 C-N-CA 123.128 2.552 . . . . 0.0 110.66 -178.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 56.3 mt 85.42 59.11 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 126.813 2.045 . . . . 0.0 111.058 173.293 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 13.1 t -147.22 -94.67 0.09 Allowed 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -176.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 157.38 -41.85 0.53 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.4 t -70.5 148.0 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.97 177.7 49.8 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 176.321 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.9 ptmt -65.38 106.44 1.38 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 165.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -138.85 -65.84 0.49 Allowed 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 173.708 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -101.13 106.51 17.77 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 -178.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -142.29 128.7 20.07 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 51.7 mt-10 -104.2 141.88 35.49 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 124.443 1.097 . . . . 0.0 108.606 -175.221 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -75.49 142.69 42.85 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 119.913 1.233 . . . . 0.0 109.73 -179.354 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.2 t -112.38 106.56 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 C-N-CA 127.629 2.372 . . . . 0.0 106.737 177.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -82.93 53.74 2.52 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 124.968 1.307 . . . . 0.0 113.372 -173.261 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 . . . . . 0 C--O 1.25 1.095 0 C-N-CA 124.451 1.1 . . . . 0.0 110.256 179.762 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.0 mttm . . . . . 0 N--CA 1.451 -0.378 0 CA-C-O 122.121 0.962 . . . . 0.0 113.012 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -78.0 163.13 26.22 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.595 -178.372 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -138.31 140.51 39.58 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 118.971 -0.538 . . . . 0.0 109.852 175.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.3 t -90.69 160.31 15.92 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 118.014 0.37 . . . . 0.0 111.151 173.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 51.5 t -81.37 -121.01 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 125.558 1.543 . . . . 0.0 107.452 175.435 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 12.6 t -160.49 -46.08 0.05 OUTLIER 'General case' 0 CA--C 1.535 0.368 0 O-C-N 121.427 -0.796 . . . . 0.0 110.415 -175.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.5 p -104.65 -66.75 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 C-N-CA 123.42 0.688 . . . . 0.0 111.271 179.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.5 p -67.59 -38.77 84.5 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 123.713 0.805 . . . . 0.0 110.626 -176.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.73 31.03 30.77 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 179.197 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 18.6 m-85 -65.76 87.21 0.09 Allowed 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 117.742 0.771 . . . . 0.0 109.439 168.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.4 mt -57.44 111.04 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 C-N-CA 123.293 0.637 . . . . 0.0 109.293 172.4 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.544 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 20.1 t80 -73.69 133.37 43.37 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 173.203 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 50.7 t-20 -121.45 112.78 32.52 Favored Pre-proline 0 N--CA 1.455 -0.191 0 C-N-CA 124.255 1.022 . . . . 0.0 109.753 177.613 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -62.85 -38.83 45.51 Favored 'Trans proline' 0 N--CA 1.45 -1.03 0 C-N-CA 121.474 1.449 . . . . 0.0 112.083 -171.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -58.75 -32.31 69.15 Favored 'General case' 0 N--CA 1.446 -0.625 0 O-C-N 123.151 0.282 . . . . 0.0 111.059 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -87.46 -31.38 20.05 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.494 0.717 . . . . 0.0 109.92 177.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.11 -157.36 43.32 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -166.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.31 61.57 12.08 Favored Pre-proline 0 CA--C 1.54 0.588 0 C-N-CA 125.457 1.503 . . . . 0.0 107.455 171.035 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -61.87 -33.86 83.43 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.62 2.213 . . . . 0.0 111.2 -169.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -56.1 -30.48 62.13 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 125.438 1.495 . . . . 0.0 110.66 178.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.0 m-80 -97.02 -32.84 11.79 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 125.531 1.533 . . . . 0.0 110.432 -177.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 139.39 11.24 0.77 Allowed Glycine 0 CA--C 1.53 1.013 0 C-N-CA 123.898 0.761 . . . . 0.0 114.015 171.106 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 68.6 t -109.31 112.18 39.36 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.215 0 CA-C-N 118.898 1.349 . . . . 0.0 108.791 -176.608 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.19 154.35 82.97 Favored Pre-proline 0 CA--C 1.533 0.306 0 O-C-N 121.91 -0.494 . . . . 0.0 110.904 -177.564 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -58.38 147.02 87.55 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 121.408 1.405 . . . . 0.0 110.947 170.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 77.04 15.39 81.69 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 125.051 1.31 . . . . 0.0 112.838 -176.326 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 98.7 m -87.78 117.48 26.65 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 119.956 1.878 . . . . 0.0 107.421 177.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -57.86 135.48 56.86 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 171.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -43.88 -36.95 2.59 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 123.389 0.676 . . . . 0.0 112.154 170.421 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -66.51 -39.98 88.96 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 118.017 -1.473 . . . . 0.0 110.066 -178.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -80.04 -12.86 59.66 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 125.718 1.607 . . . . 0.0 110.741 -172.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.544 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.5 mt -56.36 132.8 76.24 Favored Pre-proline 0 N--CA 1.444 -0.752 0 CA-C-O 118.356 -0.831 . . . . 0.0 108.949 174.221 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -54.89 136.26 71.53 Favored 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 124.152 3.235 . . . . 0.0 110.551 176.555 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.73 -18.44 63.52 Favored 'General case' 0 CA--C 1.533 0.296 0 O-C-N 121.352 -0.843 . . . . 0.0 111.319 -179.482 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -76.55 -11.48 59.88 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 125.876 1.67 . . . . 0.0 112.104 171.092 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -71.65 149.77 45.24 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 119.07 0.85 . . . . 0.0 110.526 176.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 2.1 m -128.39 153.45 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 C-N-CA 126.082 1.753 . . . . 0.0 109.881 -175.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 8.2 t -73.71 138.48 77.05 Favored Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 123.658 0.783 . . . . 0.0 111.042 -175.079 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -58.64 127.53 24.88 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 123.416 2.744 . . . . 0.0 111.77 -177.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 24.5 mt 54.65 34.89 22.5 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.688 1.195 . . . . 0.0 111.857 -179.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.1 t -131.93 -176.22 3.99 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -139.01 47.57 0.91 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.036 -0.825 . . . . 0.0 111.036 -175.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -155.65 156.98 4.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 177.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.78 -179.6 50.03 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 178.405 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.8 ptmt -62.69 -19.56 64.0 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 170.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 29.26 -94.42 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 129.408 3.083 . . . . 0.0 111.529 -176.258 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.1 mm-40 -145.91 69.93 1.23 Allowed 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 164.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.4 m-30 -47.73 156.26 0.33 Allowed 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 125.656 1.582 . . . . 0.0 110.375 169.18 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -94.82 147.46 23.32 Favored 'General case' 0 C--O 1.225 -0.236 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -172.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -75.05 143.9 43.26 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 118.726 0.693 . . . . 0.0 109.198 -179.308 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 11.0 t -107.95 110.88 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 C-N-CA 126.121 1.768 . . . . 0.0 106.494 177.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -76.03 55.29 0.91 Allowed 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 125.454 1.502 . . . . 0.0 113.272 -177.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 117.231 -1.366 . . . . 0.0 108.085 158.569 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 56.4 mttm . . . . . 0 N--CA 1.451 -0.399 0 N-CA-C 113.351 0.871 . . . . 0.0 113.351 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -77.71 163.65 25.97 Favored 'General case' 0 N--CA 1.447 -0.591 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.201 -179.514 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 23.6 m-85 -144.55 146.69 32.49 Favored 'General case' 0 CA--C 1.528 0.124 0 CA-C-O 119.046 -0.502 . . . . 0.0 110.732 176.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.5 t -99.0 143.48 29.24 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 174.251 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.452 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 48.9 t -82.65 120.23 25.3 Favored 'General case' 0 C--N 1.344 0.346 0 C-N-CA 126.678 1.991 . . . . 0.0 109.963 177.745 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 20.2 m -41.6 -76.18 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 127.617 2.367 . . . . 0.0 114.063 -175.256 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.2 p -99.7 48.5 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 O-C-N 121.233 -0.917 . . . . 0.0 109.653 -168.024 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.452 ' HB3' ' SG ' ' A' ' 6' ' ' CYS . 46.6 t -160.95 -60.95 0.06 Allowed 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -160.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.7 -13.48 63.9 Favored Glycine 0 CA--C 1.53 1.007 0 CA-C-O 119.025 -0.875 . . . . 0.0 113.137 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -59.19 143.32 49.33 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 119.42 1.61 . . . . 0.0 109.902 173.22 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 18.2 mt -112.04 121.22 64.07 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 123.89 0.876 . . . . 0.0 109.148 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.494 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 68.3 t80 -80.93 140.76 35.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 172.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 64.9 t-20 -124.68 120.1 25.79 Favored Pre-proline 0 C--O 1.224 -0.278 0 C-N-CA 124.252 1.021 . . . . 0.0 109.732 177.853 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -68.65 -40.49 7.35 Favored 'Trans proline' 0 N--CA 1.442 -1.507 0 C-N-CA 120.697 0.932 . . . . 0.0 112.122 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -60.4 -31.05 70.0 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 119.155 0.889 . . . . 0.0 110.95 -177.363 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.2 m-20 -90.11 -29.52 18.27 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.336 0.655 . . . . 0.0 109.967 177.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.48 -160.05 40.86 Favored Glycine 0 CA--C 1.529 0.951 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -165.615 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -139.64 62.43 23.17 Favored Pre-proline 0 CA--C 1.538 0.498 0 C-N-CA 125.181 1.393 . . . . 0.0 107.679 169.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -61.64 -32.12 86.99 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.345 2.03 . . . . 0.0 111.137 -171.244 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -57.05 -31.69 65.44 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.898 1.279 . . . . 0.0 110.587 178.39 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -95.43 -32.7 12.78 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.15 1.38 . . . . 0.0 110.483 -178.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.83 14.67 0.66 Allowed Glycine 0 CA--C 1.531 1.08 0 C-N-CA 124.053 0.835 . . . . 0.0 114.108 170.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.438 HG23 ' CD1' ' A' ' 37' ' ' TRP . 46.6 t -112.9 112.7 41.54 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.264 0 CA-C-N 118.808 1.304 . . . . 0.0 109.053 -176.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -64.58 155.94 79.62 Favored Pre-proline 0 C--N 1.328 -0.338 0 O-C-N 121.967 -0.458 . . . . 0.0 111.116 -177.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.64 148.29 88.27 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 121.569 1.513 . . . . 0.0 110.981 171.489 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.94 17.25 79.34 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 125.296 1.427 . . . . 0.0 112.662 -175.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 93.3 m -87.76 117.65 26.73 Favored 'General case' 0 N--CA 1.442 -0.875 0 CA-C-N 119.838 1.819 . . . . 0.0 107.59 176.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -58.1 134.35 56.37 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.401 171.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -40.47 -40.08 1.14 Allowed 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 123.901 0.88 . . . . 0.0 112.415 169.069 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.2 pttp -68.48 -38.29 80.9 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 118.295 -1.362 . . . . 0.0 109.973 -176.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -78.34 -15.62 58.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.805 1.642 . . . . 0.0 110.3 -174.358 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.494 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.4 mt -54.97 133.9 67.42 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-O 118.389 -0.815 . . . . 0.0 109.308 174.727 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 10.2 Cg_exo -57.69 137.3 80.53 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 123.597 2.865 . . . . 0.0 110.883 176.18 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -66.03 -18.43 65.33 Favored 'General case' 0 N--CA 1.45 -0.459 0 O-C-N 121.299 -0.875 . . . . 0.0 111.426 176.635 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -82.93 -6.21 59.37 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.563 1.545 . . . . 0.0 111.944 173.699 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . 0.438 ' CD1' HG23 ' A' ' 24' ' ' VAL . 71.0 t90 -69.94 160.43 31.89 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 119.053 0.842 . . . . 0.0 110.093 172.474 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -139.5 150.17 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 C-N-CA 125.585 1.554 . . . . 0.0 108.465 176.656 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.4 p -83.68 165.27 40.75 Favored Pre-proline 0 CA--C 1.539 0.557 0 N-CA-C 108.785 -0.821 . . . . 0.0 108.785 -179.182 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.51 124.13 9.61 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 121.301 1.334 . . . . 0.0 110.842 -168.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 12.6 mt 66.29 44.17 2.56 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 125.258 1.423 . . . . 0.0 112.201 172.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.3 t -138.45 179.63 6.35 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.913 0.885 . . . . 0.0 108.818 -177.345 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -100.98 -87.81 1.99 Allowed Glycine 0 CA--C 1.526 0.72 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 178.047 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.6 p -82.99 102.2 8.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 178.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -108.54 145.82 16.44 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 108.751 -1.74 . . . . 0.0 108.751 176.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER 59.5 101.78 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.42 1.488 . . . . 0.0 111.749 -170.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -138.8 -75.73 0.37 Allowed 'General case' 0 CA--C 1.521 -0.139 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 160.341 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 10.3 tm0? -144.69 55.34 1.25 Allowed 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 124.739 1.216 . . . . 0.0 107.846 -174.575 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 4.1 m-30 -55.51 150.99 11.09 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 125.059 1.343 . . . . 0.0 108.894 175.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -87.39 150.86 23.53 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.491 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -78.83 145.84 34.04 Favored 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 123.676 0.791 . . . . 0.0 109.088 179.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 14.5 t -110.84 111.44 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 C-N-CA 126.622 1.969 . . . . 0.0 107.081 174.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -71.86 67.09 0.59 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.305 1.842 . . . . 0.0 113.116 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 . . . . . 0 C--O 1.255 1.372 0 CA-C-O 117.86 -1.067 . . . . 0.0 111.098 164.514 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 7.9 mttm . . . . . 0 N--CA 1.449 -0.519 0 CA-C-O 121.61 0.719 . . . . 0.0 111.586 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 78.7 mttt -73.9 174.6 8.29 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 124.907 1.283 . . . . 0.0 109.46 174.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -144.32 131.03 20.13 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-O 118.831 -0.604 . . . . 0.0 111.628 176.419 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.6 m -79.87 143.72 34.07 Favored 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 123.872 0.869 . . . . 0.0 110.811 174.429 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.406 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 9.0 t -70.43 -175.68 1.07 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.209 1.404 . . . . 0.0 109.569 168.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 63.5 m -82.29 -99.26 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 123.688 0.795 . . . . 0.0 110.06 -176.612 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.8 p -87.33 -30.69 5.76 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 O-C-N 120.967 -1.083 . . . . 0.0 110.85 -178.071 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . 0.406 ' HB3' ' SG ' ' A' ' 6' ' ' CYS . 50.8 t -39.62 -55.48 1.86 Allowed 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 128.931 2.892 . . . . 0.0 112.365 175.247 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 100.91 -15.06 58.48 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-O 119.043 -0.865 . . . . 0.0 113.279 177.404 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -62.38 159.32 15.57 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.307 1.553 . . . . 0.0 111.574 176.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 28.7 mt -123.4 124.94 70.87 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 C-N-CA 125.227 1.411 . . . . 0.0 107.282 175.376 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.504 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 72.5 t80 -78.28 135.38 37.53 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 167.872 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -118.01 116.75 35.83 Favored Pre-proline 0 C--O 1.225 -0.204 0 C-N-CA 124.24 1.016 . . . . 0.0 109.948 175.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -64.82 -42.57 14.66 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 121.927 1.751 . . . . 0.0 111.793 -178.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -61.98 -28.61 69.68 Favored 'General case' 0 N--CA 1.446 -0.658 0 O-C-N 123.27 0.356 . . . . 0.0 110.862 -174.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -90.63 -31.62 16.58 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.997 0.919 . . . . 0.0 110.399 174.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.98 -162.07 31.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.289 0.947 . . . . 0.0 110.984 -165.177 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -137.94 62.27 32.58 Favored Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 125.894 1.678 . . . . 0.0 107.485 171.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.1 -33.32 82.66 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 122.75 2.3 . . . . 0.0 111.28 -170.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -56.79 -28.99 62.25 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.674 1.189 . . . . 0.0 110.738 178.634 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.6 m-80 -102.11 -26.47 13.35 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 125.607 1.563 . . . . 0.0 110.684 -175.516 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.81 6.86 1.68 Allowed Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.167 0.889 . . . . 0.0 113.786 168.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 75.7 t -107.58 109.87 29.77 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.156 0 CA-C-N 118.595 1.198 . . . . 0.0 108.509 -174.332 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.87 155.97 81.25 Favored Pre-proline 0 C--N 1.329 -0.321 0 O-C-N 121.734 -0.604 . . . . 0.0 111.086 -176.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.32 147.68 89.91 Favored 'Trans proline' 0 N--CA 1.449 -1.102 0 C-N-CA 121.496 1.464 . . . . 0.0 111.032 171.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.28 14.98 81.8 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.682 -176.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 99.2 m -86.67 113.72 22.77 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 119.798 1.799 . . . . 0.0 107.546 178.042 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -53.4 133.26 40.44 Favored 'General case' 0 N--CA 1.446 -0.654 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 167.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.425 ' CD1' HD12 ' A' ' 33' ' ' ILE . 5.1 t80 -45.2 -31.84 1.64 Allowed 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 173.758 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 7.3 pttt -68.57 -45.65 71.49 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 118.398 -1.321 . . . . 0.0 110.065 179.538 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -67.58 -19.51 65.27 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 125.58 1.552 . . . . 0.0 111.222 -175.59 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.504 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 15.2 mt -53.29 131.37 52.27 Favored Pre-proline 0 N--CA 1.443 -0.812 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 176.089 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_endo -61.96 140.34 84.21 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 122.393 2.062 . . . . 0.0 109.455 -178.432 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -67.35 -14.38 62.87 Favored 'General case' 0 CA--C 1.535 0.373 0 O-C-N 121.968 -0.457 . . . . 0.0 111.87 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -75.34 -15.07 60.51 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.491 0.716 . . . . 0.0 112.204 171.545 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 85.5 t90 -73.7 151.8 40.62 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 176.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 12.1 p -141.29 164.61 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 C-N-CA 124.927 1.291 . . . . 0.0 107.777 -177.345 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . 0.416 ' SG ' ' HD2' ' A' ' 40' ' ' PRO . 4.3 t -48.79 138.86 12.17 Favored Pre-proline 0 CA--C 1.54 0.561 0 C-N-CA 124.391 1.076 . . . . 0.0 110.111 176.606 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . 0.416 ' HD2' ' SG ' ' A' ' 39' ' ' CYS . 39.2 Cg_endo -59.89 -36.88 89.11 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.323 2.015 . . . . 0.0 112.881 -173.391 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 41.0 mt -136.95 42.11 2.45 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.301 0.641 . . . . 0.0 110.096 -175.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -164.71 173.68 11.59 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 -174.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -133.35 67.84 0.55 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 -174.14 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.7 p -128.92 141.42 46.66 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 172.289 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.38 147.84 49.18 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 6.2 ptmt -60.19 -38.52 83.52 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 117.226 0.513 . . . . 0.0 111.549 -179.472 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -72.35 71.63 0.91 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 124.295 1.038 . . . . 0.0 109.682 178.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 4.0 tp-100 -171.92 -38.66 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 125.728 1.611 . . . . 0.0 109.666 -175.524 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -57.84 137.21 56.86 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.048 0.939 . . . . 0.0 109.636 -176.777 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -96.01 149.49 21.52 Favored 'General case' 0 C--O 1.22 -0.496 0 C-N-CA 124.627 1.171 . . . . 0.0 109.364 -175.104 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -71.93 138.49 48.14 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 119.883 1.219 . . . . 0.0 110.039 -178.381 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.3 t -101.2 107.86 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 C-N-CA 125.467 1.507 . . . . 0.0 107.08 177.25 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -72.06 65.95 0.59 Allowed 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 126.348 1.859 . . . . 0.0 113.397 -177.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 . . . . . 0 C--O 1.257 1.467 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 150.768 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 9.6 mttm . . . . . 0 N--CA 1.448 -0.531 0 CA-C-O 121.449 0.643 . . . . 0.0 111.494 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 58.2 mttt -71.02 171.33 11.05 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 124.678 1.191 . . . . 0.0 109.862 172.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -141.69 134.35 28.48 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 172.77 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.5 t -85.8 154.53 21.52 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 118.312 0.506 . . . . 0.0 111.282 174.281 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 19.9 t -75.01 170.2 16.48 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 125.15 1.38 . . . . 0.0 107.852 172.639 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 6.9 t -125.72 16.7 8.09 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.063 0.945 . . . . 0.0 110.497 177.248 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 74.1 t -132.5 -60.54 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.34 0.179 0 C-N-CA 123.932 0.893 . . . . 0.0 109.52 -179.1 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.6 p -95.92 -89.31 0.26 Allowed 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 176.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 164.12 28.95 0.02 OUTLIER Glycine 0 CA--C 1.529 0.94 0 C-N-CA 125.487 1.518 . . . . 0.0 110.638 176.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -80.73 73.66 7.69 Favored 'General case' 0 N--CA 1.453 -0.322 0 O-C-N 121.819 -0.812 . . . . 0.0 108.83 -170.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.0 mt -45.35 112.52 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 C-N-CA 123.33 0.652 . . . . 0.0 110.978 -178.484 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.538 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 35.7 t80 -73.53 134.44 43.82 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 173.041 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 46.3 t-20 -123.07 114.63 29.35 Favored Pre-proline 0 N--CA 1.446 -0.652 0 C-N-CA 123.437 0.695 . . . . 0.0 109.387 176.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -65.36 -43.77 10.21 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 122.317 2.012 . . . . 0.0 111.327 -177.256 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -56.84 -29.39 62.79 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 123.636 0.774 . . . . 0.0 111.226 -176.679 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -100.45 -23.41 14.74 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.879 0.872 . . . . 0.0 110.455 179.033 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.11 -160.59 30.73 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 124.829 1.204 . . . . 0.0 110.983 -172.333 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -140.34 61.4 16.69 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 125.281 1.432 . . . . 0.0 107.497 171.719 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_endo -62.38 -30.86 81.14 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 122.199 1.933 . . . . 0.0 111.076 -172.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -59.02 -29.65 67.43 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 124.463 1.105 . . . . 0.0 110.337 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -98.81 -29.29 13.06 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 125.544 1.537 . . . . 0.0 110.964 -177.154 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.36 18.24 0.93 Allowed Glycine 0 CA--C 1.532 1.15 0 C-N-CA 124.249 0.928 . . . . 0.0 113.798 170.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.2 t -117.26 110.02 29.71 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.216 0 CA-C-N 118.334 1.067 . . . . 0.0 108.443 -175.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -63.36 155.76 73.14 Favored Pre-proline 0 CA--C 1.534 0.337 0 O-C-N 121.835 -0.541 . . . . 0.0 110.976 -177.253 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -60.54 149.37 87.16 Favored 'Trans proline' 0 N--CA 1.449 -1.129 0 C-N-CA 121.464 1.443 . . . . 0.0 110.717 171.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.04 14.93 81.76 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 125.129 1.347 . . . . 0.0 113.047 -175.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 97.8 m -89.34 114.89 26.36 Favored 'General case' 0 N--CA 1.443 -0.815 0 CA-C-N 119.919 1.86 . . . . 0.0 107.836 178.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -56.17 134.72 53.15 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 169.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -42.38 -35.6 1.06 Allowed 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 123.709 0.803 . . . . 0.0 112.881 171.217 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 51.0 pttt -69.69 -42.48 74.05 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.625 -178.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -68.08 -21.44 64.97 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 125.658 1.583 . . . . 0.0 110.438 -176.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.538 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.8 mt -53.63 130.6 55.08 Favored Pre-proline 0 N--CA 1.445 -0.688 0 CA-C-N 118.758 0.708 . . . . 0.0 109.216 175.331 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -63.94 140.52 73.3 Favored 'Trans proline' 0 N--CA 1.445 -1.335 0 C-N-CA 122.479 2.12 . . . . 0.0 109.758 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -57.84 -23.22 51.78 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.537 0.735 . . . . 0.0 111.522 175.225 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.57 -18.75 63.66 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 124.745 1.218 . . . . 0.0 112.057 177.633 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 80.1 t90 -75.55 154.54 36.76 Favored 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 121.629 -0.669 . . . . 0.0 110.095 -179.563 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.1 t -139.73 149.57 22.43 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 C-N-CA 124.905 1.282 . . . . 0.0 108.569 -169.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.1 t -73.41 127.39 88.98 Favored Pre-proline 0 CA--C 1.545 0.757 0 C-N-CA 122.974 0.509 . . . . 0.0 110.879 179.153 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.43 139.76 50.41 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 123.196 2.597 . . . . 0.0 111.646 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 57.6 mt 58.56 31.94 21.6 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.54 1.136 . . . . 0.0 111.706 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 43.5 t -147.76 -57.61 0.24 Allowed 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -173.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.94 26.8 63.75 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 111.946 -0.461 . . . . 0.0 111.946 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 95.6 t -111.35 155.99 12.6 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 C-N-CA 124.341 1.056 . . . . 0.0 109.182 177.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -67.91 155.69 52.94 Favored Glycine 0 CA--C 1.528 0.867 0 C-N-CA 124.469 1.033 . . . . 0.0 111.743 -176.675 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.1 ptmt -67.86 -42.89 80.62 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -175.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -76.87 77.65 3.46 Favored 'General case' 0 N--CA 1.456 -0.166 0 CA-C-O 122.426 1.108 . . . . 0.0 108.879 -170.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -179.37 -30.06 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 128.582 2.753 . . . . 0.0 108.97 -168.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -57.06 141.42 45.9 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.628 0.771 . . . . 0.0 110.888 169.629 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -111.66 145.16 39.74 Favored 'General case' 0 C--O 1.22 -0.458 0 C-N-CA 125.08 1.352 . . . . 0.0 109.551 -177.805 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -65.62 136.34 56.2 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-N 118.778 0.717 . . . . 0.0 110.415 -176.02 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.8 t -94.74 109.53 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 175.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -69.0 82.13 0.31 Allowed 'General case' 0 N--CA 1.443 -0.796 0 C-N-CA 125.503 1.521 . . . . 0.0 110.706 175.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 . . . . . 0 C--O 1.251 1.154 0 CA-C-O 117.229 -1.367 . . . . 0.0 110.471 169.387 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 22.6 mttm . . . . . 0 N--CA 1.45 -0.431 0 CA-C-O 122.674 1.226 . . . . 0.0 112.319 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 66.2 mttt -73.61 170.65 14.76 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.439 -0.801 . . . . 0.0 109.836 -178.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.482 ' CE1' ' HB2' ' A' ' 30' ' ' PHE . 55.3 m-85 -142.07 141.64 32.77 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 122.501 0.32 . . . . 0.0 111.323 176.419 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 91.1 m -78.25 142.44 37.85 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 123.47 0.708 . . . . 0.0 109.605 172.108 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 24.8 t -79.58 135.48 36.61 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 125.071 1.348 . . . . 0.0 108.428 175.048 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.0 m -45.32 -56.79 4.55 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.496 1.519 . . . . 0.0 114.197 -168.135 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 14.5 p -153.35 35.91 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 120.939 0.399 . . . . 0.0 110.59 -173.321 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 2.8 m -121.79 -65.25 1.14 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.485 0.714 . . . . 0.0 109.188 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 116.78 56.33 0.31 Allowed Glycine 0 CA--C 1.53 0.995 0 C-N-CA 124.717 1.151 . . . . 0.0 111.948 176.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -139.18 87.66 2.22 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.457 1.103 . . . . 0.0 109.052 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.4 mt -57.23 127.13 15.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 O-C-N 121.439 -0.788 . . . . 0.0 111.035 -176.541 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.566 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 27.7 t80 -81.4 137.29 35.7 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 172.448 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 51.7 t-20 -122.55 112.44 31.02 Favored Pre-proline 0 C--N 1.339 0.136 0 C-N-CA 124.168 0.987 . . . . 0.0 109.841 175.809 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_endo -65.15 -37.44 32.23 Favored 'Trans proline' 0 N--CA 1.45 -1.086 0 C-N-CA 121.28 1.32 . . . . 0.0 111.51 -173.567 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -58.34 -32.09 68.2 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 117.726 0.239 . . . . 0.0 111.322 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -87.49 -32.8 19.26 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.489 0.716 . . . . 0.0 109.868 177.029 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.26 -156.41 45.16 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 -168.093 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -143.37 61.29 9.83 Favored Pre-proline 0 CA--C 1.542 0.669 0 C-N-CA 125.705 1.602 . . . . 0.0 107.442 172.26 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.01 -33.41 83.27 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.671 2.247 . . . . 0.0 111.618 -169.056 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -58.15 -30.99 66.79 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 124.688 1.195 . . . . 0.0 110.394 178.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -92.4 -29.42 16.31 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 125.245 1.418 . . . . 0.0 110.351 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.14 -4.01 3.13 Favored Glycine 0 CA--C 1.529 0.938 0 C-N-CA 124.477 1.037 . . . . 0.0 113.148 172.101 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 74.3 t -94.3 109.78 22.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -172.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -62.98 154.84 75.35 Favored Pre-proline 0 CA--C 1.534 0.354 0 O-C-N 121.767 -0.583 . . . . 0.0 110.488 -177.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -59.08 149.27 80.98 Favored 'Trans proline' 0 N--CA 1.449 -1.138 0 C-N-CA 121.123 1.215 . . . . 0.0 110.417 169.499 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.03 17.93 80.22 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 125.32 1.438 . . . . 0.0 113.3 -175.355 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 98.0 m -92.1 119.41 31.75 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-N 119.983 1.892 . . . . 0.0 107.312 177.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -65.2 142.99 58.13 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 173.168 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . 0.482 ' HB2' ' CE1' ' A' ' 4' ' ' TYR . 2.2 t80 -49.22 -33.11 11.84 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 123.639 0.775 . . . . 0.0 112.366 175.106 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 10.4 pttm -67.27 -37.17 83.01 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 119.254 -0.978 . . . . 0.0 110.926 178.291 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 -77.43 -21.0 53.7 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 124.742 1.217 . . . . 0.0 110.09 -174.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.566 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.4 mt -55.64 133.68 71.71 Favored Pre-proline 0 N--CA 1.445 -0.693 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.214 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 5.9 Cg_exo -59.45 134.8 60.68 Favored 'Trans proline' 0 N--CA 1.449 -1.123 0 C-N-CA 122.746 2.297 . . . . 0.0 109.374 175.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.59 -3.84 33.48 Favored 'General case' 0 N--CA 1.447 -0.577 0 O-C-N 121.632 -0.667 . . . . 0.0 112.346 -176.489 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -76.23 -12.42 60.09 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.131 0.972 . . . . 0.0 112.596 164.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 80.6 t90 -67.15 148.92 51.21 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 118.981 0.81 . . . . 0.0 111.297 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 62.7 t -125.97 144.47 35.98 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 126.732 2.013 . . . . 0.0 108.718 -175.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.8 p -82.82 132.57 51.0 Favored Pre-proline 0 CA--C 1.543 0.695 0 CA-C-N 120.038 1.29 . . . . 0.0 110.06 177.064 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -79.12 139.84 15.32 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.617 2.211 . . . . 0.0 111.066 -175.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 18.1 tp 60.37 31.87 20.5 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 124.497 1.119 . . . . 0.0 111.262 -178.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 33.3 m -125.65 -97.83 0.42 Allowed 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.977 1.311 . . . . 0.0 109.357 -179.612 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 143.88 114.18 0.95 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 108.325 -1.91 . . . . 0.0 108.325 -164.628 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.427 HG13 ' N ' ' A' ' 45' ' ' GLY 0.265 0.4 OUTLIER 76.94 -173.2 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 125.151 1.38 . . . . 0.0 110.402 -171.721 . . . . . . . . 4 4 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . 0.427 ' N ' HG13 ' A' ' 44' ' ' VAL . . . -129.53 -123.69 2.56 Favored Glycine 0 N--CA 1.449 -0.442 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 179.854 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 23.4 mtpt -82.23 167.86 18.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.429 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -159.45 -75.49 0.07 Allowed 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 124.656 1.183 . . . . 0.0 108.827 172.642 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -124.06 -38.65 2.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 127.268 2.227 . . . . 0.0 109.739 -177.626 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 25.2 p90 53.15 173.47 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.235 2.214 . . . . 0.0 112.882 -176.324 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -138.72 136.55 35.91 Favored 'General case' 0 CA--C 1.521 -0.155 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 172.491 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -74.22 137.27 42.95 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 176.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.6 t -97.59 113.97 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.823 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 175.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -74.09 51.56 0.42 Allowed 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.3 1.44 . . . . 0.0 114.113 -178.499 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 28.9 mt-10 . . . . . 0 C--O 1.253 1.288 0 C-N-CA 125.921 1.688 . . . . 0.0 107.587 157.143 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 33.2 mttt . . . . . 0 N--CA 1.451 -0.403 0 N-CA-C 113.408 0.892 . . . . 0.0 113.408 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -70.67 162.61 28.69 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.54 178.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -144.99 137.18 25.92 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 124.248 1.019 . . . . 0.0 111.423 -178.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.8 m -75.92 155.59 35.01 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.232 1.013 . . . . 0.0 110.975 173.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 15.3 t -97.49 -37.49 9.95 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.236 1.814 . . . . 0.0 109.3 174.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 86.1 m 76.14 -62.46 0.43 Allowed 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 125.455 1.502 . . . . 0.0 112.016 166.407 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 31.2 m -78.79 43.72 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-N 119.284 0.947 . . . . 0.0 110.656 178.001 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 10.4 t 177.05 -102.49 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -156.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 121.21 64.77 0.24 Allowed Glycine 0 CA--C 1.53 0.974 0 C-N-CA 125.302 1.43 . . . . 0.0 111.035 -176.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -114.51 -57.55 2.26 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.301 1.04 . . . . 0.0 111.055 176.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . 0.251 57.8 mt 79.84 110.73 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 C-N-CA 127.548 2.339 . . . . 0.0 110.997 -170.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.535 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 51.6 t80 -74.23 141.6 45.4 Favored 'General case' 0 C--O 1.236 0.357 0 C-N-CA 124.203 1.001 . . . . 0.0 108.859 171.055 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 63.9 t-20 -126.57 116.57 22.88 Favored Pre-proline 0 C--O 1.224 -0.289 0 C-N-CA 123.488 0.715 . . . . 0.0 110.9 173.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -68.25 -41.46 6.97 Favored 'Trans proline' 0 N--CA 1.445 -1.369 0 C-N-CA 121.13 1.22 . . . . 0.0 112.042 -177.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -60.05 -30.9 69.5 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 118.706 0.684 . . . . 0.0 110.855 -178.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 -86.62 -32.71 20.45 Favored 'General case' 0 CA--C 1.53 0.192 0 C-N-CA 123.406 0.682 . . . . 0.0 109.512 176.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.89 -159.86 42.71 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -164.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -137.56 61.79 32.67 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 168.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -61.74 -38.22 62.12 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.11 2.54 . . . . 0.0 111.257 -167.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -51.02 -30.35 15.13 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.769 1.628 . . . . 0.0 110.825 177.145 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -101.48 -18.12 16.12 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 125.818 1.647 . . . . 0.0 110.976 -175.159 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 130.56 -5.18 5.87 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.583 1.087 . . . . 0.0 113.324 172.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 78.6 t -100.22 108.7 23.42 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.202 0 CA-C-N 118.2 1.0 . . . . 0.0 109.103 -171.658 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -64.73 155.16 83.31 Favored Pre-proline 0 CA--C 1.533 0.305 0 O-C-N 121.767 -0.583 . . . . 0.0 111.072 -175.634 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -57.95 147.64 80.81 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 121.322 1.348 . . . . 0.0 110.723 170.564 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 71.51 21.68 78.69 Favored Glycine 0 CA--C 1.525 0.714 0 C-N-CA 125.653 1.596 . . . . 0.0 112.945 -174.272 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.9 m -91.75 121.92 33.83 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 119.994 1.897 . . . . 0.0 107.818 174.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -63.87 137.87 58.23 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 174.325 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -42.95 -38.37 2.2 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.167 0.987 . . . . 0.0 111.733 170.277 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -67.26 -39.73 86.14 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 118.572 -1.251 . . . . 0.0 110.493 -179.448 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -82.54 -11.45 58.43 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 125.906 1.683 . . . . 0.0 110.716 -172.594 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.535 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.6 mt -54.53 133.16 63.54 Favored Pre-proline 0 N--CA 1.441 -0.878 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 171.653 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 16.7 Cg_exo -53.83 134.53 59.42 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 123.785 2.99 . . . . 0.0 109.432 176.059 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.39 -11.2 60.0 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.146 -0.972 . . . . 0.0 111.705 -175.299 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -78.01 -10.1 59.44 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 126.493 1.917 . . . . 0.0 112.181 167.027 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 78.3 t90 -66.97 158.14 31.61 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 119.089 0.859 . . . . 0.0 109.971 173.391 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.8 p -136.52 155.09 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 124.712 1.205 . . . . 0.0 108.71 -176.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.6 t -56.4 136.02 76.26 Favored Pre-proline 0 CA--C 1.534 0.339 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -58.59 -28.98 87.73 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 123.045 2.496 . . . . 0.0 113.214 -174.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.6 tp -150.8 51.5 0.86 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 118.72 0.691 . . . . 0.0 111.075 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . 0.258 1.7 p -142.84 -64.68 0.4 Allowed 'General case' 0 N--CA 1.464 0.266 0 O-C-N 122.053 -0.405 . . . . 0.0 110.552 159.715 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 142.87 -136.33 7.04 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 -179.408 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.4 t 61.77 -83.65 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 C-N-CA 126.097 1.759 . . . . 0.0 112.352 173.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.58 -139.28 6.76 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -170.02 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 48.4 mtpt -113.77 93.75 4.52 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 124.925 1.29 . . . . 0.0 108.608 174.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 55.6 p-10 -144.72 169.73 17.45 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 170.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER 36.93 47.02 0.54 Allowed 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 127.218 2.207 . . . . 0.0 113.324 -177.377 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 21.3 p90 -95.29 113.79 25.51 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.372 0.669 . . . . 0.0 110.053 179.628 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -98.33 149.4 22.67 Favored 'General case' 0 C--O 1.223 -0.31 0 C-N-CA 125.77 1.628 . . . . 0.0 108.726 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -79.72 142.02 35.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 120.273 1.397 . . . . 0.0 110.031 -178.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.2 t -105.98 109.64 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 126.35 1.86 . . . . 0.0 107.376 176.248 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -72.63 66.55 0.73 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.994 1.718 . . . . 0.0 113.131 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 . . . . . 0 C--O 1.256 1.435 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.241 158.845 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.6 mttm . . . . . 0 N--CA 1.451 -0.42 0 CA-C-O 122.072 0.939 . . . . 0.0 112.432 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -78.39 166.76 22.26 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.236 -174.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -151.62 150.39 30.23 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 123.367 0.667 . . . . 0.0 112.409 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.5 m -78.28 156.24 29.77 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 123.876 0.87 . . . . 0.0 112.355 171.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 34.0 t -70.93 166.71 20.62 Favored 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 125.026 1.33 . . . . 0.0 108.768 166.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 5.4 m -45.16 -41.88 8.51 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 126.463 1.905 . . . . 0.0 112.302 170.208 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.3 p -160.98 -32.74 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 113.53 0.937 . . . . 0.0 113.53 -172.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.9 p -77.58 172.46 13.33 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 120.213 1.369 . . . . 0.0 110.58 -177.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -89.5 51.69 3.65 Favored Glycine 0 CA--C 1.527 0.83 0 O-C-N 121.318 -0.864 . . . . 0.0 111.732 -176.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -125.84 86.73 2.57 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 118.25 1.025 . . . . 0.0 110.445 -177.557 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 15.9 mt -67.63 127.26 28.97 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 O-C-N 121.73 -0.607 . . . . 0.0 109.605 174.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 40.0 t80 -78.48 136.94 37.71 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 170.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.6 t-20 -122.19 113.11 31.24 Favored Pre-proline 0 C--O 1.227 -0.123 0 C-N-CA 124.312 1.045 . . . . 0.0 110.34 177.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -65.33 -38.98 24.24 Favored 'Trans proline' 0 N--CA 1.445 -1.359 0 C-N-CA 120.97 1.114 . . . . 0.0 112.246 -177.133 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -59.74 -32.13 70.28 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 118.562 0.619 . . . . 0.0 111.102 -178.054 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -88.06 -32.02 18.97 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 123.471 0.709 . . . . 0.0 109.75 178.083 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.1 -158.62 37.85 Favored Glycine 0 CA--C 1.529 0.952 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 -165.35 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.76 61.69 11.32 Favored Pre-proline 0 CA--C 1.54 0.595 0 C-N-CA 125.955 1.702 . . . . 0.0 107.113 171.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -61.11 -33.86 90.51 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.572 2.181 . . . . 0.0 111.045 -170.227 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -54.58 -30.61 54.83 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 125.294 1.437 . . . . 0.0 110.736 178.175 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -102.97 -23.03 13.73 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 125.432 1.493 . . . . 0.0 110.778 -174.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 132.42 11.05 2.02 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 124.287 0.946 . . . . 0.0 113.401 169.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 70.6 t -110.3 108.76 26.23 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 CA-C-N 118.544 1.172 . . . . 0.0 108.762 -175.732 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -63.1 155.04 75.25 Favored Pre-proline 0 CA--C 1.535 0.379 0 O-C-N 121.662 -0.649 . . . . 0.0 110.876 -178.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.79 148.78 86.8 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 121.118 1.212 . . . . 0.0 110.719 170.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.46 17.0 78.81 Favored Glycine 0 CA--C 1.526 0.73 0 C-N-CA 125.256 1.408 . . . . 0.0 112.963 -174.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 54.1 m -88.6 122.01 31.59 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 119.797 1.798 . . . . 0.0 107.977 178.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -63.88 135.56 56.66 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 171.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -40.39 -41.63 1.42 Allowed 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.4 0.68 . . . . 0.0 111.634 167.348 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.3 pttt -66.91 -34.74 78.44 Favored 'General case' 0 CA--C 1.536 0.429 0 O-C-N 120.241 -1.537 . . . . 0.0 110.823 -178.381 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -76.49 -22.1 54.94 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 125.13 1.372 . . . . 0.0 109.801 -177.64 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 15.8 mt -55.85 134.31 72.95 Favored Pre-proline 0 N--CA 1.445 -0.693 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.757 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_endo -62.05 137.3 66.0 Favored 'Trans proline' 0 N--CA 1.443 -1.443 0 C-N-CA 121.755 1.637 . . . . 0.0 108.889 176.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -72.46 -3.35 23.81 Favored 'General case' 0 N--CA 1.444 -0.741 0 O-C-N 121.914 -0.491 . . . . 0.0 111.908 -179.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.06 -23.16 64.01 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 125.509 1.524 . . . . 0.0 112.315 164.179 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 84.6 t90 -70.56 152.43 43.96 Favored 'General case' 0 CA--C 1.53 0.176 0 O-C-N 121.628 -0.67 . . . . 0.0 110.855 -176.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.6 t -139.24 151.8 23.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 C-N-CA 125.901 1.68 . . . . 0.0 107.441 -173.288 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 9.8 t -54.12 133.14 59.75 Favored Pre-proline 0 CA--C 1.541 0.632 0 C-N-CA 125.557 1.543 . . . . 0.0 110.119 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -59.19 -52.49 4.86 Favored 'Trans proline' 0 N--CA 1.459 -0.546 0 C-N-CA 123.674 2.916 . . . . 0.0 113.699 -166.383 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 96.1 mt -128.68 59.92 1.53 Allowed 'General case' 0 N--CA 1.462 0.135 0 C-N-CA 123.68 0.792 . . . . 0.0 109.541 -173.2 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -162.9 -66.79 0.05 OUTLIER 'General case' 0 CA--C 1.529 0.158 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 -171.637 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 101.1 51.76 1.13 Allowed Glycine 0 CA--C 1.528 0.879 0 C-N-CA 123.641 0.638 . . . . 0.0 112.493 175.21 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 34.7 m -125.56 152.92 32.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 C-N-CA 123.953 0.901 . . . . 0.0 108.91 168.002 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.12 -175.59 44.97 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 110.81 -0.916 . . . . 0.0 110.81 175.334 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 41.2 mtpt -78.41 84.43 4.57 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 122.931 0.492 . . . . 0.0 109.824 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -139.28 150.73 45.79 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.502 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.4 tp-100 48.32 55.82 8.3 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.993 2.117 . . . . 0.0 112.17 175.003 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -103.24 115.88 31.41 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.746 0.818 . . . . 0.0 110.077 -179.254 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -86.24 146.36 26.57 Favored 'General case' 0 C--O 1.226 -0.175 0 C-N-CA 125.431 1.492 . . . . 0.0 109.206 178.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -81.42 141.82 33.56 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 119.089 0.859 . . . . 0.0 109.36 -179.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.4 t -109.03 102.49 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.837 0 C-N-CA 127.109 2.164 . . . . 0.0 107.757 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -76.59 76.36 3.28 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 126.207 1.803 . . . . 0.0 112.682 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 51.2 mm-40 . . . . . 0 C--O 1.255 1.392 0 CA-C-O 116.671 -1.633 . . . . 0.0 108.414 153.42 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.3 mttm . . . . . 0 N--CA 1.455 -0.203 0 CA-C-O 121.568 0.699 . . . . 0.0 111.394 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -75.33 168.27 20.32 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 124.213 1.005 . . . . 0.0 108.567 174.045 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 29.4 m-85 -144.62 139.12 27.86 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-O 118.899 -0.572 . . . . 0.0 112.306 -179.045 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.8 m -87.1 137.78 32.06 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 119.175 0.898 . . . . 0.0 111.298 178.154 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 40.8 t -62.73 149.7 43.14 Favored 'General case' 0 C--N 1.34 0.171 0 CA-C-N 118.699 0.682 . . . . 0.0 109.708 174.075 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 58.1 m -43.05 -36.67 1.68 Allowed 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 125.477 1.511 . . . . 0.0 112.113 172.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 m -129.71 -40.76 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 123.368 0.667 . . . . 0.0 112.46 178.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 m -76.79 160.65 29.11 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.346 0.976 . . . . 0.0 112.413 -171.558 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -99.38 12.59 61.67 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 119.222 -0.766 . . . . 0.0 112.406 174.106 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 38.8 m-85 -60.58 -43.91 96.81 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 118.873 1.336 . . . . 0.0 111.308 -175.696 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.7 mt 69.64 113.01 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 C-N-CA 126.137 1.775 . . . . 0.0 111.368 -177.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' TYR . . . . . 0.504 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 80.4 t80 -69.62 132.49 46.28 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 171.109 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -120.35 113.23 33.88 Favored Pre-proline 0 N--CA 1.456 -0.168 0 C-N-CA 124.205 1.002 . . . . 0.0 109.685 177.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -59.67 -42.19 49.0 Favored 'Trans proline' 0 N--CA 1.45 -1.045 0 C-N-CA 122.017 1.811 . . . . 0.0 112.443 -176.561 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -59.64 -31.41 69.5 Favored 'General case' 0 N--CA 1.447 -0.606 0 O-C-N 123.108 0.255 . . . . 0.0 111.653 -178.266 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 -90.09 -29.59 18.24 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 123.304 0.641 . . . . 0.0 110.422 177.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.79 -154.99 42.38 Favored Glycine 0 CA--C 1.53 1.029 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -167.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -146.34 61.33 6.95 Favored Pre-proline 0 CA--C 1.543 0.702 0 C-N-CA 125.595 1.558 . . . . 0.0 107.842 173.558 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -61.33 -34.53 87.17 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 122.944 2.429 . . . . 0.0 111.599 -168.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -54.64 -29.88 53.55 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 125.253 1.421 . . . . 0.0 111.38 177.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -98.03 -33.98 10.97 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 125.493 1.517 . . . . 0.0 109.774 -177.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 141.27 11.51 0.56 Allowed Glycine 0 CA--C 1.532 1.132 0 C-N-CA 123.933 0.778 . . . . 0.0 114.06 169.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.462 HG23 ' CD1' ' A' ' 37' ' ' TRP . 52.2 t -107.61 112.73 41.35 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.245 0 CA-C-N 119.174 1.487 . . . . 0.0 108.947 -177.379 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -65.05 153.79 88.19 Favored Pre-proline 0 C--N 1.329 -0.283 0 O-C-N 122.016 -0.428 . . . . 0.0 110.406 -179.367 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -59.22 146.77 93.5 Favored 'Trans proline' 0 N--CA 1.449 -1.113 0 C-N-CA 121.631 1.554 . . . . 0.0 110.955 172.185 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 78.03 18.01 77.43 Favored Glycine 0 CA--C 1.524 0.642 0 CA-C-O 118.553 -1.137 . . . . 0.0 112.764 -177.159 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 83.0 m -89.96 120.84 31.52 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 119.577 1.689 . . . . 0.0 107.678 177.133 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -57.55 133.55 55.35 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 169.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -48.43 -32.27 7.45 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.753 174.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -68.73 -40.89 79.67 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 119.375 -0.93 . . . . 0.0 109.345 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -75.36 -15.32 60.48 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 125.546 1.539 . . . . 0.0 110.494 -172.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.504 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 12.9 mt -55.94 132.17 73.59 Favored Pre-proline 0 N--CA 1.441 -0.891 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 172.427 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -63.41 140.2 75.09 Favored 'Trans proline' 0 N--CA 1.443 -1.486 0 C-N-CA 122.633 2.222 . . . . 0.0 109.042 178.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.37 -18.12 57.23 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 122.555 0.342 . . . . 0.0 111.224 177.243 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.25 -18.53 62.44 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.784 1.234 . . . . 0.0 112.076 176.357 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' TRP . . . . . 0.462 ' CD1' HG23 ' A' ' 24' ' ' VAL . 73.3 t90 -68.76 159.47 32.24 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 121.668 0.747 . . . . 0.0 110.943 -178.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 15.9 m -136.51 151.4 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.796 0 C-N-CA 125.66 1.584 . . . . 0.0 109.279 -171.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.3 t -72.31 135.75 81.83 Favored Pre-proline 0 CA--C 1.537 0.472 0 C-N-CA 124.428 1.091 . . . . 0.0 108.886 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.58 131.7 30.55 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 122.173 1.916 . . . . 0.0 110.058 179.318 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 57.1 mt 56.97 49.46 13.89 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.544 0.738 . . . . 0.0 110.991 176.363 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 53.8 t -163.58 -176.62 4.77 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 127.877 2.471 . . . . 0.0 105.092 -174.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.71 -100.35 0.56 Allowed Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.161 0.886 . . . . 0.0 111.08 178.025 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.3 m -142.35 160.13 19.64 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.117 0 C-N-CA 123.93 0.892 . . . . 0.0 108.687 -177.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 142.84 149.05 5.06 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 177.165 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.8 ptmt -161.75 -177.58 5.96 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 125.291 1.436 . . . . 0.0 107.447 169.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 t0 69.59 -63.24 0.39 Allowed 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 126.992 2.117 . . . . 0.0 111.817 169.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 38.5 tt0 -56.73 -22.68 37.08 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.707 2.003 . . . . 0.0 113.188 174.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 6.0 m-30 -45.18 143.95 1.48 Allowed 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.865 1.666 . . . . 0.0 109.494 170.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -75.16 155.39 37.01 Favored 'General case' 0 C--O 1.224 -0.263 0 CA-C-N 119.429 1.013 . . . . 0.0 108.555 -177.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -83.03 133.87 35.06 Favored 'General case' 0 N--CA 1.442 -0.837 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 173.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 13.4 t -93.51 116.59 35.04 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.983 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 172.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -70.96 56.88 0.2 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.683 1.993 . . . . 0.0 114.491 -177.454 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 . . . . . 0 C--O 1.255 1.352 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 159.832 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.379 20.6 ptm . . . . . 0 N--CA 1.475 0.813 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 21.4 mttm 58.72 167.41 0.05 Allowed 'General case' 0 N--CA 1.452 -0.35 0 C-N-CA 125.885 1.674 . . . . 0.0 112.77 -165.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.4 mtpt -74.0 170.39 15.52 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.734 -178.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 38.2 m-85 -146.89 147.18 30.53 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 122.863 0.465 . . . . 0.0 110.648 -177.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 51.4 p -64.95 165.61 10.57 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-O 120.644 0.259 . . . . 0.0 111.075 167.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 4.4 t -68.77 -97.56 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 105.97 -1.863 . . . . 0.0 105.97 159.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.5 t -172.95 -41.65 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 126.578 1.951 . . . . 0.0 107.133 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 9.8 p -147.79 -38.62 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 114.495 1.294 . . . . 0.0 114.495 176.361 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 13.6 p -64.97 -41.47 95.41 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 120.345 1.43 . . . . 0.0 111.282 -170.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 109.39 47.67 0.85 Allowed Glycine 0 CA--C 1.527 0.793 0 C-N-CA 124.805 1.193 . . . . 0.0 111.779 175.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -114.87 89.4 3.09 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.129 0.972 . . . . 0.0 109.041 176.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 16.0 mt -63.82 125.52 20.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 O-C-N 121.509 -0.744 . . . . 0.0 109.601 176.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.557 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 39.9 t80 -81.56 138.89 35.35 Favored 'General case' 0 N--CA 1.451 -0.416 0 N-CA-C 108.351 -0.981 . . . . 0.0 108.351 173.077 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.1 t-20 -122.88 114.33 29.73 Favored Pre-proline 0 N--CA 1.456 -0.157 0 C-N-CA 123.862 0.865 . . . . 0.0 110.292 174.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -67.46 -38.89 13.61 Favored 'Trans proline' 0 N--CA 1.448 -1.196 0 C-N-CA 121.337 1.358 . . . . 0.0 111.777 -174.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 20.5 mt-10 -59.87 -30.86 69.27 Favored 'General case' 0 N--CA 1.448 -0.563 0 CA-C-N 118.141 0.428 . . . . 0.0 111.05 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -87.39 -31.73 19.94 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 123.477 0.711 . . . . 0.0 109.886 176.261 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.21 -159.4 37.05 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 -166.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -139.91 61.16 17.31 Favored Pre-proline 0 CA--C 1.54 0.559 0 C-N-CA 125.485 1.514 . . . . 0.0 107.535 170.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -63.41 -30.65 72.59 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.527 2.151 . . . . 0.0 111.212 -170.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -59.9 -28.24 67.41 Favored 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 124.283 1.033 . . . . 0.0 109.858 179.155 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 21.6 m-80 -102.36 -26.22 13.36 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 125.73 1.612 . . . . 0.0 110.874 -175.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 135.83 10.96 1.31 Allowed Glycine 0 CA--C 1.531 1.077 0 C-N-CA 124.177 0.894 . . . . 0.0 113.86 169.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 70.7 t -112.95 110.22 31.41 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.294 0 CA-C-N 118.644 1.222 . . . . 0.0 108.709 -174.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.0 m-80 -63.63 155.06 77.91 Favored Pre-proline 0 CA--C 1.535 0.366 0 O-C-N 121.631 -0.668 . . . . 0.0 111.073 -176.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -59.27 149.02 83.48 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 121.19 1.26 . . . . 0.0 110.665 170.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.26 15.76 80.98 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-O 118.368 -1.24 . . . . 0.0 112.616 -175.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 88.0 m -89.08 116.16 27.15 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 119.805 1.803 . . . . 0.0 107.073 177.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -57.84 136.06 56.93 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 170.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -44.18 -37.68 3.3 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 123.851 0.86 . . . . 0.0 111.79 171.255 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 56.9 pttt -67.22 -42.39 84.13 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 117.561 -1.656 . . . . 0.0 109.986 -178.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -71.36 -18.33 62.38 Favored 'General case' 0 N--CA 1.453 -0.315 0 C-N-CA 125.806 1.642 . . . . 0.0 111.138 -176.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.557 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.7 mt -53.38 133.4 52.87 Favored Pre-proline 0 N--CA 1.448 -0.569 0 CA-C-N 119.194 0.906 . . . . 0.0 108.941 174.252 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -64.9 142.17 74.35 Favored 'Trans proline' 0 N--CA 1.445 -1.331 0 C-N-CA 122.106 1.871 . . . . 0.0 109.946 179.472 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -68.47 -12.34 61.06 Favored 'General case' 0 N--CA 1.45 -0.444 0 O-C-N 121.946 -0.471 . . . . 0.0 111.962 178.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -74.77 -17.18 60.68 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 118.275 0.489 . . . . 0.0 112.193 169.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 87.6 t90 -75.27 147.61 40.11 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 121.55 0.691 . . . . 0.0 109.529 179.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 59.3 t -131.51 161.22 41.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 125.097 1.359 . . . . 0.0 107.633 -177.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -43.79 144.49 1.42 Allowed Pre-proline 0 CA--C 1.537 0.475 0 C-N-CA 124.775 1.23 . . . . 0.0 110.031 170.406 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -64.34 -42.43 17.4 Favored 'Trans proline' 0 N--CA 1.452 -0.945 0 C-N-CA 122.271 1.981 . . . . 0.0 111.569 -176.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 88.9 mt -135.41 44.9 2.51 Favored 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 123.904 0.881 . . . . 0.0 109.983 -176.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -158.36 152.01 23.44 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 106.007 -1.849 . . . . 0.0 106.007 179.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -120.78 86.65 0.4 Allowed Glycine 0 C--N 1.335 0.506 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -169.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 14.8 p -145.46 -51.85 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 C-N-CA 123.115 0.566 . . . . 0.0 110.699 -178.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 109.36 154.68 15.79 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -176.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.4 ptmt -64.46 107.79 1.47 Allowed 'General case' 0 CA--C 1.537 0.478 0 CA-C-N 118.153 0.976 . . . . 0.0 109.572 177.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 29.2 t0 -160.46 157.89 28.43 Favored 'General case' 0 N--CA 1.451 -0.419 0 N-CA-C 106.652 -1.61 . . . . 0.0 106.652 172.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 44.6 54.24 6.62 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 126.321 1.848 . . . . 0.0 111.549 173.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.6 p90 -100.28 117.86 35.37 Favored 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 126.507 1.923 . . . . 0.0 108.705 -179.261 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -85.17 148.11 26.27 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 123.526 0.73 . . . . 0.0 109.06 176.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -79.46 138.7 37.67 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.0 t -102.46 105.0 17.33 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 C-N-CA 125.419 1.488 . . . . 0.0 108.266 -179.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -72.87 68.64 0.9 Allowed 'General case' 0 N--CA 1.447 -0.591 0 C-N-CA 126.348 1.859 . . . . 0.0 113.178 -179.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 43.3 mm-40 . . . . . 0 C--O 1.255 1.364 0 CA-C-O 116.78 -1.581 . . . . 0.0 108.332 154.843 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.476 0.86 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 12.1 mttm -59.83 144.91 47.33 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-O 121.72 0.772 . . . . 0.0 112.448 172.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 51.9 mtpt -76.76 174.29 10.66 Favored 'General case' 0 N--CA 1.442 -0.853 0 C-N-CA 125.617 1.567 . . . . 0.0 109.252 177.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 -147.49 145.63 29.21 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 122.773 0.429 . . . . 0.0 110.167 -177.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 42.0 m -74.96 141.59 44.02 Favored 'General case' 0 N--CA 1.453 -0.298 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 172.115 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 41.2 t -74.84 -112.08 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.494 0 N-CA-C 105.735 -1.95 . . . . 0.0 105.735 164.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 9.6 t -160.18 -158.2 0.61 Allowed 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 170.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 17.4 m -75.26 56.81 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 C-N-CA 124.079 0.952 . . . . 0.0 111.737 -177.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 15.6 p -153.19 -55.85 0.12 Allowed 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 124.989 1.316 . . . . 0.0 109.452 177.24 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -101.71 -150.36 23.42 Favored Glycine 0 CA--C 1.523 0.546 0 C-N-CA 123.716 0.674 . . . . 0.0 113.248 -169.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 44.8 t80 -130.14 160.5 33.59 Favored 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 125.948 1.699 . . . . 0.0 107.666 179.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.6 mt -47.72 125.36 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.295 0 C-N-CA 124.6 1.16 . . . . 0.0 111.341 176.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.536 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 27.0 t80 -70.19 136.6 50.19 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 170.193 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.7 t-20 -120.02 113.02 34.46 Favored Pre-proline 0 N--CA 1.454 -0.232 0 C-N-CA 123.861 0.864 . . . . 0.0 109.707 175.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -64.74 -38.15 32.35 Favored 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 121.696 1.597 . . . . 0.0 111.342 -175.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -63.09 -28.81 70.33 Favored 'General case' 0 N--CA 1.444 -0.754 0 O-C-N 123.188 0.305 . . . . 0.0 111.333 -176.542 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -86.44 -32.97 20.57 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.807 0.843 . . . . 0.0 109.716 172.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.39 -158.86 42.23 Favored Glycine 0 N--CA 1.443 -0.849 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 -166.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -140.3 61.59 17.41 Favored Pre-proline 0 C--O 1.237 0.435 0 C-N-CA 125.235 1.414 . . . . 0.0 107.891 171.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -64.24 -28.16 64.21 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 122.536 2.157 . . . . 0.0 111.222 -170.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -64.18 -30.25 71.32 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 123.24 0.616 . . . . 0.0 109.683 179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 33.9 m-80 -93.0 -30.94 15.07 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 125.085 1.354 . . . . 0.0 110.747 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.15 5.88 1.52 Allowed Glycine 0 CA--C 1.531 1.06 0 C-N-CA 124.26 0.933 . . . . 0.0 113.915 170.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 50.2 t -103.44 112.1 35.64 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.266 0 CA-C-N 118.45 1.125 . . . . 0.0 108.559 -175.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -64.59 154.87 83.5 Favored Pre-proline 0 CA--C 1.533 0.32 0 O-C-N 121.784 -0.573 . . . . 0.0 110.416 -177.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -58.79 150.05 73.67 Favored 'Trans proline' 0 N--CA 1.45 -1.033 0 C-N-CA 121.495 1.463 . . . . 0.0 110.851 170.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 79.33 14.44 81.55 Favored Glycine 0 CA--C 1.526 0.724 0 C-N-CA 125.708 1.623 . . . . 0.0 113.348 -176.332 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 93.9 m -94.35 114.77 26.88 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 120.149 1.974 . . . . 0.0 108.501 -178.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 31.9 t0 -56.42 135.24 54.15 Favored 'General case' 0 N--CA 1.45 -0.44 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 169.423 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -42.69 -35.36 1.1 Allowed 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 113.172 0.804 . . . . 0.0 113.172 171.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 53.8 pttt -68.3 -38.5 81.7 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 118.646 -1.221 . . . . 0.0 110.051 -179.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -78.0 -16.9 57.73 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 125.005 1.322 . . . . 0.0 109.99 -173.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.536 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.7 mt -54.97 132.02 67.61 Favored Pre-proline 0 N--CA 1.442 -0.836 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 174.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 2.7 Cg_exo -57.64 134.69 64.72 Favored 'Trans proline' 0 N--CA 1.45 -1.068 0 C-N-CA 123.162 2.575 . . . . 0.0 109.359 177.245 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -74.57 -7.4 53.0 Favored 'General case' 0 N--CA 1.449 -0.507 0 O-C-N 121.298 -0.876 . . . . 0.0 111.966 -176.499 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -77.4 -10.23 59.34 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.491 1.116 . . . . 0.0 112.598 165.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 77.2 t90 -66.93 156.35 36.07 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 118.88 0.764 . . . . 0.0 110.516 177.661 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 14.4 p -123.91 154.57 30.6 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 C-N-CA 125.886 1.675 . . . . 0.0 108.579 -177.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.0 m -34.57 148.55 0.1 Allowed Pre-proline 0 CA--C 1.541 0.609 0 C-N-CA 126.693 1.997 . . . . 0.0 113.715 172.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -76.49 -37.82 1.21 Allowed 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 122.964 2.443 . . . . 0.0 113.057 -174.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 96.1 mt -132.3 30.7 4.16 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.908 0.883 . . . . 0.0 109.434 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -152.16 -173.9 4.7 Favored 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 -177.087 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -134.43 58.19 0.69 Allowed Glycine 0 C--N 1.339 0.714 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -176.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.7 t -133.86 158.74 42.55 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 C-N-CA 125.296 1.438 . . . . 0.0 107.947 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.5 -174.49 35.65 Favored Glycine 0 CA--C 1.529 0.937 0 N-CA-C 111.413 -0.675 . . . . 0.0 111.413 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 52.8 mtpt -71.03 -60.62 2.13 Favored 'General case' 0 CA--C 1.529 0.154 0 O-C-N 121.978 -0.719 . . . . 0.0 109.999 175.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 54.67 -68.53 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 129.357 3.063 . . . . 0.0 114.202 176.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -138.46 140.48 39.25 Favored 'General case' 0 CA--C 1.527 0.092 0 C-N-CA 125.26 1.424 . . . . 0.0 108.203 178.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 7.6 p90 -156.29 110.13 2.74 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -168.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -86.27 133.44 33.82 Favored 'General case' 0 C--O 1.225 -0.204 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -178.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 32.2 tt0 -71.52 135.67 47.19 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 178.053 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.8 t -97.72 109.99 24.6 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 C-N-CA 126.39 1.876 . . . . 0.0 106.393 177.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -72.72 60.2 0.49 Allowed 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 125.878 1.671 . . . . 0.0 114.308 -174.073 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 . . . . . 0 C--O 1.26 1.627 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 152.236 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 49.7 mtt . . . . . 0 N--CA 1.476 0.844 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 8.9 mttm -87.25 142.91 27.54 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-O 120.89 0.376 . . . . 0.0 111.109 -178.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 90.6 mttt -71.37 171.35 11.37 Favored 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 123.557 0.743 . . . . 0.0 110.2 174.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -145.52 148.55 33.34 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.481 0.713 . . . . 0.0 111.253 -179.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.5 m -80.07 122.16 26.43 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 123.294 0.638 . . . . 0.0 110.021 176.082 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 7.2 t -58.91 94.72 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.326 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 168.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 59.3 m -66.37 141.34 57.99 Favored 'General case' 0 N--CA 1.449 -0.488 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -171.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . 0.305 12.7 p 54.37 20.5 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 125.845 1.658 . . . . 0.0 113.293 -171.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 66.9 m -139.03 -162.43 1.32 Allowed 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.591 1.557 . . . . 0.0 107.967 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.36 62.56 0.37 Allowed Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 178.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 6.1 t80 -150.82 66.13 0.92 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 124.069 0.947 . . . . 0.0 109.718 -173.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.1 mt -37.79 125.19 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 124.724 1.21 . . . . 0.0 112.791 -175.205 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.545 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 25.9 t80 -78.05 135.62 37.77 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 175.539 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 57.2 t-20 -120.11 111.52 35.38 Favored Pre-proline 0 N--CA 1.452 -0.338 0 C-N-CA 123.913 0.885 . . . . 0.0 109.807 176.103 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -64.98 -37.96 31.04 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.406 1.404 . . . . 0.0 111.479 -175.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -61.21 -29.91 70.11 Favored 'General case' 0 N--CA 1.446 -0.67 0 O-C-N 123.393 0.433 . . . . 0.0 111.074 -176.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -87.24 -33.17 19.4 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 123.962 0.905 . . . . 0.0 109.705 173.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.44 -158.14 39.83 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -167.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -142.54 62.36 12.81 Favored Pre-proline 0 CA--C 1.537 0.476 0 C-N-CA 125.503 1.521 . . . . 0.0 107.746 172.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.06 -33.98 81.25 Favored 'Trans proline' 0 N--CA 1.455 -0.788 0 C-N-CA 122.558 2.172 . . . . 0.0 111.179 -170.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -57.41 -29.89 64.51 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 124.833 1.253 . . . . 0.0 110.35 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 21.3 m-80 -99.26 -23.4 15.21 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 125.554 1.541 . . . . 0.0 110.98 -176.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 131.52 7.42 3.1 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 124.571 1.081 . . . . 0.0 113.321 169.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.0 t -107.53 110.23 31.1 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.261 0 CA-C-N 118.313 1.057 . . . . 0.0 108.612 -174.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -64.08 155.16 79.86 Favored Pre-proline 0 CA--C 1.534 0.329 0 O-C-N 121.783 -0.573 . . . . 0.0 110.537 -177.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -59.58 149.9 79.42 Favored 'Trans proline' 0 N--CA 1.449 -1.127 0 C-N-CA 121.308 1.339 . . . . 0.0 110.679 170.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.65 23.45 76.79 Favored Glycine 0 CA--C 1.524 0.656 0 C-N-CA 125.469 1.509 . . . . 0.0 112.891 -175.16 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 94.2 m -97.81 117.66 32.63 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 119.514 1.657 . . . . 0.0 107.703 176.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.8 t0 -61.08 137.37 58.24 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 173.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.3 t80 -44.12 -35.11 2.03 Favored 'General case' 0 CA--C 1.537 0.445 0 N-CA-C 113.588 0.959 . . . . 0.0 113.588 172.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 5.8 pttt -69.73 -37.89 76.66 Favored 'General case' 0 CA--C 1.532 0.279 0 O-C-N 120.813 -1.179 . . . . 0.0 110.144 -179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -73.64 -20.42 60.58 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 125.226 1.41 . . . . 0.0 109.799 -175.018 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.545 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.4 mt -54.36 131.07 62.03 Favored Pre-proline 0 N--CA 1.441 -0.882 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 176.317 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -60.66 135.84 62.99 Favored 'Trans proline' 0 N--CA 1.446 -1.276 0 C-N-CA 122.094 1.863 . . . . 0.0 108.551 178.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -72.73 -5.41 37.56 Favored 'General case' 0 CA--C 1.54 0.567 0 O-C-N 121.89 -0.507 . . . . 0.0 111.744 -178.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.4 -26.41 66.42 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 124.98 1.312 . . . . 0.0 112.08 164.488 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 83.8 t90 -69.86 149.14 48.18 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.644 0.735 . . . . 0.0 110.639 -174.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 5.2 m -123.12 157.55 28.57 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 C-N-CA 125.913 1.685 . . . . 0.0 109.645 -179.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.5 m -39.65 144.02 0.52 Allowed Pre-proline 0 CA--C 1.532 0.287 0 C-N-CA 126.351 1.861 . . . . 0.0 113.187 177.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_endo -70.19 -31.94 17.71 Favored 'Trans proline' 0 N--CA 1.451 -1.003 0 C-N-CA 123.227 2.618 . . . . 0.0 112.832 -173.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 16.1 tp -149.32 35.87 0.73 Allowed 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.68 -0.637 . . . . 0.0 110.732 -179.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.5 m -131.19 -47.41 1.0 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.625 0.77 . . . . 0.0 110.607 -178.306 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 85.43 62.32 1.65 Allowed Glycine 0 CA--C 1.531 1.057 0 C-N-CA 123.608 0.623 . . . . 0.0 112.254 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.1 p -151.69 159.18 4.16 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 172.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -68.04 167.56 42.39 Favored Glycine 0 CA--C 1.53 1.014 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 54.9 mtpt -50.33 -58.13 6.35 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.757 0.823 . . . . 0.0 111.215 177.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.8 t0 21.11 85.83 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 128.275 2.63 . . . . 0.0 115.016 -172.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER 75.2 150.66 0.11 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 125.825 1.65 . . . . 0.0 110.228 178.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.3 p90 -171.02 109.44 0.31 Allowed 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -163.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 52.5 mt-10 -87.27 135.81 33.17 Favored 'General case' 0 CA--C 1.519 -0.228 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 -176.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 25.3 tt0 -76.88 137.55 39.21 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -178.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.1 t -98.47 109.91 24.89 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.042 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 176.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -74.69 59.62 0.87 Allowed 'General case' 0 N--CA 1.451 -0.398 0 C-N-CA 126.197 1.799 . . . . 0.0 113.914 -171.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 . . . . . 0 C--O 1.259 1.596 0 CA-C-N 114.845 -1.07 . . . . 0.0 108.372 156.286 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.408 4.9 ptt? . . . . . 0 N--CA 1.469 0.503 0 N-CA-C 104.824 -2.287 . . . . 0.0 104.824 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 38.1 mttm 62.54 162.0 0.09 Allowed 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 126.278 1.831 . . . . 0.0 112.911 -171.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 72.7 mttt -80.37 165.61 22.1 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 115.219 -0.9 . . . . 0.0 108.653 -176.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -144.92 136.25 25.17 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.04 -179.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.8 t -92.11 135.79 33.69 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 111.689 0.255 . . . . 0.0 111.689 172.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 48.0 t -77.56 47.45 0.6 Allowed 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 127.223 2.209 . . . . 0.0 109.389 177.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 10.9 m 43.39 -124.27 0.81 Allowed 'General case' 0 CA--C 1.548 0.902 0 O-C-N 120.266 -1.521 . . . . 0.0 111.93 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 45.1 t -82.75 70.63 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 O-C-N 120.541 -1.35 . . . . 0.0 108.919 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 42.5 t -133.0 -70.04 0.55 Allowed 'General case' 0 CA--C 1.529 0.153 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 175.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.15 60.58 0.96 Allowed Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 2.3 t80 -131.91 -57.63 0.98 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.904 0.882 . . . . 0.0 110.393 -179.834 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 74.0 mt 75.17 119.15 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.53 0.178 0 C-N-CA 127.135 2.174 . . . . 0.0 111.683 -175.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.566 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 44.1 t80 -82.03 132.41 35.25 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 170.076 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 56.8 t-20 -118.87 112.64 36.46 Favored Pre-proline 0 C--O 1.227 -0.12 0 C-N-CA 124.348 1.059 . . . . 0.0 109.403 174.04 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -65.53 -38.23 26.27 Favored 'Trans proline' 0 N--CA 1.447 -1.265 0 C-N-CA 121.111 1.208 . . . . 0.0 111.573 -174.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -57.47 -32.22 66.74 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-N 117.97 0.35 . . . . 0.0 111.03 -179.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 60.1 m-20 -90.06 -29.83 18.11 Favored 'General case' 0 CA--C 1.534 0.327 0 C-N-CA 123.705 0.802 . . . . 0.0 110.232 177.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.08 -158.67 41.35 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -168.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -141.87 60.82 11.71 Favored Pre-proline 0 CA--C 1.539 0.555 0 C-N-CA 125.373 1.469 . . . . 0.0 107.763 172.17 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -62.17 -33.64 81.16 Favored 'Trans proline' 0 N--CA 1.455 -0.767 0 C-N-CA 122.403 2.068 . . . . 0.0 111.173 -170.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -55.85 -31.35 62.67 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 125.011 1.324 . . . . 0.0 110.641 177.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.6 m-80 -97.83 -27.76 14.15 Favored 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 125.521 1.528 . . . . 0.0 110.663 -177.059 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.23 9.34 1.44 Allowed Glycine 0 CA--C 1.532 1.154 0 C-N-CA 124.345 0.974 . . . . 0.0 113.829 169.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 54.7 t -110.06 111.63 37.0 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.248 0 CA-C-N 118.579 1.189 . . . . 0.0 109.065 -174.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -63.62 154.8 78.79 Favored Pre-proline 0 C--N 1.328 -0.335 0 O-C-N 121.9 -0.5 . . . . 0.0 111.056 -177.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -59.94 150.15 79.84 Favored 'Trans proline' 0 N--CA 1.449 -1.097 0 C-N-CA 121.423 1.416 . . . . 0.0 110.744 171.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 72.22 16.67 77.08 Favored Glycine 0 CA--C 1.525 0.704 0 CA-C-O 118.289 -1.284 . . . . 0.0 112.798 -174.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 92.4 m -87.75 117.6 26.69 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-N 119.951 1.875 . . . . 0.0 107.386 176.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 17.4 t0 -56.56 133.28 53.42 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.167 170.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.2 t80 -42.67 -38.31 2.0 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 123.326 0.65 . . . . 0.0 112.053 170.231 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.1 pttp -66.34 -39.08 88.97 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 118.181 -1.408 . . . . 0.0 109.945 -177.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -81.66 -11.37 59.11 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 126.108 1.763 . . . . 0.0 110.626 -172.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.566 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.8 mt -56.42 134.28 76.57 Favored Pre-proline 0 N--CA 1.443 -0.801 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 171.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 8.1 Cg_exo -58.08 138.35 85.5 Favored 'Trans proline' 0 N--CA 1.454 -0.796 0 C-N-CA 123.556 2.838 . . . . 0.0 110.932 176.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 69.4 m-20 -69.92 -15.02 63.0 Favored 'General case' 0 N--CA 1.448 -0.55 0 O-C-N 121.071 -1.018 . . . . 0.0 111.822 177.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -78.96 -9.75 59.62 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 124.59 1.156 . . . . 0.0 112.065 169.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 76.9 t90 -72.22 156.12 39.49 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.086 0.857 . . . . 0.0 110.369 175.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 13.1 t -130.76 143.58 40.46 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 125.174 1.389 . . . . 0.0 108.227 -170.205 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 20.2 t -68.18 137.33 91.7 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 123.438 0.695 . . . . 0.0 109.629 177.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -68.15 127.85 16.59 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 122.749 2.299 . . . . 0.0 111.42 177.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 29.1 mt 61.26 44.73 9.5 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.759 1.223 . . . . 0.0 111.97 174.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 14.4 t -149.05 178.63 8.54 Favored 'General case' 0 N--CA 1.452 -0.348 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -176.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -105.28 171.43 18.62 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 171.439 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.324 3.9 p 48.07 -149.39 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 CA-C-O 117.447 -1.263 . . . . 0.0 111.219 -173.421 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -146.13 -143.3 3.89 Favored Glycine 0 C--N 1.339 0.708 0 CA-C-N 121.475 1.943 . . . . 0.0 111.131 -173.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 4.4 ptmt -78.11 115.53 17.9 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 172.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -158.43 -63.59 0.08 Allowed 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.029 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -105.0 97.53 7.37 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.638 1.175 . . . . 0.0 109.392 179.509 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.7 p90 -141.12 135.16 30.63 Favored 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 124.201 1.001 . . . . 0.0 109.189 -178.327 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 22.6 mt-10 -108.44 155.06 21.01 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 124.734 1.213 . . . . 0.0 109.519 178.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -78.96 143.22 35.98 Favored 'General case' 0 N--CA 1.446 -0.665 0 C-N-CA 123.635 0.774 . . . . 0.0 109.646 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.3 t -112.07 108.38 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 C-N-CA 126.679 1.991 . . . . 0.0 106.564 178.384 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -81.18 55.21 2.46 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 125.005 1.322 . . . . 0.0 113.098 -175.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 . . . . . 0 C--O 1.25 1.119 0 C-N-CA 124.911 1.285 . . . . 0.0 109.681 176.454 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.378 23.2 ptm . . . . . 0 N--CA 1.473 0.7 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 43.2 mttm 60.15 168.36 0.08 Allowed 'General case' 0 N--CA 1.452 -0.366 0 C-N-CA 126.013 1.725 . . . . 0.0 112.618 -170.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 3.7 mtpt -78.91 166.97 21.8 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.205 -177.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -147.68 149.31 32.23 Favored 'General case' 0 C--N 1.331 -0.224 0 C-N-CA 123.068 0.547 . . . . 0.0 111.067 -179.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 57.4 p -74.38 170.82 14.87 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 123.281 0.633 . . . . 0.0 112.214 172.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 42.1 t -83.16 -53.06 6.07 Favored 'General case' 0 C--O 1.224 -0.254 0 C-N-CA 125.203 1.401 . . . . 0.0 109.074 162.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 85.9 m 61.25 22.74 13.04 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 124.017 0.927 . . . . 0.0 111.569 -173.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 66.1 t -123.34 -65.15 1.27 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 C-N-CA 124.421 1.088 . . . . 0.0 108.453 166.057 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 26.5 p -94.56 -60.53 1.69 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 118.633 0.651 . . . . 0.0 110.706 175.527 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 138.6 45.98 0.07 OUTLIER Glycine 0 CA--C 1.531 1.075 0 C-N-CA 124.873 1.225 . . . . 0.0 112.166 -176.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -111.13 103.27 11.69 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 125.122 1.369 . . . . 0.0 109.705 -179.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.6 mt -72.52 123.73 27.8 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 O-C-N 120.919 -1.113 . . . . 0.0 110.085 178.034 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.55 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 48.4 t80 -79.38 138.59 37.71 Favored 'General case' 0 C--O 1.236 0.392 0 C-N-CA 124.396 1.078 . . . . 0.0 108.451 170.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -124.02 114.33 27.99 Favored Pre-proline 0 C--O 1.226 -0.141 0 C-N-CA 124.005 0.922 . . . . 0.0 109.995 174.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_endo -65.95 -39.46 19.3 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 120.954 1.102 . . . . 0.0 111.969 -175.309 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 -58.66 -31.4 68.14 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-N 118.318 0.508 . . . . 0.0 111.149 -178.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -88.91 -30.86 18.53 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.505 0.722 . . . . 0.0 109.954 177.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.52 -159.99 41.13 Favored Glycine 0 CA--C 1.528 0.868 0 C-N-CA 124.095 0.855 . . . . 0.0 110.997 -168.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.04 61.25 17.2 Favored Pre-proline 0 CA--C 1.539 0.532 0 C-N-CA 125.445 1.498 . . . . 0.0 107.712 170.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_endo -63.45 -28.3 70.93 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.237 1.958 . . . . 0.0 111.229 -171.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -61.56 -28.49 69.37 Favored 'General case' 0 N--CA 1.448 -0.555 0 C-N-CA 123.534 0.734 . . . . 0.0 110.076 178.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 20.4 m-80 -99.84 -26.93 13.86 Favored 'General case' 0 N--CA 1.456 -0.154 0 C-N-CA 125.236 1.414 . . . . 0.0 110.958 -177.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 133.2 17.12 1.15 Allowed Glycine 0 CA--C 1.531 1.052 0 C-N-CA 124.216 0.913 . . . . 0.0 113.635 170.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 78.5 t -115.43 109.59 28.87 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.272 0 CA-C-N 118.466 1.133 . . . . 0.0 108.381 -175.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -63.39 155.67 73.71 Favored Pre-proline 0 C--N 1.328 -0.327 0 O-C-N 121.671 -0.643 . . . . 0.0 111.23 -176.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.0 149.02 86.68 Favored 'Trans proline' 0 N--CA 1.448 -1.147 0 C-N-CA 121.279 1.32 . . . . 0.0 110.619 171.046 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.39 16.61 78.81 Favored Glycine 0 N--CA 1.445 -0.709 0 CA-C-O 118.307 -1.274 . . . . 0.0 112.693 -174.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 81.7 m -87.95 117.72 27.0 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 119.873 1.836 . . . . 0.0 106.942 176.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -58.58 136.51 57.61 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 171.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -45.76 -37.3 5.83 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 122.975 0.51 . . . . 0.0 111.337 171.526 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 48.0 pttt -66.41 -38.49 87.58 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 117.783 -1.567 . . . . 0.0 110.468 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -76.1 -18.88 58.98 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 125.012 1.325 . . . . 0.0 110.506 -174.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.55 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.7 mt -53.81 133.92 56.67 Favored Pre-proline 0 N--CA 1.446 -0.627 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 175.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -65.18 139.66 61.53 Favored 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 122.133 1.889 . . . . 0.0 109.7 179.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -66.3 -11.33 50.07 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 123.708 0.803 . . . . 0.0 111.54 177.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.4 -22.11 61.91 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.64 1.176 . . . . 0.0 112.11 170.285 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 84.9 t90 -73.39 155.7 39.08 Favored 'General case' 0 N--CA 1.455 -0.209 0 O-C-N 121.527 -0.733 . . . . 0.0 110.386 -177.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.72 159.68 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 C-N-CA 125.541 1.536 . . . . 0.0 109.232 -177.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 44.4 t -68.17 134.91 91.43 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 124.228 1.011 . . . . 0.0 109.668 -177.083 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -62.1 126.33 18.45 Favored 'Trans proline' 0 N--CA 1.453 -0.879 0 C-N-CA 122.475 2.117 . . . . 0.0 110.883 178.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 41.0 mt 64.92 34.84 8.75 Favored 'General case' 0 CA--C 1.531 0.231 0 C-N-CA 124.467 1.107 . . . . 0.0 111.615 174.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 41.5 t -151.61 160.95 43.44 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 106.399 -1.704 . . . . 0.0 106.399 -175.041 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -115.94 110.13 2.14 Favored Glycine 0 CA--C 1.521 0.44 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 -174.125 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 36.0 t 78.84 123.35 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.264 0 C-N-CA 126.547 1.939 . . . . 0.0 108.785 -171.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -156.59 173.12 34.36 Favored Glycine 0 C--N 1.334 0.459 0 N-CA-C 107.696 -2.162 . . . . 0.0 107.696 178.04 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 53.87 74.05 0.35 Allowed 'General case' 0 CA--C 1.534 0.346 0 CA-C-O 122.941 1.353 . . . . 0.0 110.295 -170.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -152.59 -69.67 0.16 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 113.707 -1.588 . . . . 0.0 108.151 170.055 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -113.67 101.3 9.19 Favored 'General case' 0 CA--C 1.534 0.333 0 C-N-CA 124.93 1.292 . . . . 0.0 108.453 -178.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -140.27 131.93 27.25 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 125.092 1.357 . . . . 0.0 107.783 -175.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 26.7 mt-10 -96.63 149.35 21.89 Favored 'General case' 0 C--O 1.223 -0.297 0 C-N-CA 124.903 1.281 . . . . 0.0 109.28 -176.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -75.76 140.86 42.61 Favored 'General case' 0 N--CA 1.446 -0.637 0 CA-C-N 119.042 0.837 . . . . 0.0 109.218 178.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.2 t -106.63 107.57 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.858 0 C-N-CA 125.611 1.564 . . . . 0.0 106.8 176.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -76.85 57.03 1.25 Allowed 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 125.619 1.568 . . . . 0.0 113.075 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 . . . . . 0 C--O 1.251 1.144 0 CA-C-O 117.278 -1.344 . . . . 0.0 108.462 159.113 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.404 ' N ' ' OE2' ' A' ' 16' ' ' GLU . 8.1 mtt . . . . . 0 N--CA 1.478 0.932 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.5 mmmt -91.67 149.56 21.57 Favored 'General case' 0 CA--C 1.52 -0.185 0 CA-C-O 121.391 0.615 . . . . 0.0 110.08 -175.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 44.1 mtpt -74.12 169.75 16.89 Favored 'General case' 0 N--CA 1.448 -0.547 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.568 -177.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -143.02 142.59 31.62 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 119.582 -0.247 . . . . 0.0 110.724 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.8 t -85.15 141.7 30.01 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 119.61 -0.836 . . . . 0.0 109.977 170.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 52.2 t -71.19 170.46 12.94 Favored 'General case' 0 CA--C 1.539 0.54 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 154.332 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.3 p -69.28 81.02 0.36 Allowed 'General case' 0 CA--C 1.533 0.32 0 O-C-N 120.97 -1.081 . . . . 0.0 110.725 -173.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 99.1 t 66.98 -74.88 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.456 -0.158 0 C-N-CA 126.014 1.725 . . . . 0.0 108.154 -170.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 48.1 t 43.05 -122.68 0.72 Allowed 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 124.77 1.228 . . . . 0.0 109.803 174.382 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -177.42 41.11 0.1 OUTLIER Glycine 0 CA--C 1.527 0.806 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 166.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -148.45 74.6 1.29 Allowed 'General case' 0 CA--C 1.535 0.376 0 CA-C-O 121.748 0.785 . . . . 0.0 109.397 -169.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 12.6 mt -59.82 131.67 24.57 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.167 0 O-C-N 121.699 -0.626 . . . . 0.0 109.657 175.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.576 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 33.9 t80 -82.82 138.17 34.05 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 174.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 56.9 t-20 -124.17 112.47 28.26 Favored Pre-proline 0 N--CA 1.454 -0.241 0 C-N-CA 124.229 1.011 . . . . 0.0 109.705 175.424 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_endo -66.19 -35.19 33.78 Favored 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 121.076 1.184 . . . . 0.0 111.395 -174.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . 0.404 ' OE2' ' N ' ' A' ' 1' ' ' MET . 20.1 mt-10 -65.13 -27.71 68.93 Favored 'General case' 0 N--CA 1.443 -0.792 0 O-C-N 123.313 0.383 . . . . 0.0 110.934 -176.112 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 76.7 m-20 -87.37 -31.57 20.05 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.328 1.051 . . . . 0.0 109.788 171.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 70.27 -151.82 50.28 Favored Glycine 0 N--CA 1.445 -0.732 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -167.027 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 25.6 t0 -151.87 63.94 5.55 Favored Pre-proline 0 N--CA 1.443 -0.799 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 171.643 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -64.91 -28.28 58.49 Favored 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 122.701 2.267 . . . . 0.0 111.634 -166.214 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -62.37 -24.93 67.64 Favored 'General case' 0 N--CA 1.446 -0.66 0 C-N-CA 123.701 0.801 . . . . 0.0 109.727 -178.205 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.9 m-80 -111.37 17.12 20.47 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.062 1.345 . . . . 0.0 109.993 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 95.73 3.95 60.67 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 124.325 0.964 . . . . 0.0 114.63 170.861 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.9 t -104.16 107.84 23.28 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.23 0 CA-C-N 119.127 1.464 . . . . 0.0 109.345 -172.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -65.36 153.89 88.87 Favored Pre-proline 0 CA--C 1.536 0.44 0 O-C-N 121.614 -0.679 . . . . 0.0 110.697 -176.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_endo -58.38 149.11 76.24 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 121.575 1.517 . . . . 0.0 111.135 170.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.66 19.33 79.21 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 125.004 1.288 . . . . 0.0 112.47 -175.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 99.8 m -94.27 114.45 26.54 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 119.61 1.705 . . . . 0.0 106.811 176.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -59.72 138.24 57.82 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 170.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.434 ' CD1' ' CD2' ' A' ' 49' ' ' PHE . 2.1 t80 -42.14 -38.63 1.76 Allowed 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 113.194 0.813 . . . . 0.0 113.194 171.189 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 55.8 pttt -64.99 -40.13 94.51 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 118.345 -1.342 . . . . 0.0 110.224 -178.136 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -78.73 -12.45 60.02 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 125.057 1.343 . . . . 0.0 111.169 -175.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.576 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.8 mt -57.23 132.76 80.94 Favored Pre-proline 0 N--CA 1.442 -0.873 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 172.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -63.5 137.3 59.08 Favored 'Trans proline' 0 N--CA 1.442 -1.519 0 C-N-CA 121.641 1.56 . . . . 0.0 108.605 176.357 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -70.56 -3.47 18.25 Favored 'General case' 0 N--CA 1.447 -0.621 0 C-N-CA 123.543 0.737 . . . . 0.0 111.977 179.157 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -73.96 -24.71 59.67 Favored 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.968 1.707 . . . . 0.0 111.983 166.38 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 78.9 t90 -65.75 158.5 27.42 Favored 'General case' 0 CA--C 1.528 0.112 0 O-C-N 121.746 -0.596 . . . . 0.0 109.805 178.11 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.413 ' CG2' ' HA2' ' A' ' 43' ' ' GLY . 8.0 p -141.34 145.73 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 C-N-CA 123.895 0.878 . . . . 0.0 109.935 -173.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 53.2 t -66.92 125.12 90.33 Favored Pre-proline 0 C--O 1.24 0.597 0 C-N-CA 123.392 0.677 . . . . 0.0 110.029 178.472 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -66.04 133.7 34.27 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 123.26 2.64 . . . . 0.0 111.035 -175.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 48.4 mt 60.23 30.06 19.54 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 124.536 1.134 . . . . 0.0 112.042 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 8.4 t -142.67 -68.19 0.36 Allowed 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 124.097 0.959 . . . . 0.0 108.841 -176.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . 0.413 ' HA2' ' CG2' ' A' ' 38' ' ' VAL . . . 85.71 17.98 60.8 Favored Glycine 0 CA--C 1.532 1.127 0 CA-C-O 118.613 -1.104 . . . . 0.0 114.737 177.464 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.8 p -72.17 -54.98 14.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 CA-C-N 119.761 1.781 . . . . 0.0 112.94 -176.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.95 -152.82 24.32 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 108.514 -1.834 . . . . 0.0 108.514 -170.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.55 33.89 0.78 Allowed 'General case' 0 CA--C 1.53 0.189 0 CA-C-N 118.217 1.009 . . . . 0.0 112.063 169.281 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -98.27 -49.66 4.62 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 125.086 1.354 . . . . 0.0 110.114 -161.406 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 9.1 mm100 -94.23 67.23 3.53 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.057 1.343 . . . . 0.0 108.597 178.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.434 ' CD2' ' CD1' ' A' ' 30' ' ' PHE . 20.5 p90 -101.81 115.06 29.7 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 124.232 1.013 . . . . 0.0 109.214 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -99.27 142.92 30.13 Favored 'General case' 0 CA--C 1.519 -0.22 0 N-CA-C 108.164 -1.051 . . . . 0.0 108.164 174.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -73.04 134.78 44.75 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 15.3 t -93.29 108.86 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 174.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -78.64 51.28 1.06 Allowed 'General case' 0 N--CA 1.445 -0.698 0 C-N-CA 124.536 1.135 . . . . 0.0 113.489 -173.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 . . . . . 0 C--O 1.259 1.589 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 149.719 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.357 20.7 ptm . . . . . 0 N--CA 1.476 0.837 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 14.9 mttt 62.18 171.6 0.13 Allowed 'General case' 0 N--CA 1.453 -0.31 0 C-N-CA 125.867 1.667 . . . . 0.0 112.672 -171.155 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 58.9 mttt -75.02 167.07 22.63 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-N 115.241 -0.891 . . . . 0.0 109.492 -174.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -145.48 144.08 30.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.937 178.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 13.5 m -76.89 150.95 35.98 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-O 119.303 -0.379 . . . . 0.0 110.988 169.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 46.3 t -65.07 171.13 3.83 Favored 'General case' 0 CA--C 1.539 0.52 0 CA-C-O 121.345 0.593 . . . . 0.0 110.136 170.003 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 1.9 t -71.52 -42.87 67.44 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 124.944 1.298 . . . . 0.0 111.402 -176.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 29.5 m -140.5 24.22 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -178.413 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 18.4 p -147.56 -166.37 2.5 Favored 'General case' 0 N--CA 1.455 -0.198 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 168.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -83.93 -82.0 0.99 Allowed Glycine 0 CA--C 1.525 0.705 0 N-CA-C 109.211 -1.556 . . . . 0.0 109.211 175.009 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 63.5 m-85 21.0 65.27 0.03 OUTLIER 'General case' 0 C--N 1.346 0.418 0 C-N-CA 128.452 2.701 . . . . 0.0 111.941 -175.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 23.4 mt -58.55 121.59 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.015 -173.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.554 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 35.2 t80 -73.29 138.12 45.27 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 173.282 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 62.1 t-20 -125.65 111.99 25.27 Favored Pre-proline 0 N--CA 1.454 -0.243 0 C-N-CA 123.975 0.91 . . . . 0.0 109.541 176.646 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -63.65 -39.69 33.73 Favored 'Trans proline' 0 N--CA 1.448 -1.204 0 C-N-CA 121.267 1.311 . . . . 0.0 111.355 -173.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.1 mt-10 -56.12 -32.82 64.57 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 117.977 0.353 . . . . 0.0 111.254 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -91.76 -29.84 16.57 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.453 0.701 . . . . 0.0 110.334 179.271 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 66.17 -159.0 47.63 Favored Glycine 0 CA--C 1.53 1.03 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 -170.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.19 61.1 16.26 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 125.615 1.566 . . . . 0.0 107.393 171.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -61.59 -35.53 80.77 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 122.757 2.305 . . . . 0.0 111.451 -168.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -57.67 -31.38 66.28 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 124.875 1.27 . . . . 0.0 110.516 179.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.1 m-80 -92.21 -28.12 17.23 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 125.218 1.407 . . . . 0.0 110.469 -179.468 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.62 0.48 2.91 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.4 1.0 . . . . 0.0 113.205 171.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 75.2 t -100.97 111.08 29.52 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.206 0 CA-C-N 118.225 1.012 . . . . 0.0 109.002 -172.333 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -64.53 154.95 82.95 Favored Pre-proline 0 CA--C 1.533 0.308 0 O-C-N 121.765 -0.584 . . . . 0.0 110.929 -176.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -58.77 149.33 78.17 Favored 'Trans proline' 0 N--CA 1.449 -1.117 0 C-N-CA 121.425 1.416 . . . . 0.0 110.84 170.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.41 14.98 79.1 Favored Glycine 0 CA--C 1.526 0.74 0 C-N-CA 125.813 1.673 . . . . 0.0 113.082 -174.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.7 m -87.07 120.1 27.99 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 120.05 1.925 . . . . 0.0 107.871 178.343 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -59.81 134.45 57.04 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 172.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -43.04 -37.87 2.1 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 123.44 0.696 . . . . 0.0 112.176 169.356 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -68.13 -38.89 82.71 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 117.756 -1.578 . . . . 0.0 110.261 -178.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -76.63 -17.57 59.09 Favored 'General case' 0 N--CA 1.455 -0.191 0 C-N-CA 124.989 1.316 . . . . 0.0 110.704 -175.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.554 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 23.0 mt -52.49 132.76 44.64 Favored Pre-proline 0 N--CA 1.445 -0.705 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -63.43 140.13 74.56 Favored 'Trans proline' 0 N--CA 1.445 -1.355 0 C-N-CA 122.234 1.956 . . . . 0.0 109.697 178.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 74.5 m-20 -69.98 -10.16 57.64 Favored 'General case' 0 N--CA 1.444 -0.772 0 C-N-CA 123.529 0.731 . . . . 0.0 111.914 -179.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -77.21 -12.02 59.89 Favored 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 124.232 1.013 . . . . 0.0 112.57 168.355 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -73.36 153.35 40.52 Favored 'General case' 0 CA--C 1.532 0.25 0 CA-C-N 118.853 0.751 . . . . 0.0 110.303 177.646 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 97.4 t -137.02 150.01 26.44 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 125.573 1.549 . . . . 0.0 107.973 -171.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 13.2 t -79.48 130.63 67.61 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 124.854 1.262 . . . . 0.0 109.117 -176.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -64.98 147.91 89.37 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.461 2.108 . . . . 0.0 110.769 -178.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.2 mm? 68.8 -62.31 0.39 Allowed 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 126.323 1.849 . . . . 0.0 111.734 -179.495 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -59.03 -54.56 45.71 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 125.977 1.711 . . . . 0.0 110.787 178.354 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 106.84 -115.53 4.71 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 -176.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.9 t -63.71 105.92 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 O-C-N 121.263 -1.139 . . . . 0.0 110.684 -167.437 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -130.74 -165.59 11.56 Favored Glycine 0 CA--C 1.527 0.809 0 C-N-CA 125.848 1.69 . . . . 0.0 109.323 178.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 55.22 61.74 2.78 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 123.112 1.434 . . . . 0.0 110.376 -173.723 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -156.19 157.49 35.98 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 156.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 45.09 37.83 2.79 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 126.117 1.767 . . . . 0.0 113.047 173.136 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 7.5 p90 -78.07 131.62 37.38 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 124.14 0.976 . . . . 0.0 110.335 -172.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 53.1 mt-10 -97.93 135.34 39.79 Favored 'General case' 0 C--O 1.227 -0.085 0 C-N-CA 123.929 0.892 . . . . 0.0 108.813 -179.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 20.9 tt0 -72.66 138.18 46.52 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 176.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 32.2 t -105.53 105.81 19.37 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.054 0 C-N-CA 127.216 2.207 . . . . 0.0 105.418 176.579 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.0 pt-20 -81.91 54.17 2.39 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.427 1.091 . . . . 0.0 112.927 -173.574 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 . . . . . 0 C--O 1.251 1.143 0 C-N-CA 124.983 1.313 . . . . 0.0 109.617 176.508 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.352 5.9 ptt? . . . . . 0 N--CA 1.474 0.741 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 21.9 mttm 54.64 173.38 0.02 OUTLIER 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 125.102 1.361 . . . . 0.0 112.358 -168.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 28.5 mtpt -72.57 170.27 14.76 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.824 -176.272 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 35.7 m-85 -149.12 145.69 27.33 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 -177.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 44.9 p -71.42 170.62 12.86 Favored 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.213 0.53 . . . . 0.0 112.152 170.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 2.2 t -108.26 166.63 10.61 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 126.998 2.119 . . . . 0.0 105.948 166.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 1.2 p -48.0 -50.3 28.01 Favored 'General case' 0 N--CA 1.447 -0.62 0 C-N-CA 124.683 1.193 . . . . 0.0 111.665 169.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 4.7 m -148.57 16.2 0.11 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 N-CA-C 114.111 1.152 . . . . 0.0 114.111 -173.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 79.7 m -109.18 119.6 40.02 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 119.945 1.248 . . . . 0.0 111.742 178.387 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -75.88 54.35 3.0 Favored Glycine 0 CA--C 1.532 1.137 0 O-C-N 121.55 -0.719 . . . . 0.0 111.411 172.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -111.54 -47.03 3.2 Favored 'General case' 0 N--CA 1.46 0.071 0 C-N-CA 124.556 1.142 . . . . 0.0 110.353 176.175 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 11.5 mt 71.32 128.06 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 C-N-CA 125.561 1.544 . . . . 0.0 111.491 -177.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.531 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 45.3 t80 -76.06 141.61 42.0 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 172.103 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 -125.77 115.58 24.6 Favored Pre-proline 0 N--CA 1.456 -0.174 0 C-N-CA 123.679 0.792 . . . . 0.0 110.421 175.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -67.48 -39.63 12.09 Favored 'Trans proline' 0 N--CA 1.447 -1.238 0 C-N-CA 121.053 1.169 . . . . 0.0 111.695 -176.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 15.3 mt-10 -59.04 -31.08 68.53 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 118.585 0.63 . . . . 0.0 111.152 -178.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.4 m-20 -88.47 -31.71 18.62 Favored 'General case' 0 CA--C 1.53 0.206 0 C-N-CA 123.589 0.755 . . . . 0.0 110.023 176.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.9 -162.02 35.69 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -166.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -138.28 61.3 25.47 Favored Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 125.187 1.395 . . . . 0.0 107.735 171.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -62.8 -31.38 78.21 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 122.332 2.021 . . . . 0.0 111.154 -170.89 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -59.69 -30.65 68.93 Favored 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 123.864 0.866 . . . . 0.0 110.731 178.189 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -96.08 -28.07 14.78 Favored 'General case' 0 N--CA 1.456 -0.129 0 C-N-CA 124.87 1.268 . . . . 0.0 110.51 -178.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.71 16.96 0.97 Allowed Glycine 0 CA--C 1.531 1.081 0 C-N-CA 124.395 0.998 . . . . 0.0 113.992 169.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.1 t -116.72 112.29 38.72 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.304 0 CA-C-N 118.578 1.189 . . . . 0.0 109.006 -175.442 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.44 156.73 75.71 Favored Pre-proline 0 CA--C 1.533 0.316 0 O-C-N 121.898 -0.501 . . . . 0.0 111.136 -177.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -59.68 150.14 78.49 Favored 'Trans proline' 0 N--CA 1.448 -1.161 0 C-N-CA 121.376 1.384 . . . . 0.0 110.802 170.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.57 16.32 79.06 Favored Glycine 0 CA--C 1.527 0.798 0 C-N-CA 125.816 1.674 . . . . 0.0 113.212 -175.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.9 m -89.48 118.56 29.22 Favored 'General case' 0 N--CA 1.445 -0.689 0 CA-C-N 119.923 1.862 . . . . 0.0 108.276 179.138 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -59.65 134.09 56.7 Favored 'General case' 0 N--CA 1.444 -0.734 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 170.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -43.17 -37.04 1.92 Allowed 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 123.596 0.758 . . . . 0.0 112.731 170.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -68.76 -37.84 79.64 Favored 'General case' 0 CA--C 1.534 0.346 0 C-N-CA 118.043 -1.463 . . . . 0.0 110.291 -178.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -77.29 -17.49 58.31 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 125.506 1.522 . . . . 0.0 110.462 -176.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.531 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.2 mt -55.81 133.56 72.77 Favored Pre-proline 0 N--CA 1.443 -0.814 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 173.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -62.97 137.1 60.44 Favored 'Trans proline' 0 N--CA 1.445 -1.359 0 C-N-CA 121.823 1.682 . . . . 0.0 108.98 175.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -71.43 -4.6 27.34 Favored 'General case' 0 N--CA 1.445 -0.683 0 O-C-N 121.95 -0.469 . . . . 0.0 111.728 -179.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.58 -22.65 63.51 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 125.034 1.333 . . . . 0.0 112.182 165.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 81.3 t90 -71.29 152.3 43.39 Favored 'General case' 0 N--CA 1.456 -0.174 0 O-C-N 121.484 -0.76 . . . . 0.0 111.237 -176.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 85.5 t -127.59 146.49 33.23 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 C-N-CA 125.72 1.608 . . . . 0.0 108.356 179.173 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -76.31 160.95 76.64 Favored Pre-proline 0 CA--C 1.538 0.519 0 C-N-CA 122.605 0.362 . . . . 0.0 110.158 -176.152 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -67.11 117.42 4.78 Favored 'Trans proline' 0 N--CA 1.45 -1.058 0 C-N-CA 121.9 1.733 . . . . 0.0 110.687 -170.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 50.5 mt 65.32 51.73 1.54 Allowed 'General case' 0 CA--C 1.534 0.33 0 C-N-CA 125.255 1.422 . . . . 0.0 111.623 177.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.0 t -142.9 -179.48 6.38 Favored 'General case' 0 N--CA 1.456 -0.165 0 C-N-CA 124.275 1.03 . . . . 0.0 108.539 179.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -107.19 -67.21 0.64 Allowed Glycine 0 CA--C 1.526 0.743 0 C-N-CA 124.504 1.05 . . . . 0.0 111.223 -175.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 25.2 m -72.66 164.03 3.66 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 CA-C-N 116.803 0.302 . . . . 0.0 110.201 -179.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -121.4 114.03 2.47 Favored Glycine 0 C--N 1.334 0.441 0 N-CA-C 110.396 -1.082 . . . . 0.0 110.396 -170.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mtpt 62.38 -88.02 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 125.412 1.485 . . . . 0.0 110.388 178.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 46.83 -72.48 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 128.799 2.84 . . . . 0.0 114.303 -172.219 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -127.92 116.78 20.63 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 126.014 1.725 . . . . 0.0 108.925 -176.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 4.9 p90 -149.99 112.68 4.77 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.194 1.397 . . . . 0.0 107.28 -171.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -82.91 145.53 29.35 Favored 'General case' 0 C--O 1.225 -0.225 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 177.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 44.9 tt0 -71.91 136.8 47.02 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 175.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.1 t -102.41 104.34 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 C-N-CA 126.248 1.819 . . . . 0.0 106.336 177.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -78.2 88.35 4.27 Favored 'General case' 0 N--CA 1.438 -1.03 0 CA-C-O 123.215 1.484 . . . . 0.0 109.125 172.182 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 . . . . . 0 C--O 1.257 1.483 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 158.701 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.387 24.9 ptm . . . . . 0 N--CA 1.474 0.75 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 51.2 mttm 64.04 167.82 0.16 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 126.65 1.98 . . . . 0.0 112.704 -172.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 82.9 mttt -80.71 165.02 22.35 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -176.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -141.3 140.95 33.94 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 123.069 0.548 . . . . 0.0 111.069 178.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.3 t -99.4 140.88 32.92 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 113.084 0.772 . . . . 0.0 113.084 175.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.455 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 42.2 t -78.68 50.48 0.98 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.846 2.058 . . . . 0.0 109.399 177.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 5.7 m 53.84 -94.41 0.04 OUTLIER 'General case' 0 CA--C 1.547 0.828 0 O-C-N 120.624 -1.297 . . . . 0.0 112.475 174.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 61.6 t -87.92 -28.93 5.46 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 125.246 1.418 . . . . 0.0 110.849 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.455 ' HB3' ' SG ' ' A' ' 6' ' ' CYS . 53.4 t -78.25 124.69 28.37 Favored 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 124.419 1.088 . . . . 0.0 109.44 -169.286 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -86.45 78.94 1.88 Allowed Glycine 0 CA--C 1.523 0.588 0 CA-C-O 119.211 -0.772 . . . . 0.0 111.283 -170.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 1.8 t80 -134.88 -57.76 0.82 Allowed 'General case' 0 CA--C 1.532 0.267 0 CA-C-N 117.796 0.798 . . . . 0.0 112.889 176.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 55.9 mt 75.22 121.25 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 C-N-CA 126.637 1.975 . . . . 0.0 111.894 -173.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.548 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 77.2 t80 -83.22 138.23 33.7 Favored 'General case' 0 N--CA 1.451 -0.377 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 169.482 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 55.1 t-20 -128.32 115.29 19.93 Favored Pre-proline 0 N--CA 1.454 -0.23 0 C-N-CA 124.582 1.153 . . . . 0.0 109.461 179.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.27 -39.48 17.55 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 C-N-CA 121.779 1.653 . . . . 0.0 112.267 -172.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.2 mt-10 -55.13 -32.78 62.34 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 118.002 0.365 . . . . 0.0 110.749 178.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -95.06 -26.03 16.22 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 123.504 0.722 . . . . 0.0 109.9 -177.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.3 -157.46 36.58 Favored Glycine 0 CA--C 1.527 0.788 0 C-N-CA 124.684 1.135 . . . . 0.0 110.979 -170.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.76 62.31 12.23 Favored Pre-proline 0 CA--C 1.538 0.495 0 C-N-CA 125.062 1.345 . . . . 0.0 107.941 170.137 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -62.43 -33.34 79.65 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.697 2.264 . . . . 0.0 111.185 -170.264 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -56.76 -29.56 62.72 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 124.661 1.184 . . . . 0.0 110.728 178.376 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 -99.07 -30.8 12.11 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 125.267 1.427 . . . . 0.0 110.615 -177.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 140.15 7.49 0.95 Allowed Glycine 0 CA--C 1.531 1.077 0 C-N-CA 123.874 0.75 . . . . 0.0 114.061 169.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.48 HG23 ' CD1' ' A' ' 37' ' ' TRP . 45.6 t -106.58 112.52 40.02 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.217 0 CA-C-N 118.885 1.342 . . . . 0.0 109.04 -176.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -63.91 154.18 82.2 Favored Pre-proline 0 C--N 1.328 -0.351 0 O-C-N 121.982 -0.448 . . . . 0.0 110.585 -178.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -59.19 148.08 87.59 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 121.352 1.368 . . . . 0.0 110.771 170.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 77.77 15.59 81.09 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 124.819 1.2 . . . . 0.0 112.546 -176.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 97.2 m -89.18 118.87 29.19 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 119.698 1.749 . . . . 0.0 107.492 177.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -58.61 135.26 57.32 Favored 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 171.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.413 ' CD1' HD12 ' A' ' 33' ' ' ILE . 6.7 t80 -46.01 -34.66 4.18 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 123.173 0.589 . . . . 0.0 112.426 171.339 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.5 pttp -66.54 -40.02 88.86 Favored 'General case' 0 N--CA 1.453 -0.287 0 C-N-CA 118.076 -1.45 . . . . 0.0 110.083 179.69 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 83.9 m-20 -80.62 -12.49 59.49 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.831 1.652 . . . . 0.0 110.588 -171.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.548 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 17.7 mt -57.2 132.67 80.82 Favored Pre-proline 0 N--CA 1.441 -0.877 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 172.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 1.2 Cg_endo -61.91 138.95 76.95 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 123.044 2.496 . . . . 0.0 109.904 178.072 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -64.66 -17.7 64.3 Favored 'General case' 0 N--CA 1.451 -0.397 0 O-C-N 121.819 -0.551 . . . . 0.0 112.024 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -75.54 -14.75 60.42 Favored 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 123.751 0.821 . . . . 0.0 112.696 173.363 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . 0.48 ' CD1' HG23 ' A' ' 24' ' ' VAL . 78.8 t90 -70.05 150.66 46.37 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-O 121.319 0.581 . . . . 0.0 111.2 -178.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 74.5 t -124.47 150.76 29.35 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.36 0 C-N-CA 125.656 1.582 . . . . 0.0 109.927 -173.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 49.8 t -57.86 136.66 83.41 Favored Pre-proline 0 CA--C 1.537 0.449 0 C-N-CA 125.844 1.658 . . . . 0.0 111.574 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -59.07 123.52 13.66 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 121.842 1.695 . . . . 0.0 110.14 173.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.2 mm? 66.71 21.79 10.5 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 124.701 1.201 . . . . 0.0 112.692 178.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -146.59 177.82 8.77 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 176.64 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -146.61 78.61 0.24 Allowed Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 -166.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.471 HG13 ' H ' ' A' ' 45' ' ' GLY . 7.2 p -143.58 -73.23 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 123.542 0.737 . . . . 0.0 109.928 179.163 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.471 ' H ' HG13 ' A' ' 44' ' ' VAL . . . 145.71 162.97 9.98 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 107.828 -2.109 . . . . 0.0 107.828 -173.547 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.5 ptmt -66.54 -18.7 65.51 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 118.836 1.318 . . . . 0.0 113.351 176.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 30.09 -93.74 0.01 OUTLIER 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 129.564 3.145 . . . . 0.0 111.964 -176.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.34 64.84 0.95 Allowed 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 166.034 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 8.3 m-30 -45.72 156.12 0.14 Allowed 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 125.093 1.357 . . . . 0.0 111.632 174.071 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 40.7 mt-10 -88.49 147.89 24.43 Favored 'General case' 0 C--O 1.225 -0.196 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 -175.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 34.3 tt0 -74.55 141.49 44.79 Favored 'General case' 0 N--CA 1.442 -0.851 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 16.7 t -106.21 113.72 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.915 0 N-CA-C 105.712 -1.958 . . . . 0.0 105.712 175.224 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -73.79 56.55 0.56 Allowed 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.546 1.539 . . . . 0.0 113.423 -178.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 4.0 mt-10 . . . . . 0 C--O 1.254 1.338 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 158.363 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.411 13.5 ptt? . . . . . 0 N--CA 1.476 0.865 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.4 mttm 57.79 174.94 0.05 Allowed 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 126.343 1.857 . . . . 0.0 112.38 -166.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 76.6 mttt -70.73 169.73 13.88 Favored 'General case' 0 N--CA 1.442 -0.854 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.239 -179.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 48.9 m-85 -147.65 142.74 27.09 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 118.636 -0.697 . . . . 0.0 110.815 -177.205 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.2 m -79.95 146.43 32.09 Favored 'General case' 0 CA--C 1.535 0.372 0 CA-C-N 119.014 0.825 . . . . 0.0 109.811 172.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 46.6 t -67.45 176.01 2.53 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 166.642 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 90.0 m -76.4 -74.18 0.24 Allowed 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 125.619 1.567 . . . . 0.0 112.297 -167.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 41.2 t -115.73 2.35 7.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 C-N-CA 124.555 1.142 . . . . 0.0 110.557 177.547 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 10.4 t -80.58 -164.98 0.79 Allowed 'General case' 0 CA--C 1.536 0.44 0 C-N-CA 125.766 1.626 . . . . 0.0 108.725 -179.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -135.98 49.21 0.89 Allowed Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 44.3 m-85 -133.41 158.86 41.97 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.14 0.976 . . . . 0.0 110.168 179.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 13.8 mt -119.9 127.66 75.89 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 125.548 1.539 . . . . 0.0 108.224 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.535 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 25.0 t80 -78.39 140.21 38.73 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 124.807 1.243 . . . . 0.0 108.353 169.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 50.7 t-20 -124.81 111.87 27.29 Favored Pre-proline 0 N--CA 1.458 -0.072 0 C-N-CA 123.99 0.916 . . . . 0.0 109.963 176.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -63.73 -39.75 32.75 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 121.11 1.206 . . . . 0.0 111.59 -173.221 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 22.2 mt-10 -57.99 -31.92 67.39 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 118.052 0.387 . . . . 0.0 111.401 -179.065 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -86.88 -34.5 19.41 Favored 'General case' 0 C--O 1.232 0.177 0 C-N-CA 123.195 0.598 . . . . 0.0 109.787 177.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 58.43 -161.96 11.11 Favored Glycine 0 CA--C 1.529 0.921 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -164.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -139.34 67.52 38.76 Favored Pre-proline 0 CA--C 1.535 0.396 0 C-N-CA 124.509 1.123 . . . . 0.0 108.299 169.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -58.63 -30.02 90.9 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 121.805 1.67 . . . . 0.0 110.855 -176.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 85.1 m-20 -60.2 -31.97 70.65 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 124.075 0.95 . . . . 0.0 110.753 178.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 9.2 m-80 -98.8 -24.19 15.1 Favored 'General case' 0 C--N 1.341 0.228 0 C-N-CA 124.136 0.974 . . . . 0.0 110.292 -177.016 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 133.11 10.65 1.92 Allowed Glycine 0 CA--C 1.531 1.046 0 C-N-CA 124.484 1.04 . . . . 0.0 113.251 171.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.3 t -110.0 109.87 30.04 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.273 0 CA-C-N 118.593 1.197 . . . . 0.0 109.298 -175.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -64.04 154.06 83.14 Favored Pre-proline 0 C--N 1.328 -0.356 0 O-C-N 121.803 -0.561 . . . . 0.0 110.754 -178.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 13.8 Cg_endo -59.13 146.88 92.97 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.317 1.345 . . . . 0.0 110.659 171.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.53 20.18 77.08 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 125.329 1.442 . . . . 0.0 112.699 -177.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 96.9 m -91.87 121.36 33.41 Favored 'General case' 0 N--CA 1.445 -0.716 0 CA-C-N 119.443 1.622 . . . . 0.0 107.869 176.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.5 t0 -62.96 136.81 58.04 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 171.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -44.66 -35.7 2.75 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 123.332 0.653 . . . . 0.0 112.455 171.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.6 pttp -67.89 -36.68 80.64 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 118.482 -1.287 . . . . 0.0 110.369 -179.109 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -80.68 -16.74 53.2 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.485 1.514 . . . . 0.0 110.277 -174.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.535 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 20.9 mt -55.39 134.22 70.09 Favored Pre-proline 0 N--CA 1.445 -0.719 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 173.584 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_endo -64.33 138.27 59.91 Favored 'Trans proline' 0 N--CA 1.447 -1.243 0 C-N-CA 122.425 2.083 . . . . 0.0 109.616 176.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -66.09 -12.63 56.85 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 123.054 0.541 . . . . 0.0 111.943 178.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.15 -19.6 64.02 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.782 1.233 . . . . 0.0 112.337 171.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 74.8 t90 -66.31 156.64 33.82 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 121.748 0.785 . . . . 0.0 111.985 -176.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -129.88 149.81 33.99 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.323 0 C-N-CA 126.904 2.082 . . . . 0.0 109.815 -178.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 14.6 t -73.64 138.38 77.27 Favored Pre-proline 0 C--O 1.236 0.351 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 -175.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -56.82 111.5 0.82 Allowed 'Trans proline' 0 N--CA 1.45 -1.074 0 C-N-CA 122.1 1.866 . . . . 0.0 110.084 178.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 15.3 mt 79.15 16.63 0.94 Allowed 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 126.352 1.861 . . . . 0.0 112.231 179.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.9 t -147.92 99.7 3.11 Favored 'General case' 0 CA--C 1.537 0.457 0 CA-C-O 123.19 1.471 . . . . 0.0 108.786 -174.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -78.33 52.9 3.83 Favored Glycine 0 CA--C 1.528 0.859 0 O-C-N 120.878 -1.139 . . . . 0.0 111.754 -177.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 51.7 t -99.5 -71.2 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 175.068 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 127.73 -163.42 21.43 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 -173.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 33.5 mtpt -86.61 168.72 13.38 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 169.149 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -163.54 -82.93 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 124.738 1.215 . . . . 0.0 108.288 168.265 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.1 mm-40 -99.55 -49.75 4.3 Favored 'General case' 0 C--O 1.226 -0.156 0 C-N-CA 125.22 1.408 . . . . 0.0 110.184 -171.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 29.8 p90 49.32 92.43 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.369 0 C-N-CA 126.194 1.798 . . . . 0.0 112.7 177.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 50.2 mt-10 -74.6 137.26 42.2 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 62.8 tt0 -75.93 134.75 40.15 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.197 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 24.5 t -101.47 115.99 44.25 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.127 0 N-CA-C 105.36 -2.089 . . . . 0.0 105.36 175.337 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -70.82 55.46 0.17 Allowed 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 125.893 1.677 . . . . 0.0 114.174 -179.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 . . . . . 0 C--O 1.253 1.264 0 C-N-CA 126.698 1.999 . . . . 0.0 107.593 161.925 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.366 19.2 ptm . . . . . 0 N--CA 1.473 0.713 0 N-CA-C 106.819 -1.549 . . . . 0.0 106.819 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 18.7 mttt 62.6 167.47 0.12 Allowed 'General case' 0 N--CA 1.453 -0.295 0 C-N-CA 126.228 1.811 . . . . 0.0 112.979 -171.051 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 81.3 mttt -76.27 167.98 20.87 Favored 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 115.085 -0.961 . . . . 0.0 109.649 -176.541 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 51.5 m-85 -148.24 135.98 20.81 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 122.748 0.419 . . . . 0.0 112.11 -178.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 19.9 m -75.4 134.95 40.8 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 119.311 -0.376 . . . . 0.0 111.118 169.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 36.6 t -68.85 140.37 55.21 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 123.284 0.634 . . . . 0.0 110.187 170.795 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 75.1 p -25.84 -82.36 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 129.661 3.185 . . . . 0.0 114.899 -175.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.1 m -127.41 54.97 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.082 0 C-N-CA 125.347 1.459 . . . . 0.0 108.535 -172.613 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 37.3 t -141.09 -78.09 0.28 Allowed 'General case' 0 N--CA 1.452 -0.373 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.3 -161.224 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 131.23 -33.11 2.85 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.334 -0.707 . . . . 0.0 111.334 -176.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 28.0 m-85 -57.09 139.79 51.3 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-N 118.352 1.076 . . . . 0.0 110.051 177.161 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.7 mt -106.1 120.01 56.38 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.242 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.518 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.542 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 44.9 t80 -72.49 138.38 46.97 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 169.714 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 53.8 t-20 -124.25 112.18 28.21 Favored Pre-proline 0 N--CA 1.455 -0.215 0 C-N-CA 124.08 0.952 . . . . 0.0 109.59 175.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -63.18 -39.2 40.13 Favored 'Trans proline' 0 N--CA 1.45 -1.08 0 C-N-CA 121.137 1.225 . . . . 0.0 112.082 -172.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 32.7 mt-10 -58.91 -31.56 68.75 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 117.751 0.251 . . . . 0.0 111.205 -179.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -87.76 -32.06 19.32 Favored 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 123.472 0.709 . . . . 0.0 109.877 177.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.32 -159.03 41.74 Favored Glycine 0 CA--C 1.529 0.947 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -167.296 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -140.49 61.38 16.13 Favored Pre-proline 0 CA--C 1.539 0.544 0 C-N-CA 125.556 1.542 . . . . 0.0 107.763 171.31 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -62.7 -30.04 78.05 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 122.404 2.069 . . . . 0.0 111.329 -170.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -61.18 -29.6 69.9 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 123.922 0.889 . . . . 0.0 110.383 179.111 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -96.63 -28.32 14.4 Favored 'General case' 0 N--CA 1.455 -0.209 0 C-N-CA 125.232 1.413 . . . . 0.0 110.687 -178.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.52 12.78 1.35 Allowed Glycine 0 CA--C 1.531 1.092 0 C-N-CA 124.296 0.951 . . . . 0.0 113.673 169.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.3 t -110.02 111.01 34.25 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.208 0 CA-C-N 118.447 1.124 . . . . 0.0 108.464 -175.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -64.3 155.34 80.32 Favored Pre-proline 0 CA--C 1.535 0.382 0 O-C-N 121.787 -0.571 . . . . 0.0 110.981 -177.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -59.57 149.55 81.55 Favored 'Trans proline' 0 N--CA 1.449 -1.093 0 C-N-CA 121.399 1.399 . . . . 0.0 110.944 171.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 74.08 15.69 79.82 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 125.125 1.345 . . . . 0.0 112.848 -175.185 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 76.3 m -87.98 119.27 28.18 Favored 'General case' 0 N--CA 1.443 -0.807 0 CA-C-N 119.813 1.806 . . . . 0.0 107.183 177.56 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -61.07 137.65 58.23 Favored 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 172.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.1 t80 -46.33 -35.76 5.69 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 123.346 0.658 . . . . 0.0 111.71 172.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 54.2 pttt -68.2 -39.2 82.49 Favored 'General case' 0 N--CA 1.452 -0.335 0 C-N-CA 118.232 -1.387 . . . . 0.0 110.205 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -73.26 -21.16 60.68 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 125.126 1.37 . . . . 0.0 110.164 -175.193 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.542 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.3 mt -53.23 133.97 51.25 Favored Pre-proline 0 N--CA 1.446 -0.665 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 176.538 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -66.13 139.58 56.18 Favored 'Trans proline' 0 N--CA 1.444 -1.434 0 C-N-CA 122.093 1.862 . . . . 0.0 109.658 178.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -67.91 -9.17 42.85 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 123.806 0.843 . . . . 0.0 111.546 177.602 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -73.15 -22.69 60.47 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.779 1.232 . . . . 0.0 112.061 169.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 81.1 t90 -69.69 152.83 44.22 Favored 'General case' 0 N--CA 1.455 -0.221 0 O-C-N 121.628 -0.67 . . . . 0.0 110.464 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 99.2 t -131.87 152.69 37.34 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.334 0 C-N-CA 124.887 1.275 . . . . 0.0 108.862 -178.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 20.1 t -69.21 140.44 90.62 Favored Pre-proline 0 CA--C 1.54 0.568 0 C-N-CA 124.526 1.131 . . . . 0.0 110.425 -177.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -63.09 118.59 5.5 Favored 'Trans proline' 0 N--CA 1.452 -0.922 0 C-N-CA 122.575 2.183 . . . . 0.0 111.305 175.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 13.2 mt 70.19 43.54 0.85 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.85 1.26 . . . . 0.0 111.176 170.053 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 53.7 t -153.61 176.05 12.52 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 106.117 -1.808 . . . . 0.0 106.117 -171.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -80.42 -156.74 13.69 Favored Glycine 0 CA--C 1.528 0.867 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 173.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.9 m -51.98 126.93 8.2 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 O-C-N 122.099 -0.647 . . . . 0.0 109.632 171.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -126.2 -175.66 14.24 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 108.707 -1.757 . . . . 0.0 108.707 -179.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 58.57 78.32 0.26 Allowed 'General case' 0 CA--C 1.537 0.446 0 CA-C-O 122.471 1.129 . . . . 0.0 110.444 -172.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -153.81 -99.68 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 114.174 -1.376 . . . . 0.0 107.653 168.635 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -76.39 60.74 1.6 Allowed 'General case' 0 CA--C 1.54 0.571 0 CA-C-N 119.4 1.0 . . . . 0.0 111.493 178.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 17.5 p90 -75.93 146.1 39.93 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 121.441 -0.787 . . . . 0.0 109.911 173.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -114.38 141.53 47.52 Favored 'General case' 0 N--CA 1.464 0.232 0 C-N-CA 124.235 1.014 . . . . 0.0 108.592 175.409 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 22.0 tt0 -77.54 138.58 39.26 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 29.9 t -103.65 104.5 16.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 C-N-CA 126.021 1.728 . . . . 0.0 107.039 178.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -77.12 57.72 1.44 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.639 1.576 . . . . 0.0 112.618 179.548 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 . . . . . 0 C--O 1.255 1.367 0 CA-C-O 117.349 -1.31 . . . . 0.0 108.446 156.776 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.373 20.4 ptt? . . . . . 0 N--CA 1.472 0.668 0 N-CA-C 105.561 -2.014 . . . . 0.0 105.561 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 40.4 mttm 59.73 170.29 0.08 Allowed 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 125.47 1.508 . . . . 0.0 112.402 -172.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 55.7 mttt -82.12 167.71 18.47 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.499 -171.425 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 25.0 m-85 -146.92 136.17 22.64 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 113.411 0.893 . . . . 0.0 113.411 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.7 m -80.98 147.89 30.01 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 123.89 0.876 . . . . 0.0 111.695 169.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 36.1 t -79.31 14.65 1.46 Allowed 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 125.19 1.396 . . . . 0.0 112.631 175.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 21.8 m 65.64 -72.37 0.07 Allowed 'General case' 0 CA--C 1.538 0.511 0 O-C-N 119.413 -2.054 . . . . 0.0 112.588 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 69.4 t -70.54 -61.88 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.172 0 C-N-CA 123.968 0.907 . . . . 0.0 109.123 -174.341 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 8.1 p -95.41 173.58 7.45 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 172.541 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -72.74 -73.3 0.87 Allowed Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.141 -1.584 . . . . 0.0 109.141 177.174 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 22.19 63.88 0.03 OUTLIER 'General case' 0 C--N 1.345 0.408 0 C-N-CA 127.785 2.434 . . . . 0.0 111.93 -172.346 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.1 mt -62.38 115.05 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 CA-C-N 115.38 -0.827 . . . . 0.0 109.617 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.54 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 41.2 t80 -68.59 129.03 38.72 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 172.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 49.8 t-20 -117.36 111.25 40.2 Favored Pre-proline 0 N--CA 1.455 -0.176 0 C-N-CA 123.76 0.824 . . . . 0.0 109.212 175.044 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.11 -38.32 46.35 Favored 'Trans proline' 0 N--CA 1.448 -1.189 0 C-N-CA 121.015 1.143 . . . . 0.0 111.386 -174.355 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 -57.92 -32.63 67.95 Favored 'General case' 0 N--CA 1.447 -0.589 0 CA-C-N 117.959 0.345 . . . . 0.0 111.098 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -88.15 -32.14 18.8 Favored 'General case' 0 CA--C 1.529 0.157 0 C-N-CA 123.591 0.756 . . . . 0.0 109.98 177.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.5 -159.4 41.87 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.821 -0.911 . . . . 0.0 110.821 -167.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -140.58 61.05 14.96 Favored Pre-proline 0 CA--C 1.539 0.528 0 C-N-CA 125.441 1.496 . . . . 0.0 107.732 171.37 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_endo -62.75 -32.4 78.18 Favored 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.438 2.092 . . . . 0.0 111.393 -169.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -59.68 -30.73 68.97 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 123.986 0.914 . . . . 0.0 110.642 178.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.2 m-80 -94.34 -28.55 15.49 Favored 'General case' 0 N--CA 1.455 -0.224 0 C-N-CA 125.115 1.366 . . . . 0.0 110.515 -178.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.72 13.67 1.22 Allowed Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.413 1.006 . . . . 0.0 113.739 169.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 54.7 t -112.45 111.61 36.9 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.285 0 CA-C-N 118.45 1.125 . . . . 0.0 108.602 -174.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 5.1 m-80 -64.12 155.15 80.1 Favored Pre-proline 0 CA--C 1.533 0.304 0 O-C-N 121.708 -0.62 . . . . 0.0 111.132 -176.156 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.2 149.5 80.08 Favored 'Trans proline' 0 N--CA 1.447 -1.206 0 C-N-CA 121.127 1.218 . . . . 0.0 110.589 169.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 68.87 20.29 74.29 Favored Glycine 0 CA--C 1.525 0.718 0 C-N-CA 125.402 1.477 . . . . 0.0 112.885 -173.001 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 65.1 m -88.03 120.78 29.71 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 120.058 1.929 . . . . 0.0 107.558 174.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -59.75 134.08 56.7 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 172.312 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -42.2 -38.35 1.72 Allowed 'General case' 0 N--CA 1.45 -0.458 0 C-N-CA 123.126 0.57 . . . . 0.0 112.092 168.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 57.9 pttt -67.32 -41.72 84.81 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 117.579 -1.649 . . . . 0.0 110.185 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -71.83 -19.28 62.0 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 125.586 1.554 . . . . 0.0 110.577 -174.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.54 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.0 mt -52.52 133.11 44.86 Favored Pre-proline 0 N--CA 1.443 -0.802 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 173.663 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -65.17 141.48 69.59 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 122.275 1.984 . . . . 0.0 110.113 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.2 -15.95 60.98 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 124.198 0.999 . . . . 0.0 111.912 177.279 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -66.83 -22.83 65.99 Favored 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 124.268 1.027 . . . . 0.0 112.181 170.683 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 89.2 t90 -78.35 149.16 33.48 Favored 'General case' 0 N--CA 1.453 -0.302 0 CA-C-O 121.628 0.727 . . . . 0.0 111.102 -174.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 2.2 m -126.99 156.29 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.225 0 C-N-CA 125.847 1.659 . . . . 0.0 109.892 -174.03 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 7.7 t -63.36 137.09 96.98 Favored Pre-proline 0 CA--C 1.543 0.689 0 C-N-CA 122.958 0.503 . . . . 0.0 110.347 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -69.6 95.81 0.55 Allowed 'Trans proline' 0 N--CA 1.451 -1.022 0 C-N-CA 123.128 2.552 . . . . 0.0 110.66 -178.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 56.3 mt 85.42 59.11 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 126.813 2.045 . . . . 0.0 111.058 173.293 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 13.1 t -147.22 -94.67 0.09 Allowed 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -176.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 157.38 -41.85 0.53 Allowed Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 40.4 t -70.5 148.0 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -75.97 177.7 49.8 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 176.321 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 5.9 ptmt -65.38 106.44 1.38 Allowed 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 165.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -138.85 -65.84 0.49 Allowed 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 173.708 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.6 tp60 -101.13 106.51 17.77 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 -178.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -142.29 128.7 20.07 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 51.7 mt-10 -104.2 141.88 35.49 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 124.443 1.097 . . . . 0.0 108.606 -175.221 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -75.49 142.69 42.85 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-N 119.913 1.233 . . . . 0.0 109.73 -179.354 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 37.2 t -112.38 106.56 21.0 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 C-N-CA 127.629 2.372 . . . . 0.0 106.737 177.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -82.93 53.74 2.52 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 124.968 1.307 . . . . 0.0 113.372 -173.261 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 . . . . . 0 C--O 1.25 1.095 0 C-N-CA 124.451 1.1 . . . . 0.0 110.256 179.762 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.382 21.9 ptm . . . . . 0 N--CA 1.474 0.749 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.0 mttm 62.47 165.33 0.11 Allowed 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 126.544 1.937 . . . . 0.0 113.012 -172.131 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 83.1 mttt -78.0 163.13 26.22 Favored 'General case' 0 N--CA 1.445 -0.71 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.595 -178.372 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.6 m-85 -138.31 140.51 39.58 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 118.971 -0.538 . . . . 0.0 109.852 175.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.3 t -90.69 160.31 15.92 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 118.014 0.37 . . . . 0.0 111.151 173.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 51.5 t -81.37 -121.01 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 125.558 1.543 . . . . 0.0 107.452 175.435 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 12.6 t -160.49 -46.08 0.05 OUTLIER 'General case' 0 CA--C 1.535 0.368 0 O-C-N 121.427 -0.796 . . . . 0.0 110.415 -175.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.5 p -104.65 -66.75 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 C-N-CA 123.42 0.688 . . . . 0.0 111.271 179.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.5 p -67.59 -38.77 84.5 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 123.713 0.805 . . . . 0.0 110.626 -176.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 82.73 31.03 30.77 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 179.197 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 18.6 m-85 -65.76 87.21 0.09 Allowed 'General case' 0 N--CA 1.456 -0.17 0 CA-C-N 117.742 0.771 . . . . 0.0 109.439 168.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 56.4 mt -57.44 111.04 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 C-N-CA 123.293 0.637 . . . . 0.0 109.293 172.4 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.544 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 20.1 t80 -73.69 133.37 43.37 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 173.203 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 50.7 t-20 -121.45 112.78 32.52 Favored Pre-proline 0 N--CA 1.455 -0.191 0 C-N-CA 124.255 1.022 . . . . 0.0 109.753 177.613 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -62.85 -38.83 45.51 Favored 'Trans proline' 0 N--CA 1.45 -1.03 0 C-N-CA 121.474 1.449 . . . . 0.0 112.083 -171.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -58.75 -32.31 69.15 Favored 'General case' 0 N--CA 1.446 -0.625 0 O-C-N 123.151 0.282 . . . . 0.0 111.059 -179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -87.46 -31.38 20.05 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 123.494 0.717 . . . . 0.0 109.92 177.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.11 -157.36 43.32 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -166.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.31 61.57 12.08 Favored Pre-proline 0 CA--C 1.54 0.588 0 C-N-CA 125.457 1.503 . . . . 0.0 107.455 171.035 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -61.87 -33.86 83.43 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 122.62 2.213 . . . . 0.0 111.2 -169.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -56.1 -30.48 62.13 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 125.438 1.495 . . . . 0.0 110.66 178.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 10.0 m-80 -97.02 -32.84 11.79 Favored 'General case' 0 N--CA 1.455 -0.217 0 C-N-CA 125.531 1.533 . . . . 0.0 110.432 -177.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 139.39 11.24 0.77 Allowed Glycine 0 CA--C 1.53 1.013 0 C-N-CA 123.898 0.761 . . . . 0.0 114.015 171.106 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 68.6 t -109.31 112.18 39.36 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.215 0 CA-C-N 118.898 1.349 . . . . 0.0 108.791 -176.608 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.19 154.35 82.97 Favored Pre-proline 0 CA--C 1.533 0.306 0 O-C-N 121.91 -0.494 . . . . 0.0 110.904 -177.564 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -58.38 147.02 87.55 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 121.408 1.405 . . . . 0.0 110.947 170.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 77.04 15.39 81.69 Favored Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 125.051 1.31 . . . . 0.0 112.838 -176.326 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 98.7 m -87.78 117.48 26.65 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 119.956 1.878 . . . . 0.0 107.421 177.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -57.86 135.48 56.86 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 171.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 4.1 t80 -43.88 -36.95 2.59 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 123.389 0.676 . . . . 0.0 112.154 170.421 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 19.7 pttp -66.51 -39.98 88.96 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 118.017 -1.473 . . . . 0.0 110.066 -178.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -80.04 -12.86 59.66 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 125.718 1.607 . . . . 0.0 110.741 -172.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.544 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.5 mt -56.36 132.8 76.24 Favored Pre-proline 0 N--CA 1.444 -0.752 0 CA-C-O 118.356 -0.831 . . . . 0.0 108.949 174.221 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -54.89 136.26 71.53 Favored 'Trans proline' 0 N--CA 1.455 -0.758 0 C-N-CA 124.152 3.235 . . . . 0.0 110.551 176.555 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -69.73 -18.44 63.52 Favored 'General case' 0 CA--C 1.533 0.296 0 O-C-N 121.352 -0.843 . . . . 0.0 111.319 -179.482 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -76.55 -11.48 59.88 Favored 'General case' 0 N--CA 1.453 -0.312 0 C-N-CA 125.876 1.67 . . . . 0.0 112.104 171.092 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 82.8 t90 -71.65 149.77 45.24 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 119.07 0.85 . . . . 0.0 110.526 176.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 2.1 m -128.39 153.45 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 C-N-CA 126.082 1.753 . . . . 0.0 109.881 -175.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 8.2 t -73.71 138.48 77.05 Favored Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 123.658 0.783 . . . . 0.0 111.042 -175.079 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -58.64 127.53 24.88 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 123.416 2.744 . . . . 0.0 111.77 -177.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 24.5 mt 54.65 34.89 22.5 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.688 1.195 . . . . 0.0 111.857 -179.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.1 t -131.93 -176.22 3.99 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -139.01 47.57 0.91 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 111.036 -0.825 . . . . 0.0 111.036 -175.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -155.65 156.98 4.36 Favored 'Isoleucine or valine' 0 C--O 1.237 0.441 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 177.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -77.78 -179.6 50.03 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 178.405 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 14.8 ptmt -62.69 -19.56 64.0 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 113.136 0.791 . . . . 0.0 113.136 170.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 29.26 -94.42 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 129.408 3.083 . . . . 0.0 111.529 -176.258 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.1 mm-40 -145.91 69.93 1.23 Allowed 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 164.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.4 m-30 -47.73 156.26 0.33 Allowed 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 125.656 1.582 . . . . 0.0 110.375 169.18 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -94.82 147.46 23.32 Favored 'General case' 0 C--O 1.225 -0.236 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -172.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -75.05 143.9 43.26 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 118.726 0.693 . . . . 0.0 109.198 -179.308 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 11.0 t -107.95 110.88 33.53 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.854 0 C-N-CA 126.121 1.768 . . . . 0.0 106.494 177.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -76.03 55.29 0.91 Allowed 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 125.454 1.502 . . . . 0.0 113.272 -177.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 . . . . . 0 C--O 1.25 1.087 0 CA-C-O 117.231 -1.366 . . . . 0.0 108.085 158.569 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.376 26.5 ptm . . . . . 0 N--CA 1.472 0.657 0 N-CA-C 106.349 -1.723 . . . . 0.0 106.349 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 56.4 mttm 66.09 162.34 0.16 Allowed 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 126.64 1.976 . . . . 0.0 113.351 -176.079 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -77.71 163.65 25.97 Favored 'General case' 0 N--CA 1.447 -0.591 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.201 -179.514 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 23.6 m-85 -144.55 146.69 32.49 Favored 'General case' 0 CA--C 1.528 0.124 0 CA-C-O 119.046 -0.502 . . . . 0.0 110.732 176.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.5 t -99.0 143.48 29.24 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 113.098 0.777 . . . . 0.0 113.098 174.251 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.452 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 48.9 t -82.65 120.23 25.3 Favored 'General case' 0 C--N 1.344 0.346 0 C-N-CA 126.678 1.991 . . . . 0.0 109.963 177.745 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 20.2 m -41.6 -76.18 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 127.617 2.367 . . . . 0.0 114.063 -175.256 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.2 p -99.7 48.5 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 O-C-N 121.233 -0.917 . . . . 0.0 109.653 -168.024 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.452 ' HB3' ' SG ' ' A' ' 6' ' ' CYS . 46.6 t -160.95 -60.95 0.06 Allowed 'General case' 0 CA--C 1.531 0.212 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 -160.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.7 -13.48 63.9 Favored Glycine 0 CA--C 1.53 1.007 0 CA-C-O 119.025 -0.875 . . . . 0.0 113.137 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -59.19 143.32 49.33 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 119.42 1.61 . . . . 0.0 109.902 173.22 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 18.2 mt -112.04 121.22 64.07 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 C-N-CA 123.89 0.876 . . . . 0.0 109.148 179.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.494 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 68.3 t80 -80.93 140.76 35.1 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 172.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 64.9 t-20 -124.68 120.1 25.79 Favored Pre-proline 0 C--O 1.224 -0.278 0 C-N-CA 124.252 1.021 . . . . 0.0 109.732 177.853 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_endo -68.65 -40.49 7.35 Favored 'Trans proline' 0 N--CA 1.442 -1.507 0 C-N-CA 120.697 0.932 . . . . 0.0 112.122 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -60.4 -31.05 70.0 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-N 119.155 0.889 . . . . 0.0 110.95 -177.363 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 80.2 m-20 -90.11 -29.52 18.27 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.336 0.655 . . . . 0.0 109.967 177.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.48 -160.05 40.86 Favored Glycine 0 CA--C 1.529 0.951 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -165.615 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -139.64 62.43 23.17 Favored Pre-proline 0 CA--C 1.538 0.498 0 C-N-CA 125.181 1.393 . . . . 0.0 107.679 169.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_endo -61.64 -32.12 86.99 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.345 2.03 . . . . 0.0 111.137 -171.244 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -57.05 -31.69 65.44 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.898 1.279 . . . . 0.0 110.587 178.39 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -95.43 -32.7 12.78 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.15 1.38 . . . . 0.0 110.483 -178.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.83 14.67 0.66 Allowed Glycine 0 CA--C 1.531 1.08 0 C-N-CA 124.053 0.835 . . . . 0.0 114.108 170.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.438 HG23 ' CD1' ' A' ' 37' ' ' TRP . 46.6 t -112.9 112.7 41.54 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.264 0 CA-C-N 118.808 1.304 . . . . 0.0 109.053 -176.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -64.58 155.94 79.62 Favored Pre-proline 0 C--N 1.328 -0.338 0 O-C-N 121.967 -0.458 . . . . 0.0 111.116 -177.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.64 148.29 88.27 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 121.569 1.513 . . . . 0.0 110.981 171.489 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.94 17.25 79.34 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 125.296 1.427 . . . . 0.0 112.662 -175.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 93.3 m -87.76 117.65 26.73 Favored 'General case' 0 N--CA 1.442 -0.875 0 CA-C-N 119.838 1.819 . . . . 0.0 107.59 176.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.4 t0 -58.1 134.35 56.37 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.401 171.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -40.47 -40.08 1.14 Allowed 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 123.901 0.88 . . . . 0.0 112.415 169.069 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.2 pttp -68.48 -38.29 80.9 Favored 'General case' 0 N--CA 1.451 -0.4 0 C-N-CA 118.295 -1.362 . . . . 0.0 109.973 -176.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -78.34 -15.62 58.53 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.805 1.642 . . . . 0.0 110.3 -174.358 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.494 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.4 mt -54.97 133.9 67.42 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-O 118.389 -0.815 . . . . 0.0 109.308 174.727 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 10.2 Cg_exo -57.69 137.3 80.53 Favored 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 123.597 2.865 . . . . 0.0 110.883 176.18 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 32.5 m-20 -66.03 -18.43 65.33 Favored 'General case' 0 N--CA 1.45 -0.459 0 O-C-N 121.299 -0.875 . . . . 0.0 111.426 176.635 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -82.93 -6.21 59.37 Favored 'General case' 0 CA--C 1.535 0.39 0 C-N-CA 125.563 1.545 . . . . 0.0 111.944 173.699 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . 0.438 ' CD1' HG23 ' A' ' 24' ' ' VAL . 71.0 t90 -69.94 160.43 31.89 Favored 'General case' 0 CA--C 1.53 0.204 0 CA-C-N 119.053 0.842 . . . . 0.0 110.093 172.474 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -139.5 150.17 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 C-N-CA 125.585 1.554 . . . . 0.0 108.465 176.656 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 2.4 p -83.68 165.27 40.75 Favored Pre-proline 0 CA--C 1.539 0.557 0 N-CA-C 108.785 -0.821 . . . . 0.0 108.785 -179.182 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.51 124.13 9.61 Favored 'Trans proline' 0 N--CA 1.451 -1.018 0 C-N-CA 121.301 1.334 . . . . 0.0 110.842 -168.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 12.6 mt 66.29 44.17 2.56 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 125.258 1.423 . . . . 0.0 112.201 172.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 7.3 t -138.45 179.63 6.35 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 123.913 0.885 . . . . 0.0 108.818 -177.345 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -100.98 -87.81 1.99 Allowed Glycine 0 CA--C 1.526 0.72 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 178.047 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.6 p -82.99 102.2 8.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 178.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -108.54 145.82 16.44 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 108.751 -1.74 . . . . 0.0 108.751 176.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER 59.5 101.78 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 125.42 1.488 . . . . 0.0 111.749 -170.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -138.8 -75.73 0.37 Allowed 'General case' 0 CA--C 1.521 -0.139 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 160.341 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 10.3 tm0? -144.69 55.34 1.25 Allowed 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 124.739 1.216 . . . . 0.0 107.846 -174.575 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 4.1 m-30 -55.51 150.99 11.09 Favored 'General case' 0 CA--C 1.537 0.475 0 C-N-CA 125.059 1.343 . . . . 0.0 108.894 175.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -87.39 150.86 23.53 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 -179.491 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 35.5 tt0 -78.83 145.84 34.04 Favored 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 123.676 0.791 . . . . 0.0 109.088 179.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 14.5 t -110.84 111.44 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 C-N-CA 126.622 1.969 . . . . 0.0 107.081 174.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -71.86 67.09 0.59 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 126.305 1.842 . . . . 0.0 113.116 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 . . . . . 0 C--O 1.255 1.372 0 CA-C-O 117.86 -1.067 . . . . 0.0 111.098 164.514 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.415 ' N ' ' OE2' ' A' ' 16' ' ' GLU . 0.7 OUTLIER . . . . . 0 N--CA 1.477 0.889 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 7.9 mttm -65.54 139.27 58.45 Favored 'General case' 0 N--CA 1.449 -0.519 0 CA-C-O 121.61 0.719 . . . . 0.0 111.586 178.093 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 78.7 mttt -73.9 174.6 8.29 Favored 'General case' 0 N--CA 1.445 -0.722 0 C-N-CA 124.907 1.283 . . . . 0.0 109.46 174.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 37.8 m-85 -144.32 131.03 20.13 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-O 118.831 -0.604 . . . . 0.0 111.628 176.419 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 5.6 m -79.87 143.72 34.07 Favored 'General case' 0 N--CA 1.47 0.552 0 C-N-CA 123.872 0.869 . . . . 0.0 110.811 174.429 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.406 ' SG ' ' HB3' ' A' ' 9' ' ' CYS . 9.0 t -70.43 -175.68 1.07 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.209 1.404 . . . . 0.0 109.569 168.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 63.5 m -82.29 -99.26 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 123.688 0.795 . . . . 0.0 110.06 -176.612 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 11.8 p -87.33 -30.69 5.76 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 O-C-N 120.967 -1.083 . . . . 0.0 110.85 -178.071 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . 0.406 ' HB3' ' SG ' ' A' ' 6' ' ' CYS . 50.8 t -39.62 -55.48 1.86 Allowed 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 128.931 2.892 . . . . 0.0 112.365 175.247 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 100.91 -15.06 58.48 Favored Glycine 0 CA--C 1.529 0.967 0 CA-C-O 119.043 -0.865 . . . . 0.0 113.279 177.404 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -62.38 159.32 15.57 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 119.307 1.553 . . . . 0.0 111.574 176.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 28.7 mt -123.4 124.94 70.87 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.201 0 C-N-CA 125.227 1.411 . . . . 0.0 107.282 175.376 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.504 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 72.5 t80 -78.28 135.38 37.53 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 167.872 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -118.01 116.75 35.83 Favored Pre-proline 0 C--O 1.225 -0.204 0 C-N-CA 124.24 1.016 . . . . 0.0 109.948 175.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -64.82 -42.57 14.66 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 121.927 1.751 . . . . 0.0 111.793 -178.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . 0.415 ' OE2' ' N ' ' A' ' 1' ' ' MET . 45.3 mt-10 -61.98 -28.61 69.68 Favored 'General case' 0 N--CA 1.446 -0.658 0 O-C-N 123.27 0.356 . . . . 0.0 110.862 -174.34 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -90.63 -31.62 16.58 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 123.997 0.919 . . . . 0.0 110.399 174.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.98 -162.07 31.97 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.289 0.947 . . . . 0.0 110.984 -165.177 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -137.94 62.27 32.58 Favored Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 125.894 1.678 . . . . 0.0 107.485 171.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.1 -33.32 82.66 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 122.75 2.3 . . . . 0.0 111.28 -170.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -56.79 -28.99 62.25 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 124.674 1.189 . . . . 0.0 110.738 178.634 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.6 m-80 -102.11 -26.47 13.35 Favored 'General case' 0 N--CA 1.454 -0.248 0 C-N-CA 125.607 1.563 . . . . 0.0 110.684 -175.516 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 136.81 6.86 1.68 Allowed Glycine 0 CA--C 1.531 1.067 0 C-N-CA 124.167 0.889 . . . . 0.0 113.786 168.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 75.7 t -107.58 109.87 29.77 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.156 0 CA-C-N 118.595 1.198 . . . . 0.0 108.509 -174.332 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -64.87 155.97 81.25 Favored Pre-proline 0 C--N 1.329 -0.321 0 O-C-N 121.734 -0.604 . . . . 0.0 111.086 -176.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.32 147.68 89.91 Favored 'Trans proline' 0 N--CA 1.449 -1.102 0 C-N-CA 121.496 1.464 . . . . 0.0 111.032 171.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.28 14.98 81.8 Favored Glycine 0 N--CA 1.447 -0.597 0 CA-C-O 118.394 -1.225 . . . . 0.0 112.682 -176.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 99.2 m -86.67 113.72 22.77 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 119.798 1.799 . . . . 0.0 107.546 178.042 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -53.4 133.26 40.44 Favored 'General case' 0 N--CA 1.446 -0.654 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 167.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.425 ' CD1' HD12 ' A' ' 33' ' ' ILE . 5.1 t80 -45.2 -31.84 1.64 Allowed 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 113.054 0.761 . . . . 0.0 113.054 173.758 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 7.3 pttt -68.57 -45.65 71.49 Favored 'General case' 0 CA--C 1.533 0.289 0 C-N-CA 118.398 -1.321 . . . . 0.0 110.065 179.538 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -67.58 -19.51 65.27 Favored 'General case' 0 N--CA 1.454 -0.232 0 C-N-CA 125.58 1.552 . . . . 0.0 111.222 -175.59 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.504 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 15.2 mt -53.29 131.37 52.27 Favored Pre-proline 0 N--CA 1.443 -0.812 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 176.089 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_endo -61.96 140.34 84.21 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 C-N-CA 122.393 2.062 . . . . 0.0 109.455 -178.432 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -67.35 -14.38 62.87 Favored 'General case' 0 CA--C 1.535 0.373 0 O-C-N 121.968 -0.457 . . . . 0.0 111.87 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -75.34 -15.07 60.51 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.491 0.716 . . . . 0.0 112.204 171.545 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 85.5 t90 -73.7 151.8 40.62 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 176.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 12.1 p -141.29 164.61 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 C-N-CA 124.927 1.291 . . . . 0.0 107.777 -177.345 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . 0.416 ' SG ' ' HD2' ' A' ' 40' ' ' PRO . 4.3 t -48.79 138.86 12.17 Favored Pre-proline 0 CA--C 1.54 0.561 0 C-N-CA 124.391 1.076 . . . . 0.0 110.111 176.606 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . 0.416 ' HD2' ' SG ' ' A' ' 39' ' ' CYS . 39.2 Cg_endo -59.89 -36.88 89.11 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.323 2.015 . . . . 0.0 112.881 -173.391 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 41.0 mt -136.95 42.11 2.45 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.301 0.641 . . . . 0.0 110.096 -175.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -164.71 173.68 11.59 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 106.023 -1.843 . . . . 0.0 106.023 -174.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -133.35 67.84 0.55 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 -174.14 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 9.7 p -128.92 141.42 46.66 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.19 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 172.289 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -62.38 147.84 49.18 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 6.2 ptmt -60.19 -38.52 83.52 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 117.226 0.513 . . . . 0.0 111.549 -179.472 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -72.35 71.63 0.91 Allowed 'General case' 0 CA--C 1.532 0.27 0 C-N-CA 124.295 1.038 . . . . 0.0 109.682 178.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 4.0 tp-100 -171.92 -38.66 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 125.728 1.611 . . . . 0.0 109.666 -175.524 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -57.84 137.21 56.86 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 124.048 0.939 . . . . 0.0 109.636 -176.777 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -96.01 149.49 21.52 Favored 'General case' 0 C--O 1.22 -0.496 0 C-N-CA 124.627 1.171 . . . . 0.0 109.364 -175.104 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -71.93 138.49 48.14 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 119.883 1.219 . . . . 0.0 110.039 -178.381 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.3 t -101.2 107.86 22.21 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.737 0 C-N-CA 125.467 1.507 . . . . 0.0 107.08 177.25 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 15.2 pt-20 -72.06 65.95 0.59 Allowed 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 126.348 1.859 . . . . 0.0 113.397 -177.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.5 mm-40 . . . . . 0 C--O 1.257 1.467 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 150.768 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.422 ' N ' ' OE2' ' A' ' 16' ' ' GLU . 1.4 tmt? . . . . . 0 N--CA 1.476 0.852 0 N-CA-C 104.793 -2.299 . . . . 0.0 104.793 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 9.6 mttm -63.23 140.53 58.88 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 119.682 1.128 . . . . 0.0 111.494 177.337 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 58.2 mttt -71.02 171.33 11.05 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 124.678 1.191 . . . . 0.0 109.862 172.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 10.1 m-85 -141.69 134.35 28.48 Favored 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 172.77 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 12.5 t -85.8 154.53 21.52 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 118.312 0.506 . . . . 0.0 111.282 174.281 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 19.9 t -75.01 170.2 16.48 Favored 'General case' 0 CA--C 1.531 0.25 0 C-N-CA 125.15 1.38 . . . . 0.0 107.852 172.639 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 6.9 t -125.72 16.7 8.09 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.063 0.945 . . . . 0.0 110.497 177.248 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 74.1 t -132.5 -60.54 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.34 0.179 0 C-N-CA 123.932 0.893 . . . . 0.0 109.52 -179.1 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.6 p -95.92 -89.31 0.26 Allowed 'General case' 0 CA--C 1.534 0.355 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 176.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 164.12 28.95 0.02 OUTLIER Glycine 0 CA--C 1.529 0.94 0 C-N-CA 125.487 1.518 . . . . 0.0 110.638 176.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 2.0 t80 -80.73 73.66 7.69 Favored 'General case' 0 N--CA 1.453 -0.322 0 O-C-N 121.819 -0.812 . . . . 0.0 108.83 -170.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 22.0 mt -45.35 112.52 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 C-N-CA 123.33 0.652 . . . . 0.0 110.978 -178.484 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.538 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 35.7 t80 -73.53 134.44 43.82 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 173.041 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 46.3 t-20 -123.07 114.63 29.35 Favored Pre-proline 0 N--CA 1.446 -0.652 0 C-N-CA 123.437 0.695 . . . . 0.0 109.387 176.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -65.36 -43.77 10.21 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 122.317 2.012 . . . . 0.0 111.327 -177.256 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . 0.422 ' OE2' ' N ' ' A' ' 1' ' ' MET . 10.6 mt-10 -56.84 -29.39 62.79 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 123.636 0.774 . . . . 0.0 111.226 -176.679 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -100.45 -23.41 14.74 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 123.879 0.872 . . . . 0.0 110.455 179.033 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.11 -160.59 30.73 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 124.829 1.204 . . . . 0.0 110.983 -172.333 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -140.34 61.4 16.69 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 125.281 1.432 . . . . 0.0 107.497 171.719 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_endo -62.38 -30.86 81.14 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 122.199 1.933 . . . . 0.0 111.076 -172.009 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -59.02 -29.65 67.43 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 124.463 1.105 . . . . 0.0 110.337 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -98.81 -29.29 13.06 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 125.544 1.537 . . . . 0.0 110.964 -177.154 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 134.36 18.24 0.93 Allowed Glycine 0 CA--C 1.532 1.15 0 C-N-CA 124.249 0.928 . . . . 0.0 113.798 170.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.2 t -117.26 110.02 29.71 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.216 0 CA-C-N 118.334 1.067 . . . . 0.0 108.443 -175.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -63.36 155.76 73.14 Favored Pre-proline 0 CA--C 1.534 0.337 0 O-C-N 121.835 -0.541 . . . . 0.0 110.976 -177.253 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -60.54 149.37 87.16 Favored 'Trans proline' 0 N--CA 1.449 -1.129 0 C-N-CA 121.464 1.443 . . . . 0.0 110.717 171.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 76.04 14.93 81.76 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 125.129 1.347 . . . . 0.0 113.047 -175.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 97.8 m -89.34 114.89 26.36 Favored 'General case' 0 N--CA 1.443 -0.815 0 CA-C-N 119.919 1.86 . . . . 0.0 107.836 178.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 22.3 t0 -56.17 134.72 53.15 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 169.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -42.38 -35.6 1.06 Allowed 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 123.709 0.803 . . . . 0.0 112.881 171.217 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 51.0 pttt -69.69 -42.48 74.05 Favored 'General case' 0 N--CA 1.452 -0.337 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.625 -178.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -68.08 -21.44 64.97 Favored 'General case' 0 N--CA 1.451 -0.375 0 C-N-CA 125.658 1.583 . . . . 0.0 110.438 -176.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.538 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 21.8 mt -53.63 130.6 55.08 Favored Pre-proline 0 N--CA 1.445 -0.688 0 CA-C-N 118.758 0.708 . . . . 0.0 109.216 175.331 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -63.94 140.52 73.3 Favored 'Trans proline' 0 N--CA 1.445 -1.335 0 C-N-CA 122.479 2.12 . . . . 0.0 109.758 -179.373 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -57.84 -23.22 51.78 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 123.537 0.735 . . . . 0.0 111.522 175.225 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.57 -18.75 63.66 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 124.745 1.218 . . . . 0.0 112.057 177.633 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 80.1 t90 -75.55 154.54 36.76 Favored 'General case' 0 N--CA 1.452 -0.363 0 O-C-N 121.629 -0.669 . . . . 0.0 110.095 -179.563 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 55.1 t -139.73 149.57 22.43 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 C-N-CA 124.905 1.282 . . . . 0.0 108.569 -169.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.1 t -73.41 127.39 88.98 Favored Pre-proline 0 CA--C 1.545 0.757 0 C-N-CA 122.974 0.509 . . . . 0.0 110.879 179.153 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.43 139.76 50.41 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 123.196 2.597 . . . . 0.0 111.646 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 57.6 mt 58.56 31.94 21.6 Favored 'General case' 0 CA--C 1.533 0.31 0 C-N-CA 124.54 1.136 . . . . 0.0 111.706 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 43.5 t -147.76 -57.61 0.24 Allowed 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 -173.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 75.94 26.8 63.75 Favored Glycine 0 CA--C 1.528 0.891 0 N-CA-C 111.946 -0.461 . . . . 0.0 111.946 177.247 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 95.6 t -111.35 155.99 12.6 Favored 'Isoleucine or valine' 0 C--O 1.236 0.387 0 C-N-CA 124.341 1.056 . . . . 0.0 109.182 177.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -67.91 155.69 52.94 Favored Glycine 0 CA--C 1.528 0.867 0 C-N-CA 124.469 1.033 . . . . 0.0 111.743 -176.675 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.1 ptmt -67.86 -42.89 80.62 Favored 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -175.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -76.87 77.65 3.46 Favored 'General case' 0 N--CA 1.456 -0.166 0 CA-C-O 122.426 1.108 . . . . 0.0 108.879 -170.874 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 4.4 mt-30 -179.37 -30.06 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 128.582 2.753 . . . . 0.0 108.97 -168.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -57.06 141.42 45.9 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.628 0.771 . . . . 0.0 110.888 169.629 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -111.66 145.16 39.74 Favored 'General case' 0 C--O 1.22 -0.458 0 C-N-CA 125.08 1.352 . . . . 0.0 109.551 -177.805 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.4 tt0 -65.62 136.34 56.2 Favored 'General case' 0 N--CA 1.445 -0.725 0 CA-C-N 118.778 0.717 . . . . 0.0 110.415 -176.02 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 2.8 t -94.74 109.53 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 175.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -69.0 82.13 0.31 Allowed 'General case' 0 N--CA 1.443 -0.796 0 C-N-CA 125.503 1.521 . . . . 0.0 110.706 175.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 17.9 mt-10 . . . . . 0 C--O 1.251 1.154 0 CA-C-O 117.229 -1.367 . . . . 0.0 110.471 169.387 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.415 25.1 ptm . . . . . 0 N--CA 1.47 0.534 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 22.6 mttm 55.83 174.82 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.431 0 O-C-N 125.473 1.733 . . . . 0.0 112.319 -172.416 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 66.2 mttt -73.61 170.65 14.76 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.439 -0.801 . . . . 0.0 109.836 -178.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.482 ' CE1' ' HB2' ' A' ' 30' ' ' PHE . 55.3 m-85 -142.07 141.64 32.77 Favored 'General case' 0 N--CA 1.462 0.152 0 C-N-CA 122.501 0.32 . . . . 0.0 111.323 176.419 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 91.1 m -78.25 142.44 37.85 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 123.47 0.708 . . . . 0.0 109.605 172.108 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 24.8 t -79.58 135.48 36.61 Favored 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 125.071 1.348 . . . . 0.0 108.428 175.048 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.0 m -45.32 -56.79 4.55 Favored 'General case' 0 N--CA 1.451 -0.381 0 C-N-CA 125.496 1.519 . . . . 0.0 114.197 -168.135 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 14.5 p -153.35 35.91 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 120.939 0.399 . . . . 0.0 110.59 -173.321 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 2.8 m -121.79 -65.25 1.14 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 123.485 0.714 . . . . 0.0 109.188 -178.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 116.78 56.33 0.31 Allowed Glycine 0 CA--C 1.53 0.995 0 C-N-CA 124.717 1.151 . . . . 0.0 111.948 176.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -139.18 87.66 2.22 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 124.457 1.103 . . . . 0.0 109.052 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 25.4 mt -57.23 127.13 15.86 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 O-C-N 121.439 -0.788 . . . . 0.0 111.035 -176.541 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.566 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 27.7 t80 -81.4 137.29 35.7 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 172.448 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 51.7 t-20 -122.55 112.44 31.02 Favored Pre-proline 0 C--N 1.339 0.136 0 C-N-CA 124.168 0.987 . . . . 0.0 109.841 175.809 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_endo -65.15 -37.44 32.23 Favored 'Trans proline' 0 N--CA 1.45 -1.086 0 C-N-CA 121.28 1.32 . . . . 0.0 111.51 -173.567 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -58.34 -32.09 68.2 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 117.726 0.239 . . . . 0.0 111.322 -179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 64.6 m-20 -87.49 -32.8 19.26 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.489 0.716 . . . . 0.0 109.868 177.029 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.26 -156.41 45.16 Favored Glycine 0 CA--C 1.53 0.998 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 -168.093 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -143.37 61.29 9.83 Favored Pre-proline 0 CA--C 1.542 0.669 0 C-N-CA 125.705 1.602 . . . . 0.0 107.442 172.26 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -62.01 -33.41 83.27 Favored 'Trans proline' 0 N--CA 1.456 -0.716 0 C-N-CA 122.671 2.247 . . . . 0.0 111.618 -169.056 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -58.15 -30.99 66.79 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 124.688 1.195 . . . . 0.0 110.394 178.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -92.4 -29.42 16.31 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 125.245 1.418 . . . . 0.0 110.351 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 138.14 -4.01 3.13 Favored Glycine 0 CA--C 1.529 0.938 0 C-N-CA 124.477 1.037 . . . . 0.0 113.148 172.101 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 74.3 t -94.3 109.78 22.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -172.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.6 m-80 -62.98 154.84 75.35 Favored Pre-proline 0 CA--C 1.534 0.354 0 O-C-N 121.767 -0.583 . . . . 0.0 110.488 -177.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -59.08 149.27 80.98 Favored 'Trans proline' 0 N--CA 1.449 -1.138 0 C-N-CA 121.123 1.215 . . . . 0.0 110.417 169.499 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 75.03 17.93 80.22 Favored Glycine 0 CA--C 1.524 0.623 0 C-N-CA 125.32 1.438 . . . . 0.0 113.3 -175.355 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 98.0 m -92.1 119.41 31.75 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-N 119.983 1.892 . . . . 0.0 107.312 177.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 24.2 t0 -65.2 142.99 58.13 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 173.168 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.482 ' HB2' ' CE1' ' A' ' 4' ' ' TYR . 2.2 t80 -49.22 -33.11 11.84 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 123.639 0.775 . . . . 0.0 112.366 175.106 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 10.4 pttm -67.27 -37.17 83.01 Favored 'General case' 0 CA--C 1.531 0.244 0 C-N-CA 119.254 -0.978 . . . . 0.0 110.926 178.291 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 -77.43 -21.0 53.7 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 124.742 1.217 . . . . 0.0 110.09 -174.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.566 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 22.4 mt -55.64 133.68 71.71 Favored Pre-proline 0 N--CA 1.445 -0.693 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.214 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 5.9 Cg_exo -59.45 134.8 60.68 Favored 'Trans proline' 0 N--CA 1.449 -1.123 0 C-N-CA 122.746 2.297 . . . . 0.0 109.374 175.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -74.59 -3.84 33.48 Favored 'General case' 0 N--CA 1.447 -0.577 0 O-C-N 121.632 -0.667 . . . . 0.0 112.346 -176.489 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -76.23 -12.42 60.09 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 124.131 0.972 . . . . 0.0 112.596 164.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 80.6 t90 -67.15 148.92 51.21 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 118.981 0.81 . . . . 0.0 111.297 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 62.7 t -125.97 144.47 35.98 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.471 0 C-N-CA 126.732 2.013 . . . . 0.0 108.718 -175.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 4.8 p -82.82 132.57 51.0 Favored Pre-proline 0 CA--C 1.543 0.695 0 CA-C-N 120.038 1.29 . . . . 0.0 110.06 177.064 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -79.12 139.84 15.32 Favored 'Trans proline' 0 N--CA 1.457 -0.651 0 C-N-CA 122.617 2.211 . . . . 0.0 111.066 -175.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 18.1 tp 60.37 31.87 20.5 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 124.497 1.119 . . . . 0.0 111.262 -178.971 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 33.3 m -125.65 -97.83 0.42 Allowed 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.977 1.311 . . . . 0.0 109.357 -179.612 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 143.88 114.18 0.95 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 108.325 -1.91 . . . . 0.0 108.325 -164.628 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.427 HG13 ' N ' ' A' ' 45' ' ' GLY 0.265 0.4 OUTLIER 76.94 -173.2 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.463 0 C-N-CA 125.151 1.38 . . . . 0.0 110.402 -171.721 . . . . . . . . 4 4 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.427 ' N ' HG13 ' A' ' 44' ' ' VAL . . . -129.53 -123.69 2.56 Favored Glycine 0 N--CA 1.449 -0.442 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 179.854 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 23.4 mtpt -82.23 167.86 18.22 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.429 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -159.45 -75.49 0.07 Allowed 'General case' 0 CA--C 1.533 0.295 0 C-N-CA 124.656 1.183 . . . . 0.0 108.827 172.642 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -124.06 -38.65 2.44 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 127.268 2.227 . . . . 0.0 109.739 -177.626 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 25.2 p90 53.15 173.47 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.235 2.214 . . . . 0.0 112.882 -176.324 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -138.72 136.55 35.91 Favored 'General case' 0 CA--C 1.521 -0.155 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 172.491 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -74.22 137.27 42.95 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 176.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 7.6 t -97.59 113.97 33.51 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.823 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 175.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -74.09 51.56 0.42 Allowed 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 125.3 1.44 . . . . 0.0 114.113 -178.499 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 28.9 mt-10 . . . . . 0 C--O 1.253 1.288 0 C-N-CA 125.921 1.688 . . . . 0.0 107.587 157.143 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.396 13.4 ptt? . . . . . 0 N--CA 1.472 0.656 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 33.2 mttt 66.32 164.38 0.18 Allowed 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 126.93 2.092 . . . . 0.0 113.408 -173.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -70.67 162.61 28.69 Favored 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.54 178.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -144.99 137.18 25.92 Favored 'General case' 0 C--N 1.33 -0.269 0 C-N-CA 124.248 1.019 . . . . 0.0 111.423 -178.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.8 m -75.92 155.59 35.01 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.232 1.013 . . . . 0.0 110.975 173.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 15.3 t -97.49 -37.49 9.95 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 126.236 1.814 . . . . 0.0 109.3 174.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 86.1 m 76.14 -62.46 0.43 Allowed 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 125.455 1.502 . . . . 0.0 112.016 166.407 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 31.2 m -78.79 43.72 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-N 119.284 0.947 . . . . 0.0 110.656 178.001 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 10.4 t 177.05 -102.49 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -156.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 121.21 64.77 0.24 Allowed Glycine 0 CA--C 1.53 0.974 0 C-N-CA 125.302 1.43 . . . . 0.0 111.035 -176.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -114.51 -57.55 2.26 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.301 1.04 . . . . 0.0 111.055 176.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . 0.251 57.8 mt 79.84 110.73 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 C-N-CA 127.548 2.339 . . . . 0.0 110.997 -170.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.535 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 51.6 t80 -74.23 141.6 45.4 Favored 'General case' 0 C--O 1.236 0.357 0 C-N-CA 124.203 1.001 . . . . 0.0 108.859 171.055 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 63.9 t-20 -126.57 116.57 22.88 Favored Pre-proline 0 C--O 1.224 -0.289 0 C-N-CA 123.488 0.715 . . . . 0.0 110.9 173.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -68.25 -41.46 6.97 Favored 'Trans proline' 0 N--CA 1.445 -1.369 0 C-N-CA 121.13 1.22 . . . . 0.0 112.042 -177.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -60.05 -30.9 69.5 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 118.706 0.684 . . . . 0.0 110.855 -178.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 -86.62 -32.71 20.45 Favored 'General case' 0 CA--C 1.53 0.192 0 C-N-CA 123.406 0.682 . . . . 0.0 109.512 176.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 64.89 -159.86 42.71 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -164.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -137.56 61.79 32.67 Favored Pre-proline 0 CA--C 1.539 0.548 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 168.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -61.74 -38.22 62.12 Favored 'Trans proline' 0 N--CA 1.456 -0.696 0 C-N-CA 123.11 2.54 . . . . 0.0 111.257 -167.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -51.02 -30.35 15.13 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.769 1.628 . . . . 0.0 110.825 177.145 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 11.7 m-80 -101.48 -18.12 16.12 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 125.818 1.647 . . . . 0.0 110.976 -175.159 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 130.56 -5.18 5.87 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.583 1.087 . . . . 0.0 113.324 172.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 78.6 t -100.22 108.7 23.42 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.202 0 CA-C-N 118.2 1.0 . . . . 0.0 109.103 -171.658 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -64.73 155.16 83.31 Favored Pre-proline 0 CA--C 1.533 0.305 0 O-C-N 121.767 -0.583 . . . . 0.0 111.072 -175.634 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -57.95 147.64 80.81 Favored 'Trans proline' 0 N--CA 1.448 -1.194 0 C-N-CA 121.322 1.348 . . . . 0.0 110.723 170.564 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 71.51 21.68 78.69 Favored Glycine 0 CA--C 1.525 0.714 0 C-N-CA 125.653 1.596 . . . . 0.0 112.945 -174.272 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 91.9 m -91.75 121.92 33.83 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 119.994 1.897 . . . . 0.0 107.818 174.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -63.87 137.87 58.23 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 174.325 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -42.95 -38.37 2.2 Favored 'General case' 0 N--CA 1.454 -0.274 0 C-N-CA 124.167 0.987 . . . . 0.0 111.733 170.277 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 20.6 pttp -67.26 -39.73 86.14 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 118.572 -1.251 . . . . 0.0 110.493 -179.448 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -82.54 -11.45 58.43 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 125.906 1.683 . . . . 0.0 110.716 -172.594 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.535 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 19.6 mt -54.53 133.16 63.54 Favored Pre-proline 0 N--CA 1.441 -0.878 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 171.653 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 33' ' ' ILE . 16.7 Cg_exo -53.83 134.53 59.42 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 123.785 2.99 . . . . 0.0 109.432 176.059 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.39 -11.2 60.0 Favored 'General case' 0 CA--C 1.536 0.424 0 O-C-N 121.146 -0.972 . . . . 0.0 111.705 -175.299 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -78.01 -10.1 59.44 Favored 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 126.493 1.917 . . . . 0.0 112.181 167.027 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 78.3 t90 -66.97 158.14 31.61 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 119.089 0.859 . . . . 0.0 109.971 173.391 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 10.8 p -136.52 155.09 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 124.712 1.205 . . . . 0.0 108.71 -176.684 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.6 t -56.4 136.02 76.26 Favored Pre-proline 0 CA--C 1.534 0.339 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -58.59 -28.98 87.73 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 C-N-CA 123.045 2.496 . . . . 0.0 113.214 -174.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 21.6 tp -150.8 51.5 0.86 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 118.72 0.691 . . . . 0.0 111.075 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . 0.258 1.7 p -142.84 -64.68 0.4 Allowed 'General case' 0 N--CA 1.464 0.266 0 O-C-N 122.053 -0.405 . . . . 0.0 110.552 159.715 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 142.87 -136.33 7.04 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 -179.408 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 41.4 t 61.77 -83.65 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 C-N-CA 126.097 1.759 . . . . 0.0 112.352 173.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 153.58 -139.28 6.76 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -170.02 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 48.4 mtpt -113.77 93.75 4.52 Favored 'General case' 0 CA--C 1.533 0.296 0 C-N-CA 124.925 1.29 . . . . 0.0 108.608 174.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 55.6 p-10 -144.72 169.73 17.45 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 107.713 -1.218 . . . . 0.0 107.713 170.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER 36.93 47.02 0.54 Allowed 'General case' 0 CA--C 1.538 0.514 0 C-N-CA 127.218 2.207 . . . . 0.0 113.324 -177.377 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 21.3 p90 -95.29 113.79 25.51 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.372 0.669 . . . . 0.0 110.053 179.628 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 30.1 mt-10 -98.33 149.4 22.67 Favored 'General case' 0 C--O 1.223 -0.31 0 C-N-CA 125.77 1.628 . . . . 0.0 108.726 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 18.1 tt0 -79.72 142.02 35.85 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-N 120.273 1.397 . . . . 0.0 110.031 -178.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 27.2 t -105.98 109.64 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.767 0 C-N-CA 126.35 1.86 . . . . 0.0 107.376 176.248 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -72.63 66.55 0.73 Allowed 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 125.994 1.718 . . . . 0.0 113.131 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 . . . . . 0 C--O 1.256 1.435 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.241 158.845 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . 2.343 12.5 ptm . . . . . 0 CA--C 1.511 -0.529 0 N-CA-C 104.72 -2.326 . . . . 0.0 104.72 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 27.6 mttm 62.09 165.76 0.1 Allowed 'General case' 0 N--CA 1.451 -0.42 0 O-C-N 124.908 1.38 . . . . 0.0 112.432 -169.545 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 56.1 mtpt -78.39 166.76 22.26 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.236 -174.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -151.62 150.39 30.23 Favored 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 123.367 0.667 . . . . 0.0 112.409 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.5 m -78.28 156.24 29.77 Favored 'General case' 0 CA--C 1.543 0.696 0 C-N-CA 123.876 0.87 . . . . 0.0 112.355 171.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 34.0 t -70.93 166.71 20.62 Favored 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 125.026 1.33 . . . . 0.0 108.768 166.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 5.4 m -45.16 -41.88 8.51 Favored 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 126.463 1.905 . . . . 0.0 112.302 170.208 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 6.3 p -160.98 -32.74 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 113.53 0.937 . . . . 0.0 113.53 -172.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 1.9 p -77.58 172.46 13.33 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 120.213 1.369 . . . . 0.0 110.58 -177.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -89.5 51.69 3.65 Favored Glycine 0 CA--C 1.527 0.83 0 O-C-N 121.318 -0.864 . . . . 0.0 111.732 -176.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -125.84 86.73 2.57 Favored 'General case' 0 CA--C 1.531 0.218 0 CA-C-N 118.25 1.025 . . . . 0.0 110.445 -177.557 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 15.9 mt -67.63 127.26 28.97 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 O-C-N 121.73 -0.607 . . . . 0.0 109.605 174.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . . . . . . . . . 40.0 t80 -78.48 136.94 37.71 Favored 'General case' 0 C--O 1.237 0.396 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 170.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 59.6 t-20 -122.19 113.11 31.24 Favored Pre-proline 0 C--O 1.227 -0.123 0 C-N-CA 124.312 1.045 . . . . 0.0 110.34 177.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -65.33 -38.98 24.24 Favored 'Trans proline' 0 N--CA 1.445 -1.359 0 C-N-CA 120.97 1.114 . . . . 0.0 112.246 -177.133 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 19.6 mt-10 -59.74 -32.13 70.28 Favored 'General case' 0 N--CA 1.448 -0.534 0 CA-C-N 118.562 0.619 . . . . 0.0 111.102 -178.054 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 85.8 m-20 -88.06 -32.02 18.97 Favored 'General case' 0 CA--C 1.529 0.172 0 C-N-CA 123.471 0.709 . . . . 0.0 109.75 178.083 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 63.1 -158.62 37.85 Favored Glycine 0 CA--C 1.529 0.952 0 N-CA-C 110.712 -0.955 . . . . 0.0 110.712 -165.35 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -142.76 61.69 11.32 Favored Pre-proline 0 CA--C 1.54 0.595 0 C-N-CA 125.955 1.702 . . . . 0.0 107.113 171.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -61.11 -33.86 90.51 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 122.572 2.181 . . . . 0.0 111.045 -170.227 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -54.58 -30.61 54.83 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 125.294 1.437 . . . . 0.0 110.736 178.175 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -102.97 -23.03 13.73 Favored 'General case' 0 N--CA 1.454 -0.253 0 C-N-CA 125.432 1.493 . . . . 0.0 110.778 -174.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 132.42 11.05 2.02 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 124.287 0.946 . . . . 0.0 113.401 169.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 70.6 t -110.3 108.76 26.23 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.229 0 CA-C-N 118.544 1.172 . . . . 0.0 108.762 -175.732 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -63.1 155.04 75.25 Favored Pre-proline 0 CA--C 1.535 0.379 0 O-C-N 121.662 -0.649 . . . . 0.0 110.876 -178.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.79 148.78 86.8 Favored 'Trans proline' 0 N--CA 1.448 -1.199 0 C-N-CA 121.118 1.212 . . . . 0.0 110.719 170.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.46 17.0 78.81 Favored Glycine 0 CA--C 1.526 0.73 0 C-N-CA 125.256 1.408 . . . . 0.0 112.963 -174.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 54.1 m -88.6 122.01 31.59 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 119.797 1.798 . . . . 0.0 107.977 178.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -63.88 135.56 56.66 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 171.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -40.39 -41.63 1.42 Allowed 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 123.4 0.68 . . . . 0.0 111.634 167.348 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.3 pttt -66.91 -34.74 78.44 Favored 'General case' 0 CA--C 1.536 0.429 0 O-C-N 120.241 -1.537 . . . . 0.0 110.823 -178.381 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 49.1 m-20 -76.49 -22.1 54.94 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 125.13 1.372 . . . . 0.0 109.801 -177.64 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 15.8 mt -55.85 134.31 72.95 Favored Pre-proline 0 N--CA 1.445 -0.693 0 N-CA-C 108.232 -1.025 . . . . 0.0 108.232 177.757 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_endo -62.05 137.3 66.0 Favored 'Trans proline' 0 N--CA 1.443 -1.443 0 C-N-CA 121.755 1.637 . . . . 0.0 108.889 176.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -72.46 -3.35 23.81 Favored 'General case' 0 N--CA 1.444 -0.741 0 O-C-N 121.914 -0.491 . . . . 0.0 111.908 -179.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.06 -23.16 64.01 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 125.509 1.524 . . . . 0.0 112.315 164.179 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . . . . . . . . . 84.6 t90 -70.56 152.43 43.96 Favored 'General case' 0 CA--C 1.53 0.176 0 O-C-N 121.628 -0.67 . . . . 0.0 110.855 -176.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 39.6 t -139.24 151.8 23.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.293 0 C-N-CA 125.901 1.68 . . . . 0.0 107.441 -173.288 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 9.8 t -54.12 133.14 59.75 Favored Pre-proline 0 CA--C 1.541 0.632 0 C-N-CA 125.557 1.543 . . . . 0.0 110.119 179.14 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -59.19 -52.49 4.86 Favored 'Trans proline' 0 N--CA 1.459 -0.546 0 C-N-CA 123.674 2.916 . . . . 0.0 113.699 -166.383 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 96.1 mt -128.68 59.92 1.53 Allowed 'General case' 0 N--CA 1.462 0.135 0 C-N-CA 123.68 0.792 . . . . 0.0 109.541 -173.2 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -162.9 -66.79 0.05 OUTLIER 'General case' 0 CA--C 1.529 0.158 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 -171.637 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . 101.1 51.76 1.13 Allowed Glycine 0 CA--C 1.528 0.879 0 C-N-CA 123.641 0.638 . . . . 0.0 112.493 175.21 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 34.7 m -125.56 152.92 32.83 Favored 'Isoleucine or valine' 0 C--O 1.232 0.164 0 C-N-CA 123.953 0.901 . . . . 0.0 108.91 168.002 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.12 -175.59 44.97 Favored Glycine 0 CA--C 1.528 0.853 0 N-CA-C 110.81 -0.916 . . . . 0.0 110.81 175.334 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 41.2 mtpt -78.41 84.43 4.57 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 122.931 0.492 . . . . 0.0 109.824 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -139.28 150.73 45.79 Favored 'General case' 0 N--CA 1.453 -0.323 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.502 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.4 tp-100 48.32 55.82 8.3 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 126.993 2.117 . . . . 0.0 112.17 175.003 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -103.24 115.88 31.41 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.746 0.818 . . . . 0.0 110.077 -179.254 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -86.24 146.36 26.57 Favored 'General case' 0 C--O 1.226 -0.175 0 C-N-CA 125.431 1.492 . . . . 0.0 109.206 178.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -81.42 141.82 33.56 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 119.089 0.859 . . . . 0.0 109.36 -179.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.4 t -109.03 102.49 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.837 0 C-N-CA 127.109 2.164 . . . . 0.0 107.757 179.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -76.59 76.36 3.28 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 126.207 1.803 . . . . 0.0 112.682 -179.078 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 51.2 mm-40 . . . . . 0 C--O 1.255 1.392 0 CA-C-O 116.671 -1.633 . . . . 0.0 108.414 153.42 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.475 0.801 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.3 mttm -82.52 149.09 27.73 Favored 'General case' 0 N--CA 1.455 -0.203 0 CA-C-N 119.757 1.162 . . . . 0.0 111.394 -178.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -75.33 168.27 20.32 Favored 'General case' 0 N--CA 1.448 -0.564 0 C-N-CA 124.213 1.005 . . . . 0.0 108.567 174.045 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 29.4 m-85 -144.62 139.12 27.86 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-O 118.899 -0.572 . . . . 0.0 112.306 -179.045 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.8 m -87.1 137.78 32.06 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 119.175 0.898 . . . . 0.0 111.298 178.154 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 40.8 t -62.73 149.7 43.14 Favored 'General case' 0 C--N 1.34 0.171 0 CA-C-N 118.699 0.682 . . . . 0.0 109.708 174.075 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 58.1 m -43.05 -36.67 1.68 Allowed 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 125.477 1.511 . . . . 0.0 112.113 172.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 m -129.71 -40.76 0.7 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 C-N-CA 123.368 0.667 . . . . 0.0 112.46 178.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' CYS . . . . . . . . . . . . . 4.7 m -76.79 160.65 29.11 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 119.346 0.976 . . . . 0.0 112.413 -171.558 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -99.38 12.59 61.67 Favored Glycine 0 CA--C 1.53 0.986 0 CA-C-O 119.222 -0.766 . . . . 0.0 112.406 174.106 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' TYR . . . . . . . . . . . . . 38.8 m-85 -60.58 -43.91 96.81 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 118.873 1.336 . . . . 0.0 111.308 -175.696 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 30.7 mt 69.64 113.01 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 C-N-CA 126.137 1.775 . . . . 0.0 111.368 -177.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' TYR . . . . . 0.504 ' CZ ' HD11 ' A' ' 33' ' ' ILE . 80.4 t80 -69.62 132.49 46.28 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 171.109 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ASN . . . . . . . . . . . . . 52.4 t-20 -120.35 113.23 33.88 Favored Pre-proline 0 N--CA 1.456 -0.168 0 C-N-CA 124.205 1.002 . . . . 0.0 109.685 177.429 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -59.67 -42.19 49.0 Favored 'Trans proline' 0 N--CA 1.45 -1.045 0 C-N-CA 122.017 1.811 . . . . 0.0 112.443 -176.561 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -59.64 -31.41 69.5 Favored 'General case' 0 N--CA 1.447 -0.606 0 O-C-N 123.108 0.255 . . . . 0.0 111.653 -178.266 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 -90.09 -29.59 18.24 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 123.304 0.641 . . . . 0.0 110.422 177.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 62.79 -154.99 42.38 Favored Glycine 0 CA--C 1.53 1.029 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -167.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -146.34 61.33 6.95 Favored Pre-proline 0 CA--C 1.543 0.702 0 C-N-CA 125.595 1.558 . . . . 0.0 107.842 173.558 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -61.33 -34.53 87.17 Favored 'Trans proline' 0 N--CA 1.457 -0.64 0 C-N-CA 122.944 2.429 . . . . 0.0 111.599 -168.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -54.64 -29.88 53.55 Favored 'General case' 0 N--CA 1.451 -0.388 0 C-N-CA 125.253 1.421 . . . . 0.0 111.38 177.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -98.03 -33.98 10.97 Favored 'General case' 0 N--CA 1.454 -0.25 0 C-N-CA 125.493 1.517 . . . . 0.0 109.774 -177.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 141.27 11.51 0.56 Allowed Glycine 0 CA--C 1.532 1.132 0 C-N-CA 123.933 0.778 . . . . 0.0 114.06 169.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.462 HG23 ' CD1' ' A' ' 37' ' ' TRP . 52.2 t -107.61 112.73 41.35 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.245 0 CA-C-N 119.174 1.487 . . . . 0.0 108.947 -177.379 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 -65.05 153.79 88.19 Favored Pre-proline 0 C--N 1.329 -0.283 0 O-C-N 122.016 -0.428 . . . . 0.0 110.406 -179.367 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -59.22 146.77 93.5 Favored 'Trans proline' 0 N--CA 1.449 -1.113 0 C-N-CA 121.631 1.554 . . . . 0.0 110.955 172.185 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 78.03 18.01 77.43 Favored Glycine 0 CA--C 1.524 0.642 0 CA-C-O 118.553 -1.137 . . . . 0.0 112.764 -177.159 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 83.0 m -89.96 120.84 31.52 Favored 'General case' 0 N--CA 1.443 -0.821 0 CA-C-N 119.577 1.689 . . . . 0.0 107.678 177.133 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -57.55 133.55 55.35 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 169.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -48.43 -32.27 7.45 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.753 174.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 18.1 pttp -68.73 -40.89 79.67 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 119.375 -0.93 . . . . 0.0 109.345 179.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 93.1 m-20 -75.36 -15.32 60.48 Favored 'General case' 0 N--CA 1.453 -0.278 0 C-N-CA 125.546 1.539 . . . . 0.0 110.494 -172.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.504 HD11 ' CZ ' ' A' ' 13' ' ' TYR . 12.9 mt -55.94 132.17 73.59 Favored Pre-proline 0 N--CA 1.441 -0.891 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 172.427 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -63.41 140.2 75.09 Favored 'Trans proline' 0 N--CA 1.443 -1.486 0 C-N-CA 122.633 2.222 . . . . 0.0 109.042 178.083 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.37 -18.12 57.23 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 122.555 0.342 . . . . 0.0 111.224 177.243 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -71.25 -18.53 62.44 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.784 1.234 . . . . 0.0 112.076 176.357 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' TRP . . . . . 0.462 ' CD1' HG23 ' A' ' 24' ' ' VAL . 73.3 t90 -68.76 159.47 32.24 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 121.668 0.747 . . . . 0.0 110.943 -178.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 15.9 m -136.51 151.4 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.796 0 C-N-CA 125.66 1.584 . . . . 0.0 109.279 -171.294 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' CYS . . . . . . . . . . . . . 41.3 t -72.31 135.75 81.83 Favored Pre-proline 0 CA--C 1.537 0.472 0 C-N-CA 124.428 1.091 . . . . 0.0 108.886 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.58 131.7 30.55 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 122.173 1.916 . . . . 0.0 110.058 179.318 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 57.1 mt 56.97 49.46 13.89 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 123.544 0.738 . . . . 0.0 110.991 176.363 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 53.8 t -163.58 -176.62 4.77 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 127.877 2.471 . . . . 0.0 105.092 -174.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLY . . . . . . . . . . . . . . . -83.71 -100.35 0.56 Allowed Glycine 0 CA--C 1.529 0.953 0 C-N-CA 124.161 0.886 . . . . 0.0 111.08 178.025 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.3 m -142.35 160.13 19.64 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.117 0 C-N-CA 123.93 0.892 . . . . 0.0 108.687 -177.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 142.84 149.05 5.06 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 177.165 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.8 ptmt -161.75 -177.58 5.96 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 125.291 1.436 . . . . 0.0 107.447 169.629 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 t0 69.59 -63.24 0.39 Allowed 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 126.992 2.117 . . . . 0.0 111.817 169.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 38.5 tt0 -56.73 -22.68 37.08 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 126.707 2.003 . . . . 0.0 113.188 174.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 6.0 m-30 -45.18 143.95 1.48 Allowed 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 125.865 1.666 . . . . 0.0 109.494 170.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -75.16 155.39 37.01 Favored 'General case' 0 C--O 1.224 -0.263 0 CA-C-N 119.429 1.013 . . . . 0.0 108.555 -177.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -83.03 133.87 35.06 Favored 'General case' 0 N--CA 1.442 -0.837 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 173.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 13.4 t -93.51 116.59 35.04 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.983 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 172.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -70.96 56.88 0.2 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.683 1.993 . . . . 0.0 114.491 -177.454 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 . . . . . 0 C--O 1.255 1.352 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 159.832 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ' FE' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_